
<html lang="en"     class="pb-page"  data-request-id="554285ec-d956-4639-915b-1cc7aca642a7"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2014.57.issue-12;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/jm500335h;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect" /></meta><meta name="dc.Creator" content="Makonen  Belema" /></meta><meta name="dc.Creator" content="Nicholas A.  Meanwell" /></meta><meta name="dc.Description" content="The discovery and development of the first-in-class hepatitis C virus (HCV) NS5A replication complex inhibitor daclatasvir (6) provides a compelling example of the power of phenotypic screening to ..." /></meta><meta name="Description" content="The discovery and development of the first-in-class hepatitis C virus (HCV) NS5A replication complex inhibitor daclatasvir (6) provides a compelling example of the power of phenotypic screening to ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 21, 2014" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm500335h" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm500335h" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm500335h" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm500335h" /></link>
        
    
    

<title>Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm500335h" /></meta><meta property="og:title" content="Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0015.jpeg" /></meta><meta property="og:description" content="The discovery and development of the first-in-class hepatitis C virus (HCV) NS5A replication complex inhibitor daclatasvir (6) provides a compelling example of the power of phenotypic screening to identify leads engaging novel targets in mechanistically unique ways. HCV NS5A replication complex inhibitors are pan-genotypic in spectrum, and this mechanistic class provides the most potent HCV inhibitors in vitro that have been described to date. Clinical trials with 6 demonstrated a potent effect on reducing plasma viral load and, in combination with mechanistically orthogonal HCV inhibitors, established the ability to cure even the most difficult infections without the need for immune stimulation. In this Drug Annotation, we describe the discovery of the original high-throughput screening lead 7 and the chemical conundrum and challenges resolved in optimizing to 6 as a clinical candidate and finally we summarize the results of select clinical studies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm500335h"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm500335h">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm500335h&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm500335h&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm500335h&amp;href=/doi/10.1021/jm500335h" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 5057-5071</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm401516c" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/jm500845y" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Makonen++Belema">Makonen Belema</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"> and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicholas+A.++Meanwell">Nicholas A. Meanwell</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div><div class="corresp-info"><strong>*</strong>M.B.: phone, 203-677-6928; e-mail, <a href="/cdn-cgi/l/email-protection#771a161c181912195915121b121a1637151a045914181a"><span class="__cf_email__" data-cfemail="1578747e7a7b707b3b777079707874557778663b767a78">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>N.A.M.: phone, 203-677-6679; e-mail, <a href="/cdn-cgi/l/email-protection#f29c9b919a9d9e9381dc9f97939c85979e9eb2909f81dc919d9f"><span class="__cf_email__" data-cfemail="9cf2f5fff4f3f0fdefb2f1f9fdf2ebf9f0f0dcfef1efb2fff3f1">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm500335h&amp;href=/doi/10.1021%2Fjm500335h" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 5057–5071</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 21, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 March 2014</li><li><span class="item_label"><b>Published</b> online</span>21 April 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 June 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm500335h" title="DOI URL">https://doi.org/10.1021/jm500335h</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5057%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMakonen%2BBelema%252C%2BNicholas%2BA.%2BMeanwell%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D12%26contentID%3Djm500335h%26title%3DDiscovery%2Bof%2BDaclatasvir%252C%2Ba%2BPan-Genotypic%2BHepatitis%2BC%2BVirus%2BNS5A%2BReplication%2BComplex%2BInhibitor%2Bwith%2BPotent%2BClinical%2BEffect%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5071%26publicationDate%3DJune%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm500335h"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5318</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">71</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm500335h" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Makonen&quot;,&quot;last_name&quot;:&quot;Belema&quot;},{&quot;first_name&quot;:&quot;Nicholas&quot;,&quot;last_name&quot;:&quot;A. Meanwell&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;21&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;5057-5071&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm500335h&quot;},&quot;abstract&quot;:&quot;The discovery and development of the first-in-class hepatitis C virus (HCV) NS5A replication complex inhibitor daclatasvir (6) provides a compelling example of the power of phenotypic screening to identify leads engaging novel targets in mechanistically unique ways. HCV NS5A replication complex inhibitors are pan-genotypic in spectrum, and this mechanistic class provides the most potent HCV inhibitors in vitro that have been described to date. Clinical trials with 6 demonstrated a potent effect on reducing plasma viral load and, in combination with mechanistically orthogonal HCV inhibitors, established the ability to cure even the most difficult infections without the need for immune stimulation. In this Drug Annotation, we describe the discovery of the original high-throughput screening lead 7 and the chemical conundrum and challenges resolved in optimizing to 6 as a clinical candidate and finally we summarize the results of select clinical studies.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500335h&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500335h" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500335h&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500335h" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500335h&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500335h" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm500335h&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500335h&amp;href=/doi/10.1021/jm500335h" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm500335h" /></input><a href="/doi/pdf/10.1021/jm500335h" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (803 KB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm500335h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm500335h%26sid%3Dliteratum%253Aachs%26pmid%3D24749835%26genre%3Darticle%26aulast%3DBelema%26date%3D2014%26atitle%3DDiscovery%2Bof%2BDaclatasvir%252C%2Ba%2BPan-Genotypic%2BHepatitis%2BC%2BVirus%2BNS5A%2BReplication%2BComplex%2BInhibitor%2Bwith%2BPotent%2BClinical%2BEffect%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D12%26spage%3D5057%26epage%3D5071%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292016" title="Therapeutics">Therapeutics</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291362" title="Antimicrobial agents">Antimicrobial agents</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jmcmar.2014.57.issue-12/production/jmcmar.2014.57.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The discovery and development of the first-in-class hepatitis C virus (HCV) NS5A replication complex inhibitor daclatasvir (<b>6</b>) provides a compelling example of the power of phenotypic screening to identify leads engaging novel targets in mechanistically unique ways. HCV NS5A replication complex inhibitors are pan-genotypic in spectrum, and this mechanistic class provides the most potent HCV inhibitors in vitro that have been described to date. Clinical trials with <b>6</b> demonstrated a potent effect on reducing plasma viral load and, in combination with mechanistically orthogonal HCV inhibitors, established the ability to cure even the most difficult infections without the need for immune stimulation. In this Drug Annotation, we describe the discovery of the original high-throughput screening lead <b>7</b> and the chemical conundrum and challenges resolved in optimizing to <b>6</b> as a clinical candidate and finally we summarize the results of select clinical studies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15517" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15517" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Although contemporary drug discovery practices have evolved to focus heavily on the design and implementation of target-based biochemical screens to discover and optimize lead molecules, phenotypic screening remains an important source of drug candidates, particularly those with novel modes of action.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> Indeed, it has been highlighted that the majority of drugs approved between 1999 and 2008 had their origins in phenotypic screens.<a onclick="showRef(event, 'cit1a'); return false;" href="javascript:void(0);" class="ref cit1a">(1a)</a> This kind of screening approach offers the opportunity to identify molecules acting by mechanisms that are unanticipated, allowing interrogation of the function of a target that may not be accessible in the isolated protein, such as those that exist in complex with other proteins within the cellular environment and are thus difficult to recapitulate in a biochemical assay. Phenotypic screening for antiviral agents has been a useful approach to lead generation that juxtaposes the diversity inherent to a compound collection with the panoply of viral targets that are represented in either a partial or full virus replication cycle in cell culture.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> However, virus-encoded proteins often play multiple roles in virus reproduction in a fashion that is distinct and temporally coordinated. This is particularly true for the smaller RNA viruses like hepatitis C virus (HCV) or human immunodeficiency virus 1 (HIV-1) where phenotypic screening may be considered to offer an additional dimension in which the unique role of viral targets at different points of the replication cycle can readily and effectively be assessed. As an example, the HIV-1 integrase strand transfer inhibitors that bind to the active site of the enzyme interfere with the integration of the viral cDNA into the host cell chromosome.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In contrast, allosteric inhibitors that associate with the lens epithelium-derived growth factor (LEDG-F) binding site appear to act at multiple points in the replication cycle, with the antiviral activity in cell culture manifested most prominently postintegration and associated with effects on the maturation of virus particles.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> We have exploited phenotypic screening to identify mechanistically novel antiviral agents that include the influenza fusion inhibitor <b>1</b>, the respiratory syncytial virus fusion inhibitor <b>2</b>, the HIV-1 attachment inhibitor <b>3</b>, the influenza nucleoprotein (NP) inhibitor <b>4</b>, and the HCV entry inhibitor <b>5</b> (Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>).<a onclick="showRef(event, 'ref6 ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9 ref10">(6-10)</a> Elucidation of the mode of action of antiviral agents discovered in this fashion is facilitated by a process involving the generation of resistant virus, the careful mapping of mutations, and demonstration of the resistant phenotype when mutations are reverse-engineered into the viral genome. However, phenotypic screening for antiviral agents may identify inhibitors of host cell processes, and in order to confirm that the biochemical target is a viral protein, we have frequently augmented this approach by preparing and utilizing affinity probes to confirm target engagement. These probes have also proven to be important tool molecules that have not only furthered our understanding of the mode of action of lead molecules but also provided unique and important insights into drug–target interactions or illumined fundamental aspects of mechanism of action that have been important for the evolution of a program.<a onclick="showRef(event, 'cit6b cit7d cit7e'); return false;" href="javascript:void(0);" class="ref cit6b cit7d cit7e">(6b, 7d, 7e)</a></div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0002.jpeg" id="GRAPHIC-d1913e199-autogenerated" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53855" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53855" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">At the initiation of our drug discovery efforts to identity and develop inhibitors of HCV, we adopted a strategy that anticipated the use of combination therapy to address the problem associated with the development of resistance that frequently occurs with therapeutic agents targeting an RNA virus. Viral RNA polymerases are associated with poor fidelity of replication due to a limited proofreading capability that results in the rapid emergence of resistant virus under the selective pressure of a drug, an evolutionary defensive posture for the virus. Combination antiviral therapy has its basis in teachings from the arena of HIV-1 drug development, and clinical trials with HCV inhibitors have not only confirmed the validity of concerns involving the emergence of resistance but have also led to a deeper understanding of viral kinetics and a fuller appreciation of the challenges associated with HCV drug development.<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11-13)</a> Consequently, we conducted multiple discovery programs simultaneously with a focus initially directed toward the NS3 protease and NS5B RNA-dependent RNA polymerase, since biochemical assays for these targets could be reconstituted in vitro. However, the advent of cell-based systems that efficiently recapitulated key aspects of HCV replication using subgenomic constructs, originally reported by Bartenschlager in 1999 almost a decade after the identification of HCV as an RNA virus, allowed the implementation of phenotypic screens that sought mechanistically unique inhibitors of virus replication.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The development of subgenomic replicons was an important advance in the HCV field since, in contrast to HIV-1, conditions under which the virus would replicate in cell culture system remained elusive until 2005.<a onclick="showRef(event, 'ref11 ref14'); return false;" href="javascript:void(0);" class="ref ref11 ref14">(11, 14)</a> Although the first generation HCV replicon systems, which were based on a genotype-1b (GT-1b) virus, captured only the basic elements of virus replication, excluding viral entry, assembly, and egress, they nevertheless facilitated drug discovery by allowing an assessment of the effects of NS3 and NS5B inhibitors in a more physiologically relevant setting.</div><div class="NLM_p">Prior to the development of the GT-1b replicon system, the only cell culture assays that were available for the evaluation of HCV inhibitors were based on bovine viral diarrhea virus (BVDV), a pestivirus that is a member of the same <i>Flaviviridae</i> family as HCV and has been considered to be sufficiently close phylogenetically to function as a surrogate for screening purposes.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> However, our experience of using BVDV as a surrogate to identify HCV inhibitors had not proven to be successful, an observation that led to the use of this virus as a counter screen designed to act as a stringent arbiter of selectivity for HCV that would help to eliminate modulators of host cell function and rapidly triage lead inhibitors.<a onclick="showRef(event, 'cit15e ref16'); return false;" href="javascript:void(0);" class="ref cit15e ref16">(15e, 16)</a> Thus, the screen implemented to discover the iminothiazolidinone chemotype that proved to be a cryptic precursor to daclatasvir (<b>6</b>, Chart <a class="ref internalNav" href="#cht2" aria-label="2">2</a>) assessed inhibition of GT-1b HCV and BVDV replicons constructed in the same Huh-7 host cell background.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> These cell lines were deployed in the same screening well in a fashion that took advantage of orthogonal reporters for each virus, thus allowing the selection of leads with high specificity for HCV. Alamar Blue staining was used to assess host cell viability at the end of the incubation period, and the cells were subsequently lysed to calibrate the inhibition of HCV replication using a FRET-based reporter assay that monitored cleavage of a substrate by the NS3/4A protease while the BVDV replicon utilized a luciferase read-out. BMS-858 (<b>7</b>) emerged from this screening campaign as a selective HCV inhibitor that targeted the NS5A protein (vide infra), and although over one million compounds were ultimately screened, it was the only chemotype identified with this antiviral mechanism. This kind of hit rate has precedent with the other high throughput screening leads described above which were typically either singletons or members of a series with only a limited number of structural homologues. These results highlight the importance of past drug discovery campaigns and the practices associated with library enrichment that shape the complexion of corporate compound collections.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><figure id="cht2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0003.jpeg" id="GRAPHIC-d1913e245-autogenerated" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>7</b> was profiled as a modestly potent GT-1b HCV inhibitor with an EC<sub>50</sub> between 0.57 and 1.0 μM, representing over 50-fold selectivity toward both BVDV (EC<sub>50</sub> > 50 μM) and host cell toxicity (CC<sub>50</sub> > 50 μM).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> This iminothiazolidinone chemotype originated as part of an opportunistic library of molecules designed and prepared for general screening campaigns in an era when that was common practice. Although iminothiazolidinones are well represented in the literature, they are frequently obtained by Knoevenagel condensation of C-5-unsubstituted compounds with aldehydes or derivatives thereof that affords C-5 vinylidene derivatives, as depicted in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>. However, although benzylidene homologues of <b>7</b> prepared from aromatic aldehydes in this fashion inhibited HCV replication with single digit micromolar EC<sub>50</sub> values, they were insensitive to replicons expressing mutations that conferred resistance to <b>7</b>, suggesting  an alternative mode of action. Ultimately, the C-5 phenyl substituent of <b>7</b> and the attendant chemical properties turned out to be of considerable importance to the discovery of <b>6</b>. Resistance selection and mapping studies with <b>7</b> and the more potent analogue <b>8</b> (EC<sub>50</sub> = 0.005 μM) implicated NS5A as the target with a Y93H substitution in domain I of the protein conferring resistance that was >5-fold to <b>7</b> and >625-fold to <b>8</b>.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> Additional resistance selection and mapping experiments identified a combination of L31V and Q54L as consensus mutations that conferred 354-fold reduced sensitivity to <b>8</b>, but replicons resistant to <b>8</b> retained sensitivity to inhibitors of NS3 protease.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> At the time of this discovery, our understanding of the function of the HCV NS5A protein in the virus replication cycle was rudimentary, with no known enzymatic activity.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> As a consequence, biochemical characterization of NS5A activity in a fashion similar to that developed for the NS3 protease and NS5B RNA-dependent RNA polymerase enzymes was precluded.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Studies with NS5A inhibitors in HCV replicons, replicating virus preparations and clinical trials, have since illuminated several aspects of NS5A function, and this protein has been suggested to be a master regulator of virus replication.<a onclick="showRef(event, 'cit20b'); return false;" href="javascript:void(0);" class="ref cit20b">(20b)</a> However, although NS5A has been shown to coordinate both HCV replication and assembly while modulating host cell responses that contribute to creating an environment conducive to virus replication and propagation, the current level of understanding of NS5A function remains elementary at best.<a onclick="showRef(event, 'cit20g'); return false;" href="javascript:void(0);" class="ref cit20g">(20g)</a></div><figure id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of the parent iminothiazolidinone chemotype and conversion to C-5-unsaturated analogues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As a screening lead, <b>7</b> suffered from several potential shortcomings including a high molecular weight (MW = 587), a cLogP of >5, an extensive polar surface area of 139 Å<sup>2</sup>, and a stereocenter at C-5 that was prone to epimerization during routine handling. However, its unique mode of action was attractive and initial structure–activity studies focused on assessing the effect of changes to the peripheral elements bound to the core scaffold of <b>7</b> (the amino acid moiety and the <i>N</i>-phenyl and the <i>N</i>-furanylmethyl substituents), a synopsis of which is captured in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a> where all compounds were assessed as mixtures containing both isomers at the C-5 center of the thiazolidinone core.<a onclick="showRef(event, 'ref18 ref21'); return false;" href="javascript:void(0);" class="ref ref18 ref21">(18, 21)</a> Modifications to the phenyl and furanylmethyl elements modulated replicon inhibitory potency over a broad dynamic range, with more polar moieties associated with higher antiviral activity. However, the structure–activity relationships (SARs) for the amino acid were much more precise, with inversion of the alanine stereoconfiguration reducing antiviral activity by more than 100-fold. Moreover, substitution of alanine revealed that glycine was 10-fold inferior, proline improved antiviral potency modestly, while all other amino acids afforded analogues that were poorly active in the replicon. A key finding in this phase of the program was that changing the carboxybenzyl moiety to a phenylacetamide cap markedly increased potency in both the alanine (<b>8</b>) and proline series, affording compounds with single digit nanomolar EC<sub>50</sub> values in the GT-1b replicon.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Synopsis of structure–activity relationships associated with <b>7</b> as an inhibitor of replication of an HCV GT-1b replicon.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As the examination of the iminothiazolidinone chemotype continued, we became aware of a chemical instability issue associated with <b>8</b> which was observed to partially decompose on standing for several days as a dimethyl sulfoxide (DMSO) solution. Initial studies identified a degradation pathway involving oxidation at C-5 leading to a thiohydantoin derivative along with small amounts of a thiourea and ketoacid products arising from hydrolytic decomposition of the putative acylated thiourea intermediate (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Follow-up studies demonstrated that <b>8</b> was also unstable in replicon medium, although surprisingly the observed HCV inhibitory activity was preserved regardless of the extent of degradation of the compound. An HPLC analysis of material extracted from the replicon medium revealed no significant additional peaks by UV detection, suggesting that the antiviral activity maybe associated with minor components of the mixture. In elucidating the origin of biological activity, the HCV replicon played a critical role by providing a highly sensitive assay with which to detect antiviral components that were not readily apparent from the initial HPLC trace because of their low concentration. After developing an extraction process that captured the biologically active fraction, an HPLC biogram analysis was used to guide identification of the active components that showed reduced potency toward the NS5A Y93H mutation. Incubating <b>8</b> in replicon media on a preparative scale led to the identification of three additional products by HPLC in addition to those characterized in the earlier decomposition study discussed above. The major additional components, two structurally related active species, were isolated in sufficient quantity to allow detailed characterization.<a onclick="showRef(event, 'ref19 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref21">(19, 21)</a> These compounds, designated as peak 4 and peak 6 from the biogram analysis, exhibited EC<sub>50</sub> values of 43 and 0.6 nM, respectively, in the replicon, and their antiviral activity was sensitive to the NS5A Y93H mutant. A detailed analysis of the <sup>1</sup>H and <sup>13</sup>C NMR spectra combined with MS spectroscopy revealed that the compounds were derived from <b>8</b> via a process of dimerization and that the connectivity for peak 4 was at C-5, leading to their identification as isomers of <b>9</b>. Interestingly, an attempt to simplify the NMR spectrum of peak 6 by warming a CD<sub>3</sub>CN solution to 55 °C, in order to homogenize the amide rotamer resonances, led to its conversion to peak 4, suggesting the latter to be the thermodynamically more stable isomer. However, the relative isomeric composition of the two dimeric compounds has not been definitively established and it is not clear if the conversion of peak 6 to peak 4 represents interconversion of atropisomers across a rotational barrier or dimer dissociation into monomeric species that recombine in a fashion that affords the alternative, more stable isomer. Dimerization of <b>8</b> to afford <b>9</b> is envisaged to arise by way of coupling of radicals generated at C-5 of <b>8</b> by hydrogen atom abstraction, presumably mediated by oxygen that is a diradical in its ground state, with the phenyl, carbonyl, and sulfur substituents providing sufficient captodative stabilization of the radical to allow dimeric combination to occur in the assay medium.<a onclick="showRef(event, 'ref19 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref21">(19, 21)</a></div><div class="NLM_p">The discovery of biologically active dimeric derivatives of <b>8</b> propelled the program in a markedly different direction that addressed the challenge associated with the high molecular weight (MW = 1139) and structural complexity of <b>9</b>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> On the basis of the premise that the precise SARs associated with the amino acid moiety identified a key pharmacophoric element, it was hypothesized that the chemical reactivity of the thiazolidinone heterocycle was functioning to convene an embedded symmetrical dimeric species and that the two thiazolidinone heterocycles of the dimer <b>9</b> could be dispensed with. This concept was readily and rapidly explored in the context of the more potent proline derivative and led to the synthesis of stilbene <b>10a</b> along with its saturated bibenzyl analogue <b>10b</b>. While <b>10b</b> exhibited an EC<sub>50</sub> value of 30 nM in the GT-1b replicon, <b>10a</b> was considerably more potent with an EC<sub>50</sub> of 86 pM, a result attributed to the conformational constraint afforded by the olefin moiety.<a onclick="showRef(event, 'ref19 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref21">(19, 21)</a> Moreover, <b>10a</b> exhibited >10 000-fold reduction in inhibitory potency toward the NS5A Y93H resistant mutant, indicative of a similar mode of inhibition as the iminothiazolidinone progenitor <b>8</b>. This dimeric pharmacophore model was corroborated several years later with the determination of the solid state structures of domain I of initially GT-1b and subsequently GT-1a NS5A as a dimeric species that complemented the symmetry associated with the structures of <b>9</b> and <b>10</b> (Chart <a class="ref internalNav" href="#cht3" aria-label="3">3</a>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Decomposition of <b>8</b> in DMSO.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="cht3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Chart 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0004.jpeg" id="GRAPHIC-d1913e488-autogenerated" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=cht3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">While the discovery of stilbene <b>10a</b> represented a significant simplification of the chemotype and an advance for the program, the potential of this chemotype as a vehicle for drug discovery was compromised by two liabilities inherent to the structure. The potential for the olefin to undergo <i>cis</i>/<i>trans</i> isomerization was viewed as problematic, while the anilide moieties were of greater concern because of the risk for the release of a potentially toxic aniline moiety in vivo should the molecule be recognized by amidases or be subject to hydrolytic decomposition in the gut.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> An additional and more substantial complication that emerged shortly after the discovery of <b>10a</b> was associated with the development of a replicon system that allowed evaluation of inhibitory activity toward the GT-1a  subtype. In this assay, the EC<sub>50</sub> value for <b>10a</b> was determined to be >10 μM, a result presenting a more significant issue that needed to be resolved if we were to advance an inhibitor with a broader antiviral profile. The clinical relevance of the GT-1a subtype as a therapeutic target is underscored by demographic analyses that reveal it to be the HCV variant with the highest prevalence in North America, while there is significant additional presence in South America, Europe, and Australia.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Moreover, GT-1a infections have proven to be a difficult subtype to treat clinically. Although enhancing GT-1a inhibitory activity was the major focus of the next phase of compound optimization, solving this problem turned out to be a considerable challenge.</div><div class="NLM_p">It quickly became apparent from initial SAR studies surrounding <b>10a</b> that the peripheral structural elements and their topological disposition were primarily responsible for antiviral potency while the stilbene element was determined to be largely playing the role of a scaffold on which to display the pharmacophore. Moreover, pharmacokinetic (PK) profiling of analogues of <b>10a</b> established the potential of this chemotype to deliver compounds that combined GT-1b replicon inhibitory activity with reasonable bioavailability following oral dosing to rats, although these properties required some compromise, as exemplified by the data associated with <b>11</b> (Chart <a class="ref internalNav" href="#cht4" aria-label="4">4</a>).<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a> Extensive variation of the phenylacetamide moiety of <b>10</b> and optimization of compounds demonstrating modestly potent GT-1a inhibition led to the discovery of <b>12a</b> as the first compound with balanced inhibition of both the GT-1a and GT-1b viral subtypes.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Gratifyingly, this compound also displayed potent antiviral activity toward replicons and hybrid replicons representing HCV genotypes 2a, 3a, and 5a with EC<sub>50</sub> values ranging from 2.2 to 14 nM, data that further heightened our interest in the NS5A mechanistic approach.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Simplification of the isoquinolinamide moiety to the phenylglyoxamide <b>13</b>, envisioned as a deannelated analogue of the heterocycle, compromised GT-1a inhibitory potency by 20-fold, but this compound displayed an antiviral profile comparable to that of <b>12b</b>, the progenitor of <b>12a</b>, further identifying salient elements of the embedded pharmacophore.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Attention was then focused on modifying the benzylic carbonyl moiety of <b>13</b> with a variety of substituents introduced in order to probe interactions with the NS5A protein. Examination of a series of mandelamide-based caps revealed that while potency toward both GT-1a and GT-1b replicons could be improved, there was considerable subtlety associated with stereochemical preferences.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> For example, the (<i>R</i>)-mandelamide <b>14a</b> was more potent than its diastereomer <b>14b</b>, whereas this scenario was reversed with the α-methylated homologues <b>15</b> where the (<i>S</i>)-capped analogue <b>15b</b> is the more potent diastereomer. In this series, enhanced GT-1a inhibitory activity was accompanied by a significant boost in potency toward the GT-1b replicon, with the single digit picomolar EC<sub>50</sub> associated with <b>15b</b> being one of the earliest demonstrations of the high level of inhibitory potency that could be achieved by disrupting the function(s) of HCV NS5A.</div><figure id="cht4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Chart 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0005.jpeg" id="GRAPHIC-d1913e592-autogenerated" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=cht4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although replacement of the alkene moiety of <b>10a</b> with an alkyne, exemplified by <b>16a</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), was accompanied by some loss of GT-1b antiviral activity, this compound was selected as the prototype for further study because it obviated the <i>cis</i>–<i>trans</i> isomerization liability associated with stilbene derivatives.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Additional examination of the cap revealed that phenylglycinamide derivatives imparted enhanced potency toward GT-1a and/or GT-1b replicons, with a marked preference for the (<i>R</i>)-stereoconfiguration at the benzylic center (compare <b>16b</b> with <b>16c</b> in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> While both a basic dimethylamine (<b>16b</b>) and a carbamate (<b>16e</b>) substituent at the benzylic carbon were associated with good antiviral potency, the less basic morpholine substituent in <b>16d</b> was more than an order of magnitude weaker than <b>16b</b> toward the GT-1a replicon. It is hypothesized that the more basic analogues such as <b>16b</b> are protonated at physiological pH, allowing them to engage the GT-1a NS5A protein through a H-bond interaction with a proximal acceptor in the binding pocket, an interaction that can be mimicked by the carbamate NH of <b>16e</b>. However, this type of H-bonding interaction with the GT-1b NS5A protein appears to be less important for maintaining antiviral activity, since all of the modifications in <b>16b</b>–<b>e</b> are associated with potent GT-1b inhibition with EC<sub>50</sub> values of less than 4.6 nM.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Antiviral Activity Associated with Alkyne Derivatives <b>16a</b>–<b>e</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0014.gif" alt="" id="fx5" /></img><div></div></div><div class="NLM_p">Having firmly established the importance of the cap region for securing potent GT-1a inhibitory activity, the final stages of the campaign to identify a clinical candidate were directed toward addressing the embedded anilide moiety. The SARs that had emerged suggested that both the NH and the carbonyl moiety of the anilide were of importance for antiviral activity and the modifications that were probed preserved these structural elements. The benzimidazoles <b>17</b> and <b>18</b> (Chart <a class="ref internalNav" href="#cht5" aria-label="5">5</a>) fulfilled these structural criteria and were potent inhibitors of GT-1b HCV, but the reduction in GT-1a potency for both of these compounds necessitated further optimization which focused on adjusting the topology of the molecule based on findings from earlier studies with GT-1b-biased inhibitors.<a onclick="showRef(event, 'ref26 ref29'); return false;" href="javascript:void(0);" class="ref ref26 ref29">(26, 29)</a> After considerable experimentation, deannelation of the benzimidazole of <b>17</b> combined with excision of the alkyne moiety to accommodate the changes in topology and core length afforded <b>19a</b> as a compound with potent antiviral activity toward both GT-1a and GT-1b that established a remarkable new benchmark for potency not only for NS5A inhibition but for HCV inhibitors in general.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Consistent with the SAR for <b>16b</b> and <b>16e</b>, the dimethylamine analogue <b>19b</b> exhibited a similar level of antiviral potency with balanced GT-1a and GT-1b inhibition. However, both <b>19a</b> and <b>19b</b> demonstrated poor absorption in rat PK studies, attributed to their high molecular weight (807 and 747 Da, respectively) and structural composition. These results catalyzed an examination of truncation of the phenyl ring within the context of carbamate <b>19a</b> as an approach to address these shortcomings. However, the initial product of this exercise, the <span class="smallcaps smallerCapital">d</span>-valine derivative <b>20</b>, which retained the cap benzylic stereoconfiguration of <b>19a</b>, exhibited a large (>40 000-fold) erosion of GT-1a inhibitory potency.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Alternative approaches that were based on abridging a single cap moiety, exemplified by the tetrahydrofuran <b>21</b>, also incurred a significant reduction in GT-1a antiviral activity, but the measurable exposure observed for this compound following oral dosing across species supported the strategy of reducing molecular weight and aromatic content in order to improve oral bioavailability. The final breakthrough emerged from an unanticipated SAR finding that the optimal antiviral activity for the alkyl- and arylglycine cap series resided in different absolute stereoconfigurations. The initial productive step in this direction occurred when the tetrahydrofuran moiety of <b>21</b> was replaced with <span class="smallcaps smallerCapital">l</span>-alanine which afforded <b>22</b>, a compound with significantly enhanced GT-1a inhibitory properties. As a follow-up, the symmetrical <span class="smallcaps smallerCapital">l</span>-alanine analogue <b>23</b> was synthesized and found to be a potent inhibitor of both  GT-1a and GT-1b subtypes with subnanomolar EC<sub>50</sub> values. A rapid optimization effort centered around <b>23</b> ultimately yielded the bis-<span class="smallcaps smallerCapital">l</span>-valine derivative <b>6</b>, in which the stereoconfiguration of the caps is inverted compared with that of <b>20</b>.<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30-32)</a> This C-2 symmetric compound <b>6</b> exhibited antiviral, absorption, distribution, metabolism, and excretion (ADME) and in vitro and in vivo toxicological profiles that supported its selection for clinical evaluation. Compound <b>6</b>, one of 10 possible stereoisomers, derives its chirality from the two natural amino acids <span class="smallcaps smallerCapital">l</span>-proline and <span class="smallcaps smallerCapital">l</span>-valine, facilitating its preparation in an efficient and convergent manner by two routes, the more efficient of which is outlined in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31, 32)</a> Alkylation of the N-protected proline <b>25</b> with the 1,1′-([1,1′-biphenyl]-4,4′-diyl)bis(2-bromoethanone) <b>24</b> afforded the bis-ketoester <b>26</b> which was converted to the bis-imidazole <b>27</b> in a one pot, multistep transformation by exposing the compound to NH<sub>4</sub>OAc in hot toluene or xylenes.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31, 32)</a> Deprotection of <b>27</b> under acidic conditions gave the salt of amine <b>28</b> which was coupled with the <span class="smallcaps smallerCapital">l</span>-valine derivative <b>29</b> to afford <b>6</b>.</div><figure id="cht5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Chart 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0013.jpeg" id="GRAPHIC-d1913e821-autogenerated" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=cht5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0006.jpeg" id="GRAPHIC-d1913e830-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>6</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>6</b> exhibited potent inhibition in all of the wild-type replicons and hybrid replicons representing the range of genotypes and subtypes that were available at the time of its discovery. These data are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> where activity toward some of the resistant mutants is also included. Just prior to the compound entering clinical trials, we established a GT-2a JFH replicating virus assay where potent inhibition, EC<sub>50</sub> = 28 pM, was also observed.<a onclick="showRef(event, 'ref14 ref30 ref31 ref33'); return false;" href="javascript:void(0);" class="ref ref14 ref30 ref31 ref33">(14, 30, 31, 33)</a> This result correlated well with GT-2a JFH replicon inhibition and provided an additional level of confidence for an untested mechanism of HCV inhibition as the compound advanced into clinical evaluation.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Potency of <b>6</b> in Replicons and Hybrid Replicons<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">replicon genotype</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-1a H77</td><td class="colsep0 rowsep0" align="left">0.050</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-1b Con1</td><td class="colsep0 rowsep0" align="left">0.009</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-2a JFH-1</td><td class="colsep0 rowsep0" align="left">0.071</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-2a J6</td><td class="colsep0 rowsep0" align="left">7.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-3a</td><td class="colsep0 rowsep0" align="left">0.146</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-3a Y-H</td><td class="colsep0 rowsep0" align="left">364</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-3a Y-H*</td><td class="colsep0 rowsep0" align="left">1451</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-4a</td><td class="colsep0 rowsep0" align="left">0.012</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-5a</td><td class="colsep0 rowsep0" align="left">0.033</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-6</td><td class="colsep0 rowsep0" align="left">0.054</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Excluding the first three entries, the remaining data are for hybrid replicons in either GT-2a JFH-1 or GT-1b Con1 backbone: GT-2a J6 (JFH-1); GT-3a or GT-3a Y-H (Con1); GT-3a Y-H* (JFH-1); GT-4a (Con1); GT-5a (JFH-1); GT-6a (JFH-1).</p></div></div></div><div class="NLM_p">Liver exposure of HCV inhibiting drugs is considered to be an important factor in treating a disease that replicates primarily in hepatocytes and has been the subject of considerable study in an effort to understand the relationship between the PK and pharmacodynamic properties of direct-acting HCV inhibitors.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> In the preclinical setting, we routinely evaluated liver exposure as part of rat PK studies with HCV inhibitors as a means of demonstrating target organ exposure. The PK properties of <b>6</b> in preclinical species are compiled in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> and reveal good bioavailability in all three species. Liver levels in the rat measured at 24 h following a 5 mg/kg dose of <b>6</b> were 103 nM, 5-fold higher than the plasma concentration and substantially higher than the replicon EC<sub>50</sub> values for all genotypes tested at this time and which surpassed the protein binding-adjusted EC<sub>90</sub> of 383 pM determined for the less sensitive GT-1a replicon.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Pharmacokinetic Properties of <b>6</b> in the Rat, Dog, and Cynomolgus Monkey</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species (no. of animals)</th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">plasma AUC (μM·h)</th><th class="colsep0 rowsep0" align="center">plasma concn at 24 h (nM)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat (3)</td><td class="colsep0 rowsep0" align="left">5.0</td><td class="colsep0 rowsep0" align="left">4.8</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog (2)</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">108</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cynomolgus monkey (3)</td><td class="colsep0 rowsep0" align="left">2.8</td><td class="colsep0 rowsep0" align="left">1.93</td><td class="colsep0 rowsep0" align="left">6.5</td><td class="colsep0 rowsep0" align="left">38</td></tr></tbody></table></div></div><div class="NLM_p">The first publication of an X-ray crystal structure of a portion of domain I of the NS5A protein appeared in the May 19, 2005, edition of <i>Nature</i>, revealing a dimeric species for which protein association created a groove lined with basic amino acids postulated as binding site for RNA.<a onclick="showRef(event, 'cit22a'); return false;" href="javascript:void(0);" class="ref cit22a">(22a)</a> We viewed the structure with considerable interest and the C-2 symmetry of the complex corroborated the palindromic chemotype that we had discovered and allowed for the generation of drug–target interaction hypotheses. Subsequent studies have confirmed the suggestion that NS5A is an RNA binding protein, and virus replication has been shown to correlate with dimerization of the protein.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35, 36)</a> A second X-ray structure of a slightly different sequence of domain I revealed a similarly shaped protein but with a very different dimer interface that placed the putative RNA binding domain on the outwardly facing surface.<a onclick="showRef(event, 'cit22b'); return false;" href="javascript:void(0);" class="ref cit22b">(22b)</a> The two structures and the more-recently determined GT-1a NS5A domain I structure<a onclick="showRef(event, 'cit22c'); return false;" href="javascript:void(0);" class="ref cit22c">(22c)</a> are viewed as anticipating an oligomeric association of NS5A that may provide potential mechanistic insights into the high inhibitory potency observed with <b>6</b>, which is exceptional when compared, for example, to NS3 protease inhibitors that are assumed to depend on a stoichiometric association with the target.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> It has been estimated that the ratio of NS5A molecules to <b>6</b> at half maximal inhibitory concentrations in a replicon is in excess of 1000 and could be as high as 10 000.<a onclick="showRef(event, 'ref31 ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref31 ref37 ref38 ref39">(31, 37-39)</a> This has led to the suggestion that the association of <b>6</b> with an oligomeric form of NS5A effects a distortion that disrupts the function of the entire complex, by a local effect or one of an allosteric nature that is propagated through the entire complex.</div><div class="NLM_p">While resistance mapping implicated the NS5A protein as the target for the evolved chemotype classes leading to <b>6</b>, evidence of target engagement was sought using the biotinylated probe <b>29</b> that incorporates the natural (<i>S</i>,<i>S</i>)-configuration at both proline stereocenters, with the unnatural (<i>R</i>,<i>R</i>) isomer <b>30</b> used as a control (Chart <a class="ref internalNav" href="#cht6" aria-label="6">6</a>).<a onclick="showRef(event, 'ref31 ref40'); return false;" href="javascript:void(0);" class="ref ref31 ref40">(31, 40)</a> The (<i>S</i>,<i>S</i>) isomer <b>29</b> exhibited antiviral activity in a GT-1b replicon, EC<sub>50</sub> = 33 nM, with sensitivity to the NS5A Y93H mutant, EC<sub>50</sub> >10 μM, while the (<i>R</i>,<i>R</i>) isomer <b>30</b> was inactive, EC<sub>50</sub> >10 μM, data that established a profile analogous to <b>6</b> and related compounds in the series. In the initial experiment, cells harboring GT-1b replicons were lysed and exposed to <b>29</b> and the mixture passed over streptavidin agarose beads, but this experimental design failed to pull down any viral proteins. However, by incubating  GT-1b replicons with <b>29</b> for 18 h before cell lysis and then passing  the lysate over streptavidin agarose beads, the HCV NS5A protein was selectively pulled down. This result indicated that in order for the probe to bind to the viral protein, it needed to be present at the time of replicon complex formation. Notably, the inactive (<i>R</i>,<i>R</i>) isomer <b>30</b> failed to pull down the HCV NS5A protein under the same experimental conditions, thus establishing a direct correlation between antiviral activity and target engagement, recently described as one of the four pillars of in vitro profiling underlying successful drug candidates.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The biotin probe <b>29</b> has proven to be a particularly useful tool to further illuminate aspects of NS5A inhibitor–protein interaction. Most interestingly, when a similar experiment was conducted with replicons that are insensitive to the inhibitory activity of <b>29</b>, including a GT-1b replicon harboring a Y93H resistant mutation or a GT-1a replicon, the HCV NS5A protein was pulled down in each case. This unanticipated finding suggests that the lack of sensitivity to HCV NS5A inhibitors may not rely upon exclusion of the inhibitor from binding but rather that the viral protein accommodates the inhibitor in a fashion that restores the function of the viral protein.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Consistent with this notion, many of the resistance mutations involve substitutions with amino acids that have smaller or more flexible side chain moieties that may allow the NS5A protein to articulate its function in the presence of the inhibitor. These observations indicate that binding of a molecule to the NS5A protein is a necessary but not sufficient condition for the expression of an antiviral effect. This hypothesis anticipates that the poor activity toward HCV GT-1a replicons associated with prototypical GT-1b inhibitors maybe a reflection of subtle differences in the function of the NS5A proteins that allow GT-1b to be more susceptible to inhibition by structurally diverse molecules while GT-1a NS5A has a more stringent demand for dimeric species that display specific pharmacophoric features.</div><figure id="cht6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Chart 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0007.jpeg" id="GRAPHIC-d1913e1199-autogenerated" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=cht6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Clinical Trials with Daclatasvir</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11777" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11777" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">HCV replicates via only RNA-based intermediates with no incorporation of the viral genome into the host cell chromosome, as occurs with HIV-1. As a consequence, HCV is a curable infection with cure defined as being free of detectable virus in plasma 24 weeks after completion of therapy, referred to as a sustained virological response-24 (SVR<sub>24</sub>), although more recent studies suggest that SVR<sub>12</sub> has predictive value. In the decade following the discovery and characterization of HCV, therapeutic treatment evolved to the use of a combination of pegylated interferon-α (PEG-IFN-α) administered as weekly subcutaneous injections in conjunction with twice-daily oral doses of the nucleoside analogue ribavirin (RBV) which was approved in 2001.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42, 43)</a> However, this therapy has significant shortcomings with the most prominent being the poor SVR observed in GT-1-infected subjects, which is typically only 40–50% following 48 weeks of therapy. In addition, neither of these agents exhibit specific antiviral activity toward HCV and both are associated with a significant incidence of side effects that, in the case of PEG-IFN-α, can be of sufficient severity to result in discontinuation of therapy.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> The molecular characterization of HCV provided a biochemical basis for the identification of direct-acting antiviral agents (DAAs) that has allowed the development of specifically targeted compounds with improved efficacy and tolerability profiles.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The approval of the HCV NS3/4A protease inhibitors telaprevir (<b>31</b>) and boceprevir (<b>32</b>) in 2011, the NS3/4A protease inhibitor simeprevir (<b>33</b>), and the nucleoside analogue sofosbuvir (<b>34</b>) (Chart <a class="ref internalNav" href="#cht7" aria-label="7">7</a>) in 2013 as add-on therapy to PEG-IFN-α/RBV or RBV represents important progress in that direction. However, there are many more DAAs in development with attractive profiles that act by a range of mechanisms and that, when used in combination, offer the potential to cure even the most difficult GT-1 HCV infections after just 12 weeks of therapy in the absence of the immune stimulation provided by PEG-IFN-α. Recent clinical studies with DAA combinations have assessed the effects of viral strain, baseline viral load, prior treatment experience with PEG-IFN-α/RBV, host polymorphisms in key immune response genes, liver histological status, and HIV-1 co-infection, with the results establishing efficacy regardless of the background circumstances. Since entering clinical trials in 2007, <b>6</b> has played a critical role in several of these developments, validating NS5A as an attractive and important clinically relevant target while contributing to the shaping of the clinical landscape, which has evolved rapidly toward all DAA therapeutic regimens with pan-genotype inhibition.</div><figure id="cht7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Chart 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0008.jpeg" id="GRAPHIC-d1913e1244-autogenerated" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=cht7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The clinical program with <b>6</b> was initiated with a single ascending dose (SAD) study conducted in normal healthy volunteers under a double-blind, placebo-controlled protocol that assessed the plasma exposure and tolerability of the compound after escalating doses of 1–200 mg administered as an oral solution.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Compound <b>6</b> was safe and well-tolerated at all doses with plasma exposure increasing proportionally with dose and drug levels at 24 h exceeding the protein binding-adjusted EC<sub>90</sub> value measured in the least sensitive GT-1a replicon by over 10-fold at doses of 10 mg and above. The second phase of the study recruited subjects chronically infected with HCV GT-1 who were naive to therapy or who had not responded to PEG-IFN-α/RBV treatment or who were intolerant of this therapy. In this proof-of-concept trial, doses of 1, 10, and 100 mg of <b>6</b> were administered to subjects infected with GT-1a HCV with the exception of two subjects in the 10 mg dose cohort and three in the 100 mg group who were infected with GT-1b virus. Mean plasma viral load declined rapidly by 1.8 log<sub>10</sub> IU/mL measured at 24 h following the single milligram dose of <b>6</b>, while the higher doses produced a greater effect on viral RNA reduction, with a mean decline of 3.2 log<sub>10</sub> at 24 h after the 10 mg dose while the 100 mg dose produced a maximal decline of 3.6 log<sub>10</sub>.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The 100 mg dose cohort was composed of GT-1b-infected patients, where the antiviral effect was prolonged throughout the postdosing monitoring period of 144 h, with HCV RNA below the limit of quantification (25 IU/mL) in one subject. Collectively, these data confirmed that the high in vitro potency of <b>6</b> translated into a potent clinical effect while the duration of the suppression of viremia was related to the prolonged PK profile of the compound. However, most remarkably, the reduction in viral load that was observed following oral dosing of <b>6</b> was considerably faster than that associated with HCV inhibitors acting by other mechanisms. This profile has since been attributed to an initial and immediate effect of <b>6</b> on virion production that is followed by inhibition of viral replication, observations that have led to a recalibration of the half-life of HCV in vivo from 2.7 h that was based on the viral kinetics in response to PEG-IFN-α therapy to ∼45 min.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><div class="NLM_p">A multiple ascending dose (MAD) study in which <b>6</b> was administered for 14 days to GT-1-infected subjects resulted in viral rebound due to the emergence of resistant virus that was faster in  GT-1a-infected subjects than those infected with GT-1b virus.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Sequencing of the virus in those experiencing breakthrough revealed mutations that correlated well with those observed in vitro using the replicon system. The observed pattern of viral breakthrough can be explained by GT-1a HCV typically requiring only a single base pair change in order to code for an amino acid, while GT-1b requires two base pair changes.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> These results indicate that although <b>6</b> is highly potent, it has a low genetic barrier to resistance, a profile that is somewhat analogous to that of the HIV-1 non-nucleoside reverse transcriptase inhibitors which are successful drugs when used as part of combination therapy.</div><div class="NLM_p">The clinical profile that emerged for <b>6</b> from these studies anticipated it being used in combination with PEG-IFN-α/RBV or mechanistically orthogonal HCV inhibitors.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The first of those options was explored in a small phase IIa clinical trial conducted in treatment-naive GT-1 patients in which once-daily doses of 3, 10, or 60 mg of <b>6</b> were added to a 48-week regimen of PEG-IFN-α/RBV.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The results of this study, which established the long-term safety profile of <b>6</b>, afforded an SVR<sub>24</sub> rate of 83% for those administered the two higher doses of drug compared with 25% for the PEG-IFN-α/RBV control arm.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> A more impactful study was the first clinical trial to explore long-term administration of a DAA-only combination which was an open label study in which <b>6</b> was administered in conjunction with the NS3 protease inhibitor asunaprevir (<b>35</b>) (Chart <a class="ref internalNav" href="#cht8" aria-label="8">8</a>).<a onclick="showRef(event, 'cit50a ref51 ref52'); return false;" href="javascript:void(0);" class="ref cit50a ref51 ref52">(50a, 51, 52)</a> This study selected what is considered to be one of the more difficult to treat patient populations: those who had been treated with PEG-IFN-α/RBV for at least 12 weeks but failed to experience a decline in viral load of ≥2 log<sub>10</sub> IU/mL. In this phase IIa trial, <b>6</b> (60 mg q.d.) and <b>35</b> (600 mg b.i.d.) were administered to 11 GT-1-infected subjects for 24 weeks with the comparator arm comprising 10 subjects who received the same dosing regimen of <b>6</b> and <b>35</b> in conjunction with PEG-IFN-α/RBV therapy.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> In the dual drug combination arm, nine of the subjects were infected with GT-1a virus with the remaining two infected with GT-1b virus and both GT-1b-infected subjects and two of the GT-1a-infected individuals achieved both SVR<sub>12</sub> and SVR<sub>24</sub>. One GT-1a-infected patient was undetectable at the end of therapy but subsequently relapsed. All of the patients receiving quadruple therapy achieved SVR<sub>12</sub>, and 90% of this cohort had undetectable levels of virus 48 weeks after the cessation of therapy with the one remaining subject having detectable viral RNA in plasma at this point but who was determined to be undetectable 13 days later. All of the patients in the dual combination arm that experienced virological breakthrough had PEG-IFN-α/RBV added to their therapy, and although all responded initially with a reduction in viral load, this was not durable. Failure due to viral breakthrough was associated with resistance mutations that emerged in both the NS3 and NS5A proteins. This trial established for the first time that a combination of small molecule HCV inhibitors could cure viral infection in the absence of PEG-IFN-α/RBV therapy and established the potential of this drug combination for the treatment of GT-1b-infected subjects. This population is prevalent in Japan to the extent of ∼75% of infections, and phase II clinical studies with the two drugs provided results that were supportive of expansion into a phase III registrational trial.<a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53, 54)</a> These studies, which evaluated the combination of <b>6</b> (60 mg q.d.) and <b>35</b> (200 mg b.i.d.) administered to Japanese patients infected with GT-1b HCV for 24 weeks, have been completed.<a onclick="showRef(event, 'cit53c ref54'); return false;" href="javascript:void(0);" class="ref cit53c ref54">(53c, 54)</a> SVR<sub>24</sub> rates ranged from 87.4% for PEG-IFN-α-intolerant or ineligible subjects to 80.5% for nonresponders to PEG-IFN-α/RBV, data that formed the basis of a filing in October, 2013 seeking marketing approval in Japan. On February 24, 2014, Bristol-Myers Squibb announced that the combination of <b>6</b> and <b>35</b> had been accorded Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of GT-1b HCV infection. On April 8th, 2014, Bristol-Myers Squibb announced the filing of NDAs with the US FDA seeking approval to market daclatasvir and asunaprevir for use in combination for the treatment of HCV GT-1b infection with the daclatasvir NDA also requesting approval for its use of in combination with other agents for the treatment of multiple HCV genotypes.</div><div class="NLM_p">In order to address the emergence of resistance in GT-1-infected subjects when treated with <b>6</b> and <b>35</b>, clinical trials evaluating a triple combination that supplements therapy with the non-nucleoside NS5B polymerase inhibitor BMS-791325 (<b>36</b>, Chart <a class="ref internalNav" href="#cht8" aria-label="8">8</a>) (75 or 150 mg b.i.d.) have begun to be explored.<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55, 56)</a> The phase IIa study examined this triple combination at doses of 60 mg q.d. of <b>6</b> and 200 mg b.i.d. of <b>35</b> with 75 or 150 mg b.i.d. of <b>36</b> in a treatment-naive patient population composed of GT-1a and GT-1b infections in a ∼3:1 ratio. The drugs were administered for 12 or 24 weeks to 66 subjects with 92% achieving SVR<sub>12</sub> based on a modified intention to treat analysis, with similar virologic response rates observed between the 12 and 24 weeks dosing arms. These results supported expansion of this study to include additional GT-1-infected subjects, including those naive to therapy, null responders to PEG-IFN-α/RBV and those with liver cirrhosis, and GT-4 infected patients. This combination is currently being evaluated in phase III clinical trials and was granted Breakthrough Therapy Designation by the FDA in March 2013.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div><figure id="cht8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Chart 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0009.jpeg" id="GRAPHIC-d1913e1426-autogenerated" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=cht8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A combination of <b>6</b> and the nucleoside phosphoramidate polymerase inhibitor sofosbuvir <b>34</b>, with and without RBV, has been examined in treatment-naive GT-1-, GT-2-, and GT-3-infected patients and in treatment-experienced GT-1-infected subjects who failed a triple therapy regimen combining either of the protease inhibitors telaprevir or boceprevir with PEG-IFN-α/RBV.<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57, 58)</a> Treatment durations of either 12 weeks (GT-1) or 24 weeks (GT-1, GT-2, and GT-3) were explored, and >90% of patients achieved an SVR<sub>12</sub>. Interestingly, the absence or inclusion of RBV in the therapeutic regimen had no significant impact on the cure rate, although including this drug did increase the incidence of adverse events.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><div class="NLM_p last">Market authorization for <b>6</b> in the European Union (EU) for the treatment of chronic genotypes 1, 2, 3, and 4 HCV infections in subjects with compensated liver disease in combination with other agents was sought in late 2013 with the compound granted accelerated regulatory review by the European Medicines Agency on January 8, 2014. This follows an EU recommendation on November 12, 2013, for the compassionate use of <b>6</b> in combination with <b>34</b> to treat chronic HCV infection in adults at a high risk of liver decompensation or death within 1 year if left untreated.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63336" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63336" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The discovery of <b>6</b> was the result of an extensive medicinal chemistry optimization campaign by a highly collaborative team that had to navigate through several significant challenges ranging from understanding the chemical instability associated with the lead to introducing potent GT-1a activity and optimizing for oral bioavailability. Although the high throughput screening lead <b>7</b> exhibited reasonable antiviral potency in a cell-based assay and excellent selectivity for HCV, the molecular properties of this lead molecule may be viewed as less than attractive as a starting point for a program. The high cLogP of >5 and a molecular weight of 586 represent less than optimal starting points for medicinal chemists who have typically increased both cLogP and molecular weight when optimizing leads.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> The characterization of a dimeric species with a molecular weight of 1139 as a contributor to the observed antiviral activity, although intriguing, heightened concerns, but the redefinition of the pharmacophore to that of stilbene <b>10</b> markedly simplified <b>9</b>. At this point in the program, elucidating the structural elements that conferred GT-1a inhibition and addressing concerns about the olefin and embedded aniline were the key problems to be solved. The ultimate solution embodied by <b>6</b> required extensive structural manipulation and refinement, along with an appreciation of SAR differences associated with the cap stereochemistry, to redefine and optimize molecular topology as structural changes were introduced that were designed to address targeted parameters. Resolving these problems required considerable effort and persistence, rewarded by the initial clinical results in which a profound and rapid effect on viral load was observed following dosing of a single milligram of <b>6</b> to HCV-infected patients. The discovery of <b>6</b> is a testament to the power of phenotypic screening to uncover unanticipated mechanisms and is particularly effective for those that cannot be readily assessed using biochemical assays as is the case for HCV NS5A.</div><div class="NLM_p last">HCV is the leading cause of liver transplant in the United States, and in 2008 it surpassed HIV-1 infection as the leading viral cause of death.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Unlike HIV-1 infection, HCV replication occurs without a DNA intermediate and is curable with small molecule DAAs. At the time of writing, we stand on the threshold of being able to eradicate a disease that in the absence of therapeutic intervention was predicted to be the underlying cause of deaths well in excess of 20 000 per year between 2022 and 2048 in the United States, a statistic projected to amount to over 1 million total deaths by 2060.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Daclatasvir has been evaluated in more than 5500 patients and has had a meaningful and lasting impact on HCV therapy, and it is anticipated that NS5A inhibitors will play a key role in the eradication of HCV, a virus that is responsible for a significant amount of human suffering.<a onclick="showRef(event, 'cit20g'); return false;" href="javascript:void(0);" class="ref cit20g">(20g)</a></div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm500335h" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12281" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12281" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Makonen Belema</span> - <span class="hlFld-Affiliation affiliation">Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#771a161c181912195915121b121a1637151a045914181a"><span class="__cf_email__" data-cfemail="2b464a4044454e4505494e474e464a6b49465805484446">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicholas A. Meanwell</span> - <span class="hlFld-Affiliation affiliation">Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#452b2c262d2a2924366b2820242b32202929052728366b262a28"><span class="__cf_email__" data-cfemail="d3bdbab0bbbcbfb2a0fdbeb6b2bda4b6bfbf93b1bea0fdb0bcbe">[email protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d1913e1492-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62420" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62420" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The discovery and development of daclatasvir represents the collective effort of a large number of individuals, the majority of whom are represented as authors of the articles cited in the reference section. From the discovery perspective, we acknowledge Min Gao for his leadership of the virology team, Lawrence B. Snyder and Lawrence G. Hamann for their chemistry leadership roles, and Carl P. Decicco for his consistent support of the program.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i10" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i10"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i11" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i11"> Abbreviations Used</h2><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">b.i.d.</td><td class="NLM_def"><p class="first last">bis in die (twice a day)</p></td></tr><tr><td class="NLM_term">BVDV</td><td class="NLM_def"><p class="first last">bovine viral diarrhea virus</p></td></tr><tr><td class="NLM_term">CC<sub>50</sub></td><td class="NLM_def"><p class="first last">concentration at which cytotoxicity is half-maximal</p></td></tr><tr><td class="NLM_term">cDNA</td><td class="NLM_def"><p class="first last">complementary deoxyribonucleic acid</p></td></tr><tr><td class="NLM_term">DAA</td><td class="NLM_def"><p class="first last">direct-acting antiviral agent</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">EC<sub>50</sub></td><td class="NLM_def"><p class="first last">concentration at which inhibition is half-maximal</p></td></tr><tr><td class="NLM_term">EU</td><td class="NLM_def"><p class="first last">European Union</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">HCV</td><td class="NLM_def"><p class="first last">hepatitis C virus</p></td></tr><tr><td class="NLM_term">HIV-1</td><td class="NLM_def"><p class="first last">human immunodeficiency virus 1</p></td></tr><tr><td class="NLM_term">GT</td><td class="NLM_def"><p class="first last">genotype 1b</p></td></tr><tr><td class="NLM_term">LEDG-F</td><td class="NLM_def"><p class="first last">lens epithelium-derived growth factor</p></td></tr><tr><td class="NLM_term">MAD</td><td class="NLM_def"><p class="first last">multiple ascending dose</p></td></tr><tr><td class="NLM_term">NS</td><td class="NLM_def"><p class="first last">nonstructural</p></td></tr><tr><td class="NLM_term">PEG-IFN-α</td><td class="NLM_def"><p class="first last">pegylated interferon α</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">q.d.</td><td class="NLM_def"><p class="first last">quaque die (once per day)</p></td></tr><tr><td class="NLM_term">RBV</td><td class="NLM_def"><p class="first last">ribavirin</p></td></tr><tr><td class="NLM_term">RNA</td><td class="NLM_def"><p class="first last">ribonucleic acid</p></td></tr><tr><td class="NLM_term">SAD</td><td class="NLM_def"><p class="first last">single ascending dose</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SVR</td><td class="NLM_def"><p class="first last">sustained virological response.</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07062" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07062" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 61 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Swinney, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anthony, J.</span><span> </span><span class="NLM_article-title">How were new medicines discovered?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">507</span><span class="NLM_x">–</span> <span class="NLM_lpage">519</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=507-519&author=D.+C.+Swinneyauthor=J.+Anthony&title=How+were+new+medicines+discovered%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26aulast%3DAnthony%26aufirst%3DJ.%26atitle%3DHow%2520were%2520new%2520medicines%2520discovered%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D507%26epage%3D519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Macarron, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banks, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bojanic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirovic, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garyantes, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, D. V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hertzberg, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janzen, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paslay, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schopfer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sittampalam, G. S.</span><span> </span><span class="NLM_article-title">Impact of high-throughput screening on biomedical research</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">189</span><span class="NLM_x">–</span> <span class="NLM_lpage">195</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=189-195&author=R.+Macarronauthor=M.+N.+Banksauthor=D.+Bojanicauthor=D.+J.+Burnsauthor=D.+A.+Cirovicauthor=T.+Garyantesauthor=D.+V.+S.+Greenauthor=R.+P.+Hertzbergauthor=W.+P.+Janzenauthor=J.+W.+Paslayauthor=U.+Schopferauthor=G.+S.+Sittampalam&title=Impact+of+high-throughput+screening+on+biomedical+research"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMacarron%26aufirst%3DR.%26aulast%3DBanks%26aufirst%3DM.%2BN.%26aulast%3DBojanic%26aufirst%3DD.%26aulast%3DBurns%26aufirst%3DD.%2BJ.%26aulast%3DCirovic%26aufirst%3DD.%2BA.%26aulast%3DGaryantes%26aufirst%3DT.%26aulast%3DGreen%26aufirst%3DD.%2BV.%2BS.%26aulast%3DHertzberg%26aufirst%3DR.%2BP.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DPaslay%26aufirst%3DJ.%2BW.%26aulast%3DSchopfer%26aufirst%3DU.%26aulast%3DSittampalam%26aufirst%3DG.%2BS.%26atitle%3DImpact%2520of%2520high-throughput%2520screening%2520on%2520biomedical%2520research%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D189%26epage%3D195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Green, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacs, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, H.</span><span> </span><span class="NLM_article-title">Cell-based assays to identify inhibitors of viral disease</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">676</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=671-676&author=N.+Greenauthor=R.+D.+Ottauthor=R.+J.+Isaacsauthor=H.+Fang&title=Cell-based+assays+to+identify+inhibitors+of+viral+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGreen%26aufirst%3DN.%26aulast%3DOtt%26aufirst%3DR.%2BD.%26aulast%3DIsaacs%26aufirst%3DR.%2BJ.%26aulast%3DFang%26aufirst%3DH.%26atitle%3DCell-based%2520assays%2520to%2520identify%2520inhibitors%2520of%2520viral%2520disease%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D671%26epage%3D676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Keller, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.-Y.</span><span> </span><span class="NLM_article-title">Anti-infectives: Can cellular screening deliver<i>?</i></span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2Fj.cbpa.2011.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=21723774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFClt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=529-533&author=T.+H.+Kellerauthor=P.-Y.+Shiauthor=Q.-Y.+Wang&title=Anti-infectives%3A+Can+cellular+screening+deliver%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-infectives: Can cellular screening deliver?</span></div><div class="casAuthors">Keller, Thomas H.; Shi, Pei-Yong; Wang, Qing-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">529-533</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In an era of emerging and reemerging infectious diseases, and increasing multidrug resistance, the need to identify novel therapy is imperative.  Unfortunately, the recent shift of the drug discovery paradigm from cellular screening to target-based approaches has not delivered the anticipated benefits.  A recent renaissance of the traditional cell-based approach, on the other hand, has yielded several clin. candidates.  Three successful examples are illustrated in this review, namely spiroindolone, thiazolidinone, and diarylquinoline for the treatment of malaria, hepatitis C virus, and tuberculosis, resp.  We describe in detail their identification, mechanism of action (MoA), and common features in the chem. structures.  The challenges of the cell-based approach for anti-infective drug discovery are also discussed.  We propose a shift from std. libraries to synthetic natural-product-like compd. collections to improve the success of phenotypic lead finding and to facilitate the validation of hits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovjXnq-69ZQLVg90H21EOLACvtfcHk0ljDyv36sk-NSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFClt78%253D&md5=0313e255dec7bf47b39b23f6d354987f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2011.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2011.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DShi%26aufirst%3DP.-Y.%26aulast%3DWang%26aufirst%3DQ.-Y.%26atitle%3DAnti-infectives%253A%2520Can%2520cellular%2520screening%2520deliver%253F%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D15%26spage%3D529%26epage%3D533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Di Santo, R.</span><span> </span><span class="NLM_article-title">Inhibiting the HIV integration process: past, present, and the future</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400674a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=539-566&author=R.+Di+Santo&title=Inhibiting+the+HIV+integration+process%3A+past%2C+present%2C+and+the+future"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm400674a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400674a%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BSanto%26aufirst%3DR.%26atitle%3DInhibiting%2520the%2520HIV%2520integration%2520process%253A%2520past%252C%2520present%252C%2520and%2520the%2520future%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D539%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jurado, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slaughter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessl, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballandras-Colas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchs, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kvaratskhelia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, A.</span><span> </span><span class="NLM_article-title">Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">8690</span><span class="NLM_x">–</span> <span class="NLM_lpage">8695</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1073%2Fpnas.1300703110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=23610442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSjt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=8690-8695&author=K.+A.+Juradoauthor=H.+Wangauthor=A.+Slaughterauthor=L.+Fengauthor=J.+J.+Kesslauthor=Y.+Kohauthor=W.+Wangauthor=A.+Ballandras-Colasauthor=P.+P.+Patelauthor=J.+R.+Fuchsauthor=M.+Kvaratskheliaauthor=A.+Engelman&title=Allosteric+integrase+inhibitor+potency+is+determined+through+the+inhibition+of+HIV-1+particle+maturation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation</span></div><div class="casAuthors">Jurado, Kellie A.; Wang, Hao; Slaughter, Alison; Feng, Lei; Kessl, Jacques J.; Koh, Yasuhiro; Wang, Weifeng; Ballandras-Colas, Allison; Patel, Pratiq A.; Fuchs, James R.; Kvaratskhelia, Mamuka; Engelman, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8690-8695, S8690/1-S8690/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Integration is essential for HIV-1 replication, and the viral integrase (IN) protein is an important therapeutic target.  Allosteric IN inhibitors (ALUNIs) that engage the IN dimer interface at the binding site for the host protein lens epithelium-derived growth factor (LEDGF)/ transcriptional coactivator p75 are an emerging class of small mol. antagonists.  Consistent with the inhibition of a multivalent drug target, ALLINIs display steep antiviral dose-response curves ex vivo.  ALUNIs multimerize IN protein and concordantly block its assembly with viral DNA in vitro, indicating that the disruption of two integration-assocd. functions, IN catalysis and the IN-LEDGF/p75 interaction, dets. the multimode mechanism of ALUNI action.  We now demonstrate that ALLINI potency is unexpectedly accounted for during the late phase of HIV-1 replication.  The compds. promote virion IN multimerization and, reminiscent of class II IN mutations, block the formation of the electron-dense viral core and inhibit reverse transcription and integration in subsequently infected target cells.  Mature virions are recalcitrant to ALLINI treatment and compd. potency during virus prodn. is independent of the level of LEDGF/p75 expression.  We conclude that cooperative multimerization of IN by ALLINIs together with the inability for LEDGF/p75 to effectively engage the virus during its egress from cells underscores the multimodal mechanism of ALLINI action.  Our results highlight the versatile nature of allosteric inhibitors to primarily inhibit viral replication at a step that is distinct from the catalytic requirement for the target enzyme.  The vulnerability of IN to small mols. during the late phase of HIV-1 replication unveils a pharmacol. Achilles' heel for exploitation in clin. ALLINI development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiAzDFbZo0ALVg90H21EOLACvtfcHk0lh8mZZFIevk8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSjt7nO&md5=ec563f39468aabeae04685971722b070</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1300703110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1300703110%26sid%3Dliteratum%253Aachs%26aulast%3DJurado%26aufirst%3DK.%2BA.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSlaughter%26aufirst%3DA.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DKessl%26aufirst%3DJ.%2BJ.%26aulast%3DKoh%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DBallandras-Colas%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DP.%2BP.%26aulast%3DFuchs%26aufirst%3DJ.%2BR.%26aulast%3DKvaratskhelia%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DA.%26atitle%3DAllosteric%2520integrase%2520inhibitor%2520potency%2520is%2520determined%2520through%2520the%2520inhibition%2520of%2520HIV-1%2520particle%2520maturation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2013%26volume%3D110%26spage%3D8690%26epage%3D8695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Le Rouzic, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chasset, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruneau, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevreuil, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Strat, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauvoir, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amadori, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brias, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vomscheid, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lévy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delelis, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deprez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saïb, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamborlini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emiliani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ledoussal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benarous, R.</span><span> </span><span class="NLM_article-title">Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage</span> <span class="citation_source-journal">Retrovirology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">144</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1186%2F1742-4690-10-144" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=24261564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvFagtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=144&author=E.+Le+Rouzicauthor=D.+Bonnardauthor=S.+Chassetauthor=J.-M.+Bruneauauthor=F.+Chevreuilauthor=F.+Le+Stratauthor=J.+Nguyenauthor=R.+Beauvoirauthor=C.+Amadoriauthor=J.+Briasauthor=S.+Vomscheidauthor=S.+Eilerauthor=N.+L%C3%A9vyauthor=O.+Delelisauthor=E.+Deprezauthor=A.+Sa%C3%AFbauthor=A.+Zamborliniauthor=S.+Emilianiauthor=M.+Ruffauthor=B.+Ledoussalauthor=F.+Moreauauthor=R.+Benarous&title=Dual+inhibition+of+HIV-1+replication+by+integrase-LEDGF+allosteric+inhibitors+is+predominant+at+the+post-integration+stage"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage</span></div><div class="casAuthors">Le Rouzic, Erwann; Bonnard, Damien; Chasset, Sophie; Bruneau, Jean-Michel; Chevreuil, Francis; Le Strat, Frederic; Nguyen, Juliette; Beauvoir, Roxane; Amadori, Celine; Brias, Julie; Vomscheid, Sophie; Eiler, Sylvia; Levy, Nicolas; Delelis, Olivier; Deprez, Eric; Saib, Ali; Zamborlini, Alessia; Emiliani, Stephane; Ruff, Marc; Ledoussal, Benoit; Moreau, Francois; Benarous, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Retrovirology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">144/1-144/21, 21 pp.</span>CODEN:
                <span class="NLM_cas:coden">RETRBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-4690</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: LEDGF/p75 (LEDGF) is the main cellular cofactor of HIV-1 integrase (IN).  It acts as a tethering factor for IN, and targets the integration of HIV in actively transcribed gene regions of chromatin.  A recently developed class of IN allosteric inhibitors can inhibit the LEDGF-IN interaction.  Results: We describe a new series of IN-LEDGF allosteric inhibitors, the most active of which is Mut101.  We detd. the crystal structure of Mut101 in complex with IN and showed that the compd. binds to the LEDGF-binding pocket, promoting conformational changes of IN which explain at the at. level the allosteric effect of the IN/LEDGF interaction inhibitor on IN functions.  In vitro, Mut101 inhibited both IN-LEDGF interaction and IN strand transfer activity while enhancing IN-IN interaction.  Time of addn. expts. indicated that Mut101 behaved as an integration inhibitor.  Mut101 was fully active on HIV-1 mutants resistant to INSTIs and other classes of anti-HIV drugs, indicative that this compd. has a new mode of action.  However, we found that Mut101 also displayed a more potent antiretroviral activity at a post-integration step.  Infectivity of viral particles produced in presence of Mut101 was severely decreased.  This latter effect also required the binding of the compd. to the LEDGF-binding pocket.  Conclusion: Mut101 has dual anti-HIV-1 activity, at integration and post-integration steps of the viral replication cycle, by binding to a unique target on IN (the LEDGF-binding pocket).  The post-integration block of HIV-1 replication in virus-producer cells is the mechanism by which Mut101 is most active as an antiretroviral.  To explain this difference between Mut101 antiretroviral activity at integration and post-integration stages, we propose the following model: LEDGF is a nuclear, chromatin-bound protein that is absent in the cytoplasm.  Therefore, LEDGF can outcompete compd. binding to IN in the nucleus of target cells lowering its antiretroviral activity at integration, but not in the cytoplasm where post-integration prodn. of infectious viral particles takes place.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryOJ47iOvkx7Vg90H21EOLACvtfcHk0ljpq1Eq285FDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvFagtLg%253D&md5=44448a2b2a9af9c65759a02295137303</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1186%2F1742-4690-10-144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-4690-10-144%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BRouzic%26aufirst%3DE.%26aulast%3DBonnard%26aufirst%3DD.%26aulast%3DChasset%26aufirst%3DS.%26aulast%3DBruneau%26aufirst%3DJ.-M.%26aulast%3DChevreuil%26aufirst%3DF.%26aulast%3DLe%2BStrat%26aufirst%3DF.%26aulast%3DNguyen%26aufirst%3DJ.%26aulast%3DBeauvoir%26aufirst%3DR.%26aulast%3DAmadori%26aufirst%3DC.%26aulast%3DBrias%26aufirst%3DJ.%26aulast%3DVomscheid%26aufirst%3DS.%26aulast%3DEiler%26aufirst%3DS.%26aulast%3DL%25C3%25A9vy%26aufirst%3DN.%26aulast%3DDelelis%26aufirst%3DO.%26aulast%3DDeprez%26aufirst%3DE.%26aulast%3DSa%25C3%25AFb%26aufirst%3DA.%26aulast%3DZamborlini%26aufirst%3DA.%26aulast%3DEmiliani%26aufirst%3DS.%26aulast%3DRuff%26aufirst%3DM.%26aulast%3DLedoussal%26aufirst%3DB.%26aulast%3DMoreau%26aufirst%3DF.%26aulast%3DBenarous%26aufirst%3DR.%26atitle%3DDual%2520inhibition%2520of%2520HIV-1%2520replication%2520by%2520integrase-LEDGF%2520allosteric%2520inhibitors%2520is%2520predominant%2520at%2520the%2520post-integration%2520stage%26jtitle%3DRetrovirology%26date%3D2013%26volume%3D10%26spage%3D144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Balakrishnan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yant, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Sullivan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bam, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niedziela-Majka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stray, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakowicz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cihlar, T.</span><span> </span><span class="NLM_article-title">Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">e74163</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e74163&issue=9&author=M.+Balakrishnanauthor=S.+R.+Yantauthor=L.+Tsaiauthor=C.+O%E2%80%99Sullivanauthor=R.+A.+Bamauthor=A.+Tsaiauthor=A.+Niedziela-Majkaauthor=K.+M.+Strayauthor=R.+Sakowiczauthor=T.+Cihlar&title=Non-catalytic+site+HIV-1+integrase+inhibitors+disrupt+core+maturation+and+induce+a+reverse+transcription+block+in+target+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBalakrishnan%26aufirst%3DM.%26aulast%3DYant%26aufirst%3DS.%2BR.%26aulast%3DTsai%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DC.%26aulast%3DBam%26aufirst%3DR.%2BA.%26aulast%3DTsai%26aufirst%3DA.%26aulast%3DNiedziela-Majka%26aufirst%3DA.%26aulast%3DStray%26aufirst%3DK.%2BM.%26aulast%3DSakowicz%26aufirst%3DR.%26aulast%3DCihlar%26aufirst%3DT.%26atitle%3DNon-catalytic%2520site%2520HIV-1%2520integrase%2520inhibitors%2520disrupt%2520core%2520maturation%2520and%2520induce%2520a%2520reverse%2520transcription%2520block%2520in%2520target%2520cells%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D9%26spage%3De74163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Luo, G.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span> </span><span class="NLM_article-title">Characterization of a hemagglutinin-specific inhibitor of influenza A virus</span> <span class="citation_source-journal">Virology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">226</span><span class="NLM_x">, </span> <span class="NLM_fpage">66</span><span class="NLM_x">–</span> <span class="NLM_lpage">76</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=1996&pages=66-76&author=G.-X.+Luoauthor=R.+Colonnoauthor=M.+Krystal&title=Characterization+of+a+hemagglutinin-specific+inhibitor+of+influenza+A+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DG.-X.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DCharacterization%2520of%2520a%2520hemagglutinin-specific%2520inhibitor%2520of%2520influenza%2520A%2520virus%26jtitle%3DVirology%26date%3D1996%26volume%3D226%26spage%3D66%26epage%3D76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Luo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harte, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danetz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianci, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dextraze, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span> </span><span class="NLM_article-title">Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">4062</span><span class="NLM_x">–</span> <span class="NLM_lpage">4070</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1128%2FJVI.71.5.4062-4070.1997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=9094684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADyaK2sXisFWgt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1997&pages=4062-4070&author=G.+Luoauthor=A.+Torriauthor=W.+E.+Harteauthor=S.+Danetzauthor=C.+Cianciauthor=L.+Tileyauthor=S.+Dayauthor=K.-L.+Yuauthor=C.+Ouelletauthor=P.+Dextrazeauthor=N.+Meanwellauthor=R.+Colonnoauthor=M.+Krystal&title=Molecular+mechanism+underlying+the+action+of+a+novel+fusion+inhibitor+of+influenza+A+virus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus</span></div><div class="casAuthors">Luo, Guangxiang; Torri, Al; Harte, William E.; Danetz, Stephanie; Cianci, Christopher; Tiley, Laurence; Day, Susan; Mullaney, David; Yu, Kuo-Long; Ouellet, Carl; Dextraze, Pierre; Meanwell, Nicholas; Colonno, Richard; Krystal, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">4062-4070</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">In the initial stages of influenza virus infection, the hemagglutinin (HA) protein of influenza virus mediates both adsorption and penetration of the virus into the host cell.  Recently, we identified and characterized BMY-27709 as an inhibitor of the H1 and H2 subtypes of influenza A virus that specifically inhibits the HA function necessary for virus-cell membrane fusion.  Studies presented herein show that the inhibition is mediated through specific interaction with the HA protein.  This binding represses the low-pH-induced conformational change of the HA protein which is a prerequisite for membrane fusion.  In an attempt to define the binding pocket within the HA mol., a no. of drug-resistant viruses have been isolated and characterized.  Sequence analyses of the HA gene of these drug-resistant viruses mapped amino changes responsible for drug resistance to a region located near the amino terminus of HA2.  In addn., we have identified inactive analogs by BMY-27709 which are able to compete out the inhibitory activity of BMY-27709.  This finding suggests that inhibition of the HA-mediated membrane fusion by this class of compds. is not solely the result of binding within the HA mol. but requires specific interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooSWR6IhuGb7Vg90H21EOLACvtfcHk0li3peUnfFCJFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXisFWgt78%253D&md5=2a937099b047b7c332c4fcf94302ad44</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1128%2FJVI.71.5.4062-4070.1997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.71.5.4062-4070.1997%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DG.%26aulast%3DTorri%26aufirst%3DA.%26aulast%3DHarte%26aufirst%3DW.%2BE.%26aulast%3DDanetz%26aufirst%3DS.%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DTiley%26aufirst%3DL.%26aulast%3DDay%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DOuellet%26aufirst%3DC.%26aulast%3DDextraze%26aufirst%3DP.%26aulast%3DMeanwell%26aufirst%3DN.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DMolecular%2520mechanism%2520underlying%2520the%2520action%2520of%2520a%2520novel%2520fusion%2520inhibitor%2520of%2520influenza%2520A%2520virus%26jtitle%3DJ.%2520Virol.%26date%3D1997%26volume%3D71%26spage%3D4062%26epage%3D4070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cianci, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dischino, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harte, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span> </span><span class="NLM_article-title">pH-Dependent changes in photoaffinity labeling patterns of H1 influenza hemagglutinin using an inhibitor of viral fusion</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1785</span><span class="NLM_x">–</span> <span class="NLM_lpage">1794</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=9971755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADyaK1MXhvVWgu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1999&pages=1785-1794&author=C.+Cianciauthor=K.-L.+Yuauthor=D.+Dischinoauthor=W.+Harteauthor=N.+Meanwellauthor=G.+Luoauthor=R.+J.+Colonnoauthor=M.+Krystal&title=pH-Dependent+changes+in+photoaffinity+labeling+patterns+of+H1+influenza+hemagglutinin+using+an+inhibitor+of+viral+fusion"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">pH-dependent changes in photoaffinity labeling patterns of the H1 influenza virus hemagglutinin by using an inhibitor of viral fusion</span></div><div class="casAuthors">Cianci, Christopher; Yu, Kuo-Long; Dischino, Douglas D.; Harte, William; Deshpande, Milind; Luo, Guangxiang; Colonno, Richard J.; Meanwell, Nicholas A.; Krystal, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1785-1794</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The hemagglutinin (HA) protein undergoes a low-pH-induced conformational change in the acidic milieu of the endosome, resulting in fusion of viral and cellular membranes.  A class of compds. that specifically interact with the HA protein of H1 and H2 subtype viruses and inhibit this conformational change was recently described.  In this study, purified HA trimers (bromelain-cleaved HA [BHA]) are used to examine the properties and binding characteristics of these inhibitors.  Compds. were able to inhibit the low-pH-induced change of isolated trimers, as detected by resistance to digestion with trypsin.  Protection from digestion was extremely stable, as BHA-inhibitor complexes could be incubated for 24 h in low pH with almost no change in BHA structure.  One inhibitor was prepd. as a radiolabeled photoaffinity analog and used to probe for specific drug interactions with the HA protein.  Anal. of BHA after photoaffinity analog binding and UV crosslinking revealed that the HA2 subunit of the HA was specifically radiolabeled.  Crosslinking of the photoaffinity analog to BHA under neutral (native) pH conditions identified a stretch of amino acids within the α-helix of HA2 that interact with the inhibitor.  Interestingly, crosslinking of the analog under acidic conditions identified a different region within the HA2 N terminus which interacts with the photoaffinity compd.  These attachment sites help to delineate a potential binding pocket and suggest a model whereby the BHA is able to undergo a partial, reversible structural change in the presence of inhibitor compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5yO9BHxRJ-bVg90H21EOLACvtfcHk0li3peUnfFCJFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvVWgu7k%253D&md5=65818ea00473d811bd7d5d9cb2c4838b</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DDischino%26aufirst%3DD.%26aulast%3DHarte%26aufirst%3DW.%26aulast%3DMeanwell%26aufirst%3DN.%26aulast%3DLuo%26aufirst%3DG.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DpH-Dependent%2520changes%2520in%2520photoaffinity%2520labeling%2520patterns%2520of%2520H1%2520influenza%2520hemagglutinin%2520using%2520an%2520inhibitor%2520of%2520viral%2520fusion%26jtitle%3DJ.%2520Virol.%26date%3D1999%26volume%3D73%26spage%3D1785%26epage%3D1794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yu, K.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civiello, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianci, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Fundamental structure–activity relationships associated with a new structural class of respiratory syncytial virus inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2141</span><span class="NLM_x">–</span> <span class="NLM_lpage">2144</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=2141-2144&author=K.-L.+Yuauthor=Y.+Zhangauthor=R.+L.+Civielloauthor=K.+F.+Kadowauthor=C.+Cianciauthor=M.+Krystalauthor=N.+A.+Meanwell&title=Fundamental+structure%E2%80%93activity+relationships+associated+with+a+new+structural+class+of+respiratory+syncytial+virus+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCiviello%26aufirst%3DR.%2BL.%26aulast%3DKadow%26aufirst%3DK.%2BF.%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DFundamental%2520structure%25E2%2580%2593activity%2520relationships%2520associated%2520with%2520a%2520new%2520structural%2520class%2520of%2520respiratory%2520syncytial%2520virus%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D2141%26epage%3D2144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cianci, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combrink, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civiello, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovesi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venables, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulgeze, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trehan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roach, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span> </span><span class="NLM_article-title">Orally active fusion inhibitor of respiratory syncytial virus</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=413-422&author=C.+Cianciauthor=K.-L.+Yuauthor=K.+Combrinkauthor=N.+Sinauthor=B.+Pearceauthor=A.+Wangauthor=R.+Civielloauthor=S.+Vossauthor=G.+Luoauthor=K.+Kadowauthor=E.+Genovesiauthor=B.+Venablesauthor=H.+Gulgezeauthor=A.+Trehanauthor=J.+Jamesauthor=L.+Lambauthor=I.+Medinaauthor=J.+Roachauthor=R.+Colonnoauthor=J.+Clarkauthor=N.+Meanwellauthor=M.+Krystal&title=Orally+active+fusion+inhibitor+of+respiratory+syncytial+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DCombrink%26aufirst%3DK.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DPearce%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DCiviello%26aufirst%3DR.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DG.%26aulast%3DKadow%26aufirst%3DK.%26aulast%3DGenovesi%26aufirst%3DE.%26aulast%3DVenables%26aufirst%3DB.%26aulast%3DGulgeze%26aufirst%3DH.%26aulast%3DTrehan%26aufirst%3DA.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DLamb%26aufirst%3DL.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DRoach%26aufirst%3DJ.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DOrally%2520active%2520fusion%2520inhibitor%2520of%2520respiratory%2520syncytial%2520virus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26spage%3D413%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cianci, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovesi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zadjura, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combrink, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span> </span><span class="NLM_article-title">Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2448</span><span class="NLM_x">–</span> <span class="NLM_lpage">2454</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=2448-2454&author=C.+Cianciauthor=E.+Genovesiauthor=L.+Lambauthor=I.+Medinaauthor=Z.+Yangauthor=L.+Zadjuraauthor=H.-Y.+Yangauthor=C.+D%E2%80%99Arienzoauthor=N.+Sinauthor=K.-L.+Yuauthor=K.+Combrinkauthor=Z.+Liauthor=R.+Colonnoauthor=N.+Meanwellauthor=J.+Clarkauthor=M.+Krystal&title=Oral+efficacy+of+a+respiratory+syncytial+virus+inhibitor+in+rodent+models+of+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DGenovesi%26aufirst%3DE.%26aulast%3DLamb%26aufirst%3DL.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZadjura%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DH.-Y.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DCombrink%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DMeanwell%26aufirst%3DN.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DOral%2520efficacy%2520of%2520a%2520respiratory%2520syncytial%2520virus%2520inhibitor%2520in%2520rodent%2520models%2520of%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26spage%3D2448%26epage%3D2454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Cianci, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dischino, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roach, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalterio, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span> </span><span class="NLM_article-title">Targeting a binding pocket within the trimer-of-hairpins: small molecule inhibition of viral fusion</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">15046</span><span class="NLM_x">–</span> <span class="NLM_lpage">15051</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=15046-15051&author=C.+Cianciauthor=D.+R.+Langleyauthor=D.+D.+Dischinoauthor=Y.+Sunauthor=K.-L.+Yuauthor=A.+Stanleyauthor=J.+Roachauthor=Z.+Liauthor=R.+Dalterioauthor=R.+Colonnoauthor=N.+A.+Meanwellauthor=M.+Krystal&title=Targeting+a+binding+pocket+within+the+trimer-of-hairpins%3A+small+molecule+inhibition+of+viral+fusion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DDischino%26aufirst%3DD.%2BD.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DStanley%26aufirst%3DA.%26aulast%3DRoach%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DDalterio%26aufirst%3DR.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DTargeting%2520a%2520binding%2520pocket%2520within%2520the%2520trimer-of-hairpins%253A%2520small%2520molecule%2520inhibition%2520of%2520viral%2520fusion%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D15046%26epage%3D15051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Wang, X. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianci, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combrink, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuring, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civiello, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roach, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4592</span><span class="NLM_x">–</span> <span class="NLM_lpage">4598</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=4592-4598&author=X.+A.+Wangauthor=C.+W.+Cianciauthor=K.-L.+Yuauthor=K.+D.+Combrinkauthor=J.+W.+Thuringauthor=Y.+Zhangauthor=R.+L.+Civielloauthor=K.+F.+Kadowauthor=J.+Roachauthor=Z.+Liauthor=D.+R.+Langleyauthor=M.+Krystalauthor=N.+A.+Meanwell&title=Respiratory+syncytial+virus+fusion+inhibitors.+Part+5%3A+Optimization+of+benzimidazole+substitution+patterns+towards+derivatives+with+improved+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BA.%26aulast%3DCianci%26aufirst%3DC.%2BW.%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DThuring%26aufirst%3DJ.%2BW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCiviello%26aufirst%3DR.%2BL.%26aulast%3DKadow%26aufirst%3DK.%2BF.%26aulast%3DRoach%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DRespiratory%2520syncytial%2520virus%2520fusion%2520inhibitors.%2520Part%25205%253A%2520Optimization%2520of%2520benzimidazole%2520substitution%2520patterns%2520towards%2520derivatives%2520with%2520improved%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D4592%26epage%3D4598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span> </span><span class="NLM_article-title">Respiratory syncytial virus—the discovery and optimization of orally bioavailable fusion inhibitors</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">455</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1358%2Fdof.2007.032.05.1087141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFWqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=441-455&author=N.+A.+Meanwellauthor=M.+Krystal&title=Respiratory+syncytial+virus%E2%80%94the+discovery+and+optimization+of+orally+bioavailable+fusion+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7fR"><div class="casContent"><span class="casTitleNuber">7f</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus - the discovery and optimization of orally bioavailable fusion inhibitors</span></div><div class="casAuthors">Meanwell, Nicholas A.; Krystal, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">441-455</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Using a tissue cell culture assay to screen for leads, potent inhibitors of respiratory syncytial virus (RSV) that function early in the virus life cycle were discovered.  Structure-activity relationship studies optimized these leads into compds. with antiviral activity in animal models of infection.  Guided by in vitro measures of cell permeability and metabolic stability in human liver microsomes, 1-cyclopropyl-3-[[1-(4-hydroxybutyl)-1H-benzo[d]imidazol-2-yl]methyl]-1H-imidazo[4,5-c]pyridin-2(3H)-one (BMS-433771, 12) was identified as a clin. candidate with potential for the treatment of RSV infections.  BMS-433771 is a potent inhibitor of RSV lab. and clin. strains in cell culture that demonstrates antiviral activity in murine and cotton rat models of infection following oral administration.  The characterization of mutations in resistant viruses generated in response to serial passage with increasing concns. of this class of RSV inhibitor, coupled with mechanistic studies, indicated interference with the virus-host fusion process.  A radioaffinity probe was developed which, upon irradn. with light to generate a carbene, specifically labeled the RSV F protein in intact virus in a region mapped to the N-terminal heptad repeat element HR-N.  In vitro labeling expts. conducted with a portion of the HR-N known to be involved in 6-helix bundle formation identified the major site of labeling as tyrosine-198.  This finding localized the binding of these RSV inhibitors to a hydrophobic cavity created in the HR-N element after it assembles into a trimeric fusion core that subsequently assocs. with the C-terminal heptad repeats during the final stages of virus and host membrane fusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPcYuM4LQvM7Vg90H21EOLACvtfcHk0lhlJUVozOC1hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFWqtr8%253D&md5=86cfa9eb6d503ef62ee1948581754ab2</span></div><a href="/servlet/linkout?suffix=cit7f&amp;dbid=16384&amp;doi=10.1358%2Fdof.2007.032.05.1087141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2007.032.05.1087141%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DRespiratory%2520syncytial%2520virus%25E2%2580%2594the%2520discovery%2520and%2520optimization%2520of%2520orally%2520bioavailable%2520fusion%2520inhibitors%26jtitle%3DDrugs%2520Future%26date%3D2007%26volume%3D32%26spage%3D441%26epage%3D455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshpande, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zadjura, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tweedie, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranadive, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricarrdi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicer, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deminie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.-G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, P.-f.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">The discovery of 4-benzoyl-1-[(4-methoxy-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)oxoacetyl]-2-(<i>R</i>)-methylpiperazine (BMS-378806)—a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4239</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm034082o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4236-4239&author=T.+Wangauthor=Z.+Zhangauthor=O.+B.+Wallaceauthor=M.+Deshpandeauthor=H.+Fangauthor=Z.+Yangauthor=L.+M.+Zadjuraauthor=D.+L.+Tweedieauthor=S.+Huangauthor=F.+Zhaoauthor=S.+Ranadiveauthor=B.+S.+Robinsonauthor=Y.-F.+Gongauthor=K.+Ricarrdiauthor=T.+P.+Spicerauthor=C.+Deminieauthor=R.+Roseauthor=H.-G.+H.+Wangauthor=W.+S.+Blairauthor=P.-Y.+Shiauthor=P.-f.+Linauthor=R.+J.+Colonnoauthor=N.+A.+Meanwell&title=The+discovery+of+4-benzoyl-1-%5B%284-methoxy-1H-pyrrolo%5B2%2C3-b%5Dpyridin-3-yl%29oxoacetyl%5D-2-%28R%29-methylpiperazine+%28BMS-378806%29%E2%80%94a+novel+HIV-1+attachment+inhibitor+that+interferes+with+CD4-gp120+interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1021%2Fjm034082o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034082o%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWallace%26aufirst%3DO.%2BB.%26aulast%3DDeshpande%26aufirst%3DM.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZadjura%26aufirst%3DL.%2BM.%26aulast%3DTweedie%26aufirst%3DD.%2BL.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DRanadive%26aufirst%3DS.%26aulast%3DRobinson%26aufirst%3DB.%2BS.%26aulast%3DGong%26aufirst%3DY.-F.%26aulast%3DRicarrdi%26aufirst%3DK.%26aulast%3DSpicer%26aufirst%3DT.%2BP.%26aulast%3DDeminie%26aufirst%3DC.%26aulast%3DRose%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DH.-G.%2BH.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DShi%26aufirst%3DP.-Y.%26aulast%3DLin%26aufirst%3DP.-f.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DThe%2520discovery%2520of%25204-benzoyl-1-%255B%25284-methoxy-1H-pyrrolo%255B2%252C3-b%255Dpyridin-3-yl%2529oxoacetyl%255D-2-%2528R%2529-methylpiperazine%2520%2528BMS-378806%2529%25E2%2580%2594a%2520novel%2520HIV-1%2520attachment%2520inhibitor%2520that%2520interferes%2520with%2520CD4-gp120%2520interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4236%26epage%3D4239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lin, P.-f.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicer, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.-G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamanaka, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimmel, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demers, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deminie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zadjura, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span> </span><span class="NLM_article-title">A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">11013</span><span class="NLM_x">–</span> <span class="NLM_lpage">11018</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1073%2Fpnas.1832214100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=12930892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnslynurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=11013-11018&author=P.-f.+Linauthor=W.+S.+Blairauthor=T.+Wangauthor=T.+P.+Spicerauthor=Q.+Guoauthor=N.+Zhouauthor=Y.-F.+Gongauthor=H.-G.+H.+Wangauthor=R.+Roseauthor=G.+A.+Yamanakaauthor=B.+S.+Robinsonauthor=C.-B.+Liauthor=B.+J.+Kimmelauthor=H.+Fangauthor=G.+S.+Demersauthor=C.+Deminieauthor=R.+A.+Fridellauthor=Z.+Yangauthor=L.+M.+Zadjuraauthor=N.+A.+Meanwellauthor=R.+J.+Colonno&title=A+small+molecule+HIV-1+inhibitor+that+targets+the+HIV-1+envelope+and+inhibits+CD4+receptor+binding"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding</span></div><div class="casAuthors">Lin, Pin-Fang; Blair, Wade; Wang, Tao; Spicer, Timothy; Guo, Qi; Zhou, Nannan; Gong, Yi-Fei; Wang, H. -G. Heidi; Rose, Ronald; Yamanaka, Gregory; Robinson, Brett; Li, Chang-Ben; Fridell, Robert; Deminie, Carol; Demers, Gwendeline; Yang, Zheng; Zadjura, Lisa; Meanwell, Nicholas; Colonno, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">11013-11018</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">BMS-378806 is a recently discovered small mol. HIV-1 inhibitor that blocks viral entrance to cells.  The compd. exhibits potent inhibitory activity against a panel of R5- (virus using the CCR5 coreceptor), X4- (virus using the CXCR4 coreceptor), and R5/X4 HIV-1 lab. and clin. isolates of the B subtype (median EC50 of 0.04 μM) in culture assays.  BMS-378806 is selective for HIV-1 and inactive against HIV-2, SIV and a panel of other viruses, and exhibits no significant cytotoxicity in the 14 cell types tested (concn. for 50% redn. of cell growth, >225 μM).  Mechanism of action studies demonstrated that BMS-378806 binds to gp120 and inhibits the interactions of the HIV-1 envelope protein to cellular CD4 receptors.  Further confirmation that BMS-378806 targets the envelope in infected cells was obtained through the isolation of resistant variants and the mapping of resistance substitutions to the HIV-1 envelope.  In particular, two substitutions, M426L and M475I, are situated in the CD4 binding pocket of gp120.  Recombinant HIV-1 carrying these two substitutions demonstrated significantly reduced susceptibility to compd. inhibition.  BMS-378806 displays many favorable pharmacol. traits, such as low protein binding, minimal human serum effect on anti-HIV-1 potency, good oral bioavailability in animal species, and a clean safety profile in initial animal toxicol. studies.  Together, the data show that BMS-378806 is a representative of a new class of HIV inhibitors that has the potential to become a valued addn. to our current armamentarium of antiretroviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRxcq5wksNmrVg90H21EOLACvtfcHk0lhlJUVozOC1hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnslynurg%253D&md5=9066843a4e1b65984343fccd70ae4323</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1832214100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1832214100%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DP.-f.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DSpicer%26aufirst%3DT.%2BP.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DGong%26aufirst%3DY.-F.%26aulast%3DWang%26aufirst%3DH.-G.%2BH.%26aulast%3DRose%26aufirst%3DR.%26aulast%3DYamanaka%26aufirst%3DG.%2BA.%26aulast%3DRobinson%26aufirst%3DB.%2BS.%26aulast%3DLi%26aufirst%3DC.-B.%26aulast%3DKimmel%26aufirst%3DB.%2BJ.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DDemers%26aufirst%3DG.%2BS.%26aulast%3DDeminie%26aufirst%3DC.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZadjura%26aufirst%3DL.%2BM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26atitle%3DA%2520small%2520molecule%2520HIV-1%2520inhibitor%2520that%2520targets%2520the%2520HIV-1%2520envelope%2520and%2520inhibits%2520CD4%2520receptor%2520binding%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2003%26volume%3D100%26spage%3D11013%26epage%3D11018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Gerritz, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianci, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deminie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discotto, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAuliffe, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minassian, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pendri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edavettal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maskos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mörtl, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefersauer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbacher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldwin, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metzler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoeckler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schartman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leya-Grado, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, H.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span> </span><span class="NLM_article-title">Small molecules that induce higher-order nucleoprotein oligomers: a novel mode of action for the inhibition of influenza virus replication</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">15366</span><span class="NLM_x">–</span> <span class="NLM_lpage">15371</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=15366-15371&author=S.+W.+Gerritzauthor=C.+Cianciauthor=S.+Kimauthor=B.+C.+Pearceauthor=C.+Deminieauthor=L.+Discottoauthor=B.+McAuliffeauthor=B.+F.+Minassianauthor=S.+Shiauthor=S.+Zhuauthor=W.+Zhaiauthor=A.+Pendriauthor=G.+Liauthor=M.+A.+Possauthor=S.+Edavettalauthor=P.+A.+McDonnellauthor=H.+A.+Lewisauthor=K.+Maskosauthor=M.+M%C3%B6rtlauthor=R.+Kiefersauerauthor=S.+Steinbacherauthor=E.+T.+Baldwinauthor=W.+Metzlerauthor=J.+Brysonauthor=M.+Healyauthor=T.+Philipauthor=M.+Zoecklerauthor=R.+Schartmanauthor=M.+Sinzauthor=V.+Leya-Gradoauthor=H.-H.+Hoffmanauthor=D.+R.+Langleyauthor=N.+A.+Meanwellauthor=M.+Krystal&title=Small+molecules+that+induce+higher-order+nucleoprotein+oligomers%3A+a+novel+mode+of+action+for+the+inhibition+of+influenza+virus+replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGerritz%26aufirst%3DS.%2BW.%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPearce%26aufirst%3DB.%2BC.%26aulast%3DDeminie%26aufirst%3DC.%26aulast%3DDiscotto%26aufirst%3DL.%26aulast%3DMcAuliffe%26aufirst%3DB.%26aulast%3DMinassian%26aufirst%3DB.%2BF.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DW.%26aulast%3DPendri%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DEdavettal%26aufirst%3DS.%26aulast%3DMcDonnell%26aufirst%3DP.%2BA.%26aulast%3DLewis%26aufirst%3DH.%2BA.%26aulast%3DMaskos%26aufirst%3DK.%26aulast%3DM%25C3%25B6rtl%26aufirst%3DM.%26aulast%3DKiefersauer%26aufirst%3DR.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DBaldwin%26aufirst%3DE.%2BT.%26aulast%3DMetzler%26aufirst%3DW.%26aulast%3DBryson%26aufirst%3DJ.%26aulast%3DHealy%26aufirst%3DM.%26aulast%3DPhilip%26aufirst%3DT.%26aulast%3DZoeckler%26aufirst%3DM.%26aulast%3DSchartman%26aufirst%3DR.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DLeya-Grado%26aufirst%3DV.%26aulast%3DHoffman%26aufirst%3DH.-H.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DSmall%2520molecules%2520that%2520induce%2520higher-order%2520nucleoprotein%2520oligomers%253A%2520a%2520novel%2520mode%2520of%2520action%2520for%2520the%2520inhibition%2520of%2520influenza%2520virus%2520replication%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D15366%26epage%3D15371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Baldick, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wichroski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pendri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzucco, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pokornowski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggers, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerritz, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockett, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenney, D. J.</span><span> </span><span class="NLM_article-title">Identification of a small molecule antiviral inhibitor of the entry stage of hepatitis C virus infection</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">e1001086</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=e1001086&issue=9&author=C.+J.+Baldickauthor=M.+Wichroskiauthor=A.+Pendriauthor=A.+W.+Walshauthor=J.+Fangauthor=C.+Mazzuccoauthor=K.+Pokornowskiauthor=R.+Roseauthor=B.+Eggersauthor=M.+Hsuauthor=G.+Zhaiauthor=S.+W.+Gerritzauthor=M.+Possauthor=N.+A.+Meanwellauthor=M.+I.+Cockettauthor=D.+J.+Tenney&title=Identification+of+a+small+molecule+antiviral+inhibitor+of+the+entry+stage+of+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaldick%26aufirst%3DC.%2BJ.%26aulast%3DWichroski%26aufirst%3DM.%26aulast%3DPendri%26aufirst%3DA.%26aulast%3DWalsh%26aufirst%3DA.%2BW.%26aulast%3DFang%26aufirst%3DJ.%26aulast%3DMazzucco%26aufirst%3DC.%26aulast%3DPokornowski%26aufirst%3DK.%26aulast%3DRose%26aufirst%3DR.%26aulast%3DEggers%26aufirst%3DB.%26aulast%3DHsu%26aufirst%3DM.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DGerritz%26aufirst%3DS.%2BW.%26aulast%3DPoss%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DCockett%26aufirst%3DM.%2BI.%26aulast%3DTenney%26aufirst%3DD.%2BJ.%26atitle%3DIdentification%2520of%2520a%2520small%2520molecule%2520antiviral%2520inhibitor%2520of%2520the%2520entry%2520stage%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DPLoS%2520Pathog.%26date%3D2010%26volume%3D6%26issue%3D9%26spage%3De1001086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Watkins, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, M. C.</span><span> </span><span class="NLM_article-title">HCV versus HIV drug discovery: déjà vu all over again?</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">2281</span><span class="NLM_x">–</span> <span class="NLM_lpage">2287</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2281-2287&author=W.+J.+Watkinsauthor=M.+C.+Desai&title=HCV+versus+HIV+drug+discovery%3A+d%C3%A9j%C3%A0+vu+all+over+again%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DW.%2BJ.%26aulast%3DDesai%26aufirst%3DM.%2BC.%26atitle%3DHCV%2520versus%2520HIV%2520drug%2520discovery%253A%2520d%25C3%25A9j%25C3%25A0%2520vu%2520all%2520over%2520again%253F%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D2281%26epage%3D2287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sarrazin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieffer, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartels, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanzelka, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müh, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wincheringer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, H.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weegink, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reesink, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwong, A. D.</span><span> </span><span class="NLM_article-title">Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">1767</span><span class="NLM_x">–</span> <span class="NLM_lpage">1777</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2007&pages=1767-1777&author=C.+Sarrazinauthor=T.+L.+Kiefferauthor=D.+Bartelsauthor=B.+Hanzelkaauthor=U.+M%C3%BChauthor=M.+Welkerauthor=D.+Wincheringerauthor=Y.+Zhouauthor=H.-M.+Chuauthor=C.+Linauthor=C.+Weeginkauthor=H.+Reesinkauthor=S.+Zeuzemauthor=A.+D.+Kwong&title=Dynamic+hepatitis+C+virus+genotypic+and+phenotypic+changes+in+patients+treated+with+the+protease+inhibitor+telaprevir"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSarrazin%26aufirst%3DC.%26aulast%3DKieffer%26aufirst%3DT.%2BL.%26aulast%3DBartels%26aufirst%3DD.%26aulast%3DHanzelka%26aufirst%3DB.%26aulast%3DM%25C3%25BCh%26aufirst%3DU.%26aulast%3DWelker%26aufirst%3DM.%26aulast%3DWincheringer%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DChu%26aufirst%3DH.-M.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DWeegink%26aufirst%3DC.%26aulast%3DReesink%26aufirst%3DH.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DKwong%26aufirst%3DA.%2BD.%26atitle%3DDynamic%2520hepatitis%2520C%2520virus%2520genotypic%2520and%2520phenotypic%2520changes%2520in%2520patients%2520treated%2520with%2520the%2520protease%2520inhibitor%2520telaprevir%26jtitle%3DGastroenterology%26date%3D2007%26volume%3D132%26spage%3D1767%26epage%3D1777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Rapid emergence of protease inhibitor resistance in hepatitis C virus</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1126%2Fscitranslmed.3000544" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=1-9&author=L.+Rongauthor=H.+Dahariauthor=R.+M.+Ribeiroauthor=A.+S.+Perelson&title=Rapid+emergence+of+protease+inhibitor+resistance+in+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3000544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3000544%26sid%3Dliteratum%253Aachs%26aulast%3DRong%26aufirst%3DL.%26aulast%3DDahari%26aufirst%3DH.%26aulast%3DRibeiro%26aufirst%3DR.%2BM.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DRapid%2520emergence%2520of%2520protease%2520inhibitor%2520resistance%2520in%2520hepatitis%2520C%2520virus%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Susser, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zettler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domingues, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karey, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ralston, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarrazin, C.</span><span> </span><span class="NLM_article-title">Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1709</span><span class="NLM_x">–</span> <span class="NLM_lpage">1718</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=1709-1718&author=S.+Susserauthor=C.+Welschauthor=Y.+Wangauthor=M.+Zettlerauthor=F.+S.+Dominguesauthor=U.+Kareyauthor=E.+Hughesauthor=R.+Ralstonauthor=X.+Tongauthor=E.+Herrmannauthor=S.+Zeuzemauthor=C.+Sarrazin&title=Characterization+of+resistance+to+the+protease+inhibitor+boceprevir+in+hepatitis+C+virus-infected+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSusser%26aufirst%3DS.%26aulast%3DWelsch%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZettler%26aufirst%3DM.%26aulast%3DDomingues%26aufirst%3DF.%2BS.%26aulast%3DKarey%26aufirst%3DU.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DRalston%26aufirst%3DR.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DHerrmann%26aufirst%3DE.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DSarrazin%26aufirst%3DC.%26atitle%3DCharacterization%2520of%2520resistance%2520to%2520the%2520protease%2520inhibitor%2520boceprevir%2520in%2520hepatitis%2520C%2520virus-infected%2520patients%26jtitle%3DHepatology%26date%3D2009%26volume%3D50%26spage%3D1709%26epage%3D1718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Neumann, A. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gretch, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiley, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Layden, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=1998&pages=103-107&author=A.+U.+Neumannauthor=N.+P.+Lamauthor=H.+Dahariauthor=D.+R.+Gretchauthor=T.+E.+Wileyauthor=T.+J.+Laydenauthor=A.+S.+Perelson&title=Hepatitis+C+viral+dynamics+in+vivo+and+the+antiviral+efficacy+of+interferon-%CE%B1+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNeumann%26aufirst%3DA.%2BU.%26aulast%3DLam%26aufirst%3DN.%2BP.%26aulast%3DDahari%26aufirst%3DH.%26aulast%3DGretch%26aufirst%3DD.%2BR.%26aulast%3DWiley%26aufirst%3DT.%2BE.%26aulast%3DLayden%26aufirst%3DT.%2BJ.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DHepatitis%2520C%2520viral%2520dynamics%2520in%2520vivo%2520and%2520the%2520antiviral%2520efficacy%2520of%2520interferon-%25CE%25B1%2520therapy%26jtitle%3DScience%26date%3D1998%26volume%3D282%26spage%3D103%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Perelson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Micol, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span> </span><span class="NLM_article-title">New kinetic models for the hepatitis C virus</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">749</span><span class="NLM_x">–</span> <span class="NLM_lpage">754</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2005&pages=749-754&author=A.+S.+Perelsonauthor=E.+Herrmannauthor=F.+Micolauthor=S.+Zeuzem&title=New+kinetic+models+for+the+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26aulast%3DHerrmann%26aufirst%3DE.%26aulast%3DMicol%26aufirst%3DF.%26aulast%3DZeuzem%26aufirst%3DS.%26atitle%3DNew%2520kinetic%2520models%2520for%2520the%2520hepatitis%2520C%2520virus%26jtitle%3DHepatology%26date%3D2005%26volume%3D42%26spage%3D749%26epage%3D754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Shudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Modeling HCV kinetics under therapy using PK and PD information</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">–</span> <span class="NLM_lpage">332</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1517%2F17425250902787616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=19331594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkt1SmtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=321-332&author=E.+Shudoauthor=R.+M.+Ribeiroauthor=A.+S.+Perelson&title=Modeling+HCV+kinetics+under+therapy+using+PK+and+PD+information"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling HCV kinetics under therapy using PK and PD information</span></div><div class="casAuthors">Shudo, Emi; Ribeiro, Ruy M.; Perelson, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">321-332</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Math. models have proven helpful in analyzing the virol. response to antiviral therapy in hepatitis C virus (HCV) infected subjects.  Objective: To summarize the uses and limitations of different models for analyzing HCV kinetic data under pegylated IFN therapy.  Methods: We formulate math. models and fit them by nonlinear least square regression to patient data to est. model parameters.  We compare the goodness of fit and parameter values estd. by different models statistically.  Results/conclusion: The best model for parameter estn. depends on the availability and the quality of data as well as the therapy used.  We also discuss the math. models that will be needed to analyze HCV kinetic data from clin. trials with new antiviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7kS3YsFzpdrVg90H21EOLACvtfcHk0ljg46cFVYIrLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkt1SmtL8%253D&md5=eb7d5f818c186ce3e2f80bf6e29a5b4a</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1517%2F17425250902787616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425250902787616%26sid%3Dliteratum%253Aachs%26aulast%3DShudo%26aufirst%3DE.%26aulast%3DRibeiro%26aufirst%3DR.%2BM.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DModeling%2520HCV%2520kinetics%2520under%2520therapy%2520using%2520PK%2520and%2520PD%2520information%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2009%26volume%3D5%26spage%3D321%26epage%3D332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Rong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling</span> <span class="citation_source-journal">Crit. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1615%2FCritRevImmunol.v30.i2.30" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=20370626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntValsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=131-148&author=L.+Rongauthor=A.+S.+Perelson&title=Treatment+of+hepatitis+C+virus+infection+with+interferon+and+small+molecule+direct+antivirals%3A+viral+kinetics+and+modeling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13dR"><div class="casContent"><span class="casTitleNuber">13d</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling</span></div><div class="casAuthors">Rong, Libin; Perelson, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-148</span>CODEN:
                <span class="NLM_cas:coden">CCRIDE</span>;
        ISSN:<span class="NLM_cas:issn">1040-8401</span>.
    
            (<span class="NLM_cas:orgname">Begell House, Inc.</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) infection remains a threat to global public health.  Treatment with pegylated interferon (IFN) plus ribavirin leads to a sustained virol. response in about 50% of patients.  New therapies using direct antiviral agents have the potential to cure patients unresponsive to IFN-based therapies.  Math. modeling has played an important role in studying HCV kinetics.  Using models, one can evaluate the effectiveness of new treatment agents, est. important parameters that govern virus-host interactions, explore possible mechanisms of drug action against HCV, investigate the development of drug resistance, and study quasispecies dynamics during therapy.  Here we review our current knowledge of HCV kinetics under IFN-based therapy and newly developed antiviral agents specifically targeted to attack HCV, and show how math. models have helped to improve our understanding of HCV infection and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRdLbw3w12frVg90H21EOLACvtfcHk0ljg46cFVYIrLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntValsr4%253D&md5=ee1f9e95d0f1670f51739b4fa377e840</span></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=10.1615%2FCritRevImmunol.v30.i2.30&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1615%252FCritRevImmunol.v30.i2.30%26sid%3Dliteratum%253Aachs%26aulast%3DRong%26aufirst%3DL.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DTreatment%2520of%2520hepatitis%2520C%2520virus%2520infection%2520with%2520interferon%2520and%2520small%2520molecule%2520direct%2520antivirals%253A%2520viral%2520kinetics%2520and%2520modeling%26jtitle%3DCrit.%2520Rev.%2520Immunol.%26date%3D2010%26volume%3D30%26spage%3D131%26epage%3D148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Ribeiro, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoddard, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Learn, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korber, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guedj, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parrish, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">e1002881</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=e1002881&issue=8&author=R.+M.+Ribeiroauthor=H.+Liauthor=S.+Wangauthor=M.+B.+Stoddardauthor=G.+H.+Learnauthor=B.+T.+Korberauthor=T.+Bhattacharyaauthor=J.+Guedjauthor=E.+H.+Parrishauthor=B.+H.+Hahnauthor=G.+M.+Shawauthor=A.+S.+Perelson&title=Quantifying+the+diversification+of+hepatitis+C+virus+%28HCV%29+during+primary+infection%3A+estimates+of+the+in+vivo+mutation+rate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRibeiro%26aufirst%3DR.%2BM.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DStoddard%26aufirst%3DM.%2BB.%26aulast%3DLearn%26aufirst%3DG.%2BH.%26aulast%3DKorber%26aufirst%3DB.%2BT.%26aulast%3DBhattacharya%26aufirst%3DT.%26aulast%3DGuedj%26aufirst%3DJ.%26aulast%3DParrish%26aufirst%3DE.%2BH.%26aulast%3DHahn%26aufirst%3DB.%2BH.%26aulast%3DShaw%26aufirst%3DG.%2BM.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DQuantifying%2520the%2520diversification%2520of%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%2520during%2520primary%2520infection%253A%2520estimates%2520of%2520the%2520in%2520vivo%2520mutation%2520rate%26jtitle%3DPLoS%2520Pathog.%26date%3D2012%26volume%3D8%26issue%3D8%26spage%3De1002881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Chatterjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guedj, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Mathematical modeling of HCV infection: What can it teach us in the era of direct-acting antiviral agents?</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1171</span><span class="NLM_x">–</span> <span class="NLM_lpage">1182</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=1171-1182&author=A.+Chatterjeeauthor=J.+Guedjauthor=A.+S.+Perelson&title=Mathematical+modeling+of+HCV+infection%3A+What+can+it+teach+us+in+the+era+of+direct-acting+antiviral+agents%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChatterjee%26aufirst%3DA.%26aulast%3DGuedj%26aufirst%3DJ.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DMathematical%2520modeling%2520of%2520HCV%2520infection%253A%2520What%2520can%2520it%2520teach%2520us%2520in%2520the%2520era%2520of%2520direct-acting%2520antiviral%2520agents%253F%26jtitle%3DAntiviral%2520Ther.%26date%3D2012%26volume%3D17%26spage%3D1171%26epage%3D1182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Körner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herian, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theilmann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">–</span> <span class="NLM_lpage">113</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1126%2Fscience.285.5424.110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=10390360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADyaK1MXksVCqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1999&pages=110-113&author=V.+Lohmannauthor=F.+K%C3%B6rnerauthor=J.+O.+Kochauthor=U.+Herianauthor=L.+Theilmannauthor=R.+Bartenschlager&title=Replication+of+subgenomic+hepatitis+C+virus+RNAs+in+a+hepatoma+cell+line"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line</span></div><div class="casAuthors">Lohmann, V.; Korner, F.; Koch, J.-O.; Herian, U.; Theilmann, L.; Bartenschlager, R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">5424</span>),
    <span class="NLM_cas:pages">110-113</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">An estd. 170 million persons worldwide are infected with hepatitis C virus (HCV), a major cause of chronic liver disease.  Despite increasing knowledge of genome structure and individual viral proteins, studies on virus replication and pathogenesis have been hampered by the lack of reliable and efficient cell culture systems.  A full-length consensus genome was cloned from viral RNA isolated from an infected human liver and used to construct subgenomic selectable replicons.  Upon transfection into a human hepatoma cell line, these RNAs replicated to high levels, permitting metabolic radiolabeling of viral RNA and proteins.  This work defines the structure of HCV replicons functional in cell culture and provides the basis for a long-sought cellular system that should allow detailed mol. studies of HCV and the development of antiviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7X754RT8y1LVg90H21EOLACvtfcHk0liz1IyWFZ5ldw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksVCqurk%253D&md5=b075621b316209ecf4498c9b5b33e4b5</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1126%2Fscience.285.5424.110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.285.5424.110%26sid%3Dliteratum%253Aachs%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DK%25C3%25B6rner%26aufirst%3DF.%26aulast%3DKoch%26aufirst%3DJ.%2BO.%26aulast%3DHerian%26aufirst%3DU.%26aulast%3DTheilmann%26aufirst%3DL.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DReplication%2520of%2520subgenomic%2520hepatitis%2520C%2520virus%2520RNAs%2520in%2520a%2520hepatoma%2520cell%2520line%26jtitle%3DScience%26date%3D1999%26volume%3D285%26spage%3D110%26epage%3D113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Hepatitis C virus replicons: potential role for drug development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">911</span><span class="NLM_x">–</span> <span class="NLM_lpage">916</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=911-916&author=R.+Bartenschlager&title=Hepatitis+C+virus+replicons%3A+potential+role+for+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DHepatitis%2520C%2520virus%2520replicons%253A%2520potential%2520role%2520for%2520drug%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D911%26epage%3D916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">The hepatitis C virus replicon system: from basic research to clinical application</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">216</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2Fj.jhep.2005.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=15964655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvFals74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2005&pages=210-216&author=R.+Bartenschlager&title=The+hepatitis+C+virus+replicon+system%3A+from+basic+research+to+clinical+application"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14cR"><div class="casContent"><span class="casTitleNuber">14c</span><div class="casTitle"><span class="NLM_cas:atitle">The hepatitis C virus replicon system: From basic research to clinical application</span></div><div class="casAuthors">Bartenschlager, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">210-216</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The hepatitis C virus (HCV) replicon system is a valuable tool to study various aspects of the viral life cycle.  Although these RNAs are propagated in tumor cells and highly efficient RNA replication often depends on cell culture adaptive mutations, it can be assumed that HCV replicons mimic the basic principle of HCV replication as it occurs in vivo.  The recent demonstration of antiviral activity of a proteinase inhibitor in the replicon system and in HCV infected patients clearly supports this conclusion.  Caution is however, required when analyzing processes that are dominated by the host cell.  It is obvious that cell lines differ from hepatocytes in several respects and therefore, a host cell factor required for RNA replication in Huh-7 cells may not necessarily play the same role in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryr3ZhbaSqLbVg90H21EOLACvtfcHk0liz1IyWFZ5ldw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvFals74%253D&md5=416cdbec90929728e19a6406a6546a1c</span></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2005.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2005.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DThe%2520hepatitis%2520C%2520virus%2520replicon%2520system%253A%2520from%2520basic%2520research%2520to%2520clinical%2520application%26jtitle%3DJ.%2520Hepatol.%26date%3D2005%26volume%3D43%26spage%3D210%26epage%3D216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Taylor, D. R.</span><span> </span><span class="NLM_article-title">Evolution of cell culture systems for HCV</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">530</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=523-530&author=D.+R.+Taylor&title=Evolution+of+cell+culture+systems+for+HCV"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DD.%2BR.%26atitle%3DEvolution%2520of%2520cell%2520culture%2520systems%2520for%2520HCV%26jtitle%3DAntiviral%2520Ther.%26date%3D2013%26volume%3D18%26spage%3D523%26epage%3D530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">On the history of hepatitis C virus cell culture systems</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1627</span><span class="NLM_x">–</span> <span class="NLM_lpage">1642</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm401401n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1627-1642&author=V.+Lohmannauthor=R.+Bartenschlager&title=On+the+history+of+hepatitis+C+virus+cell+culture+systems"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14e&amp;dbid=16384&amp;doi=10.1021%2Fjm401401n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401401n%26sid%3Dliteratum%253Aachs%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DOn%2520the%2520history%2520of%2520hepatitis%2520C%2520virus%2520cell%2520culture%2520systems%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1627%26epage%3D1642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Wakita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietschmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Date, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murthy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habermann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krausslich, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizokami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, T. J.</span><span> </span><span class="NLM_article-title">Production of infectious hepatitis C virus in tissue culture from a cloned viral genome</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">791</span><span class="NLM_x">–</span> <span class="NLM_lpage">796</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14f&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1038%2Fnm1268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14f&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=15951748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14f&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt1aju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=791-796&author=T.+Wakitaauthor=T.+Pietschmannauthor=T.+Katoauthor=T.+Dateauthor=M.+Miyamotoauthor=Z.+Zhaoauthor=K.+Murthyauthor=A.+Habermannauthor=H.+G.+Krausslichauthor=M.+Mizokamiauthor=R.+Bartenschlagerauthor=T.+J.+Liang&title=Production+of+infectious+hepatitis+C+virus+in+tissue+culture+from+a+cloned+viral+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14fR"><div class="casContent"><span class="casTitleNuber">14f</span><div class="casTitle"><span class="NLM_cas:atitle">Production of infectious hepatitis C virus in tissue culture from a cloned viral genome</span></div><div class="casAuthors">Wakita, Takaji; Pietschmann, Thomas; Kato, Takanobu; Date, Tomoko; Miyamoto, Michiko; Zhao, Zijiang; Murthy, Krishna; Habermann, Anja; Kraeusslich, Hans-Georg; Mizokami, Masashi; Bartenschlager, Ralf; Liang, T. Jake</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">791-796</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection causes chronic liver diseases and is a global public health problem.  Detailed analyses of HCV have been hampered by the lack of viral culture systems.  Subgenomic replicons of the JFH1 genotype 2a strain cloned from an individual with fulminant hepatitis replicate efficiently in cell culture.  Here we show that the JFH1 genome replicates efficiently and supports secretion of viral particles after transfection into a human hepatoma cell line (Huh7).  Particles have a d. of about 1.15-1.17 g/mL and a spherical morphol. with an av. diam. of about 55 nm.  Secreted virus is infectious for Huh7 cells and infectivity can be neutralized by CD81-specific antibodies and by Igs from chronically infected individuals.  The cell culture-generated HCV is infectious for chimpanzee.  This system provides a powerful tool for studying the viral life cycle and developing antiviral strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqra8QhVAEyJ7Vg90H21EOLACvtfcHk0lgEPqUpdkYUxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt1aju7c%253D&md5=91235eedec98d1b3d6a4bc4bc68f6d11</span></div><a href="/servlet/linkout?suffix=cit14f&amp;dbid=16384&amp;doi=10.1038%2Fnm1268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1268%26sid%3Dliteratum%253Aachs%26aulast%3DWakita%26aufirst%3DT.%26aulast%3DPietschmann%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DT.%26aulast%3DDate%26aufirst%3DT.%26aulast%3DMiyamoto%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DMurthy%26aufirst%3DK.%26aulast%3DHabermann%26aufirst%3DA.%26aulast%3DKrausslich%26aufirst%3DH.%2BG.%26aulast%3DMizokami%26aufirst%3DM.%26aulast%3DBartenschlager%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DT.%2BJ.%26atitle%3DProduction%2520of%2520infectious%2520hepatitis%2520C%2520virus%2520in%2520tissue%2520culture%2520from%2520a%2520cloned%2520viral%2520genome%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D791%26epage%3D796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Zhong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gastaminza, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapadia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wieland, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uprichard, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chisari, F. V.</span><span> </span><span class="NLM_article-title">Robust hepatitis C virus infection in vitro</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">9294</span><span class="NLM_x">–</span> <span class="NLM_lpage">9299</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14g&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1073%2Fpnas.0503596102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14g&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=15939869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14g&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvF2rs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=9294-9299&author=J.+Zhongauthor=P.+Gastaminzaauthor=G.+Chengauthor=S.+Kapadiaauthor=T.+Katoauthor=D.+R.+Burtonauthor=S.+F.+Wielandauthor=S.+L.+Uprichardauthor=T.+Wakitaauthor=F.+V.+Chisari&title=Robust+hepatitis+C+virus+infection+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14gR"><div class="casContent"><span class="casTitleNuber">14g</span><div class="casTitle"><span class="NLM_cas:atitle">Robust hepatitis C virus infection in vitro</span></div><div class="casAuthors">Zhong, Jin; Gastaminza, Pablo; Cheng, Guofeng; Kapadia, Sharookh; Kato, Takanobu; Burton, Dennis R.; Wieland, Stefan F.; Uprichard, Susan L.; Wakita, Takaji; Chisari, Francis V.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">9294-9299</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The absence of a robust cell culture model of hepatitis C virus (HCV) infection has severely limited anal. of the HCV life cycle and the development of effective antivirals and vaccines.  Here we report the establishment of a simple yet robust HCV cell culture infection system based on the HCV JFH-1 mol. clone and Huh-7-derived cell lines that allows the prodn. of virus that can be efficiently propagated in tissue culture.  This system provides a powerful tool for the anal. of host-virus interactions that should facilitate the discovery of antiviral drugs and vaccines for this important human pathogen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi3c9MseYJNbVg90H21EOLACvtfcHk0lgEPqUpdkYUxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvF2rs78%253D&md5=6b02e510e6ed7c8f4917f26cde188ae8</span></div><a href="/servlet/linkout?suffix=cit14g&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0503596102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0503596102%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DJ.%26aulast%3DGastaminza%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DKapadia%26aufirst%3DS.%26aulast%3DKato%26aufirst%3DT.%26aulast%3DBurton%26aufirst%3DD.%2BR.%26aulast%3DWieland%26aufirst%3DS.%2BF.%26aulast%3DUprichard%26aufirst%3DS.%2BL.%26aulast%3DWakita%26aufirst%3DT.%26aulast%3DChisari%26aufirst%3DF.%2BV.%26atitle%3DRobust%2520hepatitis%2520C%2520virus%2520infection%2520in%2520vitro%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D9294%26epage%3D9299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Lindenbach, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Syder, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolk, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tellinghuisen, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, R. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeating, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span> </span><span class="NLM_article-title">Complete replication of hepatitis C virus in cell culture</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">309</span><span class="NLM_x">, </span> <span class="NLM_fpage">623</span><span class="NLM_x">–</span> <span class="NLM_lpage">626</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14h&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1126%2Fscience.1114016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14h&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=15947137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14h&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmsFChtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2005&pages=623-626&author=B.+D.+Lindenbachauthor=M.+J.+Evansauthor=A.+J.+Syderauthor=B.+Wolkauthor=T.+L.+Tellinghuisenauthor=C.+C.+Liuauthor=T.+Maruyamaauthor=R.+O.+Hynesauthor=D.+R.+Burtonauthor=J.+A.+McKeatingauthor=C.+M.+Rice&title=Complete+replication+of+hepatitis+C+virus+in+cell+culture"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14hR"><div class="casContent"><span class="casTitleNuber">14h</span><div class="casTitle"><span class="NLM_cas:atitle">Complete Replication of Hepatitis C Virus in Cell Culture</span></div><div class="casAuthors">Lindenbach, Brett D.; Evans, Matthew J.; Syder, Andrew J.; Woelk, Benno; Tellinghuisen, Timothy L.; Liu, Christopher C.; Maruyama, Toshiaki; Hynes, Richard O.; Burton, Dennis R.; McKeating, Jane A.; Rice, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">5734</span>),
    <span class="NLM_cas:pages">623-626</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Many aspects of the hepatitis C virus (HCV) life cycle have not been reproduced in cell culture, which has slowed research progress on this important human pathogen.  Here, we describe a full-length HCV genome that replicates and produces virus particles that are infectious in cell culture (HCVcc).  Replication of HCVcc was robust, producing nearly 105 infectious units per mL within 48 h.  Virus particles were filterable and neutralized with a monoclonal antibody against the viral glycoprotein E2.  Viral entry was dependent on cellular expression of a putative HCV receptor, CD81.  HCVcc replication was inhibited by interferon-α and by several HCV-specific antiviral compds., suggesting that this in vitro system will aid in the search for improved antivirals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroGMVonlJq-rVg90H21EOLACvtfcHk0lirqqFiA5ceOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmsFChtr4%253D&md5=05a4723cb8bf6b4e33cecab9be5bcdea</span></div><a href="/servlet/linkout?suffix=cit14h&amp;dbid=16384&amp;doi=10.1126%2Fscience.1114016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1114016%26sid%3Dliteratum%253Aachs%26aulast%3DLindenbach%26aufirst%3DB.%2BD.%26aulast%3DEvans%26aufirst%3DM.%2BJ.%26aulast%3DSyder%26aufirst%3DA.%2BJ.%26aulast%3DWolk%26aufirst%3DB.%26aulast%3DTellinghuisen%26aufirst%3DT.%2BL.%26aulast%3DLiu%26aufirst%3DC.%2BC.%26aulast%3DMaruyama%26aufirst%3DT.%26aulast%3DHynes%26aufirst%3DR.%2BO.%26aulast%3DBurton%26aufirst%3DD.%2BR.%26aulast%3DMcKeating%26aufirst%3DJ.%2BA.%26aulast%3DRice%26aufirst%3DC.%2BM.%26atitle%3DComplete%2520replication%2520of%2520hepatitis%2520C%2520virus%2520in%2520cell%2520culture%26jtitle%3DScience%26date%3D2005%26volume%3D309%26spage%3D623%26epage%3D626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Miller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purcell, R. H.</span><span> </span><span class="NLM_article-title">Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus super group</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">2057</span><span class="NLM_x">–</span> <span class="NLM_lpage">2061</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1990&pages=2057-2061&author=R.+H.+Millerauthor=R.+H.+Purcell&title=Hepatitis+C+virus+shares+amino+acid+sequence+similarity+with+pestiviruses+and+flaviviruses+as+well+as+members+of+two+plant+virus+super+group"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DR.%2BH.%26aulast%3DPurcell%26aufirst%3DR.%2BH.%26atitle%3DHepatitis%2520C%2520virus%2520shares%2520amino%2520acid%2520sequence%2520similarity%2520with%2520pestiviruses%2520and%2520flaviviruses%2520as%2520well%2520as%2520members%2520of%2520two%2520plant%2520virus%2520super%2520group%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1990%26volume%3D87%26spage%3D2057%26epage%3D2061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Colett, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gold, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strick, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purchio, A. F.</span><span> </span><span class="NLM_article-title">Molecular cloning and nucleotide sequence of the pestivirus bovine viral diarrhea virus</span> <span class="citation_source-journal">Virology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">165</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">199</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=1998&pages=191-199&author=M.+S.+Colettauthor=R.+Larsonauthor=C.+Goldauthor=D.+Strickauthor=D.+K.+Andersonauthor=A.+F.+Purchio&title=Molecular+cloning+and+nucleotide+sequence+of+the+pestivirus+bovine+viral+diarrhea+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DColett%26aufirst%3DM.%2BS.%26aulast%3DLarson%26aufirst%3DR.%26aulast%3DGold%26aufirst%3DC.%26aulast%3DStrick%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DD.%2BK.%26aulast%3DPurchio%26aufirst%3DA.%2BF.%26atitle%3DMolecular%2520cloning%2520and%2520nucleotide%2520sequence%2520of%2520the%2520pestivirus%2520bovine%2520viral%2520diarrhea%2520virus%26jtitle%3DVirology%26date%3D1998%26volume%3D165%26spage%3D191%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Buckwold, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beer, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donis, R. O.</span><span> </span><span class="NLM_article-title">Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2FS0166-3542%2803%2900174-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=14516916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnsVansLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2003&pages=1-15&author=V.+E.+Buckwoldauthor=B.+E.+Beerauthor=R.+O.+Donis&title=Bovine+viral+diarrhea+virus+as+a+surrogate+model+of+hepatitis+C+virus+for+the+evaluation+of+antiviral+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15cR"><div class="casContent"><span class="casTitleNuber">15c</span><div class="casTitle"><span class="NLM_cas:atitle">Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents</span></div><div class="casAuthors">Buckwold, Victor E.; Beer, Brigitte E.; Donis, Ruben O.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-15</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The identification and development of new antiviral agents that can be used to combat hepatitis C virus (HCV) infection was complicated by both tech. and logistic issues.  There are few, if any, robust methods by which HCV virions can be grown in vitro.  The development of HCV RNA replicons was a great breakthrough that has allowed for the undertaking of significant screening efforts to identify inhibitors of HCV intracellular replication.  However, since replicons do not undergo a complete replication cycle, drug screening programs and mechanism of action studies based solely on these assays will not identify compds. targeting either early (virion attachment, entry, uncoating) or late (virion assembly, egress) stages of the viral replication cycle.  Drugs that neg. affect the infectivity of new virions will also not be identified using HCV RNA replicons.  Bovine viral diarrhea virus (BVDV) shares a similar structural organization with HCV, and both viruses generally cause chronic long-term infections in their resp. hosts.  The BVDV surrogate model is attractive, since it is a virus-based system.  It is easy to culture the virus in vitro, mol. clones are available for genetic studies, and the virus undergoes a complete replication cycle.  Like HCV, BVDV utilizes the LDL receptor to enter cells, uses a functionally similar internal ribosome entry site (IRES) for translation, uses an NS4A cofactor with its homologous NS3 protease, has a similar NS3 helicase/NTPase, a mechanistically similar NS5B RNA-dependent RNA polymerase, and a seemingly equiv. mechanism of virion maturation, assembly and egress.  While the concordance between drugs active in either BVDV or HCV is largely unknown at this time, BVDV remains a popular model system with which drugs can be evaluated for potential antiviral activity against HCV and in studies of drug mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovmWXl_t8xT7Vg90H21EOLACvtfcHk0lirqqFiA5ceOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnsVansLg%253D&md5=aeb8d9bbbd58122b8c302266bbf409ed</span></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1016%2FS0166-3542%2803%2900174-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0166-3542%252803%252900174-8%26sid%3Dliteratum%253Aachs%26aulast%3DBuckwold%26aufirst%3DV.%2BE.%26aulast%3DBeer%26aufirst%3DB.%2BE.%26aulast%3DDonis%26aufirst%3DR.%2BO.%26atitle%3DBovine%2520viral%2520diarrhea%2520virus%2520as%2520a%2520surrogate%2520model%2520of%2520hepatitis%2520C%2520virus%2520for%2520the%2520evaluation%2520of%2520antiviral%2520agents%26jtitle%3DAntiviral%2520Res.%26date%3D2003%26volume%3D60%26spage%3D1%26epage%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Pierra, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amador, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benzaria, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cretton-Scott, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Amours, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moussa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Standring, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommadossi, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gosselin, G.</span><span> </span><span class="NLM_article-title">Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-<i>C</i>-methylcytidine</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6614</span><span class="NLM_x">–</span> <span class="NLM_lpage">6620</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0603623" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6614-6620&author=C.+Pierraauthor=A.+Amadorauthor=S.+Benzariaauthor=E.+Cretton-Scottauthor=M.+D%E2%80%99Amoursauthor=J.+Maoauthor=S.+Mathieuauthor=A.+Moussaauthor=E.+G.+Bridgesauthor=D.+N.+Standringauthor=J.-P.+Sommadossiauthor=R.+Storerauthor=G.+Gosselin&title=Synthesis+and+pharmacokinetics+of+valopicitabine+%28NM283%29%2C+an+efficient+prodrug+of+the+potent+anti-HCV+agent+2%E2%80%B2-C-methylcytidine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15d&amp;dbid=16384&amp;doi=10.1021%2Fjm0603623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603623%26sid%3Dliteratum%253Aachs%26aulast%3DPierra%26aufirst%3DC.%26aulast%3DAmador%26aufirst%3DA.%26aulast%3DBenzaria%26aufirst%3DS.%26aulast%3DCretton-Scott%26aufirst%3DE.%26aulast%3DD%25E2%2580%2599Amours%26aufirst%3DM.%26aulast%3DMao%26aufirst%3DJ.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DMoussa%26aufirst%3DA.%26aulast%3DBridges%26aufirst%3DE.%2BG.%26aulast%3DStandring%26aufirst%3DD.%2BN.%26aulast%3DSommadossi%26aufirst%3DJ.-P.%26aulast%3DStorer%26aufirst%3DR.%26aulast%3DGosselin%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520pharmacokinetics%2520of%2520valopicitabine%2520%2528NM283%2529%252C%2520an%2520efficient%2520prodrug%2520of%2520the%2520potent%2520anti-HCV%2520agent%25202%25E2%2580%25B2-C-methylcytidine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6614%26epage%3D6620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Racela, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Specific inhibition of bovine diarrhea virus replicase</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">6753</span><span class="NLM_x">–</span> <span class="NLM_lpage">6760</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15e&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1128%2FJVI.77.12.6753-6760.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15e&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=12767995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15e&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksFGhsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2003&pages=6753-6760&author=J.-H.+Sunauthor=J.+A.+Lemmauthor=D.+R.+O%E2%80%99Boyleauthor=J.+Racelaauthor=R.+Colonnoauthor=M.+Gao&title=Specific+inhibition+of+bovine+diarrhea+virus+replicase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15eR"><div class="casContent"><span class="casTitleNuber">15e</span><div class="casTitle"><span class="NLM_cas:atitle">Specific inhibition of bovine viral diarrhea virus replicase</span></div><div class="casAuthors">Sun, Jin-Hua; Lemm, Julie A.; O'Boyle, Donald R.; Racela, Jason; Colonno, Richard; Gao, Min</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6753-6760</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Compd.-1453 was identified and characterized as a specific inhibitor of bovine viral diarrhea virus (BVDV).  The concn. of compd.-1453 which results in 50% protection from virus-induced cytopathic effect is ∼2.2, μM, with a therapeutic index of 60, and it is not active against a panel of RNA and DNA viruses.  A time-of-addn. expt. suggested that compd.-1453 targets a stage of the viral life cycle after viral entry.  To det. the target of compd.-1453, resistant virus was generated.  Resistant variants grew efficiently in the presence or absence of 33,IM compd.-1453 and exhibited replication efficiency in the presence of compd.-1453 approx. 1,000-fold higher than that of the wild-type (wt.) virus.  Functional mapping and sequence anal. of resistant cDNAs revealed a single amino acid substitution (Glu to Gly) at residue 291 in the NS5B polymerase in all eight independently generated cDNA clones.  Recombinant virus contg. this single mutation retained the resistance phenotype and a replication efficiency similar to that of the original isolated resistant virus.  Since compd.-1453 did not inhibit BVDV polymerase activity in vitro (50% inhibitory concn. >300,IM), we developed a membrane-based assay that consisted of a BVDV RNA replicase complex isolated from virus-infected cells.  Compd.-1453 inhibited the activity of the wt., but not the drug-resistant, replicase in the membrane assay at concns. similar to those obsd. in the viral infection assay.  This work presents a novel inhibitor of a viral RNA-dependent RNA replicase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt-Ptgl6-5NLVg90H21EOLACvtfcHk0ljSUjfF_NuaKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksFGhsr4%253D&md5=0e5da514bbc5c33c9bc8c35c50bd2062</span></div><a href="/servlet/linkout?suffix=cit15e&amp;dbid=16384&amp;doi=10.1128%2FJVI.77.12.6753-6760.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.77.12.6753-6760.2003%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DRacela%26aufirst%3DJ.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DSpecific%2520inhibition%2520of%2520bovine%2520diarrhea%2520virus%2520replicase%26jtitle%3DJ.%2520Virol.%26date%3D2003%26volume%3D77%26spage%3D6753%26epage%3D6760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1346</span><span class="NLM_x">–</span> <span class="NLM_lpage">1353</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1128%2FAAC.49.4.1346-1353.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=15793110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjt1GjsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=1346-1353&author=D.+R.+O%E2%80%99Boyleauthor=P.+T.+Nowerauthor=J.+A.+Lemmauthor=L.+Valeraauthor=J.-H.+Sunauthor=K.+Rigatauthor=R.+Colonnoauthor=M.+Gao&title=Development+of+a+cell-based+high-throughput+specificity+screen+using+a+hepatitis+C+virus-bovine+viral+diarrhea+virus+dual+replicon+assay"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay</span></div><div class="casAuthors">O'Boyle, Donald R., II; Nower, Peter T.; Lemm, Julie A.; Valera, Lourdes; Sun, Jin-Hua; Rigat, Karen; Colonno, Richard; Gao, Min</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1346-1353</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The hepatitis C virus (HCV) replicon is a unique system for the development of a high-throughput screen (HTS), since the anal. of inhibitors requires the quantification of a decrease in a steady-state level of HCV RNA.  HCV replicon replication is dependent on host cell factors, and any toxic effects may have a significant impact on HCV replicon replication.  Therefore, detg. the antiviral specificity of compds. presents a challenge for the identification of specific HCV inhibitors.  Here we report the development of an HCV/bovine viral diarrhea virus (BVDV) dual replicon assay suitable for HTS to address these issues.  The HCV reporter enzyme is the endogenous NS3 protease contained within the HCV genome, while the BVDV reporter enzyme is a luciferase enzyme engineered into the BVDV genome.  The HTS uses a mixt. of HCV and BVDV replicon cell lines placed in the same well of a 96-well plate and isolated in the same cell backgrounds (Huh-7).  The format consists of three sep. but compatible assays: the first quantitates the amt. of cytotoxicity based upon the conversion of Alamar blue dye via cellular enzymes, while the second indirectly quantitates HCV replicon replication through measurement of the amt. of NS3 protease activity present.  The final assay measures the amt. of luciferase activity present from the BVDV replicon cells, as an indicator of the specificity of the test compds.  This HCV/BVDV dual replicon assay provides a reliable format to det. the potency and specificity of HCV replicon inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX8Ni-3CK40LVg90H21EOLACvtfcHk0liFN_I34C_6XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjt1GjsrY%253D&md5=0f9a5c1fa35bf1aa1ea4ac5b2d71b859</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FAAC.49.4.1346-1353.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.49.4.1346-1353.2005%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DRigat%26aufirst%3DK.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DDevelopment%2520of%2520a%2520cell-based%2520high-throughput%2520specificity%2520screen%2520using%2520a%2520hepatitis%2520C%2520virus-bovine%2520viral%2520diarrhea%2520virus%2520dual%2520replicon%2520assay%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D1346%26epage%3D1353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Schamberger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmeyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillisch, A.</span><span> </span><span class="NLM_article-title">Rendezvous in chemical space? Comparing the small molecule compound libraries of Bayer and Schering</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">636</span><span class="NLM_x">–</span> <span class="NLM_lpage">641</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=636-641&author=J.+Schambergerauthor=M.+Grimmauthor=A.+Steinmeyerauthor=A.+Hillisch&title=Rendezvous+in+chemical+space%3F+Comparing+the+small+molecule+compound+libraries+of+Bayer+and+Schering"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchamberger%26aufirst%3DJ.%26aulast%3DGrimm%26aufirst%3DM.%26aulast%3DSteinmeyer%26aufirst%3DA.%26aulast%3DHillisch%26aufirst%3DA.%26atitle%3DRendezvous%2520in%2520chemical%2520space%253F%2520Comparing%2520the%2520small%2520molecule%2520compound%2520libraries%2520of%2520Bayer%2520and%2520Schering%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D636%26epage%3D641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshpande, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Identification of hepatitis C virus NS5A inhibitors</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">482</span><span class="NLM_x">–</span> <span class="NLM_lpage">491</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1128%2FJVI.01360-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=19812153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A280%3ADC%252BD1Mfhslamtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=482-491&author=J.+A.+Lemmauthor=D.+R.+O%E2%80%99Boyleauthor=M.+Liuauthor=P.+T.+Nowerauthor=R.+Colonnoauthor=M.+S.+Deshpandeauthor=L.+B.+Snyderauthor=S.+W.+Martinauthor=D.+R.+St.+Laurentauthor=M.+H.+Serrano-Wuauthor=J.+L.+Romineauthor=N.+A.+Meanwellauthor=M.+Gao&title=Identification+of+hepatitis+C+virus+NS5A+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of hepatitis C virus NS5A inhibitors</span></div><div class="casAuthors">Lemm Julie A; O'Boyle Donald 2nd; Liu Mengping; Nower Peter T; Colonno Richard; Deshpande Milind S; Snyder Lawrence B; Martin Scott W; St Laurent Denis R; Serrano-Wu Michael H; Romine Jeffrey L; Meanwell Nicholas A; Gao Min</div><div class="citationInfo"><span class="NLM_cas:title">Journal of virology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">482-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Using a cell-based replicon screen, we identified a class of compounds with a thiazolidinone core structure as inhibitors of hepatitis C virus (HCV) replication.  The concentration of one such compound, BMS-824, that resulted in a 50% inhibition of HCV replicon replication was approximately 5 nM, with a therapeutic index of >10,000.  The compound showed good specificity for HCV, as it was not active against several other RNA and DNA viruses.  Replicon cells resistant to BMS-824 were isolated, and mutations were identified.  A combination of amino acid substitutions of leucine to valine at residue 31 (L31V) and glutamine to leucine at residue 54 (Q54L) in NS5A conferred resistance to this chemotype, as did a single substitution of tyrosine to histidine at amino acid 93 (Y93H) in NS5A.  To further explore the region(s) of NS5A involved in inhibitor sensitivity, genotype-specific NS5A inhibitors were used to evaluate a series of genotype 1a/1b hybrid replicons.  Our results showed that, consistent with resistance mapping, the inhibitor sensitivity domain also mapped to the N terminus of NS5A, but it could be distinguished from the key resistance sites.  In addition, we demonstrated that NS5A inhibitors, as well as an active-site inhibitor that specifically binds NS3 protease, could block the hyperphosphorylation of NS5A, which is believed to play an essential role in the viral life cycle.  Clinical proof of concept has recently been achieved with derivatives of these NS5A inhibitors, indicating that small molecules targeting a nontraditional viral protein like NS5A, without any known enzymatic activity, can also have profound antiviral effects on HCV-infected subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTeii-SeNfkQYUSrryheKE6fW6udTcc2eY3fmuU0cmML7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mfhslamtg%253D%253D&md5=691db815a886509d5b225bbbd068b82c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1128%2FJVI.01360-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01360-09%26sid%3Dliteratum%253Aachs%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DDeshpande%26aufirst%3DM.%2BS.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520hepatitis%2520C%2520virus%2520NS5A%2520inhibitors%26jtitle%3DJ.%2520Virol.%26date%3D2010%26volume%3D84%26spage%3D482%26epage%3D491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alberts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantone, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">3795</span><span class="NLM_x">–</span> <span class="NLM_lpage">3802</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1128%2FAAC.00146-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=21576451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslGgs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=3795-3802&author=J.+A.+Lemmauthor=J.+E.+Leetauthor=D.+R.+O%E2%80%99Boyleauthor=J.+L.+Romineauthor=X.+S.+Huangauthor=D.+R.+Schroederauthor=J.+Albertsauthor=J.+L.+Cantoneauthor=J.-H.+Sunauthor=P.+T.+Nowerauthor=S.+W.+Martinauthor=M.+H.+Serrano-Wuauthor=N.+A.+Meanwellauthor=L.+B.+Snyderauthor=M.+Gao&title=Discovery+of+potent+hepatitis+C+virus+NS5A+inhibitors+with+dimeric+structures"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures</span></div><div class="casAuthors">Lemm, Julie A.; Leet, John E.; O'Boyle, Donald R., II; Romine, Jeffrey L.; Huang, Xiaohua Stella; Schroeder, Daniel R.; Alberts, Jeffrey; Cantone, Joseph L.; Sun, Jin-Hua; Nower, Peter T.; Martin, Scott W.; Serrano-Wu, Michael H.; Meanwell, Nicholas A.; Snyder, Lawrence B.; Gao, Min</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3795-3802</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The exceptional in vitro potency of the hepatitis C virus (HCV) NS5A inhibitor BMS-790052 has translated into an in vivo effect in proof-of-concept clin. trials.  Although the 50% effective concn. (EC50) of the initial lead, the thiazolidinone BMS-824, was ∼10 nM in the replicon assay, it underwent transformation to other inhibitory species after incubation in cell culture medium.  The biol. profile of BMS-824, including the EC50, the drug concn. required to reduce cell growth by 50% (CC50), and the resistance profile, however, remained unchanged, triggering an investigation to identify the biol. active species.  High-performance liq. chromatog. (HPLC) biogram fractionation of a sample of BMS-824 incubated in medium revealed that the most active fractions could readily be sepd. from the parental compd. and retained the biol. profile of BMS-824.  From mass spectral and NMR data, the active species was detd. to be a dimer of BMS-824 derived from an intermol. radical-mediated reaction of the parent compd.  Based upon an anal. of the structural elements of the dimer deemed necessary for anti-HCV activity, the stilbene deriv. BMS-346 was synthesized.  This compd. exhibited excellent anti-HCV activity and showed a resistance profile similar to that of BMS-824, with changes in compd. sensitivity mapped to the N terminus of NS5A.  The N terminus of NS5A has been crystd. as a dimer, complementing the symmetry of BMS-346 and allowing a potential mode of inhibition of NS5A to be discussed.  Identification of the stable, active pharmacophore assocd. with these NS5A inhibitors provided the foundation for the design of more potent inhibitors with broad genotype inhibition.  This culminated in the identification of BMS-790052, a compd. that preserves the symmetry discovered with BMS-346.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5YeVXSMPBNLVg90H21EOLACvtfcHk0liGFp0HZoeQHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslGgs74%253D&md5=8a0fea78b0d42bf7285e6916c40fbc91</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1128%2FAAC.00146-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00146-11%26sid%3Dliteratum%253Aachs%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DLeet%26aufirst%3DJ.%2BE.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DHuang%26aufirst%3DX.%2BS.%26aulast%3DSchroeder%26aufirst%3DD.%2BR.%26aulast%3DAlberts%26aufirst%3DJ.%26aulast%3DCantone%26aufirst%3DJ.%2BL.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520potent%2520hepatitis%2520C%2520virus%2520NS5A%2520inhibitors%2520with%2520dimeric%2520structures%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D3795%26epage%3D3802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Macdonald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, M.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A: tales of a promiscuous protein</span> <span class="citation_source-journal">J. Gen. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">2485</span><span class="NLM_x">–</span> <span class="NLM_lpage">2502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1099%2Fvir.0.80204-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=15302943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsVegsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2004&pages=2485-2502&author=A.+Macdonaldauthor=M.+Harris&title=Hepatitis+C+virus+NS5A%3A+tales+of+a+promiscuous+protein"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus NS5A: Tales of a promiscuous protein</span></div><div class="casAuthors">MacDonald, Andrew; Harris, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2485-2502</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    
            (<span class="NLM_cas:orgname">Society for General Microbiology</span>)
        </div><div class="casAbstract">A review.  The non-structural 5A (NS5A) protein of hepatitis C virus (HCV) has been the subject of intensive research over the last decade.  It is generally accepted that NS5A is a pleiotropic protein with key roles in both viral RNA replication and modulation of the physiol. of the host cell.  Our understanding of the role of NS5A in the virus life cycle has been hampered by the lack of a robust in vitro system for the study of HCV replication, although the recent development of the subgenomic replicon has at least allowed us to begin to dissect the involvement of NS5A in the process of viral RNA replication.  Early studies into the effects of NS5A on cell physiol. relied on expression of NS5A either alone or in the context of other non-structural proteins; the advent of the replicon system has allowed the extrapolation of these studies to a more physiol. relevant cellular context.  Despite recent progress, this field is controversial, and there is much work to be accomplished before we fully understand the many functions of this protein.  In this article, the current state of our knowledge of NS5A, discussing in detail its direct involvement in virus replication, together with its role in modulating the cellular environment to favor virus replication and persistence, are reviewed.  The effects of NS5A on interferon signaling, and the regulation of cell growth and apoptosis are highlighted, demonstrating that this protein is indeed of crit. importance for HCV and is worthy of further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqk1qXYUj29LVg90H21EOLACvtfcHk0liGFp0HZoeQHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsVegsr4%253D&md5=784583dfdcae57864433db2941acd985</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1099%2Fvir.0.80204-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fvir.0.80204-0%26sid%3Dliteratum%253Aachs%26aulast%3DMacdonald%26aufirst%3DA.%26aulast%3DHarris%26aufirst%3DM.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%253A%2520tales%2520of%2520a%2520promiscuous%2520protein%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2004%26volume%3D85%26spage%3D2485%26epage%3D2502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Szabo, G.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A protein—a master regulator?</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">996</span><span class="NLM_x">–</span> <span class="NLM_lpage">999</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2006&pages=996-999&author=G.+Szabo&title=Hepatitis+C+virus+NS5A+protein%E2%80%94a+master+regulator%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSzabo%26aufirst%3DG.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%2520protein%25E2%2580%2594a%2520master%2520regulator%253F%26jtitle%3DGastroenterology%26date%3D2006%26volume%3D130%26spage%3D996%26epage%3D999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Najarro, P.; Mathews, N.; Cockerill, S.</span><span> </span><span class="NLM_article-title">NS5A inhibitors</span>. In  <span class="citation_source-book">Hepatitis C Viruses</span>; <span class="NLM_contrib-group">Tan, S.-L.</span>, Ed., <span class="NLM_publisher-name">Horizon Bioscience</span>: <span class="NLM_publisher-loc">Wymondham, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">292</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=271-292&author=P.+Najarro&author=N.+Mathews&author=S.+Cockerillauthor=S.-L.+Tan&title=Hepatitis+C+Viruses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DNajarro%26aufirst%3DP.%26atitle%3DNS5A%2520inhibitors%26btitle%3DHepatitis%2520C%2520Viruses%26aulast%3DTan%26aufirst%3DS.-L.%26pub%3DHorizon%2520Bioscience%26date%3D2006%26spage%3D271%26epage%3D292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Schmitz, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, S.-L.</span><span> </span><span class="NLM_article-title">NS5A—from obscurity to new target for HCV therapy</span> <span class="citation_source-journal">Recent Pat. Anti-Infect. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20d&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.2174%2F157489108784746597" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20d&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXos1Kjs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=77-92&author=U.+Schmitzauthor=S.-L.+Tan&title=NS5A%E2%80%94from+obscurity+to+new+target+for+HCV+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20dR"><div class="casContent"><span class="casTitleNuber">20d</span><div class="casTitle"><span class="NLM_cas:atitle">NS5A - from obscurity to new target for HCV therapy</span></div><div class="casAuthors">Schmitz, Uli; Tan, Seng-Lai</div><div class="citationInfo"><span class="NLM_cas:title">Recent Patents on Anti-Infective Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">77-92</span>CODEN:
                <span class="NLM_cas:coden">RPADCX</span>;
        ISSN:<span class="NLM_cas:issn">1574-891X</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The hepatitis C virus (HCV) non-structural 5A (NS5A) protein is essential for viral RNA replication and may play a role in subverting host intracellular signaling pathways.  Although no intrinsic enzymic activity has been ascribed to NS5A, this proline-rich hydrophilic phosphoprotein is likely to exert its functions by interacting with viral and cellular factors.  Recent studies using the HCV replicon cell culture system as a model for HCV RNA replication as well as for high-throughput screening of pharmacol. inhibitors have revealed blockade of NS5A as a promising therapeutic strategy for the treatment of HCV.  This review will summarize our progress in understanding the role of NS5A in HCV RNA replication and will introduce the most recent patents on inhibitors of NS5A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEYaqZrcncjbVg90H21EOLACvtfcHk0li2eUG9OEVj6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXos1Kjs70%253D&md5=29d24e11907fe2c10f5649426b864a87</span></div><a href="/servlet/linkout?suffix=cit20d&amp;dbid=16384&amp;doi=10.2174%2F157489108784746597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157489108784746597%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitz%26aufirst%3DU.%26aulast%3DTan%26aufirst%3DS.-L.%26atitle%3DNS5A%25E2%2580%2594from%2520obscurity%2520to%2520new%2520target%2520for%2520HCV%2520therapy%26jtitle%3DRecent%2520Pat.%2520Anti-Infect.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D77%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Cordek, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bechtel, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maynard, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazmierski, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, C. E.</span><span> </span><span class="NLM_article-title">Targeting the NS5A protein of HCV: an emerging option</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">711</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20e&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1358%2Fdof.2011.036.09.1641618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20e&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=23378700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20e&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1eis7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=691-711&author=D.+G.+Cordekauthor=J.+T.+Bechtelauthor=A.+T.+Maynardauthor=W.+M.+Kazmierskiauthor=C.+E.+Cameron&title=Targeting+the+NS5A+protein+of+HCV%3A+an+emerging+option"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20eR"><div class="casContent"><span class="casTitleNuber">20e</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the protein NS5A protein of HCV: an emerging option</span></div><div class="casAuthors">Cordek, D. G.; Bechtel, J. T.; Maynard, A. T.; Kazmierski, W. M.; Cameron, C. E.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">691-711</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) infects more than 3% of the world's population, leading to an increased risk of cirrhosis and hepatocellular carcinoma.  The current std. of care, a combination of pegylated interferon alfa and ribavirin, is poorly tolerated and often ineffective against the most prevalent genotype of the virus, genotype 7.  The very recent approval of boceprevir and telaprevir, two HCV protease inhibitors, promises to significantly improve treatment options and outcomes.  In addn. to the viral protease NS3 and the viral polymerase NS5B, direct-acting antivirals are now in development against NS5A.  A multifunctional phosphoprotein, NS5A is essential to HCV genome replication, but has no known enzymic function.  Here we report how the design of small-mol. inhibitors against NS5A has evolved from promising monomers to highly potent dimeric compds. effective against many HCV genotypes.  We also highlight recent clin. data and how the inhibitors may bind to NS5A, itself capable of forming dimers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2lefIUXhmK7Vg90H21EOLACvtfcHk0li2eUG9OEVj6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1eis7nE&md5=7e779d99491df4f8631c7848cb9e56dc</span></div><a href="/servlet/linkout?suffix=cit20e&amp;dbid=16384&amp;doi=10.1358%2Fdof.2011.036.09.1641618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2011.036.09.1641618%26sid%3Dliteratum%253Aachs%26aulast%3DCordek%26aufirst%3DD.%2BG.%26aulast%3DBechtel%26aufirst%3DJ.%2BT.%26aulast%3DMaynard%26aufirst%3DA.%2BT.%26aulast%3DKazmierski%26aufirst%3DW.%2BM.%26aulast%3DCameron%26aufirst%3DC.%2BE.%26atitle%3DTargeting%2520the%2520NS5A%2520protein%2520of%2520HCV%253A%2520an%2520emerging%2520option%26jtitle%3DDrugs%2520Future%26date%3D2011%26volume%3D36%26spage%3D691%26epage%3D711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Hamatake, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maynard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazmierski, W. M.</span><span> </span><span class="NLM_article-title">HCV inhibition mediated through the non-structural protein 5A (NS5A) replication complex</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">345</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2012&pages=331-345&author=R.+Hamatakeauthor=A.+Maynardauthor=W.+M.+Kazmierski&title=HCV+inhibition+mediated+through+the+non-structural+protein+5A+%28NS5A%29+replication+complex"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHamatake%26aufirst%3DR.%26aulast%3DMaynard%26aufirst%3DA.%26aulast%3DKazmierski%26aufirst%3DW.%2BM.%26atitle%3DHCV%2520inhibition%2520mediated%2520through%2520the%2520non-structural%2520protein%25205A%2520%2528NS5A%2529%2520replication%2520complex%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2012%26volume%3D47%26spage%3D331%26epage%3D345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">The discovery and development of hepatitis C virus NS5A replication complex inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1643</span><span class="NLM_x">–</span> <span class="NLM_lpage">1672</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm401793m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1643-1672&author=M.+Belemaauthor=O.+D.+Lopezauthor=J.+A.+Benderauthor=J.+L.+Romineauthor=D.+R.+Laurentauthor=D.+R.+Langleyauthor=J.+A.+Lemmauthor=D.+R.+O%E2%80%99Boyleauthor=J.-H.+Sunauthor=C.+Wangauthor=R.+A.+Fridellauthor=N.+A.+Meanwell&title=The+discovery+and+development+of+hepatitis+C+virus+NS5A+replication+complex+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20g&amp;dbid=16384&amp;doi=10.1021%2Fjm401793m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401793m%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DBender%26aufirst%3DJ.%2BA.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DLaurent%26aufirst%3DD.%2BR.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DThe%2520discovery%2520and%2520development%2520of%2520hepatitis%2520C%2520virus%2520NS5A%2520replication%2520complex%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1643%26epage%3D1672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshpande, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">Inhibitors of HCV NS5A: from iminothiazolidinones to symmetrical stilbenes</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">224</span><span class="NLM_x">–</span> <span class="NLM_lpage">229</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml1002647" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFCmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=224-229&author=J.+L.+Romineauthor=D.+R.+St.+Laurentauthor=J.+E.+Leetauthor=S.+W.+Martinauthor=M.+H.+Serrano-Wuauthor=F.+Yangauthor=M.+Gaoauthor=D.+R.+O%E2%80%99Boyleauthor=J.+A.+Lemmauthor=J.-H.+Sunauthor=P.+T.+Nowerauthor=X.+Huangauthor=M.+S.+Deshpandeauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=Inhibitors+of+HCV+NS5A%3A+from+iminothiazolidinones+to+symmetrical+stilbenes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes</span></div><div class="casAuthors">Romine, Jeffrey L.; St. Laurent, Denis R.; Leet, John E.; Martin, Scott W.; Serrano-Wu, Michael H.; Yang, Fukang; Gao, Min; O'Boyle, Donald R.; Lemm, Julie A.; Sun, Jin-Hua; Nower, Peter T.; Huang, Xiaohua; Deshpande, Milind S.; Meanwell, Nicholas A.; Snyder, Lawrence B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">224-229</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The iminothiazolidinone BMS-858 (2) was identified as a specific inhibitor of HCV replication in a genotype 1b replicon assay via a high-throughput screening campaign.  A more potent analog, BMS-824 (18), was used in resistance mapping studies, which revealed that inhibitory activity was related to disrupting the function of the HCV nonstructural protein 5A.  Despite the development of coherent and interpretable SAR, it was subsequently discovered that in DMSO 18 underwent an oxidn. and structural rearrangement to afford the thiohydantoin 47, a compd. with reduced HCV inhibitory activity.  However, HPLC bioassay fractionation studies performed after incubation of 18 in assay media led to the identification of fractions contg. a dimeric species 48 that exhibited potent antiviral activity.  Excision of the key elements hypothesized to be responsible for antiviral activity based on SAR observations reduced 48 to a simplified, sym., pharmacophore realized most effectively with the stilbene 55, a compd. that demonstrated potent inhibition of HCV in a genotype 1b replicon with an EC50 = 86 pM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj8qij0fE1q7Vg90H21EOLACvtfcHk0liVp7X0H76qdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFCmsg%253D%253D&md5=466b1f5dc09b9e2ecc6b581069506169</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fml1002647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1002647%26sid%3Dliteratum%253Aachs%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DLeet%26aufirst%3DJ.%2BE.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DDeshpande%26aufirst%3DM.%2BS.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DInhibitors%2520of%2520HCV%2520NS5A%253A%2520from%2520iminothiazolidinones%2520to%2520symmetrical%2520stilbenes%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D224%26epage%3D229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tellinghuisen, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotrigiano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span> </span><span class="NLM_article-title">Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">435</span><span class="NLM_x">, </span> <span class="NLM_fpage">374</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=435&publication_year=2005&pages=374-379&author=T.+L.+Tellinghuisenauthor=J.+Marcotrigianoauthor=C.+M.+Rice&title=Structure+of+the+zinc-binding+domain+of+an+essential+component+of+the+hepatitis+C+virus+replicase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTellinghuisen%26aufirst%3DT.%2BL.%26aulast%3DMarcotrigiano%26aufirst%3DJ.%26aulast%3DRice%26aufirst%3DC.%2BM.%26atitle%3DStructure%2520of%2520the%2520zinc-binding%2520domain%2520of%2520an%2520essential%2520component%2520of%2520the%2520hepatitis%2520C%2520virus%2520replicase%26jtitle%3DNature%26date%3D2005%26volume%3D435%26spage%3D374%26epage%3D379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Love, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodsky, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, C. N.</span><span> </span><span class="NLM_article-title">Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">4395</span><span class="NLM_x">–</span> <span class="NLM_lpage">4403</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1128%2FJVI.02352-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=19244328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlt1Kqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2009&pages=4395-4403&author=R.+A.+Loveauthor=O.+Brodskyauthor=M.+J.+Hickeyauthor=P.+A.+Wellsauthor=C.+N.+Cronin&title=Crystal+structure+of+a+novel+dimeric+form+of+NS5A+domain+I+protein+from+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus</span></div><div class="casAuthors">Love, Robert A.; Brodsky, Oleg; Hickey, Michael J.; Wells, Peter A.; Cronin, Ciaran N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4395-4403</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A new protein expression vector design utilizing an N-terminal six-histidine tag and tobacco etch virus protease cleavage site upstream of the hepatitis C virus NS5A sequence has resulted in a more straightforward purifn. method and improved yields of purified NS5A domain I protein.  High-resoln. diffracting crystals of NS5A domain I (amino acids 33 to 202) [NS5A(33-202)] were obtained by using detergent additive crystn. screens, leading to the structure of a homodimer which is organized differently from that published previously, yet is consistent with a membrane assocn. model for NS5A.  The monomer-monomer interface of NS5A(33-202) features an extensive buried surface area involving the most-highly conserved face of each monomer.  The two alternate structural forms of domain I now available may be indicative of the multiple roles emerging for NS5A in viral RNA replication and viral particle assembly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNYc2eJlR_hLVg90H21EOLACvtfcHk0liVp7X0H76qdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlt1Kqu7s%253D&md5=70ea61461a99afb962e76a4c3f5495db</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1128%2FJVI.02352-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02352-08%26sid%3Dliteratum%253Aachs%26aulast%3DLove%26aufirst%3DR.%2BA.%26aulast%3DBrodsky%26aufirst%3DO.%26aulast%3DHickey%26aufirst%3DM.%2BJ.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DCronin%26aufirst%3DC.%2BN.%26atitle%3DCrystal%2520structure%2520of%2520a%2520novel%2520dimeric%2520form%2520of%2520NS5A%2520domain%2520I%2520protein%2520from%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Virol.%26date%3D2009%26volume%3D83%26spage%3D4395%26epage%3D4403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lambert, S. M.; Langley, D. R.; Garnett, J. A.; Hedgethorne, K.; Meanwell, N. A.; Matthews, S. J.</span><span> </span><span class="NLM_article-title">The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors</span>.  <span class="citation_source-journal">Protein Sci.</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1002/pro.2456</span> . Published Online: Apr 5,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1002%2Fpro.2456" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=S.+M.+Lambert&author=D.+R.+Langley&author=J.+A.+Garnett&author=K.+Hedgethorne&author=N.+A.+Meanwell&author=S.+J.+Matthews&title=The+crystal+structure+of+NS5A+domain+1+from+genotype+1a+reveals+new+clues+to+the+mechanism+of+action+for+dimeric+HCV+inhibitors&doi=10.1002%2Fpro.2456"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22c&amp;dbid=16384&amp;doi=10.1002%2Fpro.2456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.2456%26sid%3Dliteratum%253Aachs%26aulast%3DLambert%26aufirst%3DS.%2BM.%26atitle%3DThe%2520crystal%2520structure%2520of%2520NS5A%2520domain%25201%2520from%2520genotype%25201a%2520reveals%2520new%2520clues%2520to%2520the%2520mechanism%2520of%2520action%2520for%2520dimeric%2520HCV%2520inhibitors%26jtitle%3DProtein%2520Sci.%26doi%3D10.1002%2Fpro.2456%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Benigni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruska, A.</span><span> </span><span class="NLM_article-title">Quantitative structure–activity relationships of mutagenic and carcinogenic aromatic amines</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">3697</span><span class="NLM_x">–</span> <span class="NLM_lpage">3714</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr9901079" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2000&pages=3697-3714&author=R.+Benigniauthor=A.+Giulianiauthor=R.+Frankeauthor=A.+Gruska&title=Quantitative+structure%E2%80%93activity+relationships+of+mutagenic+and+carcinogenic+aromatic+amines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=10.1021%2Fcr9901079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr9901079%26sid%3Dliteratum%253Aachs%26aulast%3DBenigni%26aufirst%3DR.%26aulast%3DGiuliani%26aufirst%3DA.%26aulast%3DFranke%26aufirst%3DR.%26aulast%3DGruska%26aufirst%3DA.%26atitle%3DQuantitative%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520mutagenic%2520and%2520carcinogenic%2520aromatic%2520amines%26jtitle%3DChem.%2520Rev.%26date%3D2000%26volume%3D100%26spage%3D3697%26epage%3D3714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kugler-Steigmeier, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friederich, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graf, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlatter, C.</span><span> </span><span class="NLM_article-title">Genotoxicity of aniline derivatives in various short-term tests</span> <span class="citation_source-journal">Mutat. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">211</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">289</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2F0027-5107%2889%2990011-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=2494442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADyaL1MXitVOmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=211&publication_year=1989&pages=279-289&author=M.+E.+Kugler-Steigmeierauthor=U.+Friederichauthor=U.+Grafauthor=W.+K.+Lutzauthor=P.+Maierauthor=C.+Schlatter&title=Genotoxicity+of+aniline+derivatives+in+various+short-term+tests"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">Genotoxicity of aniline derivatives in various short-term tests</span></div><div class="casAuthors">Kugler-Steigmeier, M. E.; Friederich, U.; Graf, U.; Lutz, W. K.; Maier, P.; Schlatter, C.</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research, Fundamental and Molecular Mechanisms of Mutagenesis</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">211</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">279-89</span>CODEN:
                <span class="NLM_cas:coden">MUREAV</span>;
        ISSN:<span class="NLM_cas:issn">0027-5107</span>.
    </div><div class="casAbstract">Various substituted aniline derivs. were tested for genotoxicity in several short-term tests to examine the hypothesis that a substitution at both ortho positions (2,6-disubstitution) could prevent genotoxicity due to steric hindrance of an enzymic activation to electrophilic intermediates.  In the Salmonella/microsome assay, 2,6-dialkylsubstituted anilines and 2,4,6-trimethylaniline (2,4,6-TMA) were weakly mutagenic in strain TA100 when 20% S9 mix was used, although effects were small compared to those of 2,4-dimethylaniline and 2,4,5-trimethylaniline (2,4,5-TMA).  In Drosophila melanogaster, however, 2,4,6-TMA and 2,4,6-trichloroaniline were mutagenic in the wing spot test at 2-3 times lower doses than 2,4,5-TMA.  In the 6-thioguanine resistance test in cultured fibroblasts, 2,4,6-TMA was again mutagenic at lower doses than 2,4,5-TMA.  Two methylene-bis-aniline derivs. were also tested with the above methods: 4,4'-methylene-bis-[(2-chloroaniline)] (MOCA) was moderately genotoxic in all 3 tests systems whereas 4,4'-methylene-bis-[(2-ethyl-6-methylaniline)] (MMEA) showed no genotoxicity at all.  DNA binding studies in rats, however, revealed that MOCA and MMEA produced DNA adducts in the liver at levels typically found for moderately strong genotoxic carcinogens.  Thus, the predictive value of the in vitro test systems and particularly the Salmonella/microsome assay is inadequate to detect genotoxicity in arom. amines.  Genotoxicity seems to be a general property of aniline derivs. and does not seem to be greatly influenced by substitution at both ortho positions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7X8K383lt8bVg90H21EOLACvtfcHk0lh5Mvw7NjPMYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXitVOmtbg%253D&md5=f362df1cf93da42f697b7ca4d19ff59f</span></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1016%2F0027-5107%2889%2990011-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0027-5107%252889%252990011-0%26sid%3Dliteratum%253Aachs%26aulast%3DKugler-Steigmeier%26aufirst%3DM.%2BE.%26aulast%3DFriederich%26aufirst%3DU.%26aulast%3DGraf%26aufirst%3DU.%26aulast%3DLutz%26aufirst%3DW.%2BK.%26aulast%3DMaier%26aufirst%3DP.%26aulast%3DSchlatter%26aufirst%3DC.%26atitle%3DGenotoxicity%2520of%2520aniline%2520derivatives%2520in%2520various%2520short-term%2520tests%26jtitle%3DMutat.%2520Res.%26date%3D1989%26volume%3D211%26spage%3D279%26epage%3D289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Shamovsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ripa, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Börjesson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordén, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasselgren, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjö, P.</span><span> </span><span class="NLM_article-title">Explanation for main features of structure–genotoxicity relationships of aromatic amines by theoretical studies of their activation pathways in CYP1A2</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">16168</span><span class="NLM_x">–</span> <span class="NLM_lpage">16185</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja206427u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=16168-16185&author=I.+Shamovskyauthor=L.+Ripaauthor=L.+B%C3%B6rjessonauthor=C.+Meeauthor=B.+Nord%C3%A9nauthor=P.+Hansenauthor=C.+Hasselgrenauthor=M.+O%E2%80%99Donovanauthor=P.+Sj%C3%B6&title=Explanation+for+main+features+of+structure%E2%80%93genotoxicity+relationships+of+aromatic+amines+by+theoretical+studies+of+their+activation+pathways+in+CYP1A2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23c&amp;dbid=16384&amp;doi=10.1021%2Fja206427u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja206427u%26sid%3Dliteratum%253Aachs%26aulast%3DShamovsky%26aufirst%3DI.%26aulast%3DRipa%26aufirst%3DL.%26aulast%3DB%25C3%25B6rjesson%26aufirst%3DL.%26aulast%3DMee%26aufirst%3DC.%26aulast%3DNord%25C3%25A9n%26aufirst%3DB.%26aulast%3DHansen%26aufirst%3DP.%26aulast%3DHasselgren%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%26aulast%3DSj%25C3%25B6%26aufirst%3DP.%26atitle%3DExplanation%2520for%2520main%2520features%2520of%2520structure%25E2%2580%2593genotoxicity%2520relationships%2520of%2520aromatic%2520amines%2520by%2520theoretical%2520studies%2520of%2520their%2520activation%2520pathways%2520in%2520CYP1A2%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26spage%3D16168%26epage%3D16185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Garcia, G. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pye, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galbreath, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isovitsch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fradinger, E. A.</span><span> </span><span class="NLM_article-title">The functional group on (<i>E</i>)-4,4′-disubstituted stilbenes influences toxicity and antioxidative activity in differentiated PC-12 cells</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">6355</span><span class="NLM_x">–</span> <span class="NLM_lpage">6359</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=6355-6359&author=G.+X.+Garciaauthor=S.+W.+Larsenauthor=C.+Pyeauthor=M.+Galbreathauthor=R.+Isovitschauthor=E.+A.+Fradinger&title=The+functional+group+on+%28E%29-4%2C4%E2%80%B2-disubstituted+stilbenes+influences+toxicity+and+antioxidative+activity+in+differentiated+PC-12+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%26aufirst%3DG.%2BX.%26aulast%3DLarsen%26aufirst%3DS.%2BW.%26aulast%3DPye%26aufirst%3DC.%26aulast%3DGalbreath%26aufirst%3DM.%26aulast%3DIsovitsch%26aufirst%3DR.%26aulast%3DFradinger%26aufirst%3DE.%2BA.%26atitle%3DThe%2520functional%2520group%2520on%2520%2528E%2529-4%252C4%25E2%2580%25B2-disubstituted%2520stilbenes%2520influences%2520toxicity%2520and%2520antioxidative%2520activity%2520in%2520differentiated%2520PC-12%2520cells%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D6355%26epage%3D6359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Cunningham, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, E.</span><span> </span><span class="NLM_article-title">Hydrolysis of oleylanilide in the rat</span> <span class="citation_source-journal">Arch. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23e&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1007%2FBF01261384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23e&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=6651528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23e&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADyaL3sXmtFWhu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1983&pages=157-162&author=V.+J.+Cunninghamauthor=S.+P.+Tuckerauthor=E.+Bailey&title=Hydrolysis+of+oleylanilide+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23eR"><div class="casContent"><span class="casTitleNuber">23e</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrolysis of oleylanilide in the rat</span></div><div class="casAuthors">Cunningham, V. J.; Tucker, S. P.; Bailey, E.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Toxicology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-62</span>CODEN:
                <span class="NLM_cas:coden">ARTODN</span>;
        ISSN:<span class="NLM_cas:issn">0340-5761</span>.
    </div><div class="casAbstract">The fate of oleylanilide  [637-54-7], administered as a single intragastric dose in rape oil, was studied in rats.  Following a dose of oleyl[U-14C]anilide, ∼60% of the label was recovered in the feces over a 3-day period, and identified principally as unchanged anilide.  Most of the remainder of the dose was recovered in urine as hydrophilic metabolites.  p-Hydroxyacetanilide  [103-90-2], which is a major metabolite of aniline in the rat, was identified in the hydrolyzed samples of urine from anilide-treated rats.  Following administration of [9,10(n)-3H]oleyl[U-14C]-anilide to rats which had been fitted with a cannula in the thoracic lymph duct, the [3H]label which was absorbed was recovered principally in triglycerides showing that extensive hydrolysis of the anilide occurs prior to or during uptake from the gut.  Oleylanilide was identified in lymph by gas chromatog. but amounted to <6% of the dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpPELq46rYJ7Vg90H21EOLACvtfcHk0ljHF15UXxA4Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXmtFWhu70%253D&md5=6140abfffc8bda65bb72fada61ce3e1a</span></div><a href="/servlet/linkout?suffix=cit23e&amp;dbid=16384&amp;doi=10.1007%2FBF01261384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01261384%26sid%3Dliteratum%253Aachs%26aulast%3DCunningham%26aufirst%3DV.%2BJ.%26aulast%3DTucker%26aufirst%3DS.%2BP.%26aulast%3DBailey%26aufirst%3DE.%26atitle%3DHydrolysis%2520of%2520oleylanilide%2520in%2520the%2520rat%26jtitle%3DArch.%2520Toxicol.%26date%3D1983%26volume%3D54%26spage%3D157%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mondelli, M. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silini, E.</span><span> </span><span class="NLM_article-title">Clinical signficance of hepatitis C virus genotypes</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2FS0168-8278%2899%2980377-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252Fos1aktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1999&pages=65-70&issue=Suppl.+1&author=M.+U.+Mondelliauthor=E.+Silini&title=Clinical+signficance+of+hepatitis+C+virus+genotypes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24aR"><div class="casContent"><span class="casTitleNuber">24a</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical significance of hepatitis C virus genotypes</span></div><div class="casAuthors">Mondelli M U; Silini E</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hepatology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">31 Suppl 1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">65-70</span>
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    </div><div class="casAbstract">The advent of genotyping assays has stimulated investigators around the world to study the molecular epidemiology of hepatitis C virus (HCV) infection in specific patient categories, as well as possible correlations with the clinical and histological features of chronic liver disease and response to antiviral treatment.  While a general consensus has been reached on the worldwide epidemiology and distribution of HCV types in certain risk categories (i.e. intravenous drug users), the association between genotype 1b and severe liver disease is still controversial.  Although generalized use of genotyping is not presently recommended for clinical or epidemiological monitoring, several studies emphasize to the importance of HCV genotyping as part of a therapeutic algorithm.  This recommendation is based on overwhelming evidence in support of a correlation between genotype 1 and a poor response to interferon-a alone or in combination with ribavirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTHH6NTPVN1lPx2phytoz6_fW6udTcc2ebfhjbLYOjCprntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252Fos1aktw%253D%253D&md5=4e3961532bb293dd940f40339fad01a0</span></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1016%2FS0168-8278%2899%2980377-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0168-8278%252899%252980377-8%26sid%3Dliteratum%253Aachs%26aulast%3DMondelli%26aufirst%3DM.%2BU.%26aulast%3DSilini%26aufirst%3DE.%26atitle%3DClinical%2520signficance%2520of%2520hepatitis%2520C%2520virus%2520genotypes%26jtitle%3DJ.%2520Hepatol.%26date%3D1999%26volume%3D31%26issue%3DSuppl.%25201%26spage%3D65%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zein, N. N.</span><span> </span><span class="NLM_article-title">Clinical significance of hepatitis C virus genotypes</span> <span class="citation_source-journal">Clin. Microbiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">235</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1128%2FCMR.13.2.223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=10755999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtVOqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2000&pages=223-235&author=N.+N.+Zein&title=Clinical+significance+of+hepatitis+C+virus+genotypes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical significance of hepatitis C virus genotypes</span></div><div class="casAuthors">Zein, Nizar N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-235</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">0893-8512</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review with 149 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIyz_GrutS8LVg90H21EOLACvtfcHk0lgMCO24vHZcYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtVOqs7k%253D&md5=c3dbf9e23541db288f77cfabdf5c2e45</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1128%2FCMR.13.2.223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.13.2.223%26sid%3Dliteratum%253Aachs%26aulast%3DZein%26aufirst%3DN.%2BN.%26atitle%3DClinical%2520significance%2520of%2520hepatitis%2520C%2520virus%2520genotypes%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2000%26volume%3D13%26spage%3D223%26epage%3D235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Simmonds, P.</span><span> </span><span class="NLM_article-title">Genetic diversity and evolution of hepatitis C virus—15 years on</span> <span class="citation_source-journal">J. Gen. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">3173</span><span class="NLM_x">–</span> <span class="NLM_lpage">3188</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1099%2Fvir.0.80401-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=15483230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVSmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2004&pages=3173-3188&author=P.+Simmonds&title=Genetic+diversity+and+evolution+of+hepatitis+C+virus%E2%80%9415+years+on"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24cR"><div class="casContent"><span class="casTitleNuber">24c</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic diversity and evolution of hepatitis C virus - 15 years on</span></div><div class="casAuthors">Simmonds, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3173-3188</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    
            (<span class="NLM_cas:orgname">Society for General Microbiology</span>)
        </div><div class="casAbstract">A review.  In the 15 years since the discovery of hepatitis C virus (HCV), much has been learned about its role as a major causative agent of human liver disease and its ability to persist in the face of host-cell defenses and the immune system.  This review describes what is known about the diversity of HCV, the current classification of HCV genotypes within the family Flaviviridae and how this genetic diversity contributes to its pathogenesis.  On one hand, diversification of HCV was constrained by its intimate adaptation to its host.  Despite the >30% nucleotide sequence divergence between genotypes, HCV variants nevertheless remain remarkably similar in their transmission dynamics, persistence and disease development.  Nowhere is this more evident than in the evolutionary conservation of numerous evasion methods to counteract the cell's innate antiviral defense pathways; this series of highly complex virus-host interactions may represent key components in establishing its ecol. niche in the human liver.  On the other hand, the mutability and large population size of HCV enables it to respond very rapidly to new selection pressures, manifested by immune-driven changes in T- and B-cell epitopes that are encountered on transmission between individuals with different antigen-recognition repertoires.  If human immunodeficiency virus type 1 is a precedent, future therapies that target virus protease or polymerase enzymes may also select very rapidly for antiviral-resistant mutants.  These contrasting aspects of conservatism and adaptability provide a fascinating paradigm in which to explore the complex selection pressures that underlie the evolution of HCV and other persistent viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotwOpXQZprmrVg90H21EOLACvtfcHk0lgMCO24vHZcYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVSmsr0%253D&md5=a07b3411b6b18b5e7ab3cf9bc3b89026</span></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=10.1099%2Fvir.0.80401-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fvir.0.80401-0%26sid%3Dliteratum%253Aachs%26aulast%3DSimmonds%26aufirst%3DP.%26atitle%3DGenetic%2520diversity%2520and%2520evolution%2520of%2520hepatitis%2520C%2520virus%25E2%2580%259415%2520years%2520on%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2004%26volume%3D85%26spage%3D3173%26epage%3D3188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Nainan, O. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alter, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruszon-Moran, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, F.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQuillan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margolis, H. S.</span><span> </span><span class="NLM_article-title">Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">478</span><span class="NLM_x">–</span> <span class="NLM_lpage">484</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2006&pages=478-484&author=O.+V.+Nainanauthor=M.+J.+Alterauthor=D.+Kruszon-Moranauthor=F.-X.+Gaoauthor=G.+Xiaauthor=G.+McQuillanauthor=H.+S.+Margolis&title=Hepatitis+C+virus+genotypes+and+viral+concentrations+in+participants+of+a+general+population+survey+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNainan%26aufirst%3DO.%2BV.%26aulast%3DAlter%26aufirst%3DM.%2BJ.%26aulast%3DKruszon-Moran%26aufirst%3DD.%26aulast%3DGao%26aufirst%3DF.-X.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DMcQuillan%26aufirst%3DG.%26aulast%3DMargolis%26aufirst%3DH.%2BS.%26atitle%3DHepatitis%2520C%2520virus%2520genotypes%2520and%2520viral%2520concentrations%2520in%2520participants%2520of%2520a%2520general%2520population%2520survey%2520in%2520the%2520United%2520States%26jtitle%3DGastroenterology%26date%3D2006%26volume%3D131%26spage%3D478%26epage%3D484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakarla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 2: Investigation of stilbene prolinamides</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">6063</span><span class="NLM_x">–</span> <span class="NLM_lpage">6066</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2Fj.bmcl.2012.08.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=22959243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlajsLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6063-6066&author=D.+R.+St.+Laurentauthor=M.+Belemaauthor=M.+Gaoauthor=J.+Goodrichauthor=R.+Kakarlaauthor=J.+O.+Knipeauthor=J.+A.+Lemmauthor=M.+Liuauthor=O.+D.+Lopezauthor=V.+N.+Nguyenauthor=P.+T.+Nowerauthor=D.+O%E2%80%99Boyleauthor=Y.+Qiuauthor=J.+L.+Romineauthor=M.+H.+Serrano-Wuauthor=J.-H.+Sunauthor=L.+Valeraauthor=F.+Yangauthor=X.+Yangauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+2%3A+Investigation+of+stilbene+prolinamides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">HCV NS5A replication complex inhibitors. Part 2: Investigation of stilbene prolinamides</span></div><div class="casAuthors">St. Laurent, Denis R.; Belema, Makonen; Gao, Min; Goodrich, Jason; Kakarla, Ramesh; Knipe, Jay O.; Lemm, Julie A.; Liu, Mengping; Lopez, Omar D.; Nguyen, Van N.; Nower, Peter T.; O'Boyle, Donald; Qiu, Yuping; Romine, Jeffrey L.; Serrano-Wu, Michael H.; Sun, Jin-Hua; Valera, Lourdes; Yang, Fukang; Yang, Xuejie; Meanwell, Nicholas A.; Snyder, Lawrence B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6063-6066</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein the preliminary structure-activity relationships and early PK characterization for a series of stilbene prolinamides I [R = Me, Ph, PhCH2, (R)-PhCHMe, 3-pyridylmethyl, 3-indolyl, etc.] and their analogs that formed a basis for the ultimate identification of daclatasvir (BMS-79052), a compd. that has demonstrated clin. proof-of-concept for inhibiting the NS5A replication complex in the treatment of HCV infection, are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vTKMN_UrxLVg90H21EOLACvtfcHk0ljzkksRH90lmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlajsLjK&md5=48ceadc7d3a60a5f99c0d02984e3a2b4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.049%26sid%3Dliteratum%253Aachs%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DGoodrich%26aufirst%3DJ.%26aulast%3DKakarla%26aufirst%3DR.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25202%253A%2520Investigation%2520of%2520stilbene%2520prolinamides%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6063%26epage%3D6066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ripka, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 3: Discovery of potent analogs with distinct core topologies</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">779</span><span class="NLM_x">–</span> <span class="NLM_lpage">784</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=779-784&author=O.+D.+Lopezauthor=V.+N.+Nguyenauthor=D.+R.+St.+Laurentauthor=M.+Belemaauthor=M.+H.+Serrano-Wuauthor=J.+T.+Goodrichauthor=F.+Yangauthor=Y.+Qiuauthor=A.+S.+Ripkaauthor=P.+T.+Nowerauthor=L.+Valeraauthor=M.+Liuauthor=D.+R.+O%E2%80%99Boyleauthor=J.-H.+Sunauthor=R.+A.+Fridellauthor=J.+A.+Lemmauthor=M.+Gaoauthor=A.+C.+Goodauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+3%3A+Discovery+of+potent+analogs+with+distinct+core+topologies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DGoodrich%26aufirst%3DJ.%2BT.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DRipka%26aufirst%3DA.%2BS.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25203%253A%2520Discovery%2520of%2520potent%2520analogs%2520with%2520distinct%2520core%2520topologies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D779%26epage%3D784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 4: Optimization for genotype 1a replicon inhibitory activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1976</span><span class="NLM_x">–</span> <span class="NLM_lpage">1994</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301796k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1976-1994&author=D.+R.+St.+Laurentauthor=M.+H.+Serrano-Wuauthor=M.+Belemaauthor=M.+Dingauthor=H.+Fangauthor=M.+Gaoauthor=J.+T.+Goodrichauthor=R.+G.+Krauseauthor=J.+A.+Lemmauthor=M.+Liuauthor=O.+D.+Lopezauthor=V.+N.+Nguyenauthor=P.+T.+Nowerauthor=D.+R.+O%E2%80%99Boyleauthor=B.+C.+Pearceauthor=J.+L.+Romineauthor=L.+Valeraauthor=J.-H.+Sunauthor=Y.-K.+Wangauthor=F.+Yangauthor=X.+Yangauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+4%3A+Optimization+for+genotype+1a+replicon+inhibitory+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm301796k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301796k%26sid%3Dliteratum%253Aachs%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DGoodrich%26aufirst%3DJ.%2BT.%26aulast%3DKrause%26aufirst%3DR.%2BG.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DPearce%26aufirst%3DB.%2BC.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DWang%26aufirst%3DY.-K.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25204%253A%2520Optimization%2520for%2520genotype%25201a%2520replicon%2520inhibitory%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1976%26epage%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic HCV NS5A replication complex inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4428</span><span class="NLM_x">–</span> <span class="NLM_lpage">4435</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4428-4435&author=M.+Belemaauthor=V.+N.+Nguyenauthor=D.+R.+St.+Laurentauthor=O.+D.+Lopezauthor=Y.+Qiuauthor=A.+C.+Goodauthor=P.+T.+Nowerauthor=L.+Valeraauthor=D.+R.+O%E2%80%99Boyleauthor=J.-H.+Sunauthor=R.+A.+Fridellauthor=J.+A.+Lemmauthor=M.+Gaoauthor=J.+O.+Knipeauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+5%3A+Discovery+of+potent+and+pan-genotypic+HCV+NS5A+replication+complex+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25205%253A%2520Discovery%2520of%2520potent%2520and%2520pan-genotypic%2520HCV%2520NS5A%2520replication%2520complex%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4428%26epage%3D4435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A replication complex inhibitors. Part 6: The discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotype 1a and 1b replicons</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1995</span><span class="NLM_x">–</span> <span class="NLM_lpage">2012</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm4016203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1995-2012&author=M.+Belemaauthor=V.+N.+Nguyenauthor=J.+L.+Romineauthor=D.+R.+St.+Laurentauthor=O.+D.+Lopezauthor=J.+Goodrichauthor=P.+T.+Nowerauthor=D.+R.+O%E2%80%99Boyleauthor=J.+A.+Lemmauthor=R.+A.+Fridellauthor=M.+Gaoauthor=H.+Fangauthor=R.+G.+Krauseauthor=Y.-K.+Wangauthor=A.+J.+Oliverauthor=A.+C.+Goodauthor=J.+O.+Knipeauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=Hepatitis+C+virus+NS5A+replication+complex+inhibitors.+Part+6%3A+The+discovery+of+a+novel+and+highly+potent+biarylimidazole+chemotype+with+inhibitory+activity+toward+genotype+1a+and+1b+replicons"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm4016203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016203%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DGoodrich%26aufirst%3DJ.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DKrause%26aufirst%3DR.%2BG.%26aulast%3DWang%26aufirst%3DY.-K.%26aulast%3DOliver%26aufirst%3DA.%2BJ.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25206%253A%2520The%2520discovery%2520of%2520a%2520novel%2520and%2520highly%2520potent%2520biarylimidazole%2520chemotype%2520with%2520inhibitory%2520activity%2520toward%2520genotype%25201a%2520and%25201b%2520replicons%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1995%26epage%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachand, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deon, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavoie, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruediger, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantor, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chimalakonda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, L. G.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2013</span><span class="NLM_x">–</span> <span class="NLM_lpage">2032</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm401836p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2013-2032&author=M.+Belemaauthor=V.+N.+Nguyenauthor=C.+Bachandauthor=D.+H.+Deonauthor=J.+T.+Goodrichauthor=C.+A.+Jamesauthor=R.+Lavoieauthor=O.+D.+Lopezauthor=A.+Martelauthor=J.+L.+Romineauthor=E.+H.+Ruedigerauthor=L.+B.+Snyderauthor=D.+R.+St.+Laurentauthor=F.+Yangauthor=J.+Zhuauthor=H.+S.+Wongauthor=D.+R.+Langleyauthor=S.+P.+Adamsauthor=G.+H.+Cantorauthor=A.+Chimalakondaauthor=A.+Furaauthor=B.+M.+Johnsonauthor=J.+O.+Knipeauthor=D.+D.+Parkerauthor=K.+S.+Santoneauthor=R.+A.+Fridellauthor=J.+A.+Lemmauthor=D.+R.+O%E2%80%99Boyleauthor=R.+J.+Colonnoauthor=M.+Gaoauthor=N.+A.+Meanwellauthor=L.+G.+Hamann&title=Hepatitis+C+virus+NS5A+replication+complex+inhibitors%3A+the+discovery+of+daclatasvir"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm401836p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401836p%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DBachand%26aufirst%3DC.%26aulast%3DDeon%26aufirst%3DD.%2BH.%26aulast%3DGoodrich%26aufirst%3DJ.%2BT.%26aulast%3DJames%26aufirst%3DC.%2BA.%26aulast%3DLavoie%26aufirst%3DR.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DMartel%26aufirst%3DA.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DRuediger%26aufirst%3DE.%2BH.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DH.%2BS.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DAdams%26aufirst%3DS.%2BP.%26aulast%3DCantor%26aufirst%3DG.%2BH.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DB.%2BM.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DParker%26aufirst%3DD.%2BD.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%2520replication%2520complex%2520inhibitors%253A%2520the%2520discovery%2520of%2520daclatasvir%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2013%26epage%3D2032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettles, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, L. G.</span><span> </span><span class="NLM_article-title">Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">465</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1038%2Fnature08960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=20410884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2010&pages=96-100&author=M.+Gaoauthor=R.+E.+Nettlesauthor=M.+Belemaauthor=L.+B.+Snyderauthor=V.+N.+Nguyenauthor=R.+A.+Fridellauthor=M.+H.+Serrano-Wuauthor=D.+R.+Langleyauthor=J.-H.+Sunauthor=D.+R.+O%E2%80%99Boyleauthor=J.+A.+Lemmauthor=C.+Wangauthor=J.+O.+Knipeauthor=C.+Chienauthor=R.+J.+Colonnoauthor=D.+M.+Graselaauthor=N.+A.+Meanwellauthor=L.+G.+Hamann&title=Chemical+genetics+strategy+identifies+an+HCV+NS5A+inhibitor+with+a+potent+clinical+effect"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect</span></div><div class="casAuthors">Gao, Min; Nettles, Richard E.; Belema, Makonen; Snyder, Lawrence B.; Nguyen, Van N.; Fridell, Robert A.; Serrano-Wu, Michael H.; Langley, David R.; Sun, Jin-Hua; O'Boyle, Donald R., II; Lemm, Julie A.; Wang, Chunfu; Knipe, Jay O.; Chien, Caly; Colonno, Richard J.; Grasela, Dennis M.; Meanwell, Nicholas A.; Hamann, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">7294</span>),
    <span class="NLM_cas:pages">96-100</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estd. to be approaching 200 million people.  Current therapy relies upon a combination of pegylated interferon-α and ribavirin, a poorly tolerated regimen typically assocd. with less than 50% sustained virol. response rate in those infected with genotype 1 virus.  The development of direct-acting antiviral agents to treat HCV has focused predominantly on inhibitors of the viral enzymes NS3 protease and the RNA-dependent RNA polymerase NS5B.  Here we describe the profile of BMS-790052, a small mol. inhibitor of the HCV NS5A protein that exhibits picomolar half-max. effective concns. (EC50) towards replicons expressing a broad range of HCV genotypes and the JFH-1 genotype 2a infectious virus in cell culture.  In a phase I clin. trial in patients chronically infected with HCV, administration of a single 100-mg dose of BMS-790052 was assocd. with a 3.3 log10 redn. in mean viral load measured 24 h post-dose that was sustained for an addnl. 120 h in two patients infected with genotype 1b virus.  Genotypic anal. of samples taken at baseline, 24 and 144 h post-dose revealed that the major HCV variants obsd. had substitutions at amino-acid positions identified using the in vitro replicon system.  These results provide the first clin. validation of an inhibitor of HCV NS5A, a protein with no known enzymic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations of HCV inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAY7Lig0xT9LVg90H21EOLACvtfcHk0ljnarOpMLJpDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbo%253D&md5=620427e987f2bccd153270cde2ef5027</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnature08960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08960%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DM.%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DChien%26aufirst%3DC.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26atitle%3DChemical%2520genetics%2520strategy%2520identifies%2520an%2520HCV%2520NS5A%2520inhibitor%2520with%2520a%2520potent%2520clinical%2520effect%26jtitle%3DNature%26date%3D2010%26volume%3D465%26spage%3D96%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bachand, C.; Belema, M.; Deon, D. H.; Good, A. C.; Goodrich, J.; James, C. A.; Lavoie, R.; Lopez, O. D.; Martel, A.; Meanwell, N. A.; Nguyen, V. N.; Romine, J. L.; Ruediger, E. H.; Snyder, L. B.; St. Laurent, D. R.; Yang, F.; Langley, D. R.; Wang, G.; Hamann, L. G.</span><span> </span><span class="NLM_article-title">Hepatitis C virus inhibitors</span>. World Patent Application WO-2008-021927, February 21,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=C.+Bachand&author=M.+Belema&author=D.+H.+Deon&author=A.+C.+Good&author=J.+Goodrich&author=C.+A.+James&author=R.+Lavoie&author=O.+D.+Lopez&author=A.+Martel&author=N.+A.+Meanwell&author=V.+N.+Nguyen&author=J.+L.+Romine&author=E.+H.+Ruediger&author=L.+B.+Snyder&author=D.+R.+St.+Laurent&author=F.+Yang&author=D.+R.+Langley&author=G.+Wang&author=L.+G.+Hamann&title=Hepatitis+C+virus+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBachand%26aufirst%3DC.%26atitle%3DHepatitis%2520C%2520virus%2520inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pack, S. K.; Geng, P.; Smith, M. J.; Hamm, J.</span><span> </span><span class="NLM_article-title">Process for synthesizing compounds useful for treating hepatitis C</span>. World Patent Application WO-2009-020825, February 11,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=S.+K.+Pack&author=P.+Geng&author=M.+J.+Smith&author=J.+Hamm&title=Process+for+synthesizing+compounds+useful+for+treating+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPack%26aufirst%3DS.%2BK.%26atitle%3DProcess%2520for%2520synthesizing%2520compounds%2520useful%2520for%2520treating%2520hepatitis%2520C%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Reviriego, C.</span><span> </span><span class="NLM_article-title">Daclatasvir hydrochloride: treatment of hepatitis C virus HCV NS5A inhibitor</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">735</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVCksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=735-739&author=C.+Reviriego&title=Daclatasvir+hydrochloride%3A+treatment+of+hepatitis+C+virus+HCV+NS5A+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33aR"><div class="casContent"><span class="casTitleNuber">33a</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir dihydrochloride: treatment of hepatitis C virus HCV NS5A inhibitor</span></div><div class="casAuthors">Reviriego, C.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">735-739</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) is a major chronic disease and infected individuals are at risk of developing multiple and highly severe liver complications, such as cirrhosis or liver carcinoma.  The current std. of care for the treatment of HCV is a combination of pegylated interferon alfa and ribavirin, a poorly tolerated regimen with limiting side effects and low sustained virol. response rates in genotype 1-infected patients.  Therefore, the exploration of alternative treatment regimens is of utmost importance.  Daclatasvir dihydrochloride (BMS-790052) is a novel, small-mol., first-in-class inhibitor of HCV replication that targets non-structural protein 5A (NS5A).  It has shown impressive clin. efficacy, high selectivity, picomolar activity and broad genotype coverage in vitro.  Daclatasvir is safe and generally well tolerated, and it has a pharmacokinetic profile suggestive of once-daily administration.  With its extraordinary potency and non-overlapping resistance profile, daclatasvir has the potential to be an important component in future combination strategies for HCV therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrALLJfJjhdI7Vg90H21EOLACvtfcHk0ljnarOpMLJpDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVCksr8%253D&md5=5e4a7324e33a0351f609304f88e289cd</span></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReviriego%26aufirst%3DC.%26atitle%3DDaclatasvir%2520hydrochloride%253A%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520HCV%2520NS5A%2520inhibitor%26jtitle%3DDrugs%2520Future%26date%3D2011%26volume%3D36%26spage%3D735%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit33b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Herbst, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span> </span><span class="NLM_article-title">NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1337</span><span class="NLM_x">–</span> <span class="NLM_lpage">1346</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1517%2F13543784.2013.826189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=23931586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVekurzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=1337-1346&author=D.+A.+Herbstauthor=K.+R.+Reddy&title=NS5A+inhibitor%2C+daclatasvir%2C+for+the+treatment+of+chronic+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33bR"><div class="casContent"><span class="casTitleNuber">33b</span><div class="casTitle"><span class="NLM_cas:atitle">NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection</span></div><div class="casAuthors">Herbst, D. Alan; Reddy, K. Rajender</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1337-1346</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Chronic Hepatitis C virus (HCV) infection is a major pandemic.  The current std. of care includes peginterferon and ribavirin plus one of two protease inhibitors, boceprevir and telaprevir, for Genotype 1 patients and peginterferon and ribavirin for all other genotypes.  The treatment landscape is rapidly evolving as a no. of direct-acting antivirals (DAA) are being developed in clin. trials.  Areas covered: , formerly labeled BMS-790052, is a first-in-class HCV NS5A inhibitor that has been demonstrated in Phase I and II trials to have a very potent antiviral effect across all genotypes and to have a potent clin. efficacy in both treatment naive and experienced cohorts.  This review covers the whole spectrum of development of daclatasvir from Phase I to III programs.  Expert opinion: While daclatasvir has pangenotypic activity, it has a lower barrier to resistance in Genotype 1a but has been found to be very effective in Genotype 1b patients.  However, Genotype 1a patients can be successfully treated with the addn. of one or more DAAs alone or in combination with peginterferon and ribavirin.  The future for daclatasvir and other DAAs is very encouraging in that all-oral therapies are likely to be effective and well-tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouHATdIV9yA7Vg90H21EOLACvtfcHk0lhJSBPrY6b9EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVekurzK&md5=d1b220d6ed004a580cd6920ffaecde19</span></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=10.1517%2F13543784.2013.826189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2013.826189%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DD.%2BA.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26atitle%3DNS5A%2520inhibitor%252C%2520daclatasvir%252C%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2013%26volume%3D22%26spage%3D1337%26epage%3D1346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshpande, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. D.</span><span> </span><span class="NLM_article-title">Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">338</span><span class="NLM_x">–</span> <span class="NLM_lpage">348</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1111%2Fj.1365-2893.2010.01314.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=20456634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A280%3ADC%252BC3Mvht1yrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=338-348&author=H.+Moauthor=C.+Yangauthor=K.+Wangauthor=Y.+Wangauthor=M.+Huangauthor=B.+Murrayauthor=X.+Qiauthor=S.-C.+Sunauthor=M.+Deshpandeauthor=G.+Rhodesauthor=M.+D.+Miller&title=Estimation+of+inhibitory+quotient+using+a+comparative+equilibrium+dialysis+assay+for+prediction+of+viral+response+to+hepatitis+C+virus+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34aR"><div class="casContent"><span class="casTitleNuber">34a</span><div class="casTitle"><span class="NLM_cas:atitle">Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors</span></div><div class="casAuthors">Mo H; Yang C; Wang K; Wang Y; Huang M; Murray B; Qi X; Sun S-C; Deshpande M; Rhodes G; Miller M D</div><div class="citationInfo"><span class="NLM_cas:title">Journal of viral hepatitis</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">338-48</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The relationship of inhibitory quotient (IQ) with the virologic response to specific inhibitors of human hepatitis C virus (HCV) and the best method to correct for serum protein binding in calculating IQ have not been addressed.  A common method is to determine a fold shift by comparing the EC(50) values determined in cell culture in the absence and presence of human serum (fold shift in EC(50) ), but this method has a number of disadvantages.  In the present study, the fold shifts in drug concentrations between 100% human plasma (HP) and cell culture medium (CCM) were directly measured using a modified comparative equilibrium dialysis (CED) assay for three HCV protease inhibitors (PIs) and for a novel HCV inhibitor GS-9132.  The fold shift values in drug concentration between the HP and CCM (CED ratio) were ∼1 for SCH-503034, VX-950 and GS-9132 and 13 for BILN-2061.  These values were ∼3-10-fold lower than the fold shift values calculated from the EC(50) assay for all inhibitors except BILN-2061.  Using the CED values, a consistent pharmacokinetic and pharmacodynamic relationship was observed for the four HCV inhibitors analysed.  Specifically, an approximate 1 log(10) reduction in HCV RNA was achieved with an IQ close to 1, while 2-3 and greater log(10) reductions in HCV RNA were achieved with IQ values of 3-5 and greater, respectively.  Thus, use of CED to define IQ provides a predictive and quantitative approach for the assessment of the in vivo potency of HCV PIs and GS-9132.  This method provides a framework for the evaluation of other classes of drugs that are bound by serum proteins but require the presence of serum for in vitro evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWE-deUA9i3xFwe7cAcrfPfW6udTcc2ebhEKyERs5uCrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mvht1yrtw%253D%253D&md5=5d92ab2852b739d5e7b4809b40d3d98e</span></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2893.2010.01314.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2893.2010.01314.x%26sid%3Dliteratum%253Aachs%26aulast%3DMo%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DB.%26aulast%3DQi%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DS.-C.%26aulast%3DDeshpande%26aufirst%3DM.%26aulast%3DRhodes%26aufirst%3DG.%26aulast%3DMiller%26aufirst%3DM.%2BD.%26atitle%3DEstimation%2520of%2520inhibitory%2520quotient%2520using%2520a%2520comparative%2520equilibrium%2520dialysis%2520assay%2520for%2520prediction%2520of%2520viral%2520response%2520to%2520hepatitis%2520C%2520virus%2520inhibitors%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D2011%26volume%3D18%26spage%3D338%26epage%3D348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit34b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Reddy, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morcos, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Pogam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lave, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span> </span><span class="NLM_article-title">Pharmacokinetic/pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">3144</span><span class="NLM_x">–</span> <span class="NLM_lpage">3156</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=3144-3156&author=M.+B.+Reddyauthor=P.+N.+Morcosauthor=S.+Le+Pogamauthor=Y.+Ouauthor=K.+Frankauthor=T.+Laveauthor=P.+Smith&title=Pharmacokinetic%2Fpharmacodynamic+predictors+of+clinical+potency+for+hepatitis+C+virus+nonnucleoside+polymerase+and+protease+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DM.%2BB.%26aulast%3DMorcos%26aufirst%3DP.%2BN.%26aulast%3DLe%2BPogam%26aufirst%3DS.%26aulast%3DOu%26aufirst%3DY.%26aulast%3DFrank%26aufirst%3DK.%26aulast%3DLave%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DP.%26atitle%3DPharmacokinetic%252Fpharmacodynamic%2520predictors%2520of%2520clinical%2520potency%2520for%2520hepatitis%2520C%2520virus%2520nonnucleoside%2520polymerase%2520and%2520protease%2520inhibitors%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D3144%26epage%3D3156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit34c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batonga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montpetit, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jutras, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapeyre, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhéaume, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethell, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span> </span><span class="NLM_article-title">The liver partition coefficient-corrected inhibitory quotient and the pharmacokinetic–pharmacodynamic relationship of directly acting anti-hepatitis C virus agents in humans</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5381</span><span class="NLM_x">–</span> <span class="NLM_lpage">5386</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=5381-5386&author=J.+Duanauthor=G.+Bolgerauthor=M.+Garneauauthor=M.+Amadauthor=J.+Batongaauthor=H.+Montpetitauthor=F.+Otisauthor=M.+Jutrasauthor=N.+Lapeyreauthor=M.+Rh%C3%A9aumeauthor=G.+Kukoljauthor=P.+W.+Whiteauthor=R.+C.+Bethellauthor=M.+G.+Cordingley&title=The+liver+partition+coefficient-corrected+inhibitory+quotient+and+the+pharmacokinetic%E2%80%93pharmacodynamic+relationship+of+directly+acting+anti-hepatitis+C+virus+agents+in+humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DAmad%26aufirst%3DM.%26aulast%3DBatonga%26aufirst%3DJ.%26aulast%3DMontpetit%26aufirst%3DH.%26aulast%3DOtis%26aufirst%3DF.%26aulast%3DJutras%26aufirst%3DM.%26aulast%3DLapeyre%26aufirst%3DN.%26aulast%3DRh%25C3%25A9aume%26aufirst%3DM.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DWhite%26aufirst%3DP.%2BW.%26aulast%3DBethell%26aufirst%3DR.%2BC.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26atitle%3DThe%2520liver%2520partition%2520coefficient-corrected%2520inhibitory%2520quotient%2520and%2520the%2520pharmacokinetic%25E2%2580%2593pharmacodynamic%2520relationship%2520of%2520directly%2520acting%2520anti-hepatitis%2520C%2520virus%2520agents%2520in%2520humans%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D5381%26epage%3D5386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargittai, M. R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raney, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, C. E.</span><span> </span><span class="NLM_article-title">Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">36417</span><span class="NLM_x">–</span> <span class="NLM_lpage">36428</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=36417-36428&author=L.+Huangauthor=J.+Hwangauthor=S.+D.+Sharmaauthor=M.+R.+S.+Hargittaiauthor=Y.+Chenauthor=J.+J.+Arnoldauthor=K.+D.+Raneyauthor=C.+E.+Cameron&title=Hepatitis+C+virus+nonstructural+protein+5A+%28NS5A%29+is+an+RNA-binding+protein"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DHwang%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%2BD.%26aulast%3DHargittai%26aufirst%3DM.%2BR.%2BS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DArnold%26aufirst%3DJ.%2BJ.%26aulast%3DRaney%26aufirst%3DK.%2BD.%26aulast%3DCameron%26aufirst%3DC.%2BE.%26atitle%3DHepatitis%2520C%2520virus%2520nonstructural%2520protein%25205A%2520%2528NS5A%2529%2520is%2520an%2520RNA-binding%2520protein%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D36417%26epage%3D36428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hwang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordek, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kihara, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raney, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kao, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, C. E.</span><span> </span><span class="NLM_article-title">Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">12480</span><span class="NLM_x">–</span> <span class="NLM_lpage">12491</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1128%2FJVI.01319-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=20926572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVaruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=12480-12491&author=J.+Hwangauthor=L.+Huangauthor=D.+G.+Cordekauthor=R.+Vaughanauthor=S.+L.+Reynoldsauthor=G.+Kiharaauthor=K.+D.+Raneyauthor=C.+C.+Kaoauthor=C.+E.+Cameron&title=Hepatitis+C+virus+nonstructural+protein+5A%3A+biochemical+characterization+of+a+novel+structural+class+of+RNA-binding+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35bR"><div class="casContent"><span class="casTitleNuber">35b</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins</span></div><div class="casAuthors">Hwang, Jungwook; Huang, Luyun; Cordek, Daniel G.; Vaughan, Robert; Reynolds, Shelley L.; Kihara, George; Raney, Kevin D.; Kao, C. Cheng; Cameron, Craig E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">12480-12491</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) nonstructural protein 5A (NS5A) exhibits a preference for G/U-rich RNA in vitro.  Biol. anal. of the NS5A RNA-binding activity and its target sites in the genome will be facilitated by a description of the NS5A-RNA complex.  We demonstrate that the C-4 carbonyl of the uracil base and, by inference, the C-6 carbonyl of the guanine base interact with NS5A.  U-rich RNA of 5 to 6 nucleotides (nt) is sufficient for high-affinity binding to NS5A.  The minimal RNA-binding domain of NS5A consists of residues 2005 to 2221 (referred to as domain I-plus).  This region of the protein includes the amino-terminal domain I as well as the subsequent linker that separates domains I and II.  This linker region is the site of adaptive mutations.  U-rich RNA-binding activity is not obsd. for an NS5A deriv. contg. only residues 2194 to 2419 (domains II and III).  Mass spectrometric anal. of an NS5A-poly(rU) complex identified domains I and II as sites for interaction with RNA.  Dimerization of NS5A was demonstrated by glutaraldehyde crosslinking.  This dimerization is likely mediated by domain I-plus, as dimers of this protein are trapped by crosslinking.  Dimers of the domain II-III protein are not obsd.  The monomer-dimer equil. of NS5A shifts in favor of dimer when U-rich RNA is present but not when A-rich RNA is present, consistent with an NS5A dimer being the RNA-binding-competent form of the protein.  These data provide a mol. perspective of the NS5A-RNA complex and suggest possible mechanisms for regulation of HCV and cellular gene expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWrqxkVkORnLVg90H21EOLACvtfcHk0lhg1v7G7dCd4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVaruw%253D%253D&md5=fd6bac5b9f24a27c39e63dcdfbb12f4d</span></div><a href="/servlet/linkout?suffix=cit35b&amp;dbid=16384&amp;doi=10.1128%2FJVI.01319-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01319-10%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DCordek%26aufirst%3DD.%2BG.%26aulast%3DVaughan%26aufirst%3DR.%26aulast%3DReynolds%26aufirst%3DS.%2BL.%26aulast%3DKihara%26aufirst%3DG.%26aulast%3DRaney%26aufirst%3DK.%2BD.%26aulast%3DKao%26aufirst%3DC.%2BC.%26aulast%3DCameron%26aufirst%3DC.%2BE.%26atitle%3DHepatitis%2520C%2520virus%2520nonstructural%2520protein%25205A%253A%2520biochemical%2520characterization%2520of%2520a%2520novel%2520structural%2520class%2520of%2520RNA-binding%2520proteins%26jtitle%3DJ.%2520Virol.%26date%3D2010%26volume%3D84%26spage%3D12480%26epage%3D12491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Foster, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belyaeva, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stonehouse, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, M.</span><span> </span><span class="NLM_article-title">All three domains of the hepatitis C virus nonstructural NS5A protein contribute to RNA binding</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">9267</span><span class="NLM_x">–</span> <span class="NLM_lpage">9277</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1128%2FJVI.00616-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=20592076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1WgtLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=9267-9277&author=T.+L.+Fosterauthor=T.+Belyaevaauthor=N.+J.+Stonehouseauthor=A.+R.+Pearsonauthor=M.+Harris&title=All+three+domains+of+the+hepatitis+C+virus+nonstructural+NS5A+protein+contribute+to+RNA+binding"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35cR"><div class="casContent"><span class="casTitleNuber">35c</span><div class="casTitle"><span class="NLM_cas:atitle">All three domains of the hepatitis C virus nonstructural NS5A protein contribute to RNA binding</span></div><div class="casAuthors">Foster, Toshana L.; Belyaeva, Tamara; Stonehouse, Nicola J.; Pearson, Arwen R.; Harris, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">9267-9277</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The hepatitis C virus (HCV) nonstructural protein NS5A is crit. for viral genome replication and is thought to interact directly with both the RNA-dependent RNA polymerase, NS5B, and viral RNA.  NS5A consists of three domains which have, as yet, undefined roles in viral replication and assembly.  To define the regions that mediate the interaction with RNA, specifically the HCV 3' untranslated region (UTR) pos.-strand RNA, constructs of different domain combinations were cloned, bacterially expressed, and purified to homogeneity.  Each of these purified proteins was probed for its ability to interact with the 3' UTR RNA using filter binding and gel electrophoretic mobility shift assays, revealing differences in their RNA binding efficiencies and affinities.  A specific interaction between domains I and II of NS5A and the 3' UTR RNA was identified, suggesting that these are the RNA binding domains of NS5A.  Domain III showed low in vitro RNA binding capacity.  Filter binding and competition analyses identified differences between NS5A and NS5B in their specificities for defined regions of the 3' UTR.  The preference of NS5A, in contrast to NS5B, for the polypyrimidine tract highlights an aspect of 3' UTR RNA recognition by NS5A which may play a role in the control or enhancement of HCV genome replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCPXBZZdd7WLVg90H21EOLACvtfcHk0ljlIRFGhuwTmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1WgtLbP&md5=29a7e066d5ac2cc589c0125e3504e9ff</span></div><a href="/servlet/linkout?suffix=cit35c&amp;dbid=16384&amp;doi=10.1128%2FJVI.00616-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00616-10%26sid%3Dliteratum%253Aachs%26aulast%3DFoster%26aufirst%3DT.%2BL.%26aulast%3DBelyaeva%26aufirst%3DT.%26aulast%3DStonehouse%26aufirst%3DN.%2BJ.%26aulast%3DPearson%26aufirst%3DA.%2BR.%26aulast%3DHarris%26aufirst%3DM.%26atitle%3DAll%2520three%2520domains%2520of%2520the%2520hepatitis%2520C%2520virus%2520nonstructural%2520NS5A%2520protein%2520contribute%2520to%2520RNA%2520binding%26jtitle%3DJ.%2520Virol.%26date%3D2010%26volume%3D84%26spage%3D9267%26epage%3D9277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Lim, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterju, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordek, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Rivera, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Targett-Adams, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallay, P. A.</span><span> </span><span class="NLM_article-title">Correlation between NS5A dimerization and HCV replication</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">30861</span><span class="NLM_x">–</span> <span class="NLM_lpage">30873</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=30861-30873&author=P.+J.+Limauthor=U.+Chatterjuauthor=D.+Cordekauthor=S.+D.+Sharmaauthor=J.+A.+Garcia-Riveraauthor=C.+E.+Cameronauthor=K.+Linauthor=P.+Targett-Adamsauthor=P.+A.+Gallay&title=Correlation+between+NS5A+dimerization+and+HCV+replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DP.%2BJ.%26aulast%3DChatterju%26aufirst%3DU.%26aulast%3DCordek%26aufirst%3DD.%26aulast%3DSharma%26aufirst%3DS.%2BD.%26aulast%3DGarcia-Rivera%26aufirst%3DJ.%2BA.%26aulast%3DCameron%26aufirst%3DC.%2BE.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DTargett-Adams%26aufirst%3DP.%26aulast%3DGallay%26aufirst%3DP.%2BA.%26atitle%3DCorrelation%2520between%2520NS5A%2520dimerization%2520and%2520HCV%2520replication%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D30861%26epage%3D30873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Targett-Adams, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, E. J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavender, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brain, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakenhut, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stammen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pryde, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickford, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westby, M.</span><span> </span><span class="NLM_article-title">Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">6353</span><span class="NLM_x">–</span> <span class="NLM_lpage">6368</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1128%2FJVI.00215-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=21507963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFOntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=6353-6368&author=P.+Targett-Adamsauthor=E.+J.+S.+Grahamauthor=J.+Middletonauthor=A.+Palmerauthor=S.+M.+Shawauthor=H.+Lavenderauthor=P.+Brainauthor=T.+D.+Tranauthor=L.+H.+Jonesauthor=F.+Wakenhutauthor=B.+Stammenauthor=D.+Prydeauthor=C.+Pickfordauthor=M.+Westby&title=Small+molecules+targeting+hepatitis+C+virus-encoded+NS5A+cause+subcellular+redistribution+of+their+target%3A+insights+into+compound+modes+of+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37aR"><div class="casContent"><span class="casTitleNuber">37a</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: Insights into compound modes of action</span></div><div class="casAuthors">Targett-Adams, Paul; Graham, Emily J. S.; Middleton, Jenny; Palmer, Amy; Shaw, Stephen M.; Lavender, Helen; Brain, Philip; Tran, Thien Duc; Jones, Lyn H.; Wakenhut, Florian; Stammen, Blanda; Pryde, David; Pickford, Chris; Westby, Mike</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6353-6368</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The current std. of care for hepatitis C virus (HCV)-infected patients consists of lengthy treatment with interferon and ribavirin.  To increase the effectiveness of HCV therapy, future regimens will incorporate multiple direct-acting antiviral (DAA) drugs.  Recently, the HCV-encoded NS5A protein has emerged as a promising DAA target.  Compds. targeting NS5A exhibit remarkable potency in vitro and demonstrate early clin. promise, suggesting that NS5A inhibitors could feature in future DAA combination therapies.  Since the mechanisms through which these mols. operate are unknown, we have used NS5A inhibitors as tools to investigate their modes of action.  Anal. of replicon-contg. cells revealed dramatic phenotypic alterations in NS5A localization following treatment with NS5A inhibitors; NS5A was redistributed from the endoplasmic reticulum to lipid droplets.  The NS5A relocalization did not occur in cells treated with other classes of HCV inhibitors, and NS5A-targeting mols. did not cause similar alterations in the localization of other HCV-encoded proteins.  Time course anal. of the redistribution of NS5A revealed that the transfer of protein to lipid droplets was concomitant with the onset of inhibition, as judged by the kinetic profiles for these compds.  Furthermore, anal. of the kinetic profile of inhibition for a panel of test mols. permitted the sepn. of compds. into different kinetic classes based on their modes of action.  The results from this approach suggested that NS5A inhibitors perturbed the function of new replication complexes, rather than acting on preformed complexes.  The data reveal novel biol. consequences of NS5A inhibition, which may help enable the development of future assay platforms for the identification of new and/or different NS5A inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_D0ZIz1nPk7Vg90H21EOLACvtfcHk0ljlIRFGhuwTmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFOntbg%253D&md5=99efbc4b114c7f8129b43f51b4d584b7</span></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=10.1128%2FJVI.00215-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00215-11%26sid%3Dliteratum%253Aachs%26aulast%3DTargett-Adams%26aufirst%3DP.%26aulast%3DGraham%26aufirst%3DE.%2BJ.%2BS.%26aulast%3DMiddleton%26aufirst%3DJ.%26aulast%3DPalmer%26aufirst%3DA.%26aulast%3DShaw%26aufirst%3DS.%2BM.%26aulast%3DLavender%26aufirst%3DH.%26aulast%3DBrain%26aufirst%3DP.%26aulast%3DTran%26aufirst%3DT.%2BD.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DWakenhut%26aufirst%3DF.%26aulast%3DStammen%26aufirst%3DB.%26aulast%3DPryde%26aufirst%3DD.%26aulast%3DPickford%26aufirst%3DC.%26aulast%3DWestby%26aufirst%3DM.%26atitle%3DSmall%2520molecules%2520targeting%2520hepatitis%2520C%2520virus-encoded%2520NS5A%2520cause%2520subcellular%2520redistribution%2520of%2520their%2520target%253A%2520insights%2520into%2520compound%2520modes%2520of%2520action%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26spage%3D6353%26epage%3D6368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hang, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leveque, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sklan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elazar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klumpp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, J. S.</span><span> </span><span class="NLM_article-title">The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein</span> <span class="citation_source-journal">Virology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">414</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2Fj.virol.2011.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=21513964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvVyit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=414&publication_year=2011&pages=10-18&author=C.+Leeauthor=H.+Maauthor=J.+Q.+Hangauthor=V.+Levequeauthor=E.+H.+Sklanauthor=M.+Elazarauthor=K.+Klumppauthor=J.+S.+Glenn&title=The+hepatitis+C+virus+NS5A+inhibitor+%28BMS-790052%29+alters+the+subcellular+localization+of+the+NS5A+non-structural+viral+protein"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37bR"><div class="casContent"><span class="casTitleNuber">37b</span><div class="casTitle"><span class="NLM_cas:atitle">The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein</span></div><div class="casAuthors">Lee, Choongho; Ma, Han; Hang, Julie Qi; Leveque, Vincent; Sklan, Ella H.; Elazar, Menashe; Klumpp, Klaus; Glenn, Jeffrey S.</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">414</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-18</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The hepatitis C virus (HCV) non-structural (NS) 5A protein plays an essential role in the replication of the viral RNA by the membrane-assocd. replication complex (RC).  Recently, a putative NS5A inhibitor, BMS-790052, exhibited the highest potency of any known anti-HCV compd. in inhibiting HCV replication in vitro and showed a promising clin. effect in HCV-infected patients.  The precise mechanism of action for this new class of potential anti-HCV therapeutics, however, is still unclear.  In order to gain further insight into its mode of action, we sought to test the hypothesis that the antiviral effect of BMS-790052 might be mediated by interfering with the functional assembly of the HCV RC.  We obsd. that BMS-790052 indeed altered the subcellular localization and biochem. fractionation of NS5A.  Taken together, our data suggest that NS5A inhibitors such as BMS-790052 can suppress viral genome replication by altering the proper localization of NS5A into functional RCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYMSRcOmX36rVg90H21EOLACvtfcHk0lhD0kZbcGccIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvVyit7c%253D&md5=b4212a1dd1365aedfd384e685afdefeb</span></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2011.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2011.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DHang%26aufirst%3DJ.%2BQ.%26aulast%3DLeveque%26aufirst%3DV.%26aulast%3DSklan%26aufirst%3DE.%2BH.%26aulast%3DElazar%26aufirst%3DM.%26aulast%3DKlumpp%26aufirst%3DK.%26aulast%3DGlenn%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520hepatitis%2520C%2520virus%2520NS5A%2520inhibitor%2520%2528BMS-790052%2529%2520alters%2520the%2520subcellular%2520localization%2520of%2520the%2520NS5A%2520non-structural%2520viral%2520protein%26jtitle%3DVirology%26date%3D2011%26volume%3D414%26spage%3D10%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Gao, M.</span> Bristol-Myers Squibb. Personal communication.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Gao%2C+M.+Bristol-Myers+Squibb.+Personal+communication."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DM." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Appel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">From structure to function: new insights into hepatitis C virus RNA replication</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">9833</span><span class="NLM_x">–</span> <span class="NLM_lpage">9836</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=9833-9836&author=N.+Appelauthor=T.+Schallerauthor=F.+Peninauthor=R.+Bartenschlager&title=From+structure+to+function%3A+new+insights+into+hepatitis+C+virus+RNA+replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAppel%26aufirst%3DN.%26aulast%3DSchaller%26aufirst%3DT.%26aulast%3DPenin%26aufirst%3DF.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DFrom%2520structure%2520to%2520function%253A%2520new%2520insights%2520into%2520hepatitis%2520C%2520virus%2520RNA%2520replication%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D9833%26epage%3D9836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Characterizations of HCV NS5A replication complex inhibitors</span> <span class="citation_source-journal">Virology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">444</span><span class="NLM_x">, </span> <span class="NLM_fpage">343</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=444&publication_year=2013&pages=343-354&author=D.+R.+O%E2%80%99Boyleauthor=J.-H.+Sunauthor=P.+Nowerauthor=J.+Lemmauthor=R.+Fridellauthor=C.+Wangauthor=J.+L.+Romineauthor=M.+Belemaauthor=V.+Nguyenauthor=D.+R.+St.+Laurentauthor=M.+Serrano-Wuauthor=L.+B.+Snyderauthor=N.+A.+Meanwellauthor=D.+R.+Langleyauthor=M.+Gao&title=Characterizations+of+HCV+NS5A+replication+complex+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DNower%26aufirst%3DP.%26aulast%3DLemm%26aufirst%3DJ.%26aulast%3DFridell%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DV.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DSerrano-Wu%26aufirst%3DM.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DCharacterizations%2520of%2520HCV%2520NS5A%2520replication%2520complex%2520inhibitors%26jtitle%3DVirology%26date%3D2013%26volume%3D444%26spage%3D343%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Ghosh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. H.</span><span> </span><span class="NLM_article-title">Target validation using in-cell small molecule clickable imaging probes</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">–</span> <span class="NLM_lpage">254</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=247-254&author=B.+Ghoshauthor=L.+H.+Jones&title=Target+validation+using+in-cell+small+molecule+clickable+imaging+probes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DB.%26aulast%3DJones%26aufirst%3DL.%2BH.%26atitle%3DTarget%2520validation%2520using%2520in-cell%2520small%2520molecule%2520clickable%2520imaging%2520probes%26jtitle%3DMedChemComm%26date%3D2014%26volume%3D5%26spage%3D247%26epage%3D254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Choo, Q. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overby, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, M.</span><span> </span><span class="NLM_article-title">Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">244</span><span class="NLM_x">, </span> <span class="NLM_fpage">359</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1126%2Fscience.2523562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=2523562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADyaL1MXit1Khtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=244&publication_year=1989&pages=359-362&author=Q.+L.+Chooauthor=G.+Kuoauthor=A.+J.+Weinerauthor=L.+R.+Overbyauthor=D.+W.+Bradleyauthor=M.+Houghton&title=Isolation+of+a+cDNA+clone+derived+from+a+blood-borne+non-A%2C+non-B+viral+hepatitis+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome</span></div><div class="casAuthors">Choo, Qui Lim; Kuo, George; Weiner, Amy J.; Overby, Lacy R.; Bradley, Daniel W.; Houghton, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">244</span>
        (<span class="NLM_cas:issue">4902</span>),
    <span class="NLM_cas:pages">359-62</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A random-primed cDNA library was constructed from plasma contg. the uncharacterized non-A, non-B hepatitis (NANBH) agent and screened with serum from a patient diagnosed with NANBH.  A cDNA clone was isolated that was shown to encode an antigen assocd. specifically with NANBH infections.  This clone is not derived from host DNA but from an RNA mol. present in NANBH infections that consists of ≥10,000 nucleotides, and that is pos.-stranded with respect to the encoded NANBH antigen.  These data indicate that this clone is derived from the genome of the NANBH agent and are consistent with the agent being similar to the togaviridae or flaviviridae.  This mol. approach should be of great value in the isolation and characterization of other unidentified infectious agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqorpVFx7nEkrVg90H21EOLACvtfcHk0lhqSV_lD6FT6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXit1Khtrk%253D&md5=25161cf212790856dd29d3aaf78f20b8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1126%2Fscience.2523562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2523562%26sid%3Dliteratum%253Aachs%26aulast%3DChoo%26aufirst%3DQ.%2BL.%26aulast%3DKuo%26aufirst%3DG.%26aulast%3DWeiner%26aufirst%3DA.%2BJ.%26aulast%3DOverby%26aufirst%3DL.%2BR.%26aulast%3DBradley%26aufirst%3DD.%2BW.%26aulast%3DHoughton%26aufirst%3DM.%26atitle%3DIsolation%2520of%2520a%2520cDNA%2520clone%2520derived%2520from%2520a%2520blood-borne%2520non-A%252C%2520non-B%2520viral%2520hepatitis%2520genome%26jtitle%3DScience%26date%3D1989%26volume%3D244%26spage%3D359%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chevaliez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawlotsky, J.-M.</span><span> </span><span class="NLM_article-title">Interferon-based therapy of hepatitis C</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1222</span><span class="NLM_x">–</span> <span class="NLM_lpage">1241</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2Fj.addr.2007.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=17869375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1yls73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2007&pages=1222-1241&author=S.+Chevaliezauthor=J.-M.+Pawlotsky&title=Interferon-based+therapy+of+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43aR"><div class="casContent"><span class="casTitleNuber">43a</span><div class="casTitle"><span class="NLM_cas:atitle">Interferon-based therapy of hepatitis C</span></div><div class="casAuthors">Chevaliez, Stephane; Pawlotsky, Jean-Michel</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1222-1241</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In 2007, the world celebrated the 50th anniversary of the discovery of interferon (IFN).  The first clin. trial of recombinant IFN-α in patients with chronic hepatitis C was published in 1986.  This article reviews the classification of IFNs, IFN prodn. during viral infections, IFN signaling pathways and the mechanisms of their antiviral and immunomodulatory properties.  Hepatitis C virus infection treatment is currently based on the combination of pegylated IFN-α and ribavirin.  The pegylated IFN-α mols. are described, as well as the putative mechanisms of action of ribavirin.  Current treatment guidelines are discussed and new results suggesting that the treatment schedule should be tailored to the early virol. response during therapy are presented.  Finally, insights into new hepatitis C drug developments are given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppHRhqAbvmRrVg90H21EOLACvtfcHk0lhqSV_lD6FT6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1yls73M&md5=aec8eda578b92a56112b241930ff7b85</span></div><a href="/servlet/linkout?suffix=cit43a&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2007.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2007.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DChevaliez%26aufirst%3DS.%26aulast%3DPawlotsky%26aufirst%3DJ.-M.%26atitle%3DInterferon-based%2520therapy%2520of%2520hepatitis%2520C%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2007%26volume%3D59%26spage%3D1222%26epage%3D1241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit43b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Keating, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, M. P.</span><span> </span><span class="NLM_article-title">Peginterferon-α2a (40kD) plus ribavirin—a review of its use in the management of chronic hepatitis C</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">701</span><span class="NLM_x">–</span> <span class="NLM_lpage">730</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=701-730&author=G.+M.+Keatingauthor=M.+P.+Curran&title=Peginterferon-%CE%B12a+%2840kD%29+plus+ribavirin%E2%80%94a+review+of+its+use+in+the+management+of+chronic+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DG.%2BM.%26aulast%3DCurran%26aufirst%3DM.%2BP.%26atitle%3DPeginterferon-%25CE%25B12a%2520%252840kD%2529%2520plus%2520ribavirin%25E2%2580%2594a%2520review%2520of%2520its%2520use%2520in%2520the%2520management%2520of%2520chronic%2520hepatitis%2520C%26jtitle%3DDrugs%26date%3D2003%26volume%3D63%26spage%3D701%26epage%3D730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Sulkowski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunyady, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogurtsov, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peck-Radosavljevic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiffman, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yurdaydin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgard, O.</span><span> </span><span class="NLM_article-title">Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">212</span><span class="NLM_x">–</span> <span class="NLM_lpage">223</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1038%2Fnrgastro.2011.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=21386812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFKntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=212-223&author=M.+S.+Sulkowskiauthor=C.+Cooperauthor=B.+Hunyadyauthor=J.+Jiaauthor=P.+Ogurtsovauthor=M.+Peck-Radosavljevicauthor=M.+L.+Shiffmanauthor=C.+Yurdaydinauthor=O.+Dalgard&title=Management+of+adverse+effects+of+Peg-IFN+and+ribavirin+therapy+for+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C</span></div><div class="casAuthors">Sulkowski, Mark S.; Cooper, Curtis; Hunyady, Bela; Jia, Jidong; Ogurtsov, Pavel; Peck-Radosavljevic, Markus; Shiffman, Mitchell L.; Yurdaydin, Cihan; Dalgard, Olav</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">212-223</span>CODEN:
                <span class="NLM_cas:coden">NRGHA9</span>;
        ISSN:<span class="NLM_cas:issn">1759-5045</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A major barrier to hepatitis C treatment uptake and delivery is the assocn. of this therapy with frequent, and at times serious, adverse effects.  This Review article provides a comprehensive literature review that systematically describes the adverse effects of Peg-IFN-α and ribavirin on various organ systems and, more importantly, recommends consensus approaches to managing those effects.  HCV infects approx. 2-3% of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma.  Treatment of HCV infection with Peg-IFN in combination with ribavirin can eradicate HCV infection in 40-90% of patients; however, a major barrier to treatment uptake and delivery is the assocn. of this therapy with frequent and, at times, serious adverse effects.  Recognition and effective management of these adverse effects are crit. components of the successful treatment of chronic HCV infection.  In clin. trials, approx. 10-15% of patients discontinue Peg-IFN and ribavirin therapy due to adverse effects; however, in clin. practice, the rate of treatment discontinuation has been reported to be substantially higher.  The off-target effect of Peg-IFN and ribavirin impacts most, if not all, organ systems; the most common adverse effects are hematol., dermatol., neurol., immunol., gastrointestinal, pulmonary, cardiovascular, and ocular.  Regional and global variability exists in the nature of these adverse effects and the strategies employed to ameliorate their impact.  This article provides a comprehensive literature review that systematically describes the adverse effects of Peg-IFN-α and ribavirin on various organ systems and, more importantly, recommends consensus approaches to managing those effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr33IzKUC2BjLVg90H21EOLACvtfcHk0lhqSV_lD6FT6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFKntr0%253D&md5=ca3908f7d85bd8b857c1c7e9429a769f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2011.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2011.21%26sid%3Dliteratum%253Aachs%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DHunyady%26aufirst%3DB.%26aulast%3DJia%26aufirst%3DJ.%26aulast%3DOgurtsov%26aufirst%3DP.%26aulast%3DPeck-Radosavljevic%26aufirst%3DM.%26aulast%3DShiffman%26aufirst%3DM.%2BL.%26aulast%3DYurdaydin%26aufirst%3DC.%26aulast%3DDalgard%26aufirst%3DO.%26atitle%3DManagement%2520of%2520adverse%2520effects%2520of%2520Peg-IFN%2520and%2520ribavirin%2520therapy%2520for%2520hepatitis%2520C%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2011%26volume%3D8%26spage%3D212%26epage%3D223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Guedj, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sansone, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettles, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotler, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Layden, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uprichard, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">3991</span><span class="NLM_x">–</span> <span class="NLM_lpage">3996</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1073%2Fpnas.1203110110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=23431163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVWms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=3991-3996&author=J.+Guedjauthor=H.+Dahariauthor=L.+Rongauthor=N.+D.+Sansoneauthor=R.+E.+Nettlesauthor=S.+J.+Cotlerauthor=T.+J.+Laydenauthor=S.+L.+Uprichardauthor=A.+S.+Perelson&title=Modeling+shows+that+the+NS5A+inhibitor+daclatasvir+has+two+modes+of+action+and+yields+a+shorter+estimate+of+the+hepatitis+C+virus+half-life"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life</span></div><div class="casAuthors">Guedj, Jeremie; Dahari, Harel; Rong, Libin; Sansone, Natasha D.; Nettles, Richard E.; Cotler, Scott J.; Layden, Thomas J.; Uprichard, Susan L.; Perelson, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3991-3996, S3991/1-S3991/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The nonstructural 5A (NS5A) protein is a target for drug development against hepatitis C virus (HCV).  Interestingly, the NS5A inhibitor daclatasvir (BMS-790052) caused a decrease in serum HCV RNA levels by about two orders of magnitude within 6 h of administration.  However, NS5A has no known enzymic functions, making it difficult to understand daclatasvir's mode of action (MOA) and to est. its antiviral effectiveness.  Modeling viral kinetics during therapy has provided important insights into the MOA and effectiveness of a variety of anti-HCV agents.  Here, we show that understanding the effects of daclatasvir in vivo requires a multiscale model that incorporates drug effects on the HCV intracellular lifecycle, and we validated this approach with in vitro HCV infection expts.  The model predicts that daclatasvir efficiently blocks two distinct stages of the viral lifecycle, namely viral RNA synthesis and virion assembly/secretion with mean effectiveness of 99% and 99.8%, resp., and yields a more precise est. of the serum HCV half-life, 45 min, i.e., around four times shorter than previous ests.  Intracellular HCV RNA in HCV-infected cells treated with daclatasvir and the HCV polymerase inhibitor NM107 showed a similar pattern of decline.  However, daclatasvir treatment led to an immediate and rapid decline of extracellular HCV titers compared to a delayed (6-9 h) and slower decline with NM107, confirming an effect of daclatasvir on both viral replication and assembly/secretion.  The multiscale modeling approach, validated with in vitro kinetic expts., brings a unique conceptual framework for understanding the mechanism of action of a variety of agents in development for the treatment of HCV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSYdT4WQUN7LVg90H21EOLACvtfcHk0lhydQl9rxmYDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVWms7g%253D&md5=81f3b8c49b97120f70b440211b4bf979</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1203110110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1203110110%26sid%3Dliteratum%253Aachs%26aulast%3DGuedj%26aufirst%3DJ.%26aulast%3DDahari%26aufirst%3DH.%26aulast%3DRong%26aufirst%3DL.%26aulast%3DSansone%26aufirst%3DN.%2BD.%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DCotler%26aufirst%3DS.%2BJ.%26aulast%3DLayden%26aufirst%3DT.%2BJ.%26aulast%3DUprichard%26aufirst%3DS.%2BL.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DModeling%2520shows%2520that%2520the%2520NS5A%2520inhibitor%2520daclatasvir%2520has%2520two%2520modes%2520of%2520action%2520and%2520yields%2520a%2520shorter%2520estimate%2520of%2520the%2520hepatitis%2520C%2520virus%2520half-life%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2013%26volume%3D110%26spage%3D3991%26epage%3D3996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Nettles, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marbury, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldwater, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMicco, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vutikullird, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuentes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Talavera, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span> </span><span class="NLM_article-title">Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1956</span><span class="NLM_x">–</span> <span class="NLM_lpage">1965</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1956-1965&author=R.+E.+Nettlesauthor=M.+Gaoauthor=M.+Bifanoauthor=E.+Chungauthor=A.+Perssonauthor=T.+C.+Marburyauthor=R.+Goldwaterauthor=M.+P.+DeMiccoauthor=M.+Rodriguez-Torresauthor=A.+Vutikullirdauthor=E.+Fuentesauthor=E.+Lawitzauthor=J.+C.+Lopez-Talaveraauthor=D.+M.+Grasela&title=Multiple+ascending+dose+study+of+BMS-790052%2C+a+nonstructural+protein+5A+replication+complex+inhibitor%2C+in+patients+infected+with+hepatitis+C+virus+genotype+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DBifano%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DE.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DMarbury%26aufirst%3DT.%2BC.%26aulast%3DGoldwater%26aufirst%3DR.%26aulast%3DDeMicco%26aufirst%3DM.%2BP.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DVutikullird%26aufirst%3DA.%26aulast%3DFuentes%26aufirst%3DE.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DLopez-Talavera%26aufirst%3DJ.%2BC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26atitle%3DMultiple%2520ascending%2520dose%2520study%2520of%2520BMS-790052%252C%2520a%2520nonstructural%2520protein%25205A%2520replication%2520complex%2520inhibitor%252C%2520in%2520patients%2520infected%2520with%2520hepatitis%2520C%2520virus%2520genotype%25201%26jtitle%3DHepatology%26date%3D2011%26volume%3D54%26spage%3D1956%26epage%3D1965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Cento, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mirabelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salpini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimonte, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artese, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercurio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svicher, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parrotta, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciotti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Paolo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarrecchia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreoni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alcaro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angelico, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Federico Perno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceccherini-Silberstein, F.</span><span> </span><span class="NLM_article-title">HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">e39652</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e39652&issue=7&author=V.+Centoauthor=C.+Mirabelliauthor=R.+Salpiniauthor=S.+Dimonteauthor=A.+Arteseauthor=G.+Costaauthor=F.+Mercurioauthor=V.+Svicherauthor=L.+Parrottaauthor=A.+Bertoliauthor=M.+Ciottiauthor=D.+Di+Paoloauthor=C.+Sarrecchiaauthor=M.+Andreoniauthor=S.+Alcaroauthor=M.+Angelicoauthor=C.+Federico+Pernoauthor=F.+Ceccherini-Silberstein&title=HCV+genotypes+are+differently+prone+to+the+development+of+resistance+to+linear+and+macrocyclic+protease+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCento%26aufirst%3DV.%26aulast%3DMirabelli%26aufirst%3DC.%26aulast%3DSalpini%26aufirst%3DR.%26aulast%3DDimonte%26aufirst%3DS.%26aulast%3DArtese%26aufirst%3DA.%26aulast%3DCosta%26aufirst%3DG.%26aulast%3DMercurio%26aufirst%3DF.%26aulast%3DSvicher%26aufirst%3DV.%26aulast%3DParrotta%26aufirst%3DL.%26aulast%3DBertoli%26aufirst%3DA.%26aulast%3DCiotti%26aufirst%3DM.%26aulast%3DDi%2BPaolo%26aufirst%3DD.%26aulast%3DSarrecchia%26aufirst%3DC.%26aulast%3DAndreoni%26aufirst%3DM.%26aulast%3DAlcaro%26aufirst%3DS.%26aulast%3DAngelico%26aufirst%3DM.%26aulast%3DFederico%2BPerno%26aufirst%3DC.%26aulast%3DCeccherini-Silberstein%26aufirst%3DF.%26atitle%3DHCV%2520genotypes%2520are%2520differently%2520prone%2520to%2520the%2520development%2520of%2520resistance%2520to%2520linear%2520and%2520macrocyclic%2520protease%2520inhibitors%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26issue%3D7%26spage%3De39652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Nakamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirasawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokosuka, O.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A inhibitors and drug resistance mutations</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2902</span><span class="NLM_x">–</span> <span class="NLM_lpage">2912</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.3748%2Fwjg.v20.i11.2902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=24659881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovFWhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2902-2912&author=S.+Nakamotoauthor=T.+Kandaauthor=S.+Wuauthor=H.+Shirasawaauthor=O.+Yokosuka&title=Hepatitis+C+virus+NS5A+inhibitors+and+drug+resistance+mutations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus NS5A inhibitors and drug resistance mutations</span></div><div class="casAuthors">Nakamoto, Shingo; Kanda, Tatsuo; Wu, Shuang; Shirasawa, Hiroshi; Yokosuka, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2902-2912, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">Baishideng Publishing Group Co., Ltd.</span>)
        </div><div class="casAbstract">Some direct-acting antiviral agents for hepatitis C virus (HCV), such as telaprevir and boceprevir have been available since 2011.  It was reported that HCV NS5A is assocd. with interferon signaling related to HCV replication and hepatocarcinogenesis.  HCV NS5A inhibitors efficiently inhibited HCV replication in vitro.  Human studies showed that dual, triple and quad regimens with HCV NS5A inhibitors, such as daclatasvir and ledipasvir, in combination with other direct-acting antiviral agents against other regions of HCV with or without peginterferon/ribavirin, could efficiently inhibit HCV replication according to HCV genotypes.  These combinations might be a powerful tool for "difficult-to-treat" HCV-infected patients. "First generation" HCV NS5A inhibitors such as daclatasvir, ledipasvir and ABT-267, which are now in phase III clin. trials, could result in resistance mutations. "Second generation" NS5A inhibitors such as GS-5816, ACH-3102, and MK-8742, have displayed improvements in the genetic barrier while maintaining potency.  HCV NS5A inhibitors are safe at low concns., which make them attractive for use despite low genetic barriers, although, in fact, HCV NS5A inhibitors should be used with HCV NS3/4A inhibitors, HCV NS5B inhibitors or peginterferon plus ribavirin.  This review article describes HCV NS5A inhibitor resistance mutations and recommends that HCV NS5A inhibitors be used in combination regimens potent enough to prevent the emergence of resistant variants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaLRN4u5IUN7Vg90H21EOLACvtfcHk0lhDJgBvh1bNug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovFWhsL4%253D&md5=b068987f16ed03672fb57194e492264d</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v20.i11.2902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v20.i11.2902%26sid%3Dliteratum%253Aachs%26aulast%3DNakamoto%26aufirst%3DS.%26aulast%3DKanda%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DShirasawa%26aufirst%3DH.%26aulast%3DYokosuka%26aufirst%3DO.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%2520inhibitors%2520and%2520drug%2520resistance%2520mutations%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2014%26volume%3D20%26spage%3D2902%26epage%3D2912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matorell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatum, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hezode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronowicki, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reindollar, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diva, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hindes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnittman, S.</span><span> </span><span class="NLM_article-title">Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomized, parallel-group, double-blind, placebo-controlled, dose-finding phase 2a trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">677</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2FS1473-3099%2812%2970138-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=22714001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GlsL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=671-677&author=S.+Polauthor=R.+H.+Ghalibauthor=V.+K.+Rustgiauthor=C.+Matorellauthor=G.+T.+Eversonauthor=H.+A.+Tatumauthor=C.+Hezodeauthor=J.+K.+Limauthor=J.+P.+Bronowickiauthor=G.+A.+Abramsauthor=N.+Brauauthor=D.+W.+Morrisauthor=P.+J.+Thuluvathauthor=R.+W.+Reindollarauthor=P.+D.+Yinauthor=U.+Divaauthor=R.+Hindesauthor=F.+McPheeauthor=D.+Hernandezauthor=M.+Wind-Rotoloauthor=E.+A.+Hughesauthor=S.+Schnittman&title=Daclatasvir+for+previously+untreated+chronic+hepatitis+C+genotype-1+infection%3A+a+randomized%2C+parallel-group%2C+double-blind%2C+placebo-controlled%2C+dose-finding+phase+2a+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial</span></div><div class="casAuthors">Pol, Stanislas; Ghalib, Reem H.; Rustgi, Vinod K.; Martorell, Claudia; Everson, Greg T.; Tatum, Harvey A.; Hezode, Christophe; Lim, Joseph K.; Bronowicki, Jean-Pierre; Abrams, Gary A.; Braeu, Norbert; Morris, David W.; Thuluvath, Paul J.; Reindollar, Robert W.; Yin, Philip D.; Diva, Ulysses; Hindes, Robert; McPhee, Fiona; Hernandez, Dennis; Wind-Rotolo, Megan; Hughes, Eric A.; Schnittman, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">671-677</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Several direct-acting antivirals for chronic hepatitis C virus (HCV) infection are available, but they are limited by tolerability and dosing schedules.  Once-daily daclatasvir, a potent NS5A replication complex inhibitor, was generally well tolerated in phase 1 studies.  We assessed daclatasvir in combination with pegylated interferon (peginterferon) and ribavirin for chronic HCV.  Methods: In this double-blind, parallel-group, dose-finding, phase 2a study, treatment-naive patients with HCV genotype-1 infection (without cirrhosis) from 14 centers in the USA and France were randomly assigned (1:1:1:1) to receive peginterferon alfa-2a (180 μg per wk) and ribavirin (1000-1200 mg daily) plus placebo or 3 mg, 10 mg, or 60 mg of daclatasvir taken once daily, for 48 wk.  The primary efficacy endpoint was undetectable HCV RNA at 4 wk and 12 wk after start of treatment (extended rapid virol. response, eRVR).  Anal. was of all participants who received one dose of study drug.  We used descriptive analyses to compare results.  This study is registered with ClinicalTrials.gov, no. NCT00874770.  Findings: 48 patients were randomly assigned (12 per group); all received at least one dose of study drug. 15 patients discontinued treatment before week 48.  Five of 12 patients (42%, 80% CI 22-64%) who received 3 mg daclatasvir achieved eRVR, compared with ten of 12 (83%, 61-96%) who received 10 mg daclatasvir, nine of 12 (75%, 53-90%) who received 60 mg daclatasvir, and one of 12 (8%, 1-29%) who received placebo.  Adverse events and discontinuations as a result of adverse events occurred with similar frequency across groups.  Interpretation: Daclatasvir seems to be a potent NS5A replication complex inhibitor that increases the antiviral potency of peginterferon and ribavirin.  Our findings support the further development of regimens contg. 60 mg daclatasvir for the treatment of chronic genotype-1 HCV infection.  Funding: Bristol-Myers Squibb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0jrF6ixurObVg90H21EOLACvtfcHk0lhDJgBvh1bNug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GlsL%252FJ&md5=fb310d15629ecd376196a92faa8291ba</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2812%2970138-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252812%252970138-X%26sid%3Dliteratum%253Aachs%26aulast%3DPol%26aufirst%3DS.%26aulast%3DGhalib%26aufirst%3DR.%2BH.%26aulast%3DRustgi%26aufirst%3DV.%2BK.%26aulast%3DMatorell%26aufirst%3DC.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DTatum%26aufirst%3DH.%2BA.%26aulast%3DHezode%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DBronowicki%26aufirst%3DJ.%2BP.%26aulast%3DAbrams%26aufirst%3DG.%2BA.%26aulast%3DBrau%26aufirst%3DN.%26aulast%3DMorris%26aufirst%3DD.%2BW.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DReindollar%26aufirst%3DR.%2BW.%26aulast%3DYin%26aufirst%3DP.%2BD.%26aulast%3DDiva%26aufirst%3DU.%26aulast%3DHindes%26aufirst%3DR.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26aulast%3DSchnittman%26aufirst%3DS.%26atitle%3DDaclatasvir%2520for%2520previously%2520untreated%2520chronic%2520hepatitis%2520C%2520genotype-1%2520infection%253A%2520a%2520randomized%252C%2520parallel-group%252C%2520double-blind%252C%2520placebo-controlled%252C%2520dose-finding%2520phase%25202a%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D12%26spage%3D671%26epage%3D677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lok, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martorell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reindollar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrova, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span> </span><span class="NLM_article-title">Preliminary study of two antiviral agents for hepatitis C genotype 1</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">216</span><span class="NLM_x">–</span> <span class="NLM_lpage">224</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50a&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1056%2FNEJMoa1104430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50a&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=22256805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50a&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=216-224&author=A.+S.+Lokauthor=D.+F.+Gardinerauthor=E.+Lawitzauthor=C.+Martorellauthor=G.+T.+Eversonauthor=R.+Ghalibauthor=R.+Reindollarauthor=V.+Rustgiauthor=F.+McPheeauthor=M.+Wind-Rotoloauthor=A.+Perssonauthor=K.+Zhuauthor=D.+I.+Dimitrovaauthor=T.+Eleyauthor=T.+Guoauthor=D.+M.+Graselaauthor=C.+Pasquinelli&title=Preliminary+study+of+two+antiviral+agents+for+hepatitis+C+genotype+1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50aR"><div class="casContent"><span class="casTitleNuber">50a</span><div class="casTitle"><span class="NLM_cas:atitle">Preliminary study of two antiviral agents for hepatitis C genotype 1</span></div><div class="casAuthors">Lok, Anna S.; Gardiner, David F.; Lawitz, Eric; Martorell, Claudia; Everson, Gregory T.; Ghalib, Reem; Reindollar, Robert; Rustgi, Vinod; McPhee, Fiona; Wind-Rotolo, Megan; Persson, Anna; Zhu, Kurt; Dimitrova, Dessislava I.; Eley, Timothy; Guo, Tong; Grasela, Dennis M.; Pasquinelli, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">216-224</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addn. of multiple direct-acting antiviral agents to their treatment regimen.  METHODS: This open-label, phase 2a study included an exploratory cohort of 21 patients with chronic HCV genotype 1 infection who had not had a response to previous therapy (i.e., had not had ≥2 log10 decline in HCV RNA after ≥12 wk of treatment with peginterferon and ribavirin).  We randomly assigned patients to receive the NS5A replication complex inhibitor daclatasvir (60 mg once daily) and the NS3 protease inhibitor asunaprevir (600 mg twice daily) alone (group A, 11 patients) or in combination with peginterferon alfa-2a and ribavirin (group B, 10 patients) for 24 wk.  The primary end point was the percentage of patients with a sustained virol. response 12 wk after the end of the treatment period.  RESULTS: A total of 4 patients in group A (36%; 2 of 9 with HCV genotype la and 2 of 2 with genotype lb) had a sustained virol. response at 12 wk after treatment and also at 24 wk after treatment.  Six patients (all with HCV genotype la) had viral breakthrough while receiving therapy, and resistance mutations to both antiviral agents were found in all cases; 1 patient had a viral response at the end of treatment but had a relapse after the treatment period.  All 10 patients in group B had a sustained virol. response at 12 wk after treatment, and 9 had a sustained virol. response at 24 wk after treatment Diarrhea was the most common adverse event in both groups.  Six patients had transient elevations of alanine aminotransferase levels to more than 3 times the upper limit of the normal range.  CONCLUSIONS: This preliminary study involving patients with HCV genotype 1 infection who had not had a response to prior therapy showed that a sustained virol. response can be achieved with two direct-acting antiviral agents only.  In addn., a high rate of sustained virol. response was achieved when the two direct-acting antiviral agents were combined with peginterferon alfa-2a and ribavirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiY7QiDziiRbVg90H21EOLACvtfcHk0lgg1eDZu9r-OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yltrw%253D&md5=5b986bac6ea53144898c91e8e2eaf5bc</span></div><a href="/servlet/linkout?suffix=cit50a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1104430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1104430%26sid%3Dliteratum%253Aachs%26aulast%3DLok%26aufirst%3DA.%2BS.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DMartorell%26aufirst%3DC.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DGhalib%26aufirst%3DR.%26aulast%3DReindollar%26aufirst%3DR.%26aulast%3DRustgi%26aufirst%3DV.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DDimitrova%26aufirst%3DD.%2BI.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DPasquinelli%26aufirst%3DC.%26atitle%3DPreliminary%2520study%2520of%2520two%2520antiviral%2520agents%2520for%2520hepatitis%2520C%2520genotype%25201%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D216%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit50b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lok, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serfaty, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span> </span><span class="NLM_article-title">Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">490</span><span class="NLM_x">–</span> <span class="NLM_lpage">499</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2Fj.jhep.2013.10.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=24444658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlartw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=490-499&author=A.+S.+Lokauthor=D.+F.+Gardinerauthor=C.+H%C3%A9zodeauthor=E.+J.+Lawitzauthor=M.+Bourli%C3%A8reauthor=G.+T.+Eversonauthor=P.+Marcellinauthor=M.+Rodriguez-Torresauthor=S.+Polauthor=L.+Serfatyauthor=T.+Eleyauthor=S.-P.+Huangauthor=J.+Liauthor=M.+Wind-Rotoloauthor=F.+Yuauthor=F.+McPheeauthor=D.+M.+Graselaauthor=C.+Pasquinelli&title=Randomized+trial+of+daclatasvir+and+asunaprevir+with+or+without+PegIFN%2FRBV+for+hepatitis+C+virus+genotype+1+null+responders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50bR"><div class="casContent"><span class="casTitleNuber">50b</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders</span></div><div class="casAuthors">Lok, Anna S.; Gardiner, David F.; Hezode, Christophe; Lawitz, Eric J.; Bourliere, Marc; Everson, Gregory T.; Marcellin, Patrick; Rodriguez-Torres, Maribel; Pol, Stanislas; Serfaty, Lawrence; Eley, Timothy; Huang, Shu-Pang; Li, Jianling; Wind-Rotolo, Megan; Yu, Fei; McPhee, Fiona; Grasela, Dennis M.; Pasquinelli, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">490-499</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Patients with chronic hepatitis C virus (HCV) infection and prior null response (<2 log HCV RNA decline after ≥12 wk of PegIFN/RBV) have limited options.  We evaluated daclatasvir plus once- or twice-daily asunaprevir in non-cirrhotic genotype 1 null responders.  In this randomized, phase 2a, open-label, 24-wk treatment study, 101 patients received daclatasvir (60 mg) once-daily.  In addn., 38 genotype 1b patients received asunaprevir (200 mg) twice- (DUAL A1) or once-daily (DUAL A2); 36 genotype 1a and 5 genotype 1b patients received asunaprevir twice- (QUAD B1) or once-daily (QUAD B2) plus PegIFN/RBV; and 18 genotype 1a and 4 genotype 1b patients received asunaprevir twice-daily plus ribavirin (TRIPLE B3).  The primary endpoint was undetectable HCV RNA 12 wk post-treatment (sustained virol. response, SVR12).  Across all groups, mean HCV RNA was ≥6 log IU/mL, and 99% of patients had a non-CC IL28B genotype.  SVR12 rates were 78% (A1), 65% (A2), 95% (B1), and 95% (B2).  In B3, most genotype 1a patients experienced virol. breakthrough.  The most common adverse events were headache, diarrhea, and asthenia.  Grade 3-4 aminotransferase elevations were infrequent and not treatment-limiting.  In genotype 1 null responders, daclatasvir plus twice-daily asunaprevir DUAL therapy is effective for most genotype 1b patients, and daclatasvir, asunaprevir, and PegIFN/RBV QUAD therapy is effective for nearly all genotype 1a and 1b patients; but neither DUAL nor TRIPLE therapy is effective for genotype 1a patients.  Interferon-free regimens including daclatasvir and twice-daily asunaprevir for genotype 1 null responders should be tailored to subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmaQLpKkbNoLVg90H21EOLACvtfcHk0lgg1eDZu9r-OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlartw%253D%253D&md5=d216b31a62adc838c4f2215fcfff4838</span></div><a href="/servlet/linkout?suffix=cit50b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2013.10.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2013.10.019%26sid%3Dliteratum%253Aachs%26aulast%3DLok%26aufirst%3DA.%2BS.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DLawitz%26aufirst%3DE.%2BJ.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DSerfaty%26aufirst%3DL.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DS.-P.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DPasquinelli%26aufirst%3DC.%26atitle%3DRandomized%2520trial%2520of%2520daclatasvir%2520and%2520asunaprevir%2520with%2520or%2520without%2520PegIFN%252FRBV%2520for%2520hepatitis%2520C%2520virus%2520genotype%25201%2520null%2520responders%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D60%26spage%3D490%26epage%3D499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Scola, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venables, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sit, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocuzza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilder, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friborg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schartman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donoso, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosure, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajamani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tredup, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levesque, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span> </span><span class="NLM_article-title">The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1730</span><span class="NLM_x">–</span> <span class="NLM_lpage">1752</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm500297k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVeqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1730-1752&author=P.+M.+Scolaauthor=L.-Q.+Sunauthor=A.+X.+Wangauthor=J.+Chenauthor=N.+Sinauthor=B.+L.+Venablesauthor=S.-Y.+Sitauthor=Y.+Chenauthor=A.+Cocuzzaauthor=D.+M.+Bilderauthor=S.+V.+D%E2%80%99Andreaauthor=B.+Zhengauthor=P.+Hewawasamauthor=Y.+Tuauthor=J.+Friborgauthor=P.+Falkauthor=D.+Hernandezauthor=S.+Levineauthor=C.+Chenauthor=F.+Yuauthor=A.+K.+Sheafferauthor=G.+Zhaiauthor=D.+Barryauthor=J.+O.+Knipeauthor=Y.-H.+Hanauthor=R.+Schartmanauthor=M.+Donosoauthor=K.+Mosureauthor=M.+W.+Sinzauthor=T.+Zvyagaauthor=A.+C.+Goodauthor=R.+Rajamaniauthor=K.+Kishauthor=J.+Tredupauthor=H.+E.+Kleiauthor=Q.+Gaoauthor=L.+Muellerauthor=R.+J.+Colonnoauthor=D.+M.+Graselaauthor=S.+P.+Adamsauthor=J.+Loyauthor=P.+C.+Levesqueauthor=H.+Sunauthor=H.+Shiauthor=L.+Sunauthor=W.+Warnerauthor=D.+Liauthor=J.+Zhuauthor=N.+A.+Meanwellauthor=F.+McPhee&title=The+discovery+of+asunaprevir+%28BMS-650032%29%2C+an+orally+efficacious+NS3+protease+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Scola, Paul M.; Sun, Li-Qiang; Wang, Alan Xiangdong; Chen, Jie; Sin, Ny; Venables, Brian L.; Sit, Sing-Yuen; Chen, Yan; Cocuzza, Anthony; Bilder, Donna M.; D'Andrea, Stanley V.; Zheng, Barbara; Hewawasam, Piyasena; Tu, Yong; Friborg, Jacques; Falk, Paul; Hernandez, Dennis; Levine, Steven; Chen, Chaoqun; Yu, Fei; Sheaffer, Amy K.; Zhai, Guangzhi; Barry, Diana; Knipe, Jay O.; Han, Yong-Hae; Schartman, Richard; Donoso, Maria; Mosure, Kathy; Sinz, Michael W.; Zvyaga, Tatyana; Good, Andrew C.; Rajamani, Ramkumar; Kish, Kevin; Tredup, Jeffrey; Klei, Herbert E.; Gao, Qi; Mueller, Luciano; Colonno, Richard J.; Grasela, Dennis M.; Adams, Stephen P.; Loy, James; Levesque, Paul C.; Sun, Huabin; Shi, Hong; Sun, Lucy; Warner, William; Li, Danshi; Zhu, Jialong; Meanwell, Nicholas A.; McPhee, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1730-1752</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of asunaprevir (BMS-650032) is described.  This tripeptidic acylsulfonamide inhibitor of the NS3/4A enzyme is currently in phase III clin. trials for the treatment of hepatitis C virus infection.  The discovery of Asunaprevir was enabled by employing an isolated rabbit heart model to screen for the cardiovascular (CV) liabilities (changes to HR and SNRT) that were responsible for the discontinuation of an earlier lead from this chem. series, BMS-605339, from clin. trials.  The structure-activity relationships (SARs) developed with respect to CV effects established that small structural changes to the P2* subsite of the mol. had a significant impact on the CV profile of a given compd.  The antiviral activity, preclin. PK profile, and toxicol. studies in rat and dog supported clin. development of BMS-650032.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCzMFiXs8YO7Vg90H21EOLACvtfcHk0liCAElLdhCMRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVeqsLc%253D&md5=e8015d3874b80be645a9b80b5bd05865</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm500297k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500297k%26sid%3Dliteratum%253Aachs%26aulast%3DScola%26aufirst%3DP.%2BM.%26aulast%3DSun%26aufirst%3DL.-Q.%26aulast%3DWang%26aufirst%3DA.%2BX.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DSit%26aufirst%3DS.-Y.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCocuzza%26aufirst%3DA.%26aulast%3DBilder%26aufirst%3DD.%2BM.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DS.%2BV.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DFriborg%26aufirst%3DJ.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DLevine%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DBarry%26aufirst%3DD.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DHan%26aufirst%3DY.-H.%26aulast%3DSchartman%26aufirst%3DR.%26aulast%3DDonoso%26aufirst%3DM.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DRajamani%26aufirst%3DR.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DMueller%26aufirst%3DL.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DAdams%26aufirst%3DS.%2BP.%26aulast%3DLoy%26aufirst%3DJ.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DWarner%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DMcPhee%26aufirst%3DF.%26atitle%3DThe%2520discovery%2520of%2520asunaprevir%2520%2528BMS-650032%2529%252C%2520an%2520orally%2520efficacious%2520NS3%2520protease%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1730%26epage%3D1752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><div class="note"><p class="first last">The first clinical trial with a combination of HCV DAAs in the absence of interferon and ribavirin evaluated the nucleoside analog RG7128 (mericitabine) with the NS3 protease inhibitor danoprevir dosed for 13 days. For details, see:</p></div><span class="NLM_contrib-group">Gane, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stedman, C. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angus, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritchie, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elston, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ipe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morcos, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Najera, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopatin, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berrey, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradford, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laughlin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shulman, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. F.</span><span> </span><span class="NLM_article-title">Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">376</span><span class="NLM_x">, </span> <span class="NLM_fpage">1467</span><span class="NLM_x">–</span> <span class="NLM_lpage">1475</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2010&pages=1467-1475&author=E.+J.+Ganeauthor=S.+K.+Robertsauthor=C.+A.+M.+Stedmanauthor=P.+W.+Angusauthor=B.+Ritchieauthor=R.+Elstonauthor=D.+Ipeauthor=P.+N.+Morcosauthor=L.+Baherauthor=I.+Najeraauthor=T.+Chuauthor=U.+Lopatinauthor=M.+M.+Berreyauthor=W.+Bradfordauthor=M.+Laughlinauthor=N.+S.+Shulmanauthor=P.+F.+Smith&title=Oral+combination+therapy+with+a+nucleoside+polymerase+inhibitor+%28RG7128%29+and+danoprevir+for+chronic+hepatitis+C+genotype+1+infection+%28INFORM-1%29%3A+a+randomised%2C+double-blind%2C+placebo-controlled%2C+dose-escalation+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DRoberts%26aufirst%3DS.%2BK.%26aulast%3DStedman%26aufirst%3DC.%2BA.%2BM.%26aulast%3DAngus%26aufirst%3DP.%2BW.%26aulast%3DRitchie%26aufirst%3DB.%26aulast%3DElston%26aufirst%3DR.%26aulast%3DIpe%26aufirst%3DD.%26aulast%3DMorcos%26aufirst%3DP.%2BN.%26aulast%3DBaher%26aufirst%3DL.%26aulast%3DNajera%26aufirst%3DI.%26aulast%3DChu%26aufirst%3DT.%26aulast%3DLopatin%26aufirst%3DU.%26aulast%3DBerrey%26aufirst%3DM.%2BM.%26aulast%3DBradford%26aufirst%3DW.%26aulast%3DLaughlin%26aufirst%3DM.%26aulast%3DShulman%26aufirst%3DN.%2BS.%26aulast%3DSmith%26aufirst%3DP.%2BF.%26atitle%3DOral%2520combination%2520therapy%2520with%2520a%2520nucleoside%2520polymerase%2520inhibitor%2520%2528RG7128%2529%2520and%2520danoprevir%2520for%2520chronic%2520hepatitis%2520C%2520genotype%25201%2520infection%2520%2528INFORM-1%2529%253A%2520a%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%252C%2520dose-escalation%2520trial%26jtitle%3DLancet%26date%3D2010%26volume%3D376%26spage%3D1467%26epage%3D1475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, H.</span><span> </span><span class="NLM_article-title">Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=742-748&author=K.+Chayamaauthor=S.+Takahashiauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Ikedaauthor=H.+Ishikawaauthor=H.+Watanabeauthor=F.+McPheeauthor=E.+Hughesauthor=H.+Kumada&title=Dual+therapy+with+the+nonstructural+protein+5A+inhibitor%2C+daclatasvir%2C+and+the+nonstructural+protein+3+protease+inhibitor%2C+asunaprevir%2C+in+hepatitis+C+virus+genotype+1b-infected+null+responders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DDual%2520therapy%2520with%2520the%2520nonstructural%2520protein%25205A%2520inhibitor%252C%2520daclatasvir%252C%2520and%2520the%2520nonstructural%2520protein%25203%2520protease%2520inhibitor%252C%2520asunaprevir%252C%2520in%2520hepatitis%2520C%2520virus%2520genotype%25201b-infected%2520null%2520responders%26jtitle%3DHepatology%26date%3D2012%26volume%3D55%26spage%3D742%26epage%3D748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit53b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, H.</span><span> </span><span class="NLM_article-title">Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">646</span><span class="NLM_x">–</span> <span class="NLM_lpage">654</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2Fj.jhep.2012.11.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=23178977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvFeksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=646-654&author=Y.+Karinoauthor=J.+Toyotaauthor=K.+Ikedaauthor=F.+Suzukiauthor=K.+Chayamaauthor=Y.+Kawakamiauthor=H.+Ishikawaauthor=H.+Watanabeauthor=D.+Hernandezauthor=F.+Yuauthor=F.+McPheeauthor=H.+Kumada&title=Characterization+of+virologic+escape+in+hepatitis+C+virus+genotype+1b+patients+treated+with+the+direct-acting+antivirals+daclatasvir+and+asunaprevir"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53bR"><div class="casContent"><span class="casTitleNuber">53b</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir</span></div><div class="casAuthors">Karino, Yoshiyasu; Toyota, Joji; Ikeda, Kenji; Suzuki, Fumitaka; Chayama, Kazuaki; Kawakami, Yoshiiku; Ishikawa, Hiroki; Watanabe, Hideaki; Hernandez, Dennis; Yu, Fei; McPhee, Fiona; Kumada, Hiromitsu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">646-654</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Daclatasvir and asunaprevir are NS5A and NS3 protease-targeted antivirals currently under development for treatment of chronic hepatitis C virus infection.  Clin. data on baseline and on-treatment correlates of drug resistance and response to these agents are currently limited.Hepatitis C virus genotype 1b Japanese patients (prior null responders to PegIFN-α/RBV [n = 21] or PegIFN-α/RBV ineligible or intolerant [n = 22]) were administered daclatasvir/asunaprevir for 24 wk during a phase 2a open-label study.  Genotypic and phenotypic analyses of NS3 and NS5A substitutions were performed at baseline, after virol. failure, and post-treatment through follow-up week 36.There were three viral breakthroughs and four relapsers.  Baseline NS3 polymorphisms (T54S, Q80L, V170M) at amino acid positions previously assocd. with low-level resistance (<9-fold) to select NS3 protease inhibitors were detected in four null responders and three ineligibles, but were not assocd. with virol. failure.  Baseline NS5A polymorphisms (L28M, L31M, Y93H) assocd. with daclatasvir resistance (<25-fold) were detected in five null responders and six ineligibles.  All three viral breakthroughs and 2/4 relapsers carried a baseline NS5A-Y93H polymorphism.  NS3 and NS5A resistance-assocd. variants were detected together (NS3-D168A/V, NS5A-L31M/V-Y93H) after virol. failure.  Generally, daclatasvir-resistant substitutions persisted through 48 wk post-treatment, whereas asunaprevir-resistant substitutions were no longer detectable.  Overall, 5/10 patients with baseline NS5A-Y93H experienced virol. failure, while 5/10 achieved a sustained virol. response.The potential assocn. of a pre-existing NS5A-Y93H polymorphism with virol. failure on daclatasvir/asunaprevir combination treatment will be examd. in larger studies.  The persistence of treatment-emergent daclatasvir- and asunaprevir-resistant substitutions will require assessment in longer-term follow-up studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6FdD0algZ2rVg90H21EOLACvtfcHk0lhnw739QQ6mtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvFeksQ%253D%253D&md5=be5c769092743c85ce74039cb262b6ac</span></div><a href="/servlet/linkout?suffix=cit53b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.11.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.11.012%26sid%3Dliteratum%253Aachs%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DF.%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DCharacterization%2520of%2520virologic%2520escape%2520in%2520hepatitis%2520C%2520virus%2520genotype%25201b%2520patients%2520treated%2520with%2520the%2520direct-acting%2520antivirals%2520daclatasvir%2520and%2520asunaprevir%26jtitle%3DJ.%2520Hepatol.%26date%3D2013%26volume%3D58%26spage%3D646%26epage%3D654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit53c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, H.</span><span> </span><span class="NLM_article-title">Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">–</span> <span class="NLM_lpage">662</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53c&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2Fj.jhep.2012.09.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53c&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=23183526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53c&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2jtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=655-662&author=Y.+Suzukiauthor=K.+Ikedaauthor=F.+Suzukiauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Chayamaauthor=Y.+Kawakamiauthor=H.+Ishikawaauthor=J.+Watanabeauthor=W.+Huauthor=T.+Eleyauthor=F.+McPheeauthor=E.+Hughesauthor=H.+Kumada&title=Dual+oral+therapy+with+daclatasvir+and+asunaprevir+for+patients+with+HCV+genotype+1b+infection+and+limited+treatment+options"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53cR"><div class="casContent"><span class="casTitleNuber">53c</span><div class="casTitle"><span class="NLM_cas:atitle">Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options</span></div><div class="casAuthors">Suzuki, Yoshiyuki; Ikeda, Kenji; Suzuki, Fumitaka; Toyota, Joji; Karino, Yoshiyasu; Chayama, Kazuaki; Kawakami, Yoshiiku; Ishikawa, Hiroki; Watanabe, Hideaki; Hu, Wenhua; Eley, Timothy; McPhee, Fiona; Hughes, Eric; Kumada, Hiromitsu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">655-662</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Improved therapeutic options for chronic hepatitis C virus (HCV) infection are needed for patients who are poor candidates for treatment with current regimens due to anticipated intolerability or low likelihood of response.  In this open-label, phase 2a study of Japanese patients with chronic HCV genotype 1b infection, 21 null responders (<2 log10 HCV RNA redn. after 12 wk of peginterferon/ribavirin) and 22 patients intolerant to or medically ineligible for peginterferon/ribavirin therapy received dual oral treatment for 24 wk with the NS5A replication complex inhibitor daclatasvir (DCV) and the NS3 protease inhibitor asunaprevir (ASV).  The primary efficacy end point was sustained virol. response at 12 wk post-treatment (SVR12).  Thirty-six of 43 enrolled patients completed 24 wk of therapy.  Serum HCV RNA levels declined rapidly, becoming undetectable in all patients on therapy by week 8.  Overall, 76.7% of patients achieved SVR12 and SVR24, including 90.5% of null responders and 63.6% of ineligible/intolerant patients.  There were no virol. failures among null responders.  Three ineligible/intolerant patients experienced viral breakthrough and four relapsed post-treatment.  Diarrhea, nasopharyngitis, headache, and ALT/AST increases, generally mild, were the most common adverse events; three discontinuations before week 24 were due to adverse events that included hyperbilirubinemia and transaminase elevations (two patients).  Dual therapy with daclatasvir and asunaprevir, without peginterferon/ribavirin, was well tolerated and achieved high SVR rates in two groups of difficult-to-treat patients with hepatitis C virus genotype 1b infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq1ZlrHtPRHLVg90H21EOLACvtfcHk0lhnw739QQ6mtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2jtbw%253D&md5=48caec88fbfc444ea629aac577c2ed95</span></div><a href="/servlet/linkout?suffix=cit53c&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.09.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.09.037%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DF.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DDual%2520oral%2520therapy%2520with%2520daclatasvir%2520and%2520asunaprevir%2520for%2520patients%2520with%2520HCV%2520genotype%25201b%2520infection%2520and%2520limited%2520treatment%2520options%26jtitle%3DJ.%2520Hepatol.%26date%3D2013%26volume%3D58%26spage%3D655%26epage%3D662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit53d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Kumada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ido, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izumi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koike, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takehara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyagoshi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damokosh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span> </span><span class="NLM_article-title">Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1002/hep.27113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53d&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1002%2Fhep.27113" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=H.+Kumadaauthor=Y.+Suzukiauthor=K.+Ikedaauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Chayamaauthor=Y.+Kawakamiauthor=A.+Idoauthor=K.+Yamamotoauthor=K.+Takaguchiauthor=N.+Izumiauthor=K.+Koikeauthor=T.+Takeharaauthor=N.+Kawadaauthor=M.+Sataauthor=H.+Miyagoshiauthor=T.+Eleyauthor=F.+McPheeauthor=A.+Damokoshauthor=H.+Ishikawaauthor=E.+Hughes&title=Daclatasvir+plus+asunaprevir+for+chronic+HCV+genotype+1b+infection&doi=10.1002%2Fhep.27113"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53d&amp;dbid=16384&amp;doi=10.1002%2Fhep.27113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27113%26sid%3Dliteratum%253Aachs%26aulast%3DKumada%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DIdo%26aufirst%3DA.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DTakaguchi%26aufirst%3DK.%26aulast%3DIzumi%26aufirst%3DN.%26aulast%3DKoike%26aufirst%3DK.%26aulast%3DTakehara%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DN.%26aulast%3DSata%26aufirst%3DM.%26aulast%3DMiyagoshi%26aufirst%3DH.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DDamokosh%26aufirst%3DA.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DHughes%26aufirst%3DE.%26atitle%3DDaclatasvir%2520plus%2520asunaprevir%2520for%2520chronic%2520HCV%2520genotype%25201b%2520infection%26jtitle%3DHepatology%26date%3D2014%26doi%3D10.1002%2Fhep.27113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Manion, D.</span><span> </span><span class="NLM_article-title">Daclatasvir: present and future DAA combinations</span>. Presented at HepDart, The Big Island, HI, December 8–12,<span class="NLM_x"> </span><span class="NLM_year">2013</span>. Available at <a href="http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Manion_REVISED%20HepDart2013_V3_3Dec2013_FINAL%20(v2).pdf" class="extLink">http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Manion_REVISED%20HepDart2013_V3_3Dec2013_FINAL%20(v2).pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=D.+Manion&title=Daclatasvir%3A+present+and+future+DAA+combinations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DManion%26aufirst%3DD.%26atitle%3DDaclatasvir%253A%2520present%2520and%2520future%2520DAA%2520combinations%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loustaud-Ratti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatum, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span> </span><span class="NLM_article-title">Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">420</span><span class="NLM_x">–</span> <span class="NLM_lpage">429</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2014&pages=420-429&author=G.+T.+Eversonauthor=K.+D.+Simsauthor=M.+Rodriguez-Torresauthor=C.+H%C3%A9zodeauthor=E.+Lawitzauthor=M.+Bourli%C3%A8reauthor=V.+Loustaud-Rattiauthor=V.+Rustgiauthor=H.+Schwartzauthor=H.+Tatumauthor=P.+Marcellinauthor=S.+Polauthor=P.+J.+Thuluvathauthor=T.+Eleyauthor=X.+Wangauthor=S.-P.+Huangauthor=F.+McPheeauthor=M.+Wind-Rotoloauthor=E.+Chungauthor=C.+Pasquinelliauthor=D.+M.+Graselaauthor=D.+F.+Gardiner&title=Efficacy+of+an+interferon-+and+ribavirin-free+regimen+of+daclatasvir%2C+asunaprevir%2C+and+BMS-791325+in+treatment-naive+patients+with+HCV+genotype+1+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DSims%26aufirst%3DK.%2BD.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DLoustaud-Ratti%26aufirst%3DV.%26aulast%3DRustgi%26aufirst%3DV.%26aulast%3DSchwartz%26aufirst%3DH.%26aulast%3DTatum%26aufirst%3DH.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DS.-P.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DE.%26aulast%3DPasquinelli%26aufirst%3DC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26atitle%3DEfficacy%2520of%2520an%2520interferon-%2520and%2520ribavirin-free%2520regimen%2520of%2520daclatasvir%252C%2520asunaprevir%252C%2520and%2520BMS-791325%2520in%2520treatment-naive%2520patients%2520with%2520HCV%2520genotype%25201%2520infection%26jtitle%3DGastroenterology%26date%3D2014%26volume%3D146%26spage%3D420%26epage%3D429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Gentles, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant-Young, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudyma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regueiro-Ren, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, K.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beno, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camac, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheriff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tredup, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witmer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanumegowda, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosure, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuo, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelosi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J. F.</span><span> </span><span class="NLM_article-title">Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1855</span><span class="NLM_x">–</span> <span class="NLM_lpage">1879</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm4016894" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1855-1879&author=R.+G.+Gentlesauthor=M.+Dingauthor=J.+A.+Benderauthor=C.+P.+Bergstromauthor=K.+Grant-Youngauthor=P.+Hewawasamauthor=T.+Hudymaauthor=S.+Martinauthor=A.+Nickelauthor=A.+Regueiro-Renauthor=Y.+Tuauthor=Z.+Yangauthor=K.-S.+Yeungauthor=X.+Zhengauthor=B.+R.+Benoauthor=D.+M.+Camacauthor=C.-H.+Changauthor=M.+Gaoauthor=P.+E.+Morinauthor=S.+Sheriffauthor=J.+Tredupauthor=J.+Wanauthor=M.+R.+Witmerauthor=D.+Xieauthor=U.+Hanumegowdaauthor=J.+Knipeauthor=K.+Mosureauthor=K.+S.+Santoneauthor=D.+D.+Parkerauthor=X.+Zhuoauthor=J.+Lemmauthor=M.+Liuauthor=L.+Pelosiauthor=K.+Rigatauthor=S.+Vossauthor=Y.+Wangauthor=Y.-K.+Wangauthor=R.+J.+Colonnoauthor=M.+Gaoauthor=S.+B.+Robertsauthor=Q.+Gaoauthor=A.+Ngauthor=N.+A.+Meanwellauthor=J.+F.+Kadow&title=Discovery+and+preclinical+characterization+of+the+cyclopropylindolobenzazepine+BMS-791325%2C+a+potent+allosteric+inhibitor+of+the+hepatitis+C+virus+NS5B+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm4016894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016894%26sid%3Dliteratum%253Aachs%26aulast%3DGentles%26aufirst%3DR.%2BG.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DBender%26aufirst%3DJ.%2BA.%26aulast%3DBergstrom%26aufirst%3DC.%2BP.%26aulast%3DGrant-Young%26aufirst%3DK.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DHudyma%26aufirst%3DT.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DNickel%26aufirst%3DA.%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYeung%26aufirst%3DK.-S.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DChang%26aufirst%3DC.-H.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DMorin%26aufirst%3DP.%2BE.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DWitmer%26aufirst%3DM.%2BR.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DHanumegowda%26aufirst%3DU.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DParker%26aufirst%3DD.%2BD.%26aulast%3DZhuo%26aufirst%3DX.%26aulast%3DLemm%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DPelosi%26aufirst%3DL.%26aulast%3DRigat%26aufirst%3DK.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.-K.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DNg%26aufirst%3DA.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26atitle%3DDiscovery%2520and%2520preclinical%2520characterization%2520of%2520the%2520cyclopropylindolobenzazepine%2520BMS-791325%252C%2520a%2520potent%2520allosteric%2520inhibitor%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1855%26epage%3D1879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Sulkowski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassanein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lok, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinestrosa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hindes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">AI444040 Study Group</span><span> </span><span class="NLM_article-title">Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1056%2FNEJMoa1306218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=24428467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFymtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=211-221&author=M.+S.+Sulkowskiauthor=D.+F.+Gardinerauthor=M.+Rodriguez-Torresauthor=K.+R.+Reddyauthor=T.+Hassaneinauthor=I.+Jacobsonauthor=E.+Lawitzauthor=A.+S.+Lokauthor=F.+Hinestrosaauthor=P.+J.+Thuluvathauthor=H.+Schwartzauthor=D.+R.+Nelsonauthor=G.+T.+Eversonauthor=T.+Eleyauthor=M.+Wind-Rotoloauthor=S.-P.+Huangauthor=M.+Gaoauthor=D.+Hernandezauthor=F.+McPheeauthor=D.+Shermanauthor=R.+Hindesauthor=W.+Symondsauthor=C.+Pasquinelliauthor=D.+M.+Graselaauthor=AI444040+Study+Group&title=Daclatasvir+plus+sofosbuvir+for+previously+treated+or+untreated+chronic+HCV+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection</span></div><div class="casAuthors">Sulkowski, Mark S.; Gardiner, David F.; Rodriguez-Torres, Maribel; Reddy, K. Rajender; Hassanein, Tarek; Jacobson, Ira; Lawitz, Eric; Lok, Anna S.; Hinestrosa, Federico; Thuluvath, Paul J.; Schwartz, Howard; Nelson, David R.; Everson, Gregory T.; Eley, Timothy; Wind-Rotolo, Megan; Huang, Shu-Pang; Gao, Min; Hernandez, Dennis; McPhee, Fiona; Sherman, Diane; Hindes, Robert; Symonds, William; Pasquinelli, Claudio; Grasela, Dennis M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">211-221</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection.  We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analog HCV NS5B polymerase inhibitor) in patients infected with HCV genotype 1, 2, or 3.  METHODS In this open-label study, we initially randomly assigned 44 previously untreated patients with HCV genotype 1 infection and 44 patients infected with HCV genotype 2 or 3 to daclatasvir at a dose of 60 mg orally once daily plus sofosbuvir at a dose of 400 mg orally once daily, with or without ribavirin, for 24 wk.  The study was expanded to include 123 addnl. patients with genotype 1 infection who were randomly assigned to daclatasvir plus sofosbuvir, with or without ribavirin, for 12 wk (82 previously untreated patients) or 24 wk (41 patients who had previous virol. failure with telaprevir or boceprevir plus peginterferon alfa ribavirin).  The primary end point was a sustained virol. response (an HCV RNA level of <25 IU per mL) at week 12 after the end of therapy.  RESULTS Overall, 211 patients received treatment.  Among patients with genotype 1 infection, 98% of 126 previously untreated patients and 98% of 41 patients who did not have a sustained virol. response with HCV protease inhibitors had a sustained virol. response at week 12 after the end of therapy.  A total of 92% of 26 patients with genotype 2 infection and 89% of 18 patients with genotype 3 infection had a sustained virol. response at week 12.  High rates of sustained virol. response at week 12 were obsd. among patients with HCV subtypes 1a and 1b (98% and 100%, resp.) and those with CC and non-CC IL28B genotypes (93% and 98%, resp.), as well as among patients who received ribavirin and those who did not (94% and 98%, resp.).  The most common adverse events were fatigue, headache, and nausea.  CONCLUSIONS Once-daily oral daclatasvir plus sofosbuvir was assocd. with high rates of sustained virol. response among patients infected with HCV genotype 1, 2, or 3, including patients with no response to prior therapy with telaprevir or boceprevir.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMiCkoKS-KUrVg90H21EOLACvtfcHk0lhV5I9tj3_4Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFymtb0%253D&md5=bc9eff52401d2f1e00505d30fcffd2c5</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1306218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1306218%26sid%3Dliteratum%253Aachs%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DHassanein%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DI.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DLok%26aufirst%3DA.%2BS.%26aulast%3DHinestrosa%26aufirst%3DF.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DSchwartz%26aufirst%3DH.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DS.-P.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DSherman%26aufirst%3DD.%26aulast%3DHindes%26aufirst%3DR.%26aulast%3DSymonds%26aufirst%3DW.%26aulast%3DPasquinelli%26aufirst%3DC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3D%26atitle%3DDaclatasvir%2520plus%2520sofosbuvir%2520for%2520previously%2520treated%2520or%2520untreated%2520chronic%2520HCV%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D211%26epage%3D221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Sofia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagarathnam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rachakonda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bansal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espiritu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keilman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steuer, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, P. A.</span><span> </span><span class="NLM_article-title">Discovery of a β-<span class="smallcaps smallerCapital">d</span>-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7202</span><span class="NLM_x">–</span> <span class="NLM_lpage">7218</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100863x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKmtb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7202-7218&author=M.+J.+Sofiaauthor=D.+Baoauthor=W.+Changauthor=J.+Duauthor=D.+Nagarathnamauthor=S.+Rachakondaauthor=P.+G.+Reddyauthor=B.+S.+Rossauthor=P.+Wangauthor=H.-R.+Zhangauthor=S.+Bansalauthor=C.+Espirituauthor=M.+Keilmanauthor=A.+M.+Lamauthor=H.+M.+Steuerauthor=C.+Niuauthor=M.+J.+Ottoauthor=P.+A.+Furman&title=Discovery+of+a+%CE%B2-d-2%E2%80%B2-deoxy-2%E2%80%B2-%CE%B1-fluoro-2%E2%80%B2-%CE%B2-C-methyluridine+nucleotide+prodrug+%28PSI-7977%29+for+the+treatment+of+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a β-D-2'-Deoxy-2'-α-fluoro-2'-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus</span></div><div class="casAuthors">Sofia, Michael J.; Bao, Donghui; Chang, Wonsuk; Du, Jinfa; Nagarathnam, Dhanapalan; Rachakonda, Suguna; Reddy, P. Ganapati; Ross, Bruce S.; Wang, Peiyuan; Zhang, Hai-Ren; Bansal, Shalini; Espiritu, Christine; Keilman, Meg; Lam, Angela M.; Steuer, Holly M. Micolochick; Niu, Congrong; Otto, Michael J.; Furman, Phillip A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7202-7218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is a global health problem requiring novel approaches for effective treatment of this disease.  The HCV NS5B polymerase has been demonstrated to be a viable target for the development of HCV therapies.  β-D-2'-Deoxy-2'-α-fluoro-2'-β-C-Me nucleosides are selective inhibitors of the HCV NS5B polymerase and have demonstrated potent activity in the clinic.  Phosphoramidate prodrugs of the 5'-phosphate deriv. of the β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleoside were prepd. and showed significant potency in the HCV subgenomic replicon assay (<1 μM) and produced high levels of triphosphate 6 in primary hepatocytes and in the livers of rats, dogs, and monkeys when administered in vivo.  The single diastereomer 51 of diastereomeric mixt. 14 was crystd., and an X-ray structure was detd. establishing the phosphoramidate stereochem. as Sp, thus correlating for the first time the stereochem. of a phosphoramidate prodrug with biol. activity.  51 (PSI-7977) was selected as a clin. development candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWAkLi9-odWbVg90H21EOLACvtfcHk0lhMQQh53SaURw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKmtb%252FO&md5=33d371e557e9d70562a326f97798f45c</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm100863x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100863x%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DBao%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DRachakonda%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.-R.%26aulast%3DBansal%26aufirst%3DS.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DKeilman%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DSteuer%26aufirst%3DH.%2BM.%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520%25CE%25B2-d-2%25E2%2580%25B2-deoxy-2%25E2%2580%25B2-%25CE%25B1-fluoro-2%25E2%2580%25B2-%25CE%25B2-C-methyluridine%2520nucleotide%2520prodrug%2520%2528PSI-7977%2529%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7202%26epage%3D7218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wenlock, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span> </span><span class="NLM_article-title">A comparison of physiochemical property profiles of development and marketed oral drugs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1250</span><span class="NLM_x">–</span> <span class="NLM_lpage">1256</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm021053p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59a&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1250-1256&author=M.+C.+Wenlockauthor=R.+P.+Austinauthor=P.+Bartonauthor=A.+M.+Davisauthor=P.+D.+Leeson&title=A+comparison+of+physiochemical+property+profiles+of+development+and+marketed+oral+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59aR"><div class="casContent"><span class="casTitleNuber">59a</span><div class="casTitle"><span class="NLM_cas:atitle">A Comparison of Physiochemical Property Profiles of Development and Marketed Oral Drugs</span></div><div class="casAuthors">Wenlock, Mark C.; Austin, Rupert P.; Barton, Patrick; Davis, Andrew M.; Leeson, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1250-1256</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The process of drug discovery applies rigorous selection pressures.  Marketed oral drugs will generally possess favorable physiochem. properties with respect to absorption, metab., distribution, and clearance.  This paper describes a study in which the distributions of physiochem. properties of oral drugs in different phases of clin. development are compared to those already marketed.  The aim is to identify the trends in physiochem. properties that favor a drug's successful passage through clin. development and on to the market.  Two libraries were created, one of current development oral drugs and one of marketed oral drugs.  Statistical anal. of the two showed that the mean mol. wt. of orally administered drugs in development decreases on passing through each of the different clin. phases and gradually converges toward the mean mol. wt. of marketed oral drugs.  It is also clear that the most lipophilic compds. are being discontinued from development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF0PksUFJq0bVg90H21EOLACvtfcHk0lhMQQh53SaURw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbY%253D&md5=b9809c803a61ec99a1b4171e97952452</span></div><a href="/servlet/linkout?suffix=cit59a&amp;dbid=16384&amp;doi=10.1021%2Fjm021053p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm021053p%26sid%3Dliteratum%253Aachs%26aulast%3DWenlock%26aufirst%3DM.%2BC.%26aulast%3DAustin%26aufirst%3DR.%2BP.%26aulast%3DBarton%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DA.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26atitle%3DA%2520comparison%2520of%2520physiochemical%2520property%2520profiles%2520of%2520development%2520and%2520marketed%2520oral%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1250%26epage%3D1256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit59b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Perola, E.</span><span> </span><span class="NLM_article-title">An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2986</span><span class="NLM_x">–</span> <span class="NLM_lpage">2997</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100118x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtlWqu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2986-2997&author=E.+Perola&title=An+analysis+of+the+binding+efficiencies+of+drugs+and+their+leads+in+successful+drug+discovery+programs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59bR"><div class="casContent"><span class="casTitleNuber">59b</span><div class="casTitle"><span class="NLM_cas:atitle">An Analysis of the Binding Efficiencies of Drugs and their Leads in Successful Drug Discovery Programs</span></div><div class="casAuthors">Perola, Emanuele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2986-2997</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to investigate the evolution of binding efficiency in successful drug discovery programs, a data set of 60 lead/drug pairs with known binding affinities has been compiled and analyzed.  Low-end thresholds for the binding efficiencies of viable leads and drugs have been derived.  On av., the drugs in the set are significantly larger and more potent but have similar lipophilicity relative to their originating leads, suggesting that the ability to maintain low levels of lipophilicity while increasing mol. wt. is one of the keys to a successful drug discovery program.  A no. of examples demonstrate that large increases in binding efficiency from leads to more elaborate drugs sharing the same scaffold can be achieved.  The importance of dissecting a lead structure to identify the most efficient fragments and the option of sacrificing binding efficiency to optimize other properties are discussed, and relevant examples are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRqzYFBuX2Q7Vg90H21EOLACvtfcHk0ljIXCXJFyxuHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtlWqu7o%253D&md5=a7eaad792f1518d093588951df64d22f</span></div><a href="/servlet/linkout?suffix=cit59b&amp;dbid=16384&amp;doi=10.1021%2Fjm100118x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100118x%26sid%3Dliteratum%253Aachs%26aulast%3DPerola%26aufirst%3DE.%26atitle%3DAn%2520analysis%2520of%2520the%2520binding%2520efficiencies%2520of%2520drugs%2520and%2520their%2520leads%2520in%2520successful%2520drug%2520discovery%2520programs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2986%26epage%3D2997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit59c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keserü, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, C. H.</span><span> </span><span class="NLM_article-title">The role of ligand efficiency metrics in drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59c&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1038%2Fnrd4163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59c&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=24481311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59c&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=105-121&author=A.+L.+Hopkinsauthor=G.+M.+Keser%C3%BCauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynolds&title=The+role+of+ligand+efficiency+metrics+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59cR"><div class="casContent"><span class="casTitleNuber">59c</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ligand efficiency metrics in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.; Keserue, Gyoergy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-121</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The judicious application of ligand or binding efficiency metrics, which quantify the mol. properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads.  Retrospective anal. of recently marketed oral drugs shows that they frequently have highly optimized ligand efficiency values for their targets.  Optimizing ligand efficiency metrics based on both mol. mass and lipophilicity, when set in the context of the specific target, has the potential to ameliorate the inflation of these properties that has been obsd. in current medicinal chem. practice, and to increase the quality of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96uhvE1OZ5LVg90H21EOLACvtfcHk0ljIXCXJFyxuHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D&md5=344030e59f499180f79d311302a27532</span></div><a href="/servlet/linkout?suffix=cit59c&amp;dbid=16384&amp;doi=10.1038%2Fnrd4163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4163%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeser%25C3%25BC%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26atitle%3DThe%2520role%2520of%2520ligand%2520efficiency%2520metrics%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D105%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit59d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Hann, M. M.</span><span> </span><span class="NLM_article-title">Molecular obesity, potency and other addictions in drug discovery</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">355</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59d&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1039%2FC1MD00017A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59d&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Kht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=349-355&author=M.+M.+Hann&title=Molecular+obesity%2C+potency+and+other+addictions+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59dR"><div class="casContent"><span class="casTitleNuber">59d</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular obesity, potency and other addictions in drug discovery</span></div><div class="casAuthors">Hann, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">349-355</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Despite the increase in global biol. and chem. knowledge the discovery of effective and safe new drugs seems to become harder rather than easier.  Some of this challenge is due to increasing demands for safety and novelty, but some of the risk involved in this should be controllable if we had more effectively learned from our failures.  This perspective reflects on some of the learnings of recent years in relation to the causes of attrition.  The term Mol. Obesity is introduced to describe our tendency to build potency into mols. by the inappropriate use of lipophilicity which leads to the premature demise of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSlF7TPy6fHLVg90H21EOLACvtfcHk0ljIXCXJFyxuHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Kht7g%253D&md5=954870db4b1d9e846612c3bb256582f7</span></div><a href="/servlet/linkout?suffix=cit59d&amp;dbid=16384&amp;doi=10.1039%2FC1MD00017A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC1MD00017A%26sid%3Dliteratum%253Aachs%26aulast%3DHann%26aufirst%3DM.%2BM.%26atitle%3DMolecular%2520obesity%252C%2520potency%2520and%2520other%2520addictions%2520in%2520drug%2520discovery%26jtitle%3DMedChemComm%26date%3D2011%26volume%3D2%26spage%3D349%26epage%3D355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Ly, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klevens, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiles, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmberg, S. D.</span><span> </span><span class="NLM_article-title">The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">278</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.7326%2F0003-4819-156-4-201202210-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=22351712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A280%3ADC%252BC383kvFCkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2012&pages=271-278&author=K.+N.+Lyauthor=J.+Xingauthor=R.+M.+Klevensauthor=R.+B.+Jilesauthor=J.+W.+Wardauthor=S.+D.+Holmberg&title=The+increasing+burden+of+mortality+from+viral+hepatitis+in+the+United+States+between+1999+and+2007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007</span></div><div class="casAuthors">Ly Kathleen N; Xing Jian; Klevens R Monina; Jiles Ruth B; Ward John W; Holmberg Scott D</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">271-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The increasing health burden and mortality from hepatitis B virus (HBV) and hepatitis C virus (HCV) in the United States are underappreciated.  OBJECTIVE:  To examine mortality from HBV; HCV; and, for comparison, HIV.  DESIGN:  Analysis of U.S. multiple-cause mortality data from 1999 to 2007 from the National Center for Health Statistics.  SETTING:  All U.S. states and the District of Columbia.  PARTICIPANTS:  Approximately 22 million decedents.  MEASUREMENTS:  Age-adjusted mortality rates from HBV, HCV, and HIV.  Logistic regression analyses of 2007 data generated 4 independent models per outcome (HCV- or HBV-related deaths) that each included 1 of 4 comorbid conditions and all sociodemographic characteristics.  RESULTS:  Between 1999 and 2007, recorded deaths from HCV [corrected] increased significantly to 15,106, whereas deaths from HIV declined to 12,734 by 2007.  Factors associated with HCV-related deaths included chronic liver disease, HBV co-infection, alcohol-related conditions, minority status, and HIV co-infection.  Factors that increased odds of HBV-related death included chronic liver disease, HCV co-infection, Asian or Pacific Islander descent, HIV co-infection, and alcohol-related conditions.  Most deaths from HBV and HCV occurred in middle-aged persons.  LIMITATION:  A person other than the primary physician of the decedent frequently completed the death certificate, and HCV and HBV often were not detected and thus not reported as causes of death.  CONCLUSION:  By 2007, HCV had superseded HIV as a cause of death in the United States, and deaths from HCV and HBV disproportionately occurred in middle-aged persons.  To achieve decreases in mortality similar to those seen with HIV requires new policy initiatives to detect patients with chronic hepatitis and link them to care and treatment.  PRIMARY FUNDING SOURCE:  Centers for Disease Control and Prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4NjyWh_C-GsrRqEXsZufAfW6udTcc2eb-qgNreN4o0rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383kvFCkuw%253D%253D&md5=365f7666e37e4aefd608b4e3cd2a8d8c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-156-4-201202210-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-156-4-201202210-00004%26sid%3Dliteratum%253Aachs%26aulast%3DLy%26aufirst%3DK.%2BN.%26aulast%3DXing%26aufirst%3DJ.%26aulast%3DKlevens%26aufirst%3DR.%2BM.%26aulast%3DJiles%26aufirst%3DR.%2BB.%26aulast%3DWard%26aufirst%3DJ.%2BW.%26aulast%3DHolmberg%26aufirst%3DS.%2BD.%26atitle%3DThe%2520increasing%2520burden%2520of%2520mortality%2520from%2520viral%2520hepatitis%2520in%2520the%2520United%2520States%2520between%25201999%2520and%25202007%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2012%26volume%3D156%26spage%3D271%26epage%3D278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Rein, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittenborn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinbaum, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesesne, S. B.</span><span> </span><span class="NLM_article-title">Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States</span> <span class="citation_source-journal">Dig. Liver Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">66</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2011&pages=66-72&author=D.+B.+Reinauthor=J.+S.+Wittenbornauthor=C.+M.+Weinbaumauthor=M.+Sabinauthor=B.+D.+Smithauthor=S.+B.+Lesesne&title=Forecasting+the+morbidity+and+mortality+associated+with+prevalent+cases+of+pre-cirrhotic+chronic+hepatitis+C+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRein%26aufirst%3DD.%2BB.%26aulast%3DWittenborn%26aufirst%3DJ.%2BS.%26aulast%3DWeinbaum%26aufirst%3DC.%2BM.%26aulast%3DSabin%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DLesesne%26aufirst%3DS.%2BB.%26atitle%3DForecasting%2520the%2520morbidity%2520and%2520mortality%2520associated%2520with%2520prevalent%2520cases%2520of%2520pre-cirrhotic%2520chronic%2520hepatitis%2520C%2520in%2520the%2520United%2520States%26jtitle%3DDig.%2520Liver%2520Dis.%26date%3D2011%26volume%3D43%26spage%3D66%26epage%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5a','cit5b','cit5c'],'ref6':['cit6a','cit6b','cit6c'],'ref7':['cit7a','cit7b','cit7c','cit7d','cit7e','cit7f'],'ref8':['cit8a','cit8b'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12a','cit12b','cit12c'],'ref13':['cit13a','cit13b','cit13c','cit13d','cit13e','cit13f'],'ref14':['cit14a','cit14b','cit14c','cit14d','cit14e','cit14f','cit14g','cit14h'],'ref15':['cit15a','cit15b','cit15c','cit15d','cit15e'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20a','cit20b','cit20c','cit20d','cit20e','cit20f','cit20g'],'ref21':['cit21'],'ref22':['cit22a','cit22b','cit22c'],'ref23':['cit23a','cit23b','cit23c','cit23d','cit23e'],'ref24':['cit24a','cit24b','cit24c','cit24d'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32a','cit32b'],'ref33':['cit33a','cit33b'],'ref34':['cit34a','cit34b','cit34c'],'ref35':['cit35a','cit35b','cit35c'],'ref36':['cit36'],'ref37':['cit37a','cit37b'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43a','cit43b'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50a','cit50b'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53a','cit53b','cit53c','cit53d'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59a','cit59b','cit59c','cit59d'],'ref60':['cit60'],'ref61':['cit61']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 71 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yong-Jin Wu, <span class="NLM_string-name hlFld-ContribAuthor">Nicholas A. Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (14)
                                     , 9786-9874. <a href="https://doi.org/10.1021/acs.jmedchem.1c00790" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00790</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00790%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DGeminal%252BDiheteroatomic%252BMotifs%25253A%252BSome%252BApplications%252Bof%252BAcetals%25252C%252BKetals%25252C%252Band%252BTheir%252BSulfur%252Band%252BNitrogen%252BHomologues%252Bin%252BMedicinal%252BChemistry%252Band%252BDrug%252BDesign%26aulast%3DWu%26aufirst%3DYong-Jin%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D30042021%26date%3D02072021%26volume%3D64%26issue%3D14%26spage%3D9786%26epage%3D9874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hongming Xie, Haiwang Liu, Yingjun Zhang, Enhuo Huang, Yahui Feng, Xuwen Xiang, Qinghong Fang, Zhihong Peng, Wanrong Dong, <span class="NLM_string-name hlFld-ContribAuthor">Delie An</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a Synthesis Process for a Novel HCV NS5A Inhibitor, Emitasvir. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2021,</strong> <em>25 </em>
                                    (4)
                                     , 838-848. <a href="https://doi.org/10.1021/acs.oprd.0c00519" title="DOI URL">https://doi.org/10.1021/acs.oprd.0c00519</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.0c00519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.0c00519%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DDevelopment%252Bof%252Ba%252BSynthesis%252BProcess%252Bfor%252Ba%252BNovel%252BHCV%252BNS5A%252BInhibitor%25252C%252BEmitasvir%26aulast%3DXie%26aufirst%3DHongming%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D30112020%26date%3D02042021%26volume%3D25%26issue%3D4%26spage%3D838%26epage%3D848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nicholas A. Meanwell, Gunda I. Georg, <span class="NLM_string-name hlFld-ContribAuthor">Shaomeng Wang</span>. </span><span class="cited-content_cbyCitation_article-title">The 2020 Nobel Prize in Physiology or Medicine. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13197-13204. <a href="https://doi.org/10.1021/acs.jmedchem.0c01877" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01877</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01877%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252B2020%252BNobel%252BPrize%252Bin%252BPhysiology%252Bor%252BMedicine%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2020%26date%3D2020%26date%3D05112020%26volume%3D63%26issue%3D22%26spage%3D13197%26epage%3D13204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xinbei Jiang, Jiali Tan, Yixuan Wang, Jinhua Chen, Jianrui Li, Zhi Jiang, Yanni Quan, Jie Jin, Yuhuan Li, Shan Cen, Yanping Li, Zonggen Peng, <span class="NLM_string-name hlFld-ContribAuthor">Zhuorong Li</span>. </span><span class="cited-content_cbyCitation_article-title">2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (11)
                                     , 5972-5989. <a href="https://doi.org/10.1021/acs.jmedchem.0c00232" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00232</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00232%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D2-%252528%2525284-Arylpiperazin-1-yl%252529methyl%252529benzonitrile%252BDerivatives%252Bas%252BOrally%252BAvailable%252BInhibitors%252Bof%252BHepatitis%252BC%252BVirus%252Bwith%252Ba%252BNovel%252BMechanism%252Bof%252BAction%26aulast%3DJiang%26aufirst%3DXinbei%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09022020%26date%3D20052020%26date%3D07052020%26volume%3D63%26issue%3D11%26spage%3D5972%26epage%3D5989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Vidya Ramdas, Rashmi Talwar, Moloy Banerjee, Advait Arun Joshi, Amit Kumar Das, Deepak Sahebrao Walke, Prashant Borhade, Usha Dhayagude, Rajesh Loriya, Ganesh Gote, Apparao Bommakanti, Aruna Sivaram, Gautam Agarwal, Arnab Goswami, Prashant Nigade, Maneesh Mehta, Vinod Patil, Dipak Modi, Hemant Kumar, Sadanand Mallurwar, Amruta Dash, Falguni Modi, Sandip Kuldharan, Pratima Srivastava, Minakshi Singh, Lakshmi Narasimham, Jayasagar Gundu, Sharad Sharma, Rajender Kumar Kamboj, <span class="NLM_string-name hlFld-ContribAuthor">Venkata P. Palle</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (23)
                                     , 10563-10582. <a href="https://doi.org/10.1021/acs.jmedchem.9b01562" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01562</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01562%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BCharacterization%252Bof%252BPotent%252BPan-Genotypic%252BHCV%252BNS5A%252BInhibitors%252BContaining%252BNovel%252BTricyclic%252BCentral%252BCore%252BLeading%252Bto%252BClinical%252BCandidate%26aulast%3DRamdas%26aufirst%3DVidya%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D19092019%26date%3D22112019%26date%3D11112019%26volume%3D62%26issue%3D23%26spage%3D10563%26epage%3D10582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yahui Feng, Zhongqing Wang, Zhonghua Luo, Jinqiang Lai, Hongming Xie, Zhenxiu Luo, Lei Zhang, Ridong Li, <span class="NLM_string-name hlFld-ContribAuthor">Yingjun Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Development of an Efficient and Scalable Biocatalytic Route to (1S,4R)-8-Hydroxy-1,2,3,4- tetrahydro-1,4-methanonaphthalen-5-yl Propionate via Enantioselective Enzymatic Desymmetrization of a Prochiral Diester. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (6)
                                     , 1243-1251. <a href="https://doi.org/10.1021/acs.oprd.9b00188" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00188</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00188%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DDevelopment%252Bof%252Ban%252BEfficient%252Band%252BScalable%252BBiocatalytic%252BRoute%252Bto%252B%2525281S%25252C4R%252529-8-Hydroxy-1%25252C2%25252C3%25252C4-%252Btetrahydro-1%25252C4-methanonaphthalen-5-yl%252BPropionate%252Bvia%252BEnantioselective%252BEnzymatic%252BDesymmetrization%252Bof%252Ba%252BProchiral%252BDiester%26aulast%3DFeng%26aufirst%3DYahui%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D30042019%26date%3D23052019%26date%3D13052019%26volume%3D23%26issue%3D6%26spage%3D1243%26epage%3D1251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kenneth Arrington, Gregg A. Barcan, Nicholas A. Calandra, Greg A. Erickson, Ling Li, Li Liu, Mark G. Nilson, Iulia I. Strambeanu, Kelsey F. VanGelder, John L. Woodard, Shiping Xie, C. Liana Allen, John A. Kowalski, <span class="NLM_string-name hlFld-ContribAuthor">David C. Leitch</span>. </span><span class="cited-content_cbyCitation_article-title">Convergent Synthesis of the NS5B Inhibitor GSK8175 Enabled by Transition Metal Catalysis. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (8)
                                     , 4680-4694. <a href="https://doi.org/10.1021/acs.joc.8b02269" title="DOI URL">https://doi.org/10.1021/acs.joc.8b02269</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b02269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b02269%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DConvergent%252BSynthesis%252Bof%252Bthe%252BNS5B%252BInhibitor%252BGSK8175%252BEnabled%252Bby%252BTransition%252BMetal%252BCatalysis%26aulast%3DArrington%26aufirst%3DKenneth%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D01092018%26date%3D29102018%26date%3D19102018%26volume%3D84%26issue%3D8%26spage%3D4680%26epage%3D4694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Robert J. Young, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Leeson</span>. </span><span class="cited-content_cbyCitation_article-title">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6421-6467. <a href="https://doi.org/10.1021/acs.jmedchem.8b00180" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00180%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMapping%252Bthe%252BEfficiency%252Band%252BPhysicochemical%252BTrajectories%252Bof%252BSuccessful%252BOptimizations%26aulast%3DYoung%26aufirst%3DRobert%2BJ.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03022018%26date%3D25042018%26date%3D05042018%26volume%3D61%26issue%3D15%26spage%3D6421%26epage%3D6467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Wensheng Yu, Ling Tong, Oleg Selyutin, Lei Chen, Bin Hu, Bin Zhong, Jinglai Hao, Tao Ji, Shuai Zan, Jingjun Yin, Rebecca T. Ruck, Stephanie Curry, Patricia McMonagle, Sony Agrawal, Laura Rokosz, Donna Carr, Paul Ingravallo, Karin Bystol, Frederick Lahser, Rong Liu, Shiying Chen, Kung-I Feng, Mark Cartwright, Ernest Asante-Appiah, <span class="NLM_string-name hlFld-ContribAuthor">Joseph A. Kozlowski</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (9)
                                     , 3984-4003. <a href="https://doi.org/10.1021/acs.jmedchem.7b01927" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01927</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01927%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BMK-6169%25252C%252Ba%252BPotent%252BPan-Genotype%252BHepatitis%252BC%252BVirus%252BNS5A%252BInhibitor%252Bwith%252BOptimized%252BActivity%252Bagainst%252BCommon%252BResistance-Associated%252BSubstitutions%26aulast%3DYu%26aufirst%3DWensheng%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D30122017%26date%3D01052018%26date%3D21042018%26volume%3D61%26issue%3D9%26spage%3D3984%26epage%3D4003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">David A. DeGoey, Hui-Ju Chen, Philip B. Cox, <span class="NLM_string-name hlFld-ContribAuthor">Michael D. Wendt</span>. </span><span class="cited-content_cbyCitation_article-title">Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (7)
                                     , 2636-2651. <a href="https://doi.org/10.1021/acs.jmedchem.7b00717" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00717</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00717%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBeyond%252Bthe%252BRule%252Bof%252B5%25253A%252BLessons%252BLearned%252Bfrom%252BAbbVie%2525E2%252580%252599s%252BDrugs%252Band%252BCompound%252BCollection%26aulast%3DDeGoey%26aufirst%3DDavid%2BA.%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D15052017%26date%3D27092017%26date%3D19092017%26volume%3D61%26issue%3D7%26spage%3D2636%26epage%3D2651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Ling    Tong </span><span class="hlFld-ContribAuthor "> Joseph A.    Kozlowski </span><span class="hlFld-ContribAuthor "> Louis-Charles    Campeau </span><span class="hlFld-ContribAuthor "> Jingjun    Yin </span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Development of Ruzasvir: An Investigational Next Generation Pan-Genotype HCV Nonstructural Protein 5A (NS5A) Inhibitor for the Cure of Hepatitis C Virus Infections. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 115-149. <a href="https://doi.org/10.1021/bk-2018-1307.ch005" title="DOI URL">https://doi.org/10.1021/bk-2018-1307.ch005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2018-1307.ch005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2018-1307.ch005%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Band%252BDevelopment%252Bof%252BRuzasvir%25253A%252BAn%252BInvestigational%252BNext%252BGeneration%252BPan-Genotype%252BHCV%252BNonstructural%252BProtein%252B5A%252B%252528NS5A%252529%252BInhibitor%252Bfor%252Bthe%252BCure%252Bof%252BHepatitis%252BC%252BVirus%252BInfections%26aulast%3DTong%26aufirst%3DLing%26date%3D2018%26date%3D2018%26spage%3D115%26epage%3D149%26atitle%3DComplete%252BAccounts%252Bof%252BIntegrated%252BDrug%252BDiscovery%252Band%252BDevelopment%25253A%252BRecent%252BExamples%252Bfrom%252Bthe%252BPharmaceutical%252BIndustry%252BVolume%252B1%26aulast%3DAbdel-Magid%26aufirst%3DAhmed%2BF.%26date%3D2018%26date%3D2018%26volume%3D1307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kap-Sun  Yeung</span>, <span class="hlFld-ContribAuthor ">Brett R.  Beno</span>, <span class="hlFld-ContribAuthor ">Kyle  Parcella</span>, <span class="hlFld-ContribAuthor ">John A.  Bender</span>, <span class="hlFld-ContribAuthor ">Katherine A.  Grant-Young</span>, <span class="hlFld-ContribAuthor ">Andrew  Nickel</span>, <span class="hlFld-ContribAuthor ">Prashantha  Gunaga</span>, <span class="hlFld-ContribAuthor ">Prakash  Anjanappa</span>, <span class="hlFld-ContribAuthor ">Rajesh Onkardas  Bora</span>, <span class="hlFld-ContribAuthor ">Kumaravel  Selvakumar</span>, <span class="hlFld-ContribAuthor ">Karen  Rigat</span>, <span class="hlFld-ContribAuthor ">Ying-Kai  Wang</span>, <span class="hlFld-ContribAuthor ">Mengping  Liu</span>, <span class="hlFld-ContribAuthor ">Julie  Lemm</span>, <span class="hlFld-ContribAuthor ">Kathy  Mosure</span>, <span class="hlFld-ContribAuthor ">Steven  Sheriff</span>, <span class="hlFld-ContribAuthor ">Changhong  Wan</span>, <span class="hlFld-ContribAuthor ">Mark  Witmer</span>, <span class="hlFld-ContribAuthor ">Kevin  Kish</span>, <span class="hlFld-ContribAuthor ">Umesh  Hanumegowda</span>, <span class="hlFld-ContribAuthor ">Xiaoliang  Zhuo</span>, <span class="hlFld-ContribAuthor ">Yue-Zhong  Shu</span>, <span class="hlFld-ContribAuthor ">Dawn  Parker</span>, <span class="hlFld-ContribAuthor ">Roy  Haskell</span>, <span class="hlFld-ContribAuthor ">Alicia  Ng</span>, <span class="hlFld-ContribAuthor ">Qi  Gao</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Colston</span>, <span class="hlFld-ContribAuthor ">Joseph  Raybon</span>, <span class="hlFld-ContribAuthor ">Dennis M.  Grasela</span>, <span class="hlFld-ContribAuthor ">Kenneth  Santone</span>, <span class="hlFld-ContribAuthor ">Min  Gao</span>, <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>, <span class="hlFld-ContribAuthor ">Michael  Sinz</span>, <span class="hlFld-ContribAuthor ">Matthew G.  Soars</span>, <span class="hlFld-ContribAuthor ">Jay O.  Knipe</span>, <span class="hlFld-ContribAuthor ">Susan B.  Roberts</span>, and <span class="hlFld-ContribAuthor ">John F.  Kadow</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (10)
                                     , 4369-4385. <a href="https://doi.org/10.1021/acs.jmedchem.7b00328" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00328</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00328%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BHepatitis%252BC%252BVirus%252BNS5B%252BReplicase%252BPalm%252BSite%252BAllosteric%252BInhibitor%252B%252528BMS-929075%252529%252BAdvanced%252Bto%252BPhase%252B1%252BClinical%252BStudies%26aulast%3DYeung%26aufirst%3DKap-Sun%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D03032017%26date%3D04052017%26date%3D25052017%26date%3D21042017%26volume%3D60%26issue%3D10%26spage%3D4369%26epage%3D4385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei-Lei  Liu</span>, <span class="hlFld-ContribAuthor ">Thi Kim Quy  Ha</span>, <span class="hlFld-ContribAuthor ">Wei  Ha</span>, <span class="hlFld-ContribAuthor ">Won Keun  Oh</span>, <span class="hlFld-ContribAuthor ">Jun-Li  Yang</span>, and <span class="hlFld-ContribAuthor ">Yan-Ping  Shi</span>  . </span><span class="cited-content_cbyCitation_article-title">Sesquiterpenoids with Various Carbocyclic Skeletons from the Flowers of Chrysanthemum indicum. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2017,</strong> <em>80 </em>
                                    (2)
                                     , 298-307. <a href="https://doi.org/10.1021/acs.jnatprod.6b00694" title="DOI URL">https://doi.org/10.1021/acs.jnatprod.6b00694</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jnatprod.6b00694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jnatprod.6b00694%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DSesquiterpenoids%252Bwith%252BVarious%252BCarbocyclic%252BSkeletons%252Bfrom%252Bthe%252BFlowers%252Bof%252BChrysanthemum%252Bindicum%26aulast%3DLiu%26aufirst%3DLei-Lei%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D26072016%26date%3D03022017%26date%3D24022017%26volume%3D80%26issue%3D2%26spage%3D298%26epage%3D307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wensheng  Yu</span>, <span class="hlFld-ContribAuthor ">Ling  Tong</span>, <span class="hlFld-ContribAuthor ">Bin  Hu</span>, <span class="hlFld-ContribAuthor ">Bin  Zhong</span>, <span class="hlFld-ContribAuthor ">Jinglai  Hao</span>, <span class="hlFld-ContribAuthor ">Tao  Ji</span>, <span class="hlFld-ContribAuthor ">Shuai  Zan</span>, <span class="hlFld-ContribAuthor ">Craig A.  Coburn</span>, <span class="hlFld-ContribAuthor ">Oleg  Selyutin</span>, <span class="hlFld-ContribAuthor ">Lei  Chen</span>, <span class="hlFld-ContribAuthor ">Laura  Rokosz</span>, <span class="hlFld-ContribAuthor ">Sony  Agrawal</span>, <span class="hlFld-ContribAuthor ">Rong  Liu</span>, <span class="hlFld-ContribAuthor ">Stephanie  Curry</span>, <span class="hlFld-ContribAuthor ">Patricia  McMonagle</span>, <span class="hlFld-ContribAuthor ">Paul  Ingravallo</span>, <span class="hlFld-ContribAuthor ">Ernest  Asante-Appiah</span>, <span class="hlFld-ContribAuthor ">Shiying  Chen</span>, and <span class="hlFld-ContribAuthor ">Joseph A.  Kozlowski</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (22)
                                     , 10228-10243. <a href="https://doi.org/10.1021/acs.jmedchem.6b01234" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01234</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01234%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BChromane%252BContaining%252BHepatitis%252BC%252BVirus%252B%252528HCV%252529%252BNS5A%252BInhibitors%252Bwith%252BImproved%252BPotency%252Bagainst%252BResistance-Associated%252BVariants%26aulast%3DYu%26aufirst%3DWensheng%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D16082016%26date%3D09112016%26date%3D23112016%26date%3D28102016%26volume%3D59%26issue%3D22%26spage%3D10228%26epage%3D10243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>  . </span><span class="cited-content_cbyCitation_article-title">2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (16)
                                     , 7311-7351. <a href="https://doi.org/10.1021/acs.jmedchem.6b00915" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00915</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00915%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D2015%252BPhilip%252BS.%252BPortoghese%252BMedicinal%252BChemistry%252BLectureship.%252BCuring%252BHepatitis%252BC%252BVirus%252BInfection%252Bwith%252BDirect-Acting%252BAntiviral%252BAgents%25253A%252BThe%252BArc%252Bof%252Ba%252BMedicinal%252BChemistry%252BTriumph%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D18062016%26date%3D08082016%26date%3D25082016%26volume%3D59%26issue%3D16%26spage%3D7311%26epage%3D7351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David L.  Hughes</span>  . </span><span class="cited-content_cbyCitation_article-title">Patent Highlights: Recently Approved HCV NS5a Drugs. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2016,</strong> <em>20 </em>
                                    (8)
                                     , 1404-1415. <a href="https://doi.org/10.1021/acs.oprd.6b00241" title="DOI URL">https://doi.org/10.1021/acs.oprd.6b00241</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.6b00241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.6b00241%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DPatent%252BHighlights%25253A%252BRecently%252BApproved%252BHCV%252BNS5a%252BDrugs%26aulast%3DHughes%26aufirst%3DDavid%2BL.%26date%3D2016%26date%3D2016%26date%3D15072016%26date%3D21072016%26date%3D19082016%26volume%3D20%26issue%3D8%26spage%3D1404%26epage%3D1415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Na  Ye</span>, <span class="hlFld-ContribAuthor ">Haiying  Chen</span>, <span class="hlFld-ContribAuthor ">Eric A.  Wold</span>, <span class="hlFld-ContribAuthor ">Pei-Yong  Shi</span>, and <span class="hlFld-ContribAuthor ">Jia  Zhou</span>  . </span><span class="cited-content_cbyCitation_article-title">Therapeutic Potential of Spirooxindoles as Antiviral Agents. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2016,</strong> <em>2 </em>
                                    (6)
                                     , 382-392. <a href="https://doi.org/10.1021/acsinfecdis.6b00041" title="DOI URL">https://doi.org/10.1021/acsinfecdis.6b00041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.6b00041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.6b00041%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DTherapeutic%252BPotential%252Bof%252BSpirooxindoles%252Bas%252BAntiviral%252BAgents%26aulast%3DYe%26aufirst%3DNa%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D17032016%26date%3D05052016%26date%3D10062016%26date%3D26042016%26volume%3D2%26issue%3D6%26spage%3D382%26epage%3D392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Zhou</span>, <span class="hlFld-ContribAuthor ">Jiang  Wang</span>, <span class="hlFld-ContribAuthor ">Zhanni  Gu</span>, <span class="hlFld-ContribAuthor ">Shuni  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Zhu</span>, <span class="hlFld-ContribAuthor ">José Luis  Aceña</span>, <span class="hlFld-ContribAuthor ">Vadim A.  Soloshonok</span>, <span class="hlFld-ContribAuthor ">Kunisuke  Izawa</span>, and <span class="hlFld-ContribAuthor ">Hong  Liu</span>  . </span><span class="cited-content_cbyCitation_article-title">Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2016,</strong> <em>116 </em>
                                    (2)
                                     , 422-518. <a href="https://doi.org/10.1021/acs.chemrev.5b00392" title="DOI URL">https://doi.org/10.1021/acs.chemrev.5b00392</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.5b00392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.5b00392%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DNext%252BGeneration%252Bof%252BFluorine-Containing%252BPharmaceuticals%25252C%252BCompounds%252BCurrently%252Bin%252BPhase%252BII%2525E2%252580%252593III%252BClinical%252BTrials%252Bof%252BMajor%252BPharmaceutical%252BCompanies%25253A%252BNew%252BStructural%252BTrends%252Band%252BTherapeutic%252BAreas%26aulast%3DZhou%26aufirst%3DYu%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D06072015%26date%3D12012016%26date%3D27012016%26volume%3D116%26issue%3D2%26spage%3D422%26epage%3D518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jonathan B.  Baell</span>  . </span><span class="cited-content_cbyCitation_article-title">Screening-Based Translation of Public Research Encounters Painful Problems. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (3)
                                     , 229-234. <a href="https://doi.org/10.1021/acsmedchemlett.5b00032" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00032%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DScreening-Based%252BTranslation%252Bof%252BPublic%252BResearch%252BEncounters%252BPainful%252BProblems%26aulast%3DBaell%26aufirst%3DJonathan%2BB.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D03022015%26date%3D23012015%26date%3D09022015%26date%3D12032015%26volume%3D6%26issue%3D3%26spage%3D229%26epage%3D234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jun-Li  Yang</span>, <span class="hlFld-ContribAuthor ">Thi-Kim-Quy  Ha</span>, <span class="hlFld-ContribAuthor ">Basanta  Dhodary</span>, <span class="hlFld-ContribAuthor ">Euisun  Pyo</span>, <span class="hlFld-ContribAuthor ">Ngoc Hieu  Nguyen</span>, <span class="hlFld-ContribAuthor ">Hyomoon  Cho</span>, <span class="hlFld-ContribAuthor ">Eunhee  Kim</span>, and <span class="hlFld-ContribAuthor ">Won Keun  Oh</span>  . </span><span class="cited-content_cbyCitation_article-title">Oleanane Triterpenes from the Flowers of Camellia japonica Inhibit Porcine Epidemic Diarrhea Virus (PEDV) Replication. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (3)
                                     , 1268-1280. <a href="https://doi.org/10.1021/jm501567f" title="DOI URL">https://doi.org/10.1021/jm501567f</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501567f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501567f%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOleanane%252BTriterpenes%252Bfrom%252Bthe%252BFlowers%252Bof%252BCamellia%252Bjaponica%252BInhibit%252BPorcine%252BEpidemic%252BDiarrhea%252BVirus%252B%252528PEDV%252529%252BReplication%26aulast%3DYang%26aufirst%3DJun-Li%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D27092014%26date%3D03022015%26date%3D12022015%26date%3D08012015%26volume%3D58%26issue%3D3%26spage%3D1268%26epage%3D1280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James H.  Nettles</span>, <span class="hlFld-ContribAuthor ">Richard A.  Stanton</span>, <span class="hlFld-ContribAuthor ">Joshua  Broyde</span>, <span class="hlFld-ContribAuthor ">Franck  Amblard</span>, <span class="hlFld-ContribAuthor ">Hongwang  Zhang</span>, <span class="hlFld-ContribAuthor ">Longhu  Zhou</span>, <span class="hlFld-ContribAuthor ">Junxing  Shi</span>, <span class="hlFld-ContribAuthor ">Tamara R.  McBrayer</span>, <span class="hlFld-ContribAuthor ">Tony  Whitaker</span>, <span class="hlFld-ContribAuthor ">Steven J.  Coats</span>, <span class="hlFld-ContribAuthor ">James J.  Kohler</span>, and <span class="hlFld-ContribAuthor ">Raymond F.  Schinazi</span>  . </span><span class="cited-content_cbyCitation_article-title">Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (23)
                                     , 10031-10043. <a href="https://doi.org/10.1021/jm501291c" title="DOI URL">https://doi.org/10.1021/jm501291c</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501291c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501291c%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAsymmetric%252BBinding%252Bto%252BNS5A%252Bby%252BDaclatasvir%252B%252528BMS-790052%252529%252Band%252BAnalogs%252BSuggests%252BTwo%252BNovel%252BModes%252Bof%252BHCV%252BInhibition%26aulast%3DNettles%26aufirst%3DJames%2BH.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D23082014%26date%3D03112014%26date%3D11122014%26volume%3D57%26issue%3D23%26spage%3D10031%26epage%3D10043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lyn H.  Jones</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal Chemical Biology. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-37. <a href="https://doi.org/10.1002/0471266949.bmc256" title="DOI URL">https://doi.org/10.1002/0471266949.bmc256</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc256%26sid%3Dliteratum%253Aachs%26atitle%3DMedicinal%252BChemical%252BBiology%26aulast%3DJones%26aufirst%3DLyn%2BH.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D37%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mai H. A.  Mousa</span>, <span class="hlFld-ContribAuthor ">Nermin S.  Ahmed</span>, <span class="hlFld-ContribAuthor ">Kai  Schwedtmann</span>, <span class="hlFld-ContribAuthor ">Efseveia  Frakolaki</span>, <span class="hlFld-ContribAuthor ">Niki  Vassilaki</span>, <span class="hlFld-ContribAuthor ">Grigoris  Zoidis</span>, <span class="hlFld-ContribAuthor ">Jan J.  Weigand</span>, <span class="hlFld-ContribAuthor ">Ashraf H.  Abadi</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Novel Symmetric Fluorene-2,7-Diamine Derivatives as Potent Hepatitis C Virus Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2021,</strong> <em>14 </em>
                                    (4)
                                     , 292. <a href="https://doi.org/10.3390/ph14040292" title="DOI URL">https://doi.org/10.3390/ph14040292</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph14040292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph14040292%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BNovel%252BSymmetric%252BFluorene-2%25252C7-Diamine%252BDerivatives%252Bas%252BPotent%252BHepatitis%252BC%252BVirus%252BInhibitors%26aulast%3DMousa%26aufirst%3DMai%2BH.%2BA.%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D4%26spage%3D292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mziyanda  Mbaba</span>, <span class="hlFld-ContribAuthor ">Setshaba D.  Khanye</span>, <span class="hlFld-ContribAuthor ">Gregory S.  Smith</span>, <span class="hlFld-ContribAuthor ">Christophe  Biot</span>. </span><span class="cited-content_cbyCitation_article-title">Organometallic Chemistry of Drugs Based on Iron. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-820206-7.00046-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-820206-7.00046-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820206-7.00046-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820206-7.00046-9%26sid%3Dliteratum%253Aachs%26atitle%3DOrganometallic%252BChemistry%252Bof%252BDrugs%252BBased%252Bon%252BIron%26aulast%3DMbaba%26aufirst%3DMziyanda%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2021%26volume%3D44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiang  Liu</span>, <span class="hlFld-ContribAuthor ">Jianlin  Han</span>, <span class="hlFld-ContribAuthor ">Kunisuke  Izawa</span>, <span class="hlFld-ContribAuthor ">Tatsunori  Sato</span>, <span class="hlFld-ContribAuthor ">Sarah  White</span>, <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>, <span class="hlFld-ContribAuthor ">Vadim A.  Soloshonok</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclic tailor-made amino acids in the design of modern pharmaceuticals. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112736. <a href="https://doi.org/10.1016/j.ejmech.2020.112736" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112736</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112736%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCyclic%252Btailor-made%252Bamino%252Bacids%252Bin%252Bthe%252Bdesign%252Bof%252Bmodern%252Bpharmaceuticals%26aulast%3DLiu%26aufirst%3DJiang%26date%3D2020%26volume%3D208%26spage%3D112736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mubarak A.  Alamri</span>, <span class="hlFld-ContribAuthor ">Muhammad  Tahir ul Qamar</span>, <span class="hlFld-ContribAuthor ">Muhammad Usman  Mirza</span>, <span class="hlFld-ContribAuthor ">Safar M.  Alqahtani</span>, <span class="hlFld-ContribAuthor ">Matheus  Froeyen</span>, <span class="hlFld-ContribAuthor ">Ling-Ling  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of human coronaviruses pan-papain-like protease inhibitors using computational approaches. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical Analysis</span><span> <strong>2020,</strong> <em>10 </em>
                                    (6)
                                     , 546-559. <a href="https://doi.org/10.1016/j.jpha.2020.08.012" title="DOI URL">https://doi.org/10.1016/j.jpha.2020.08.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpha.2020.08.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpha.2020.08.012%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520Analysis%26atitle%3DDiscovery%252Bof%252Bhuman%252Bcoronaviruses%252Bpan-papain-like%252Bprotease%252Binhibitors%252Busing%252Bcomputational%252Bapproaches%26aulast%3DAlamri%26aufirst%3DMubarak%2BA.%26date%3D2020%26volume%3D10%26issue%3D6%26spage%3D546%26epage%3D559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gururaj  Somadi</span>, <span class="hlFld-ContribAuthor ">Sree Kanth  Sivan</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of therapeutic target in S2 domain of SARS nCov-2 Spike glycoprotein: Key to design and discover drug candidates for inhibition of viral entry into host cell. </span><span class="cited-content_cbyCitation_journal-name">Journal of Theoretical and Computational Chemistry</span><span> <strong>2020,</strong> <em>19 </em>
                                    (07)
                                     , 2050028. <a href="https://doi.org/10.1142/S0219633620500285" title="DOI URL">https://doi.org/10.1142/S0219633620500285</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1142/S0219633620500285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1142%2FS0219633620500285%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Theoretical%2520and%2520Computational%2520Chemistry%26atitle%3DIdentification%252Bof%252Btherapeutic%252Btarget%252Bin%252BS2%252Bdomain%252Bof%252BSARS%252BnCov-2%252BSpike%252Bglycoprotein%25253A%252BKey%252Bto%252Bdesign%252Band%252Bdiscover%252Bdrug%252Bcandidates%252Bfor%252Binhibition%252Bof%252Bviral%252Bentry%252Binto%252Bhost%252Bcell%26aulast%3DSomadi%26aufirst%3DGururaj%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D07%26spage%3D2050028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrey A.  Ivashchenko</span>, <span class="hlFld-ContribAuthor ">Yan A.  Ivanenkov</span>, <span class="hlFld-ContribAuthor ">Vladimir A.  Aladinskiy</span>, <span class="hlFld-ContribAuthor ">Ruben N.  Karapetian</span>, <span class="hlFld-ContribAuthor ">Angela G.  Koryakova</span>, <span class="hlFld-ContribAuthor ">Alexey A.  Ryakhovskiy</span>, <span class="hlFld-ContribAuthor ">Oleg D.  Mitkin</span>, <span class="hlFld-ContribAuthor ">Dmitry V.  Kravchenko</span>, <span class="hlFld-ContribAuthor ">Nikolai P.  Savchuk</span>, <span class="hlFld-ContribAuthor ">Bogdan A.  Zagribelnyy</span>, <span class="hlFld-ContribAuthor ">Alexander V.  Ivashchenko</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, biological evaluation and in silico modeling of novel pan-genotypic NS5A inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (20)
                                     , 115716. <a href="https://doi.org/10.1016/j.bmc.2020.115716" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115716</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115716%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Bin%252Bsilico%252Bmodeling%252Bof%252Bnovel%252Bpan-genotypic%252BNS5A%252Binhibitors%26aulast%3DIvashchenko%26aufirst%3DAndrey%2BA.%26date%3D2020%26volume%3D28%26issue%3D20%26spage%3D115716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Z.  Qin</span>, <span class="hlFld-ContribAuthor ">A.  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">QSAR studies on hepatitis C virus NS5A protein tetracyclic inhibitors in wild type and mutants by CoMFA and CoMSIA. </span><span class="cited-content_cbyCitation_journal-name">SAR and QSAR in Environmental Research</span><span> <strong>2020,</strong> <em>31 </em>
                                    (4)
                                     , 281-311. <a href="https://doi.org/10.1080/1062936X.2020.1740889" title="DOI URL">https://doi.org/10.1080/1062936X.2020.1740889</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1062936X.2020.1740889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1062936X.2020.1740889%26sid%3Dliteratum%253Aachs%26jtitle%3DSAR%2520and%2520QSAR%2520in%2520Environmental%2520Research%26atitle%3DQSAR%252Bstudies%252Bon%252Bhepatitis%252BC%252Bvirus%252BNS5A%252Bprotein%252Btetracyclic%252Binhibitors%252Bin%252Bwild%252Btype%252Band%252Bmutants%252Bby%252BCoMFA%252Band%252BCoMSIA%26aulast%3DQin%26aufirst%3DZ.%26date%3D2020%26date%3D2020%26volume%3D31%26issue%3D4%26spage%3D281%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohit  Tyagi</span>, <span class="hlFld-ContribAuthor ">Fabio  Begnini</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Bradley C.  Doak</span>, <span class="hlFld-ContribAuthor ">Jan  Kihlberg</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Syntheses Beyond the Rule of 5. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2020,</strong> <em>26 </em>
                                    (1)
                                     , 49-88. <a href="https://doi.org/10.1002/chem.201902716" title="DOI URL">https://doi.org/10.1002/chem.201902716</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201902716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201902716%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DDrug%252BSyntheses%252BBeyond%252Bthe%252BRule%252Bof%252B5%26aulast%3DTyagi%26aufirst%3DMohit%26date%3D2020%26date%3D2019%26volume%3D26%26issue%3D1%26spage%3D49%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nina  Dedic</span>, <span class="hlFld-ContribAuthor ">Philip G.  Jones</span>, <span class="hlFld-ContribAuthor ">Seth C.  Hopkins</span>, <span class="hlFld-ContribAuthor ">Robert  Lew</span>, <span class="hlFld-ContribAuthor ">Liming  Shao</span>, <span class="hlFld-ContribAuthor ">John E.  Campbell</span>, <span class="hlFld-ContribAuthor ">Kerry L.  Spear</span>, <span class="hlFld-ContribAuthor ">Thomas H.  Large</span>, <span class="hlFld-ContribAuthor ">Una C.  Campbell</span>, <span class="hlFld-ContribAuthor ">Taleen  Hanania</span>, <span class="hlFld-ContribAuthor ">Emer  Leahy</span>, <span class="hlFld-ContribAuthor ">Kenneth S.  Koblan</span>. </span><span class="cited-content_cbyCitation_article-title">SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D
              2
              Receptor Mechanism of Action. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2019,</strong> <em>371 </em>
                                    (1)
                                     , 1-14. <a href="https://doi.org/10.1124/jpet.119.260281" title="DOI URL">https://doi.org/10.1124/jpet.119.260281</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.119.260281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.119.260281%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DSEP-363856%25252C%252Ba%252BNovel%252BPsychotropic%252BAgent%252Bwith%252Ba%252BUnique%25252C%252BNon-D%252B2%252BReceptor%252BMechanism%252Bof%252BAction%26aulast%3DDedic%26aufirst%3DNina%26date%3D2019%26date%3D2019%26volume%3D371%26issue%3D1%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhammad Usman  Ashraf</span>, <span class="hlFld-ContribAuthor ">Kanzal  Iman</span>, <span class="hlFld-ContribAuthor ">Muhammad Farhan  Khalid</span>, <span class="hlFld-ContribAuthor ">Hafiz Muhammad  Salman</span>, <span class="hlFld-ContribAuthor ">Talha  Shafi</span>, <span class="hlFld-ContribAuthor ">Momal  Rafi</span>, <span class="hlFld-ContribAuthor ">Nida  Javaid</span>, <span class="hlFld-ContribAuthor ">Rashid  Hussain</span>, <span class="hlFld-ContribAuthor ">Fayyaz  Ahmad</span>, <span class="hlFld-ContribAuthor ">Syed  Shahzad‐Ul‐Hussan</span>, <span class="hlFld-ContribAuthor ">Shaper  Mirza</span>, <span class="hlFld-ContribAuthor ">Muhammad  Shafiq</span>, <span class="hlFld-ContribAuthor ">Samia  Afzal</span>, <span class="hlFld-ContribAuthor ">Sadia  Hamera</span>, <span class="hlFld-ContribAuthor ">Saima  Anwar</span>, <span class="hlFld-ContribAuthor ">Romena  Qazi</span>, <span class="hlFld-ContribAuthor ">Muhammad  Idrees</span>, <span class="hlFld-ContribAuthor ">Sohail A.  Qureshi</span>, <span class="hlFld-ContribAuthor ">Safee Ullah  Chaudhary</span>. </span><span class="cited-content_cbyCitation_article-title">Evolution of efficacious pangenotypic hepatitis C virus therapies. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (3)
                                     , 1091-1136. <a href="https://doi.org/10.1002/med.21554" title="DOI URL">https://doi.org/10.1002/med.21554</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21554%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DEvolution%252Bof%252Befficacious%252Bpangenotypic%252Bhepatitis%252BC%252Bvirus%252Btherapies%26aulast%3DAshraf%26aufirst%3DMuhammad%2BUsman%26date%3D2019%26date%3D2018%26volume%3D39%26issue%3D3%26spage%3D1091%26epage%3D1136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming-Lung  Yu</span>, <span class="hlFld-ContribAuthor ">Chao-Hung  Hung</span>, <span class="hlFld-ContribAuthor ">Yi-Hsiang  Huang</span>, <span class="hlFld-ContribAuthor ">Cheng-Yuan  Peng</span>, <span class="hlFld-ContribAuthor ">Chun-Yen  Lin</span>, <span class="hlFld-ContribAuthor ">Pin-Nan  Cheng</span>, <span class="hlFld-ContribAuthor ">Rong-Nan  Chien</span>, <span class="hlFld-ContribAuthor ">Shih-Jer  Hsu</span>, <span class="hlFld-ContribAuthor ">Chen-Hua  Liu</span>, <span class="hlFld-ContribAuthor ">Chung-Feng  Huang</span>, <span class="hlFld-ContribAuthor ">Chien-Wei  Su</span>, <span class="hlFld-ContribAuthor ">Jee-Fu  Huang</span>, <span class="hlFld-ContribAuthor ">Chun-Jen  Liu</span>, <span class="hlFld-ContribAuthor ">Jia-Horng  Kao</span>, <span class="hlFld-ContribAuthor ">Wan-Long  Chuang</span>, <span class="hlFld-ContribAuthor ">Pei-Jer  Chen</span>, <span class="hlFld-ContribAuthor ">Ding-Shinn  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. </span><span class="cited-content_cbyCitation_journal-name">Journal of the Formosan Medical Association</span><span> <strong>2019,</strong> <em>118 </em>
                                    (2)
                                     , 556-564. <a href="https://doi.org/10.1016/j.jfma.2018.11.007" title="DOI URL">https://doi.org/10.1016/j.jfma.2018.11.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jfma.2018.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jfma.2018.11.007%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520Formosan%2520Medical%2520Association%26atitle%3DEfficacy%252Band%252Bsafety%252Bof%252B12%252Bweeks%252Bof%252Bdaclatasvir%25252C%252Basunaprevir%252Bplus%252Bribavirin%252Bfor%252BHCV%252Bgenotype-1b%252Binfection%252Bwithout%252BNS5A%252Bresistance-associated%252Bsubstitutions%26aulast%3DYu%26aufirst%3DMing-Lung%26date%3D2019%26volume%3D118%26issue%3D2%26spage%3D556%26epage%3D564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert G.  Gentles</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Beclabuvir: A Potent Allosteric Inhibitor of the Hepatitis C Virus Polymerase. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 193-228. <a href="https://doi.org/10.1007/7355_2018_38" title="DOI URL">https://doi.org/10.1007/7355_2018_38</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2018_38&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2018_38%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Bof%252BBeclabuvir%25253A%252BA%252BPotent%252BAllosteric%252BInhibitor%252Bof%252Bthe%252BHepatitis%252BC%252BVirus%252BPolymerase%26aulast%3DGentles%26aufirst%3DRobert%2BG.%26date%3D2019%26date%3D2019%26spage%3D193%26epage%3D228%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DHCV%25253A%252BThe%252BJourney%252Bfrom%252BDiscovery%252Bto%252Ba%252BCure%26aulast%3DSofia%26aufirst%3DMichael%2BJ.%26date%3D2019%26volume%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>, <span class="hlFld-ContribAuthor ">Makonen  Belema</span>. </span><span class="cited-content_cbyCitation_article-title">The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 27-55. <a href="https://doi.org/10.1007/7355_2018_47" title="DOI URL">https://doi.org/10.1007/7355_2018_47</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2018_47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2018_47%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BDiscovery%252Band%252BDevelopment%252Bof%252BDaclatasvir%25253A%252BAn%252BInhibitor%252Bof%252Bthe%252BHepatitis%252BC%252BVirus%252BNS5A%252BReplication%252BComplex%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2019%26date%3D2019%26spage%3D27%26epage%3D55%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DHCV%25253A%252BThe%252BJourney%252Bfrom%252BDiscovery%252Bto%252Ba%252BCure%26aulast%3DSofia%26aufirst%3DMichael%2BJ.%26date%3D2019%26volume%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>, <span class="hlFld-ContribAuthor ">Ramkumar  Rajamani</span>, <span class="hlFld-ContribAuthor ">Paul M.  Scola</span>, <span class="hlFld-ContribAuthor ">Li-Qiang  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 317-354. <a href="https://doi.org/10.1007/7355_2018_58" title="DOI URL">https://doi.org/10.1007/7355_2018_58</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2018_58&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2018_58%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BDiscovery%252Band%252BEarly%252BClinical%252BEvaluation%252Bof%252Bthe%252BHCV%252BNS3%25252F4A%252BProtease%252BInhibitor%252BAsunaprevir%252B%252528BMS-650032%252529%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2019%26date%3D2019%26spage%3D317%26epage%3D354%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DHCV%25253A%252BThe%252BJourney%252Bfrom%252BDiscovery%252Bto%252Ba%252BCure%26aulast%3DSofia%26aufirst%3DMichael%2BJ.%26date%3D2019%26volume%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Venkat R.  Gadhachanda</span>, <span class="hlFld-ContribAuthor ">Kyle J.  Eastman</span>, <span class="hlFld-ContribAuthor ">Qiuping  Wang</span>, <span class="hlFld-ContribAuthor ">Avinash S.  Phadke</span>, <span class="hlFld-ContribAuthor ">Dharaben  Patel</span>, <span class="hlFld-ContribAuthor ">Wengang  Yang</span>, <span class="hlFld-ContribAuthor ">Christopher W.  Marlor</span>, <span class="hlFld-ContribAuthor ">Milind  Deshpande</span>, <span class="hlFld-ContribAuthor ">Mingjun  Huang</span>, <span class="hlFld-ContribAuthor ">Jason A.  Wiles</span>. </span><span class="cited-content_cbyCitation_article-title">Ferrocene-based inhibitors of hepatitis C virus replication that target NS5A with low picomolar in vitro antiviral activity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (21)
                                     , 3463-3471. <a href="https://doi.org/10.1016/j.bmcl.2018.09.023" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.09.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.09.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.09.023%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DFerrocene-based%252Binhibitors%252Bof%252Bhepatitis%252BC%252Bvirus%252Breplication%252Bthat%252Btarget%252BNS5A%252Bwith%252Blow%252Bpicomolar%252Bin%252Bvitro%252Bantiviral%252Bactivity%26aulast%3DGadhachanda%26aufirst%3DVenkat%2BR.%26date%3D2018%26volume%3D28%26issue%3D21%26spage%3D3463%26epage%3D3471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Petra E de  Ruiter</span>, <span class="hlFld-ContribAuthor ">Yashna  Gadjradj</span>, <span class="hlFld-ContribAuthor ">Robert J de  Knegt</span>, <span class="hlFld-ContribAuthor ">Herold J  Metselaar</span>, <span class="hlFld-ContribAuthor ">Jan NM  Ijzermans</span>, <span class="hlFld-ContribAuthor ">Luc JW van der  Laan</span>. </span><span class="cited-content_cbyCitation_article-title">Interaction of immunosuppressants with HCV antivirals daclatasvir and asunaprevir: combined effects with mycophenolic acid. </span><span class="cited-content_cbyCitation_journal-name">World Journal of Transplantation</span><span> <strong>2018,</strong> <em>8 </em>
                                    (5)
                                     , 156-166. <a href="https://doi.org/10.5500/wjt.v8.i5.156" title="DOI URL">https://doi.org/10.5500/wjt.v8.i5.156</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5500/wjt.v8.i5.156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5500%2Fwjt.v8.i5.156%26sid%3Dliteratum%253Aachs%26jtitle%3DWorld%2520Journal%2520of%2520Transplantation%26atitle%3DInteraction%252Bof%252Bimmunosuppressants%252Bwith%252BHCV%252Bantivirals%252Bdaclatasvir%252Band%252Basunaprevir%25253A%252Bcombined%252Beffects%252Bwith%252Bmycophenolic%252Bacid%26aulast%3DRuiter%26aufirst%3DPetra%2BE%2Bde%26date%3D2018%26volume%3D8%26issue%3D5%26spage%3D156%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuvam  Chaudhuri</span>, <span class="hlFld-ContribAuthor ">Julian A.  Symons</span>, <span class="hlFld-ContribAuthor ">Jerome  Deval</span>. </span><span class="cited-content_cbyCitation_article-title">Innovation and trends in the development and approval of antiviral medicines: 1987–2017 and beyond. </span><span class="cited-content_cbyCitation_journal-name">Antiviral Research</span><span> <strong>2018,</strong> <em>155 </em>, 76-88. <a href="https://doi.org/10.1016/j.antiviral.2018.05.005" title="DOI URL">https://doi.org/10.1016/j.antiviral.2018.05.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.antiviral.2018.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.antiviral.2018.05.005%26sid%3Dliteratum%253Aachs%26jtitle%3DAntiviral%2520Research%26atitle%3DInnovation%252Band%252Btrends%252Bin%252Bthe%252Bdevelopment%252Band%252Bapproval%252Bof%252Bantiviral%252Bmedicines%25253A%252B1987%2525E2%252580%2525932017%252Band%252Bbeyond%26aulast%3DChaudhuri%26aufirst%3DShuvam%26date%3D2018%26volume%3D155%26spage%3D76%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Bradley C.  Doak</span>, <span class="hlFld-ContribAuthor ">Jan  Kihlberg</span>. </span><span class="cited-content_cbyCitation_article-title">Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2018,</strong> <em>44 </em>, 23-29. <a href="https://doi.org/10.1016/j.cbpa.2018.05.010" title="DOI URL">https://doi.org/10.1016/j.cbpa.2018.05.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2018.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2018.05.010%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DOpportunities%252Band%252Bguidelines%252Bfor%252Bdiscovery%252Bof%252Borally%252Babsorbed%252Bdrugs%252Bin%252Bbeyond%252Brule%252Bof%252B5%252Bspace%26aulast%3DPoongavanam%26aufirst%3DVasanthanathan%26date%3D2018%26volume%3D44%26spage%3D23%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Biaryls. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 83-154. <a href="https://doi.org/10.1002/9781118686263.ch4" title="DOI URL">https://doi.org/10.1002/9781118686263.ch4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118686263.ch4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118686263.ch4%26sid%3Dliteratum%253Aachs%26atitle%3DBiaryls%26date%3D2018%26date%3D2018%26spage%3D83%26epage%3D154%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DPrivileged%252BStructures%252Bin%252BDrug%252BDiscovery%26aulast%3DYet%26aufirst%3DLarry%26date%3D2018%26volume%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Youngsu  You</span>, <span class="hlFld-ContribAuthor ">Hee Sun  Kim</span>, <span class="hlFld-ContribAuthor ">Jung Woo  Park</span>, <span class="hlFld-ContribAuthor ">Gyochang  Keum</span>, <span class="hlFld-ContribAuthor ">Sung Key  Jang</span>, <span class="hlFld-ContribAuthor ">B. Moon  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Sulfur(
              vi
              ) fluoride exchange as a key reaction for synthesizing biaryl sulfate core derivatives as potent hepatitis C virus NS5A inhibitors and their structure–activity relationship studies. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2018,</strong> <em>8 </em>
                                    (55)
                                     , 31803-31821. <a href="https://doi.org/10.1039/C8RA05471A" title="DOI URL">https://doi.org/10.1039/C8RA05471A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8RA05471A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8RA05471A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DSulfur%252528%252Bvi%252B%252529%252Bfluoride%252Bexchange%252Bas%252Ba%252Bkey%252Breaction%252Bfor%252Bsynthesizing%252Bbiaryl%252Bsulfate%252Bcore%252Bderivatives%252Bas%252Bpotent%252Bhepatitis%252BC%252Bvirus%252BNS5A%252Binhibitors%252Band%252Btheir%252Bstructure%2525E2%252580%252593activity%252Brelationship%252Bstudies%26aulast%3DYou%26aufirst%3DYoungsu%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D55%26spage%3D31803%26epage%3D31821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guanghai  Jin</span>, <span class="hlFld-ContribAuthor ">Jisu  Lee</span>, <span class="hlFld-ContribAuthor ">Kyeong  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical genetics-based development of small molecules targeting hepatitis C virus. </span><span class="cited-content_cbyCitation_journal-name">Archives of Pharmacal Research</span><span> <strong>2017,</strong> <em>40 </em>
                                    (9)
                                     , 1021-1036. <a href="https://doi.org/10.1007/s12272-017-0949-3" title="DOI URL">https://doi.org/10.1007/s12272-017-0949-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12272-017-0949-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12272-017-0949-3%26sid%3Dliteratum%253Aachs%26jtitle%3DArchives%2520of%2520Pharmacal%2520Research%26atitle%3DChemical%252Bgenetics-based%252Bdevelopment%252Bof%252Bsmall%252Bmolecules%252Btargeting%252Bhepatitis%252BC%252Bvirus%26aulast%3DJin%26aufirst%3DGuanghai%26date%3D2017%26date%3D2017%26volume%3D40%26issue%3D9%26spage%3D1021%26epage%3D1036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nikolaos  Lougiakis</span>, <span class="hlFld-ContribAuthor ">Efseveia  Frakolaki</span>, <span class="hlFld-ContribAuthor ">Panagiota  Karmou</span>, <span class="hlFld-ContribAuthor ">Nicole  Pouli</span>, <span class="hlFld-ContribAuthor ">Panagiotis  Marakos</span>, <span class="hlFld-ContribAuthor ">Vanesa  Madan</span>, <span class="hlFld-ContribAuthor ">Ralf  Bartenschlager</span>, <span class="hlFld-ContribAuthor ">Niki  Vassilaki</span>. </span><span class="cited-content_cbyCitation_article-title">Novel nucleoside analogues targeting HCV replication through an NS5A-dependent inhibition mechanism. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2017,</strong> <em>90 </em>
                                    (3)
                                     , 352-367. <a href="https://doi.org/10.1111/cbdd.12966" title="DOI URL">https://doi.org/10.1111/cbdd.12966</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12966%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DNovel%252Bnucleoside%252Banalogues%252Btargeting%252BHCV%252Breplication%252Bthrough%252Ban%252BNS5A-dependent%252Binhibition%252Bmechanism%26aulast%3DLougiakis%26aufirst%3DNikolaos%26date%3D2017%26date%3D2017%26volume%3D90%26issue%3D3%26spage%3D352%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guangdi  Li</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>. </span><span class="cited-content_cbyCitation_article-title">Current therapy for chronic hepatitis C: The role of direct-acting antivirals. </span><span class="cited-content_cbyCitation_journal-name">Antiviral Research</span><span> <strong>2017,</strong> <em>142 </em>, 83-122. <a href="https://doi.org/10.1016/j.antiviral.2017.02.014" title="DOI URL">https://doi.org/10.1016/j.antiviral.2017.02.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.antiviral.2017.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.antiviral.2017.02.014%26sid%3Dliteratum%253Aachs%26jtitle%3DAntiviral%2520Research%26atitle%3DCurrent%252Btherapy%252Bfor%252Bchronic%252Bhepatitis%252BC%25253A%252BThe%252Brole%252Bof%252Bdirect-acting%252Bantivirals%26aulast%3DLi%26aufirst%3DGuangdi%26date%3D2017%26volume%3D142%26spage%3D83%26epage%3D122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jürgen  Bosch</span>. </span><span class="cited-content_cbyCitation_article-title">PPI inhibitor and stabilizer development in human diseases. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today: Technologies</span><span> <strong>2017,</strong> <em>24 </em>, 3-9. <a href="https://doi.org/10.1016/j.ddtec.2017.10.004" title="DOI URL">https://doi.org/10.1016/j.ddtec.2017.10.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ddtec.2017.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ddtec.2017.10.004%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technologies%26atitle%3DPPI%252Binhibitor%252Band%252Bstabilizer%252Bdevelopment%252Bin%252Bhuman%252Bdiseases%26aulast%3DBosch%26aufirst%3DJ%25C3%25BCrgen%26date%3D2017%26volume%3D24%26spage%3D3%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan A.  Ivanenkov</span>, <span class="hlFld-ContribAuthor ">Vladimir A.  Aladinskiy</span>, <span class="hlFld-ContribAuthor ">Nikolay A.  Bushkov</span>, <span class="hlFld-ContribAuthor ">Andrey A.  Ayginin</span>, <span class="hlFld-ContribAuthor ">Alexander G.  Majouga</span>, <span class="hlFld-ContribAuthor ">Alexandre V.  Ivachtchenko</span>. </span><span class="cited-content_cbyCitation_article-title">Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2017,</strong> <em>27 </em>
                                    (4)
                                     , 401-414. <a href="https://doi.org/10.1080/13543776.2017.1272573" title="DOI URL">https://doi.org/10.1080/13543776.2017.1272573</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2017.1272573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2017.1272573%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DSmall-molecule%252Binhibitors%252Bof%252Bhepatitis%252BC%252Bvirus%252B%252528HCV%252529%252Bnon-structural%252Bprotein%252B5A%252B%252528NS5A%252529%25253A%252Ba%252Bpatent%252Breview%252B%2525282010-2015%252529%26aulast%3DIvanenkov%26aufirst%3DYan%2BA.%26date%3D2017%26date%3D2017%26volume%3D27%26issue%3D4%26spage%3D401%26epage%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas R.  McCarty</span>, <span class="hlFld-ContribAuthor ">Joseph K.  Lim</span>. </span><span class="cited-content_cbyCitation_article-title">Developing therapies to treat hepatitis C infection in post-liver transplant recipients. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2017,</strong> <em>18 </em>
                                    (2)
                                     , 165-174. <a href="https://doi.org/10.1080/14656566.2016.1276564" title="DOI URL">https://doi.org/10.1080/14656566.2016.1276564</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2016.1276564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2016.1276564%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DDeveloping%252Btherapies%252Bto%252Btreat%252Bhepatitis%252BC%252Binfection%252Bin%252Bpost-liver%252Btransplant%252Brecipients%26aulast%3DMcCarty%26aufirst%3DThomas%2BR.%26date%3D2017%26date%3D2017%26volume%3D18%26issue%3D2%26spage%3D165%26epage%3D174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">N.A.  Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 553-627. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12406-0" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12406-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12406-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12406-0%26sid%3Dliteratum%253Aachs%26atitle%3DDirect-Acting%252BAntiviral%252BAgents%252Bfor%252Bthe%252BTreatment%252Bof%252BHepatitis%252BC%252BVirus%252BInfection%26aulast%3DMeanwell%26aufirst%3DN.A.%26date%3D2017%26spage%3D553%26epage%3D627%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017%26volume%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Axel  Kleemann</span>. </span><span class="cited-content_cbyCitation_article-title">Antiinfectives for Systemic Use, 3. Antivirals. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 1-21. <a href="https://doi.org/10.1002/14356007.c13_c01.pub3" title="DOI URL">https://doi.org/10.1002/14356007.c13_c01.pub3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/14356007.c13_c01.pub3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F14356007.c13_c01.pub3%26sid%3Dliteratum%253Aachs%26atitle%3DAntiinfectives%252Bfor%252BSystemic%252BUse%25252C%252B3.%252BAntivirals%26aulast%3DKleemann%26aufirst%3DAxel%26date%3D2016%26date%3D2016%26spage%3D1%26epage%3D21%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DUllmann%252527s%252BEncyclopedia%252Bof%252BIndustrial%252BChemistry%26date%3D2000%26date%3D2000%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ling  Tong</span>, <span class="hlFld-ContribAuthor ">Wensheng  Yu</span>, <span class="hlFld-ContribAuthor ">Craig A.  Coburn</span>, <span class="hlFld-ContribAuthor ">Lei  Chen</span>, <span class="hlFld-ContribAuthor ">Oleg  Selyutin</span>, <span class="hlFld-ContribAuthor ">Qingbei  Zeng</span>, <span class="hlFld-ContribAuthor ">Michael P.  Dwyer</span>, <span class="hlFld-ContribAuthor ">Anilkumar G.  Nair</span>, <span class="hlFld-ContribAuthor ">Bandarpalle B.  Shankar</span>, <span class="hlFld-ContribAuthor ">Seong Heon  Kim</span>, <span class="hlFld-ContribAuthor ">De-Yi  Yang</span>, <span class="hlFld-ContribAuthor ">Stuart B.  Rosenblum</span>, <span class="hlFld-ContribAuthor ">Rebecca T.  Ruck</span>, <span class="hlFld-ContribAuthor ">Ian W.  Davies</span>, <span class="hlFld-ContribAuthor ">Bin  Hu</span>, <span class="hlFld-ContribAuthor ">Bin  Zhong</span>, <span class="hlFld-ContribAuthor ">Jinglai  Hao</span>, <span class="hlFld-ContribAuthor ">Tao  Ji</span>, <span class="hlFld-ContribAuthor ">Shuai  Zan</span>, <span class="hlFld-ContribAuthor ">Rong  Liu</span>, <span class="hlFld-ContribAuthor ">Sony  Agrawal</span>, <span class="hlFld-ContribAuthor ">Donna  Carr</span>, <span class="hlFld-ContribAuthor ">Stephanie  Curry</span>, <span class="hlFld-ContribAuthor ">Patricia  McMonagle</span>, <span class="hlFld-ContribAuthor ">Karin  Bystol</span>, <span class="hlFld-ContribAuthor ">Frederick  Lahser</span>, <span class="hlFld-ContribAuthor ">Paul  Ingravallo</span>, <span class="hlFld-ContribAuthor ">Shiying  Chen</span>, <span class="hlFld-ContribAuthor ">Ernest  Asante-Appiah</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Kozlowski</span>. </span><span class="cited-content_cbyCitation_article-title">Structure–activity relationships of proline modifications around the tetracyclic-indole class of NS5A inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (21)
                                     , 5354-5360. <a href="https://doi.org/10.1016/j.bmcl.2016.08.097" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.08.097</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.08.097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.08.097%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructure%2525E2%252580%252593activity%252Brelationships%252Bof%252Bproline%252Bmodifications%252Baround%252Bthe%252Btetracyclic-indole%252Bclass%252Bof%252BNS5A%252Binhibitors%26aulast%3DTong%26aufirst%3DLing%26date%3D2016%26volume%3D26%26issue%3D21%26spage%3D5354%26epage%3D5360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ling  Tong</span>, <span class="hlFld-ContribAuthor ">Wensheng  Yu</span>, <span class="hlFld-ContribAuthor ">Craig A.  Coburn</span>, <span class="hlFld-ContribAuthor ">Peter T.  Meinke</span>, <span class="hlFld-ContribAuthor ">Anilkumar G.  Nair</span>, <span class="hlFld-ContribAuthor ">Michael P.  Dwyer</span>, <span class="hlFld-ContribAuthor ">Lei  Chen</span>, <span class="hlFld-ContribAuthor ">Oleg  Selyutin</span>, <span class="hlFld-ContribAuthor ">Stuart B.  Rosenblum</span>, <span class="hlFld-ContribAuthor ">Yueheng  Jiang</span>, <span class="hlFld-ContribAuthor ">James  Fells</span>, <span class="hlFld-ContribAuthor ">Bin  Hu</span>, <span class="hlFld-ContribAuthor ">Bin  Zhong</span>, <span class="hlFld-ContribAuthor ">Richard M.  Soll</span>, <span class="hlFld-ContribAuthor ">Rong  Liu</span>, <span class="hlFld-ContribAuthor ">Sony  Agrawal</span>, <span class="hlFld-ContribAuthor ">Ellen  Xia</span>, <span class="hlFld-ContribAuthor ">Ying  Zhai</span>, <span class="hlFld-ContribAuthor ">Rong  Kong</span>, <span class="hlFld-ContribAuthor ">Paul  Ingravallo</span>, <span class="hlFld-ContribAuthor ">Amin  Nomeir</span>, <span class="hlFld-ContribAuthor ">Ernest  Asante-Appiah</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Kozlowski</span>. </span><span class="cited-content_cbyCitation_article-title">Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (20)
                                     , 5132-5137. <a href="https://doi.org/10.1016/j.bmcl.2016.07.057" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.07.057</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.07.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.07.057%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAlternative%252Bcore%252Bdevelopment%252Baround%252Bthe%252Btetracyclic%252Bindole%252Bclass%252Bof%252BHCV%252BNS5A%252Binhibitors%26aulast%3DTong%26aufirst%3DLing%26date%3D2016%26volume%3D26%26issue%3D20%26spage%3D5132%26epage%3D5137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wensheng  Yu</span>, <span class="hlFld-ContribAuthor ">Guowei  Zhou</span>, <span class="hlFld-ContribAuthor ">Craig A.  Coburn</span>, <span class="hlFld-ContribAuthor ">Qingbei  Zeng</span>, <span class="hlFld-ContribAuthor ">Ling  Tong</span>, <span class="hlFld-ContribAuthor ">Michael P.  Dwyer</span>, <span class="hlFld-ContribAuthor ">Bin  Hu</span>, <span class="hlFld-ContribAuthor ">Bin  Zhong</span>, <span class="hlFld-ContribAuthor ">Jinglai  Hao</span>, <span class="hlFld-ContribAuthor ">Tao  Ji</span>, <span class="hlFld-ContribAuthor ">Shuai  Zan</span>, <span class="hlFld-ContribAuthor ">Lei  Chen</span>, <span class="hlFld-ContribAuthor ">Robert  Mazzola</span>, <span class="hlFld-ContribAuthor ">Jae-Hun  Kim</span>, <span class="hlFld-ContribAuthor ">Deyou  Sha</span>, <span class="hlFld-ContribAuthor ">Oleg  Selyutin</span>, <span class="hlFld-ContribAuthor ">Stuart B.  Rosenblum</span>, <span class="hlFld-ContribAuthor ">Brian  Lavey</span>, <span class="hlFld-ContribAuthor ">Anilkumar G.  Nair</span>, <span class="hlFld-ContribAuthor ">Seong  Heon Kim</span>, <span class="hlFld-ContribAuthor ">Kerry M.  Keertikar</span>, <span class="hlFld-ContribAuthor ">Laura  Rokosz</span>, <span class="hlFld-ContribAuthor ">Sony  Agrawal</span>, <span class="hlFld-ContribAuthor ">Rong  Liu</span>, <span class="hlFld-ContribAuthor ">Ellen  Xia</span>, <span class="hlFld-ContribAuthor ">Ying  Zhai</span>, <span class="hlFld-ContribAuthor ">Stephanie  Curry</span>, <span class="hlFld-ContribAuthor ">Patricia  McMonagle</span>, <span class="hlFld-ContribAuthor ">Paul  Ingravallo</span>, <span class="hlFld-ContribAuthor ">Ernest  Asante-Appiah</span>, <span class="hlFld-ContribAuthor ">Shiying  Chen</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Kozlowski</span>. </span><span class="cited-content_cbyCitation_article-title">Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (19)
                                     , 4851-4856. <a href="https://doi.org/10.1016/j.bmcl.2016.08.002" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.08.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.08.002%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSubstituted%252Btetracyclic%252Bindole%252Bcore%252Bderivatives%252Bof%252BHCV%252BNS5A%252Binhibitor%252BMK-8742%26aulast%3DYu%26aufirst%3DWensheng%26date%3D2016%26volume%3D26%26issue%3D19%26spage%3D4851%26epage%3D4856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Zhong</span>, <span class="hlFld-ContribAuthor ">Eric  Peng</span>, <span class="hlFld-ContribAuthor ">Ningwu  Huang</span>, <span class="hlFld-ContribAuthor ">Qi  Huang</span>, <span class="hlFld-ContribAuthor ">Anja  Huq</span>, <span class="hlFld-ContribAuthor ">Meiyen  Lau</span>, <span class="hlFld-ContribAuthor ">Richard  Colonno</span>, <span class="hlFld-ContribAuthor ">Leping  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (18)
                                     , 4508-4512. <a href="https://doi.org/10.1016/j.bmcl.2016.07.066" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.07.066</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.07.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.07.066%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bravidasvir%252B%252528PPI-668%252529%252Bas%252Ba%252Bpotent%252Bpan-genotypic%252BHCV%252BNS5A%252Binhibitor%26aulast%3DZhong%26aufirst%3DMin%26date%3D2016%26volume%3D26%26issue%3D18%26spage%3D4508%26epage%3D4512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wensheng  Yu</span>, <span class="hlFld-ContribAuthor ">Craig A.  Coburn</span>, <span class="hlFld-ContribAuthor ">Anilkumar G.  Nair</span>, <span class="hlFld-ContribAuthor ">Michael  Wong</span>, <span class="hlFld-ContribAuthor ">Ling  Tong</span>, <span class="hlFld-ContribAuthor ">Michael P.  Dwyer</span>, <span class="hlFld-ContribAuthor ">Bin  Hu</span>, <span class="hlFld-ContribAuthor ">Bin  Zhong</span>, <span class="hlFld-ContribAuthor ">Jinglai  Hao</span>, <span class="hlFld-ContribAuthor ">De-Yi  Yang</span>, <span class="hlFld-ContribAuthor ">Oleg  Selyutin</span>, <span class="hlFld-ContribAuthor ">Yueheng  Jiang</span>, <span class="hlFld-ContribAuthor ">Stuart B.  Rosenblum</span>, <span class="hlFld-ContribAuthor ">Seong Heon  Kim</span>, <span class="hlFld-ContribAuthor ">Brian J.  Lavey</span>, <span class="hlFld-ContribAuthor ">Guowei  Zhou</span>, <span class="hlFld-ContribAuthor ">Razia  Rizvi</span>, <span class="hlFld-ContribAuthor ">Bandarpalle B.  Shankar</span>, <span class="hlFld-ContribAuthor ">Qingbei  Zeng</span>, <span class="hlFld-ContribAuthor ">Lei  Chen</span>, <span class="hlFld-ContribAuthor ">Sony  Agrawal</span>, <span class="hlFld-ContribAuthor ">Donna  Carr</span>, <span class="hlFld-ContribAuthor ">Laura  Rokosz</span>, <span class="hlFld-ContribAuthor ">Rong  Liu</span>, <span class="hlFld-ContribAuthor ">Stephanie  Curry</span>, <span class="hlFld-ContribAuthor ">Patricia  McMonagle</span>, <span class="hlFld-ContribAuthor ">Paul  Ingravallo</span>, <span class="hlFld-ContribAuthor ">Fred  Lahser</span>, <span class="hlFld-ContribAuthor ">Ernest  Asante-Appiah</span>, <span class="hlFld-ContribAuthor ">Amin  Nomeir</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Kozlowski</span>. </span><span class="cited-content_cbyCitation_article-title">Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (15)
                                     , 3800-3805. <a href="https://doi.org/10.1016/j.bmcl.2016.05.041" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.05.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.05.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.05.041%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAlkyl%252Bsubstituted%252Baminal%252Bderivatives%252Bof%252BHCV%252BNS5A%252Binhibitor%252BMK-8742%26aulast%3DYu%26aufirst%3DWensheng%26date%3D2016%26volume%3D26%26issue%3D15%26spage%3D3800%26epage%3D3805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wensheng  Yu</span>, <span class="hlFld-ContribAuthor ">Bancha  Vibulbhan</span>, <span class="hlFld-ContribAuthor ">Stuart B.  Rosenblum</span>, <span class="hlFld-ContribAuthor ">Gregory S.  Martin</span>, <span class="hlFld-ContribAuthor ">A. Samuel  Vellekoop</span>, <span class="hlFld-ContribAuthor ">Christian L.  Holst</span>, <span class="hlFld-ContribAuthor ">Craig A.  Coburn</span>, <span class="hlFld-ContribAuthor ">Michael  Wong</span>, <span class="hlFld-ContribAuthor ">Oleg  Selyutin</span>, <span class="hlFld-ContribAuthor ">Tao  Ji</span>, <span class="hlFld-ContribAuthor ">Bin  Zhong</span>, <span class="hlFld-ContribAuthor ">Bin  Hu</span>, <span class="hlFld-ContribAuthor ">Lei  Chen</span>, <span class="hlFld-ContribAuthor ">Michael P.  Dwyer</span>, <span class="hlFld-ContribAuthor ">Yueheng  Jiang</span>, <span class="hlFld-ContribAuthor ">Anilkumar G.  Nair</span>, <span class="hlFld-ContribAuthor ">Ling  Tong</span>, <span class="hlFld-ContribAuthor ">Qingbei  Zeng</span>, <span class="hlFld-ContribAuthor ">Sony  Agrawal</span>, <span class="hlFld-ContribAuthor ">Donna  Carr</span>, <span class="hlFld-ContribAuthor ">Laura  Rokosz</span>, <span class="hlFld-ContribAuthor ">Rong  Liu</span>, <span class="hlFld-ContribAuthor ">Stephanie  Curry</span>, <span class="hlFld-ContribAuthor ">Patricia  McMonagle</span>, <span class="hlFld-ContribAuthor ">Paul  Ingravallo</span>, <span class="hlFld-ContribAuthor ">Fred  Lahser</span>, <span class="hlFld-ContribAuthor ">Ernest  Asante-Appiah</span>, <span class="hlFld-ContribAuthor ">James  Fells</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Kozlowski</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent macrocyclic HCV NS5A inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (15)
                                     , 3793-3799. <a href="https://doi.org/10.1016/j.bmcl.2016.05.042" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.05.042</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.05.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.05.042%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bpotent%252Bmacrocyclic%252BHCV%252BNS5A%252Binhibitors%26aulast%3DYu%26aufirst%3DWensheng%26date%3D2016%26volume%3D26%26issue%3D15%26spage%3D3793%26epage%3D3799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wensheng  Yu</span>, <span class="hlFld-ContribAuthor ">Craig A.  Coburn</span>, <span class="hlFld-ContribAuthor ">Anilkumar G.  Nair</span>, <span class="hlFld-ContribAuthor ">Michael  Wong</span>, <span class="hlFld-ContribAuthor ">Stuart B.  Rosenblum</span>, <span class="hlFld-ContribAuthor ">Guowei  Zhou</span>, <span class="hlFld-ContribAuthor ">Michael P.  Dwyer</span>, <span class="hlFld-ContribAuthor ">Ling  Tong</span>, <span class="hlFld-ContribAuthor ">Bin  Hu</span>, <span class="hlFld-ContribAuthor ">Bin  Zhong</span>, <span class="hlFld-ContribAuthor ">Jinglai  Hao</span>, <span class="hlFld-ContribAuthor ">Tao  Ji</span>, <span class="hlFld-ContribAuthor ">Shuai  Zan</span>, <span class="hlFld-ContribAuthor ">Seong Heon  Kim</span>, <span class="hlFld-ContribAuthor ">Qingbei  Zeng</span>, <span class="hlFld-ContribAuthor ">Oleg  Selyutin</span>, <span class="hlFld-ContribAuthor ">Lei  Chen</span>, <span class="hlFld-ContribAuthor ">Frederic  Masse</span>, <span class="hlFld-ContribAuthor ">Sony  Agrawal</span>, <span class="hlFld-ContribAuthor ">Rong  Liu</span>, <span class="hlFld-ContribAuthor ">Ellen  Xia</span>, <span class="hlFld-ContribAuthor ">Ying  Zhai</span>, <span class="hlFld-ContribAuthor ">Stephanie  Curry</span>, <span class="hlFld-ContribAuthor ">Patricia  McMonagle</span>, <span class="hlFld-ContribAuthor ">Paul  Ingravallo</span>, <span class="hlFld-ContribAuthor ">Ernest  Asante-Appiah</span>, <span class="hlFld-ContribAuthor ">Mingxiang  Lin</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Kozlowski</span>. </span><span class="cited-content_cbyCitation_article-title">Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (15)
                                     , 3414-3420. <a href="https://doi.org/10.1016/j.bmcl.2016.06.056" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.06.056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.06.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.06.056%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAryl%252Bor%252Bheteroaryl%252Bsubstituted%252Baminal%252Bderivatives%252Bof%252BHCV%252BNS5A%252Binhibitor%252BMK-8742%26aulast%3DYu%26aufirst%3DWensheng%26date%3D2016%26volume%3D26%26issue%3D15%26spage%3D3414%26epage%3D3420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael P.  Dwyer</span>, <span class="hlFld-ContribAuthor ">Kerry M.  Keertikar</span>, <span class="hlFld-ContribAuthor ">Lei  Chen</span>, <span class="hlFld-ContribAuthor ">Ling  Tong</span>, <span class="hlFld-ContribAuthor ">Oleg  Selyutin</span>, <span class="hlFld-ContribAuthor ">Anilkumar G.  Nair</span>, <span class="hlFld-ContribAuthor ">Wensheng  Yu</span>, <span class="hlFld-ContribAuthor ">Guowei  Zhou</span>, <span class="hlFld-ContribAuthor ">Brian J.  Lavey</span>, <span class="hlFld-ContribAuthor ">De-Yi  Yang</span>, <span class="hlFld-ContribAuthor ">Michael  Wong</span>, <span class="hlFld-ContribAuthor ">Seong Heon  Kim</span>, <span class="hlFld-ContribAuthor ">Craig A.  Coburn</span>, <span class="hlFld-ContribAuthor ">Stuart B.  Rosenblum</span>, <span class="hlFld-ContribAuthor ">Qingbei  Zeng</span>, <span class="hlFld-ContribAuthor ">Yueheng  Jiang</span>, <span class="hlFld-ContribAuthor ">Bandarpalle B.  Shankar</span>, <span class="hlFld-ContribAuthor ">Razia  Rizvi</span>, <span class="hlFld-ContribAuthor ">Amin A.  Nomeir</span>, <span class="hlFld-ContribAuthor ">Rong  Liu</span>, <span class="hlFld-ContribAuthor ">Sony  Agrawal</span>, <span class="hlFld-ContribAuthor ">Ellen  Xia</span>, <span class="hlFld-ContribAuthor ">Rong  Kong</span>, <span class="hlFld-ContribAuthor ">Ying  Zhai</span>, <span class="hlFld-ContribAuthor ">Paul  Ingravallo</span>, <span class="hlFld-ContribAuthor ">Ernest  Asante-Appiah</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Kozlowski</span>. </span><span class="cited-content_cbyCitation_article-title">Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (16)
                                     , 4106-4111. <a href="https://doi.org/10.1016/j.bmcl.2016.06.063" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.06.063</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.06.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.06.063%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DMatched%252Band%252Bmixed%252Bcap%252Bderivatives%252Bin%252Bthe%252Btetracyclic%252Bindole%252Bclass%252Bof%252BHCV%252BNS5A%252Binhibitors%26aulast%3DDwyer%26aufirst%3DMichael%2BP.%26date%3D2016%26volume%3D26%26issue%3D16%26spage%3D4106%26epage%3D4111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wensheng  Yu</span>, <span class="hlFld-ContribAuthor ">Craig A.  Coburn</span>, <span class="hlFld-ContribAuthor ">De-Yi  Yang</span>, <span class="hlFld-ContribAuthor ">Peter T.  Meinke</span>, <span class="hlFld-ContribAuthor ">Michael  Wong</span>, <span class="hlFld-ContribAuthor ">Stuart B.  Rosenblum</span>, <span class="hlFld-ContribAuthor ">Kevin X.  Chen</span>, <span class="hlFld-ContribAuthor ">George F.  Njoroge</span>, <span class="hlFld-ContribAuthor ">Lei  Chen</span>, <span class="hlFld-ContribAuthor ">Michael P.  Dwyer</span>, <span class="hlFld-ContribAuthor ">Yueheng  Jiang</span>, <span class="hlFld-ContribAuthor ">Anilkumar G.  Nair</span>, <span class="hlFld-ContribAuthor ">Oleg  Selyutin</span>, <span class="hlFld-ContribAuthor ">Ling  Tong</span>, <span class="hlFld-ContribAuthor ">Qingbei  Zeng</span>, <span class="hlFld-ContribAuthor ">Bin  Zhong</span>, <span class="hlFld-ContribAuthor ">Tao  Ji</span>, <span class="hlFld-ContribAuthor ">Bin  Hu</span>, <span class="hlFld-ContribAuthor ">Sony  Agrawal</span>, <span class="hlFld-ContribAuthor ">Ellen  Xia</span>, <span class="hlFld-ContribAuthor ">Ying  Zhai</span>, <span class="hlFld-ContribAuthor ">Rong  Liu</span>, <span class="hlFld-ContribAuthor ">Rong  Kong</span>, <span class="hlFld-ContribAuthor ">Paul  Ingravallo</span>, <span class="hlFld-ContribAuthor ">Ernest  Asante-Appiah</span>, <span class="hlFld-ContribAuthor ">Amin  Nomeir</span>, <span class="hlFld-ContribAuthor ">James  Fells</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Kozlowski</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (13)
                                     , 3158-3162. <a href="https://doi.org/10.1016/j.bmcl.2016.04.084" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.04.084</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.04.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.04.084%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bfused%252Btricyclic%252Bcore%252Bcontaining%252BHCV%252BNS5A%252Binhibitors%252Bwith%252Bpan-genotype%252Bactivity%26aulast%3DYu%26aufirst%3DWensheng%26date%3D2016%26volume%3D26%26issue%3D13%26spage%3D3158%26epage%3D3162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher A.  Lipinski</span>. </span><span class="cited-content_cbyCitation_article-title">Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. </span><span class="cited-content_cbyCitation_journal-name">Advanced Drug Delivery Reviews</span><span> <strong>2016,</strong> <em>101 </em>, 34-41. <a href="https://doi.org/10.1016/j.addr.2016.04.029" title="DOI URL">https://doi.org/10.1016/j.addr.2016.04.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.addr.2016.04.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.addr.2016.04.029%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Drug%2520Delivery%2520Reviews%26atitle%3DRule%252Bof%252Bfive%252Bin%252B2015%252Band%252Bbeyond%25253A%252BTarget%252Band%252Bligand%252Bstructural%252Blimitations%25252C%252Bligand%252Bchemistry%252Bstructure%252Band%252Bdrug%252Bdiscovery%252Bproject%252Bdecisions%26aulast%3DLipinski%26aufirst%3DChristopher%2BA.%26date%3D2016%26volume%3D101%26spage%3D34%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthew  Tudor</span>, <span class="hlFld-ContribAuthor ">Jeffery  Hermes</span>, <span class="hlFld-ContribAuthor ">Jing  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Translatability: what does it mean in drug discovery?. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2016,</strong> <em>21 </em>
                                    (6)
                                     , 865-867. <a href="https://doi.org/10.1016/j.drudis.2016.03.010" title="DOI URL">https://doi.org/10.1016/j.drudis.2016.03.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2016.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2016.03.010%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DTranslatability%25253A%252Bwhat%252Bdoes%252Bit%252Bmean%252Bin%252Bdrug%252Bdiscovery%25253F%26aulast%3DTudor%26aufirst%3DMatthew%26date%3D2016%26volume%3D21%26issue%3D6%26spage%3D865%26epage%3D867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias  Götte</span>, <span class="hlFld-ContribAuthor ">Jordan J.  Feld</span>. </span><span class="cited-content_cbyCitation_article-title">Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Gastroenterology & Hepatology</span><span> <strong>2016,</strong> <em>13 </em>
                                    (6)
                                     , 338-351. <a href="https://doi.org/10.1038/nrgastro.2016.60" title="DOI URL">https://doi.org/10.1038/nrgastro.2016.60</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrgastro.2016.60&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrgastro.2016.60%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Gastroenterology%2520%2526%2520Hepatology%26atitle%3DDirect-acting%252Bantiviral%252Bagents%252Bfor%252Bhepatitis%252BC%25253A%252Bstructural%252Band%252Bmechanistic%252Binsights%26aulast%3DG%25C3%25B6tte%26aufirst%3DMatthias%26date%3D2016%26date%3D2016%26volume%3D13%26issue%3D6%26spage%3D338%26epage%3D351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew C.  Flick</span>, <span class="hlFld-ContribAuthor ">Hong X.  Ding</span>, <span class="hlFld-ContribAuthor ">Carolyn A.  Leverett</span>, <span class="hlFld-ContribAuthor ">Robert E.  Kyne</span>, <span class="hlFld-ContribAuthor ">Kevin K.-C.  Liu</span>, <span class="hlFld-ContribAuthor ">Sarah J.  Fink</span>, <span class="hlFld-ContribAuthor ">Christopher J.  O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic approaches to the 2014 new drugs. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (9)
                                     , 1937-1980. <a href="https://doi.org/10.1016/j.bmc.2016.03.004" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.03.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.03.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252Bapproaches%252Bto%252Bthe%252B2014%252Bnew%252Bdrugs%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2016%26volume%3D24%26issue%3D9%26spage%3D1937%26epage%3D1980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthew L.  Scherer</span>, <span class="hlFld-ContribAuthor ">Chelsea  Sammons</span>, <span class="hlFld-ContribAuthor ">Brian  Nelson</span>, <span class="hlFld-ContribAuthor ">Scott M.  Hammer</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Verna</span>. </span><span class="cited-content_cbyCitation_article-title">Anti-Hepatitis Virus Agents. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 239-270. <a href="https://doi.org/10.1128/9781555819439.ch13" title="DOI URL">https://doi.org/10.1128/9781555819439.ch13</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/9781555819439.ch13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2F9781555819439.ch13%26sid%3Dliteratum%253Aachs%26atitle%3DAnti-Hepatitis%252BVirus%252BAgents%26aulast%3DScherer%26aufirst%3DMatthew%2BL.%26date%3D2016%26date%3D2016%26spage%3D239%26epage%3D270%26pub%3DASM%2520Press%26atitle%3DClinical%252BVirology%26aulast%3DRichman%26aufirst%3DDouglas%2BD.%26date%3D2016%26volume%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas O.  Moore</span>, <span class="hlFld-ContribAuthor ">Michael  Paradowski</span>, <span class="hlFld-ContribAuthor ">Simon E.  Ward</span>. </span><span class="cited-content_cbyCitation_article-title">An atom-efficient and convergent approach to the preparation of NS5A inhibitors by C–H activation. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2016,</strong> <em>14 </em>
                                    (12)
                                     , 3307-3313. <a href="https://doi.org/10.1039/C6OB00340K" title="DOI URL">https://doi.org/10.1039/C6OB00340K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6OB00340K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6OB00340K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DAn%252Batom-efficient%252Band%252Bconvergent%252Bapproach%252Bto%252Bthe%252Bpreparation%252Bof%252BNS5A%252Binhibitors%252Bby%252BC%2525E2%252580%252593H%252Bactivation%26aulast%3DMoore%26aufirst%3DThomas%2BO.%26date%3D2016%26date%3D2016%26volume%3D14%26issue%3D12%26spage%3D3307%26epage%3D3313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Makonen  Belema</span>, <span class="hlFld-ContribAuthor ">Shawn K.  Pack</span>, <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">Daclatasvir (Daklinza): The First-in-Class HCV NS5A Replication Complex Inhibitor. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 43-60. <a href="https://doi.org/10.1002/9781118819951.ch3" title="DOI URL">https://doi.org/10.1002/9781118819951.ch3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118819951.ch3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118819951.ch3%26sid%3Dliteratum%253Aachs%26atitle%3DDaclatasvir%252B%252528Daklinza%252529%25253A%252BThe%252BFirst-in-Class%252BHCV%252BNS5A%252BReplication%252BComplex%252BInhibitor%26aulast%3DBelema%26aufirst%3DMakonen%26date%3D2015%26date%3D2015%26spage%3D43%26epage%3D60%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DInnovative%252BDrug%252BSynthesis%26aulast%3DLi%26aufirst%3DJie%2BJack%26date%3D2015%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Il Hak  Bae</span>, <span class="hlFld-ContribAuthor ">Hee Sun  Kim</span>, <span class="hlFld-ContribAuthor ">Youngsu  You</span>, <span class="hlFld-ContribAuthor ">Chieyeon  Chough</span>, <span class="hlFld-ContribAuthor ">Weonu  Choe</span>, <span class="hlFld-ContribAuthor ">Min Kyung  Seon</span>, <span class="hlFld-ContribAuthor ">Seung Gi  Lee</span>, <span class="hlFld-ContribAuthor ">Gyochang  Keum</span>, <span class="hlFld-ContribAuthor ">Sung Key  Jang</span>, <span class="hlFld-ContribAuthor ">B.  Moon Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Novel benzidine and diaminofluorene prolinamide derivatives as potent hepatitis C virus NS5A inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>101 </em>, 163-178. <a href="https://doi.org/10.1016/j.ejmech.2015.06.033" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.06.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.06.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.06.033%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bbenzidine%252Band%252Bdiaminofluorene%252Bprolinamide%252Bderivatives%252Bas%252Bpotent%252Bhepatitis%252BC%252Bvirus%252BNS5A%252Binhibitors%26aulast%3DBae%26aufirst%3DIl%2BHak%26date%3D2015%26volume%3D101%26spage%3D163%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James A.  Henderson</span>, <span class="hlFld-ContribAuthor ">Darius  Bilimoria</span>, <span class="hlFld-ContribAuthor ">Monica  Bubenik</span>, <span class="hlFld-ContribAuthor ">Caroline  Cadilhac</span>, <span class="hlFld-ContribAuthor ">Kevin M.  Cottrell</span>, <span class="hlFld-ContribAuthor ">Evelyne  Dietrich</span>, <span class="hlFld-ContribAuthor ">Francois  Denis</span>, <span class="hlFld-ContribAuthor ">Nigel  Ewing</span>, <span class="hlFld-ContribAuthor ">Guy  Falardeau</span>, <span class="hlFld-ContribAuthor ">Simon  Giroux</span>, <span class="hlFld-ContribAuthor ">Ronald  Grey</span>, <span class="hlFld-ContribAuthor ">Lucille  L’Heureux</span>, <span class="hlFld-ContribAuthor ">Bingcan  Liu</span>, <span class="hlFld-ContribAuthor ">Nagraj  Mani</span>, <span class="hlFld-ContribAuthor ">Mark  Morris</span>, <span class="hlFld-ContribAuthor ">Olivier  Nicolas</span>, <span class="hlFld-ContribAuthor ">Oswy Z.  Pereira</span>, <span class="hlFld-ContribAuthor ">Carl  Poisson</span>, <span class="hlFld-ContribAuthor ">B.  Govinda Rao</span>, <span class="hlFld-ContribAuthor ">T. Jagadeeswar  Reddy</span>, <span class="hlFld-ContribAuthor ">Subajini  Selliah</span>, <span class="hlFld-ContribAuthor ">Rebecca S.  Shawgo</span>, <span class="hlFld-ContribAuthor ">Louis  Vaillancourt</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Constantin G.  Yannopoulos</span>, <span class="hlFld-ContribAuthor ">Nathalie  Chauret</span>, <span class="hlFld-ContribAuthor ">Francoise  Berlioz-Seux</span>, <span class="hlFld-ContribAuthor ">Laval C.  Chan</span>, <span class="hlFld-ContribAuthor ">Sanjoy K.  Das</span>, <span class="hlFld-ContribAuthor ">Anne-Laure  Grillot</span>, <span class="hlFld-ContribAuthor ">Youssef L.  Bennani</span>, <span class="hlFld-ContribAuthor ">John P.  Maxwell</span>. </span><span class="cited-content_cbyCitation_article-title">Benzimidazole-containing HCV NS5A inhibitors: Effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (4)
                                     , 944-947. <a href="https://doi.org/10.1016/j.bmcl.2014.12.045" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.12.045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.12.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.12.045%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DBenzimidazole-containing%252BHCV%252BNS5A%252Binhibitors%25253A%252BEffect%252Bof%252B4-substituted%252Bpyrrolidines%252Bin%252Bbalancing%252Bgenotype%252B1a%252Band%252B1b%252Bpotency%26aulast%3DHenderson%26aufirst%3DJames%2BA.%26date%3D2015%26volume%3D25%26issue%3D4%26spage%3D944%26epage%3D947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John H.  Ryan</span>, <span class="hlFld-ContribAuthor ">Karen E.  Jarvis</span>, <span class="hlFld-ContribAuthor ">Roger J.  Mulder</span>, <span class="hlFld-ContribAuthor ">Craig L.  Francis</span>, <span class="hlFld-ContribAuthor ">G. Paul  Savage</span>, <span class="hlFld-ContribAuthor ">Olan  Dolezal</span>, <span class="hlFld-ContribAuthor ">Thomas S.  Peat</span>, <span class="hlFld-ContribAuthor ">John J.  Deadman</span>. </span><span class="cited-content_cbyCitation_article-title">Unexpected Isomerisation of a Fragment Analogue During Fragment-Based Screening of HIV Integrase Catalytic Core Domain. </span><span class="cited-content_cbyCitation_journal-name">Australian Journal of Chemistry</span><span> <strong>2015,</strong> <em>68 </em>
                                    (12)
                                     , 1871. <a href="https://doi.org/10.1071/CH15587" title="DOI URL">https://doi.org/10.1071/CH15587</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1071/CH15587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1071%2FCH15587%26sid%3Dliteratum%253Aachs%26jtitle%3DAustralian%2520Journal%2520of%2520Chemistry%26atitle%3DUnexpected%252BIsomerisation%252Bof%252Ba%252BFragment%252BAnalogue%252BDuring%252BFragment-Based%252BScreening%252Bof%252BHIV%252BIntegrase%252BCatalytic%252BCore%252BDomain%26aulast%3DRyan%26aufirst%3DJohn%2BH.%26date%3D2015%26volume%3D68%26issue%3D12%26spage%3D1871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Zhong</span>, <span class="hlFld-ContribAuthor ">Eric  Peng</span>, <span class="hlFld-ContribAuthor ">Ningwu  Huang</span>, <span class="hlFld-ContribAuthor ">Qi  Huang</span>, <span class="hlFld-ContribAuthor ">Anja  Huq</span>, <span class="hlFld-ContribAuthor ">Meiyen  Lau</span>, <span class="hlFld-ContribAuthor ">Richard  Colonno</span>, <span class="hlFld-ContribAuthor ">Leping  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Potent bisimidazole-based HCV NS5A inhibitors bearing annulated tricyclic motifs. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>24 </em>
                                    (24)
                                     , 5738-5742. <a href="https://doi.org/10.1016/j.bmcl.2014.10.056" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.10.056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.10.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.10.056%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPotent%252Bbisimidazole-based%252BHCV%252BNS5A%252Binhibitors%252Bbearing%252Bannulated%252Btricyclic%252Bmotifs%26aulast%3DZhong%26aufirst%3DMin%26date%3D2014%26volume%3D24%26issue%3D24%26spage%3D5738%26epage%3D5742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Zhong</span>, <span class="hlFld-ContribAuthor ">Eric  Peng</span>, <span class="hlFld-ContribAuthor ">Ningwu  Huang</span>, <span class="hlFld-ContribAuthor ">Qi  Huang</span>, <span class="hlFld-ContribAuthor ">Anja  Huq</span>, <span class="hlFld-ContribAuthor ">Meiyen  Lau</span>, <span class="hlFld-ContribAuthor ">Richard  Colonno</span>, <span class="hlFld-ContribAuthor ">Leping  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of functionalized bisimidazoles bearing cyclic aliphatic-phenyl motifs as HCV NS5A inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>24 </em>
                                    (24)
                                     , 5731-5737. <a href="https://doi.org/10.1016/j.bmcl.2014.10.057" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.10.057</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.10.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.10.057%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bfunctionalized%252Bbisimidazoles%252Bbearing%252Bcyclic%252Baliphatic-phenyl%252Bmotifs%252Bas%252BHCV%252BNS5A%252Binhibitors%26aulast%3DZhong%26aufirst%3DMin%26date%3D2014%26volume%3D24%26issue%3D24%26spage%3D5731%26epage%3D5737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0002.jpeg" id="rightTab-GRAPHIC-d1913e199-autogenerated" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0003.jpeg" id="rightTab-GRAPHIC-d1913e245-autogenerated" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of the parent iminothiazolidinone chemotype and conversion to C-5-unsaturated analogues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Synopsis of structure–activity relationships associated with <b>7</b> as an inhibitor of replication of an HCV GT-1b replicon.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Decomposition of <b>8</b> in DMSO.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Chart 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0004.jpeg" id="rightTab-GRAPHIC-d1913e488-autogenerated" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=cht3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Chart 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0005.jpeg" id="rightTab-GRAPHIC-d1913e592-autogenerated" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=cht4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Chart 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0013.jpeg" id="rightTab-GRAPHIC-d1913e821-autogenerated" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=cht5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0006.jpeg" id="rightTab-GRAPHIC-d1913e830-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>6</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Chart 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0007.jpeg" id="rightTab-GRAPHIC-d1913e1199-autogenerated" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=cht6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Chart 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0008.jpeg" id="rightTab-GRAPHIC-d1913e1244-autogenerated" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=cht7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Chart 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/medium/jm-2014-00335h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0009.jpeg" id="rightTab-GRAPHIC-d1913e1426-autogenerated" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm500335h/production/images/large/jm-2014-00335h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500335h&amp;id=cht8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i12">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25622" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25622" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 61 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Swinney, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anthony, J.</span><span> </span><span class="NLM_article-title">How were new medicines discovered?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">507</span><span class="NLM_x">–</span> <span class="NLM_lpage">519</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=507-519&author=D.+C.+Swinneyauthor=J.+Anthony&title=How+were+new+medicines+discovered%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26aulast%3DAnthony%26aufirst%3DJ.%26atitle%3DHow%2520were%2520new%2520medicines%2520discovered%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D507%26epage%3D519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Macarron, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banks, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bojanic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirovic, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garyantes, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, D. V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hertzberg, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janzen, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paslay, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schopfer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sittampalam, G. S.</span><span> </span><span class="NLM_article-title">Impact of high-throughput screening on biomedical research</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">189</span><span class="NLM_x">–</span> <span class="NLM_lpage">195</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=189-195&author=R.+Macarronauthor=M.+N.+Banksauthor=D.+Bojanicauthor=D.+J.+Burnsauthor=D.+A.+Cirovicauthor=T.+Garyantesauthor=D.+V.+S.+Greenauthor=R.+P.+Hertzbergauthor=W.+P.+Janzenauthor=J.+W.+Paslayauthor=U.+Schopferauthor=G.+S.+Sittampalam&title=Impact+of+high-throughput+screening+on+biomedical+research"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMacarron%26aufirst%3DR.%26aulast%3DBanks%26aufirst%3DM.%2BN.%26aulast%3DBojanic%26aufirst%3DD.%26aulast%3DBurns%26aufirst%3DD.%2BJ.%26aulast%3DCirovic%26aufirst%3DD.%2BA.%26aulast%3DGaryantes%26aufirst%3DT.%26aulast%3DGreen%26aufirst%3DD.%2BV.%2BS.%26aulast%3DHertzberg%26aufirst%3DR.%2BP.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DPaslay%26aufirst%3DJ.%2BW.%26aulast%3DSchopfer%26aufirst%3DU.%26aulast%3DSittampalam%26aufirst%3DG.%2BS.%26atitle%3DImpact%2520of%2520high-throughput%2520screening%2520on%2520biomedical%2520research%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D189%26epage%3D195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Green, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacs, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, H.</span><span> </span><span class="NLM_article-title">Cell-based assays to identify inhibitors of viral disease</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">676</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=671-676&author=N.+Greenauthor=R.+D.+Ottauthor=R.+J.+Isaacsauthor=H.+Fang&title=Cell-based+assays+to+identify+inhibitors+of+viral+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGreen%26aufirst%3DN.%26aulast%3DOtt%26aufirst%3DR.%2BD.%26aulast%3DIsaacs%26aufirst%3DR.%2BJ.%26aulast%3DFang%26aufirst%3DH.%26atitle%3DCell-based%2520assays%2520to%2520identify%2520inhibitors%2520of%2520viral%2520disease%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D671%26epage%3D676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Keller, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.-Y.</span><span> </span><span class="NLM_article-title">Anti-infectives: Can cellular screening deliver<i>?</i></span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2Fj.cbpa.2011.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=21723774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFClt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=529-533&author=T.+H.+Kellerauthor=P.-Y.+Shiauthor=Q.-Y.+Wang&title=Anti-infectives%3A+Can+cellular+screening+deliver%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-infectives: Can cellular screening deliver?</span></div><div class="casAuthors">Keller, Thomas H.; Shi, Pei-Yong; Wang, Qing-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">529-533</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In an era of emerging and reemerging infectious diseases, and increasing multidrug resistance, the need to identify novel therapy is imperative.  Unfortunately, the recent shift of the drug discovery paradigm from cellular screening to target-based approaches has not delivered the anticipated benefits.  A recent renaissance of the traditional cell-based approach, on the other hand, has yielded several clin. candidates.  Three successful examples are illustrated in this review, namely spiroindolone, thiazolidinone, and diarylquinoline for the treatment of malaria, hepatitis C virus, and tuberculosis, resp.  We describe in detail their identification, mechanism of action (MoA), and common features in the chem. structures.  The challenges of the cell-based approach for anti-infective drug discovery are also discussed.  We propose a shift from std. libraries to synthetic natural-product-like compd. collections to improve the success of phenotypic lead finding and to facilitate the validation of hits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovjXnq-69ZQLVg90H21EOLACvtfcHk0lh0TiZ1MuwSxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFClt78%253D&md5=0313e255dec7bf47b39b23f6d354987f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2011.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2011.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DShi%26aufirst%3DP.-Y.%26aulast%3DWang%26aufirst%3DQ.-Y.%26atitle%3DAnti-infectives%253A%2520Can%2520cellular%2520screening%2520deliver%253F%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D15%26spage%3D529%26epage%3D533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Di Santo, R.</span><span> </span><span class="NLM_article-title">Inhibiting the HIV integration process: past, present, and the future</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400674a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=539-566&author=R.+Di+Santo&title=Inhibiting+the+HIV+integration+process%3A+past%2C+present%2C+and+the+future"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm400674a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400674a%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BSanto%26aufirst%3DR.%26atitle%3DInhibiting%2520the%2520HIV%2520integration%2520process%253A%2520past%252C%2520present%252C%2520and%2520the%2520future%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D539%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jurado, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slaughter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessl, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballandras-Colas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchs, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kvaratskhelia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, A.</span><span> </span><span class="NLM_article-title">Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">8690</span><span class="NLM_x">–</span> <span class="NLM_lpage">8695</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1073%2Fpnas.1300703110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=23610442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSjt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=8690-8695&author=K.+A.+Juradoauthor=H.+Wangauthor=A.+Slaughterauthor=L.+Fengauthor=J.+J.+Kesslauthor=Y.+Kohauthor=W.+Wangauthor=A.+Ballandras-Colasauthor=P.+P.+Patelauthor=J.+R.+Fuchsauthor=M.+Kvaratskheliaauthor=A.+Engelman&title=Allosteric+integrase+inhibitor+potency+is+determined+through+the+inhibition+of+HIV-1+particle+maturation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation</span></div><div class="casAuthors">Jurado, Kellie A.; Wang, Hao; Slaughter, Alison; Feng, Lei; Kessl, Jacques J.; Koh, Yasuhiro; Wang, Weifeng; Ballandras-Colas, Allison; Patel, Pratiq A.; Fuchs, James R.; Kvaratskhelia, Mamuka; Engelman, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8690-8695, S8690/1-S8690/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Integration is essential for HIV-1 replication, and the viral integrase (IN) protein is an important therapeutic target.  Allosteric IN inhibitors (ALUNIs) that engage the IN dimer interface at the binding site for the host protein lens epithelium-derived growth factor (LEDGF)/ transcriptional coactivator p75 are an emerging class of small mol. antagonists.  Consistent with the inhibition of a multivalent drug target, ALLINIs display steep antiviral dose-response curves ex vivo.  ALUNIs multimerize IN protein and concordantly block its assembly with viral DNA in vitro, indicating that the disruption of two integration-assocd. functions, IN catalysis and the IN-LEDGF/p75 interaction, dets. the multimode mechanism of ALUNI action.  We now demonstrate that ALLINI potency is unexpectedly accounted for during the late phase of HIV-1 replication.  The compds. promote virion IN multimerization and, reminiscent of class II IN mutations, block the formation of the electron-dense viral core and inhibit reverse transcription and integration in subsequently infected target cells.  Mature virions are recalcitrant to ALLINI treatment and compd. potency during virus prodn. is independent of the level of LEDGF/p75 expression.  We conclude that cooperative multimerization of IN by ALLINIs together with the inability for LEDGF/p75 to effectively engage the virus during its egress from cells underscores the multimodal mechanism of ALLINI action.  Our results highlight the versatile nature of allosteric inhibitors to primarily inhibit viral replication at a step that is distinct from the catalytic requirement for the target enzyme.  The vulnerability of IN to small mols. during the late phase of HIV-1 replication unveils a pharmacol. Achilles' heel for exploitation in clin. ALLINI development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiAzDFbZo0ALVg90H21EOLACvtfcHk0lh0TiZ1MuwSxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSjt7nO&md5=ec563f39468aabeae04685971722b070</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1300703110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1300703110%26sid%3Dliteratum%253Aachs%26aulast%3DJurado%26aufirst%3DK.%2BA.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSlaughter%26aufirst%3DA.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DKessl%26aufirst%3DJ.%2BJ.%26aulast%3DKoh%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DBallandras-Colas%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DP.%2BP.%26aulast%3DFuchs%26aufirst%3DJ.%2BR.%26aulast%3DKvaratskhelia%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DA.%26atitle%3DAllosteric%2520integrase%2520inhibitor%2520potency%2520is%2520determined%2520through%2520the%2520inhibition%2520of%2520HIV-1%2520particle%2520maturation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2013%26volume%3D110%26spage%3D8690%26epage%3D8695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Le Rouzic, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chasset, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruneau, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevreuil, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Strat, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauvoir, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amadori, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brias, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vomscheid, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lévy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delelis, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deprez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saïb, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamborlini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emiliani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ledoussal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benarous, R.</span><span> </span><span class="NLM_article-title">Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage</span> <span class="citation_source-journal">Retrovirology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">144</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1186%2F1742-4690-10-144" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=24261564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvFagtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=144&author=E.+Le+Rouzicauthor=D.+Bonnardauthor=S.+Chassetauthor=J.-M.+Bruneauauthor=F.+Chevreuilauthor=F.+Le+Stratauthor=J.+Nguyenauthor=R.+Beauvoirauthor=C.+Amadoriauthor=J.+Briasauthor=S.+Vomscheidauthor=S.+Eilerauthor=N.+L%C3%A9vyauthor=O.+Delelisauthor=E.+Deprezauthor=A.+Sa%C3%AFbauthor=A.+Zamborliniauthor=S.+Emilianiauthor=M.+Ruffauthor=B.+Ledoussalauthor=F.+Moreauauthor=R.+Benarous&title=Dual+inhibition+of+HIV-1+replication+by+integrase-LEDGF+allosteric+inhibitors+is+predominant+at+the+post-integration+stage"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage</span></div><div class="casAuthors">Le Rouzic, Erwann; Bonnard, Damien; Chasset, Sophie; Bruneau, Jean-Michel; Chevreuil, Francis; Le Strat, Frederic; Nguyen, Juliette; Beauvoir, Roxane; Amadori, Celine; Brias, Julie; Vomscheid, Sophie; Eiler, Sylvia; Levy, Nicolas; Delelis, Olivier; Deprez, Eric; Saib, Ali; Zamborlini, Alessia; Emiliani, Stephane; Ruff, Marc; Ledoussal, Benoit; Moreau, Francois; Benarous, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Retrovirology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">144/1-144/21, 21 pp.</span>CODEN:
                <span class="NLM_cas:coden">RETRBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-4690</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: LEDGF/p75 (LEDGF) is the main cellular cofactor of HIV-1 integrase (IN).  It acts as a tethering factor for IN, and targets the integration of HIV in actively transcribed gene regions of chromatin.  A recently developed class of IN allosteric inhibitors can inhibit the LEDGF-IN interaction.  Results: We describe a new series of IN-LEDGF allosteric inhibitors, the most active of which is Mut101.  We detd. the crystal structure of Mut101 in complex with IN and showed that the compd. binds to the LEDGF-binding pocket, promoting conformational changes of IN which explain at the at. level the allosteric effect of the IN/LEDGF interaction inhibitor on IN functions.  In vitro, Mut101 inhibited both IN-LEDGF interaction and IN strand transfer activity while enhancing IN-IN interaction.  Time of addn. expts. indicated that Mut101 behaved as an integration inhibitor.  Mut101 was fully active on HIV-1 mutants resistant to INSTIs and other classes of anti-HIV drugs, indicative that this compd. has a new mode of action.  However, we found that Mut101 also displayed a more potent antiretroviral activity at a post-integration step.  Infectivity of viral particles produced in presence of Mut101 was severely decreased.  This latter effect also required the binding of the compd. to the LEDGF-binding pocket.  Conclusion: Mut101 has dual anti-HIV-1 activity, at integration and post-integration steps of the viral replication cycle, by binding to a unique target on IN (the LEDGF-binding pocket).  The post-integration block of HIV-1 replication in virus-producer cells is the mechanism by which Mut101 is most active as an antiretroviral.  To explain this difference between Mut101 antiretroviral activity at integration and post-integration stages, we propose the following model: LEDGF is a nuclear, chromatin-bound protein that is absent in the cytoplasm.  Therefore, LEDGF can outcompete compd. binding to IN in the nucleus of target cells lowering its antiretroviral activity at integration, but not in the cytoplasm where post-integration prodn. of infectious viral particles takes place.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryOJ47iOvkx7Vg90H21EOLACvtfcHk0ljhpuNaCW1ELA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvFagtLg%253D&md5=44448a2b2a9af9c65759a02295137303</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1186%2F1742-4690-10-144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-4690-10-144%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BRouzic%26aufirst%3DE.%26aulast%3DBonnard%26aufirst%3DD.%26aulast%3DChasset%26aufirst%3DS.%26aulast%3DBruneau%26aufirst%3DJ.-M.%26aulast%3DChevreuil%26aufirst%3DF.%26aulast%3DLe%2BStrat%26aufirst%3DF.%26aulast%3DNguyen%26aufirst%3DJ.%26aulast%3DBeauvoir%26aufirst%3DR.%26aulast%3DAmadori%26aufirst%3DC.%26aulast%3DBrias%26aufirst%3DJ.%26aulast%3DVomscheid%26aufirst%3DS.%26aulast%3DEiler%26aufirst%3DS.%26aulast%3DL%25C3%25A9vy%26aufirst%3DN.%26aulast%3DDelelis%26aufirst%3DO.%26aulast%3DDeprez%26aufirst%3DE.%26aulast%3DSa%25C3%25AFb%26aufirst%3DA.%26aulast%3DZamborlini%26aufirst%3DA.%26aulast%3DEmiliani%26aufirst%3DS.%26aulast%3DRuff%26aufirst%3DM.%26aulast%3DLedoussal%26aufirst%3DB.%26aulast%3DMoreau%26aufirst%3DF.%26aulast%3DBenarous%26aufirst%3DR.%26atitle%3DDual%2520inhibition%2520of%2520HIV-1%2520replication%2520by%2520integrase-LEDGF%2520allosteric%2520inhibitors%2520is%2520predominant%2520at%2520the%2520post-integration%2520stage%26jtitle%3DRetrovirology%26date%3D2013%26volume%3D10%26spage%3D144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Balakrishnan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yant, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Sullivan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bam, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niedziela-Majka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stray, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakowicz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cihlar, T.</span><span> </span><span class="NLM_article-title">Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">e74163</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e74163&issue=9&author=M.+Balakrishnanauthor=S.+R.+Yantauthor=L.+Tsaiauthor=C.+O%E2%80%99Sullivanauthor=R.+A.+Bamauthor=A.+Tsaiauthor=A.+Niedziela-Majkaauthor=K.+M.+Strayauthor=R.+Sakowiczauthor=T.+Cihlar&title=Non-catalytic+site+HIV-1+integrase+inhibitors+disrupt+core+maturation+and+induce+a+reverse+transcription+block+in+target+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBalakrishnan%26aufirst%3DM.%26aulast%3DYant%26aufirst%3DS.%2BR.%26aulast%3DTsai%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DC.%26aulast%3DBam%26aufirst%3DR.%2BA.%26aulast%3DTsai%26aufirst%3DA.%26aulast%3DNiedziela-Majka%26aufirst%3DA.%26aulast%3DStray%26aufirst%3DK.%2BM.%26aulast%3DSakowicz%26aufirst%3DR.%26aulast%3DCihlar%26aufirst%3DT.%26atitle%3DNon-catalytic%2520site%2520HIV-1%2520integrase%2520inhibitors%2520disrupt%2520core%2520maturation%2520and%2520induce%2520a%2520reverse%2520transcription%2520block%2520in%2520target%2520cells%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D9%26spage%3De74163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Luo, G.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span> </span><span class="NLM_article-title">Characterization of a hemagglutinin-specific inhibitor of influenza A virus</span> <span class="citation_source-journal">Virology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">226</span><span class="NLM_x">, </span> <span class="NLM_fpage">66</span><span class="NLM_x">–</span> <span class="NLM_lpage">76</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=1996&pages=66-76&author=G.-X.+Luoauthor=R.+Colonnoauthor=M.+Krystal&title=Characterization+of+a+hemagglutinin-specific+inhibitor+of+influenza+A+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DG.-X.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DCharacterization%2520of%2520a%2520hemagglutinin-specific%2520inhibitor%2520of%2520influenza%2520A%2520virus%26jtitle%3DVirology%26date%3D1996%26volume%3D226%26spage%3D66%26epage%3D76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Luo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harte, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danetz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianci, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dextraze, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span> </span><span class="NLM_article-title">Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">4062</span><span class="NLM_x">–</span> <span class="NLM_lpage">4070</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1128%2FJVI.71.5.4062-4070.1997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=9094684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADyaK2sXisFWgt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1997&pages=4062-4070&author=G.+Luoauthor=A.+Torriauthor=W.+E.+Harteauthor=S.+Danetzauthor=C.+Cianciauthor=L.+Tileyauthor=S.+Dayauthor=K.-L.+Yuauthor=C.+Ouelletauthor=P.+Dextrazeauthor=N.+Meanwellauthor=R.+Colonnoauthor=M.+Krystal&title=Molecular+mechanism+underlying+the+action+of+a+novel+fusion+inhibitor+of+influenza+A+virus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus</span></div><div class="casAuthors">Luo, Guangxiang; Torri, Al; Harte, William E.; Danetz, Stephanie; Cianci, Christopher; Tiley, Laurence; Day, Susan; Mullaney, David; Yu, Kuo-Long; Ouellet, Carl; Dextraze, Pierre; Meanwell, Nicholas; Colonno, Richard; Krystal, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">4062-4070</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">In the initial stages of influenza virus infection, the hemagglutinin (HA) protein of influenza virus mediates both adsorption and penetration of the virus into the host cell.  Recently, we identified and characterized BMY-27709 as an inhibitor of the H1 and H2 subtypes of influenza A virus that specifically inhibits the HA function necessary for virus-cell membrane fusion.  Studies presented herein show that the inhibition is mediated through specific interaction with the HA protein.  This binding represses the low-pH-induced conformational change of the HA protein which is a prerequisite for membrane fusion.  In an attempt to define the binding pocket within the HA mol., a no. of drug-resistant viruses have been isolated and characterized.  Sequence analyses of the HA gene of these drug-resistant viruses mapped amino changes responsible for drug resistance to a region located near the amino terminus of HA2.  In addn., we have identified inactive analogs by BMY-27709 which are able to compete out the inhibitory activity of BMY-27709.  This finding suggests that inhibition of the HA-mediated membrane fusion by this class of compds. is not solely the result of binding within the HA mol. but requires specific interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooSWR6IhuGb7Vg90H21EOLACvtfcHk0lgwZf7OKGLwwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXisFWgt78%253D&md5=2a937099b047b7c332c4fcf94302ad44</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1128%2FJVI.71.5.4062-4070.1997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.71.5.4062-4070.1997%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DG.%26aulast%3DTorri%26aufirst%3DA.%26aulast%3DHarte%26aufirst%3DW.%2BE.%26aulast%3DDanetz%26aufirst%3DS.%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DTiley%26aufirst%3DL.%26aulast%3DDay%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DOuellet%26aufirst%3DC.%26aulast%3DDextraze%26aufirst%3DP.%26aulast%3DMeanwell%26aufirst%3DN.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DMolecular%2520mechanism%2520underlying%2520the%2520action%2520of%2520a%2520novel%2520fusion%2520inhibitor%2520of%2520influenza%2520A%2520virus%26jtitle%3DJ.%2520Virol.%26date%3D1997%26volume%3D71%26spage%3D4062%26epage%3D4070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cianci, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dischino, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harte, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span> </span><span class="NLM_article-title">pH-Dependent changes in photoaffinity labeling patterns of H1 influenza hemagglutinin using an inhibitor of viral fusion</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1785</span><span class="NLM_x">–</span> <span class="NLM_lpage">1794</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=9971755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADyaK1MXhvVWgu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1999&pages=1785-1794&author=C.+Cianciauthor=K.-L.+Yuauthor=D.+Dischinoauthor=W.+Harteauthor=N.+Meanwellauthor=G.+Luoauthor=R.+J.+Colonnoauthor=M.+Krystal&title=pH-Dependent+changes+in+photoaffinity+labeling+patterns+of+H1+influenza+hemagglutinin+using+an+inhibitor+of+viral+fusion"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">pH-dependent changes in photoaffinity labeling patterns of the H1 influenza virus hemagglutinin by using an inhibitor of viral fusion</span></div><div class="casAuthors">Cianci, Christopher; Yu, Kuo-Long; Dischino, Douglas D.; Harte, William; Deshpande, Milind; Luo, Guangxiang; Colonno, Richard J.; Meanwell, Nicholas A.; Krystal, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1785-1794</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The hemagglutinin (HA) protein undergoes a low-pH-induced conformational change in the acidic milieu of the endosome, resulting in fusion of viral and cellular membranes.  A class of compds. that specifically interact with the HA protein of H1 and H2 subtype viruses and inhibit this conformational change was recently described.  In this study, purified HA trimers (bromelain-cleaved HA [BHA]) are used to examine the properties and binding characteristics of these inhibitors.  Compds. were able to inhibit the low-pH-induced change of isolated trimers, as detected by resistance to digestion with trypsin.  Protection from digestion was extremely stable, as BHA-inhibitor complexes could be incubated for 24 h in low pH with almost no change in BHA structure.  One inhibitor was prepd. as a radiolabeled photoaffinity analog and used to probe for specific drug interactions with the HA protein.  Anal. of BHA after photoaffinity analog binding and UV crosslinking revealed that the HA2 subunit of the HA was specifically radiolabeled.  Crosslinking of the photoaffinity analog to BHA under neutral (native) pH conditions identified a stretch of amino acids within the α-helix of HA2 that interact with the inhibitor.  Interestingly, crosslinking of the analog under acidic conditions identified a different region within the HA2 N terminus which interacts with the photoaffinity compd.  These attachment sites help to delineate a potential binding pocket and suggest a model whereby the BHA is able to undergo a partial, reversible structural change in the presence of inhibitor compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5yO9BHxRJ-bVg90H21EOLACvtfcHk0lgwZf7OKGLwwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvVWgu7k%253D&md5=65818ea00473d811bd7d5d9cb2c4838b</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DDischino%26aufirst%3DD.%26aulast%3DHarte%26aufirst%3DW.%26aulast%3DMeanwell%26aufirst%3DN.%26aulast%3DLuo%26aufirst%3DG.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DpH-Dependent%2520changes%2520in%2520photoaffinity%2520labeling%2520patterns%2520of%2520H1%2520influenza%2520hemagglutinin%2520using%2520an%2520inhibitor%2520of%2520viral%2520fusion%26jtitle%3DJ.%2520Virol.%26date%3D1999%26volume%3D73%26spage%3D1785%26epage%3D1794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yu, K.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civiello, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianci, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Fundamental structure–activity relationships associated with a new structural class of respiratory syncytial virus inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2141</span><span class="NLM_x">–</span> <span class="NLM_lpage">2144</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=2141-2144&author=K.-L.+Yuauthor=Y.+Zhangauthor=R.+L.+Civielloauthor=K.+F.+Kadowauthor=C.+Cianciauthor=M.+Krystalauthor=N.+A.+Meanwell&title=Fundamental+structure%E2%80%93activity+relationships+associated+with+a+new+structural+class+of+respiratory+syncytial+virus+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCiviello%26aufirst%3DR.%2BL.%26aulast%3DKadow%26aufirst%3DK.%2BF.%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DFundamental%2520structure%25E2%2580%2593activity%2520relationships%2520associated%2520with%2520a%2520new%2520structural%2520class%2520of%2520respiratory%2520syncytial%2520virus%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D2141%26epage%3D2144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cianci, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combrink, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civiello, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovesi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venables, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulgeze, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trehan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roach, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span> </span><span class="NLM_article-title">Orally active fusion inhibitor of respiratory syncytial virus</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=413-422&author=C.+Cianciauthor=K.-L.+Yuauthor=K.+Combrinkauthor=N.+Sinauthor=B.+Pearceauthor=A.+Wangauthor=R.+Civielloauthor=S.+Vossauthor=G.+Luoauthor=K.+Kadowauthor=E.+Genovesiauthor=B.+Venablesauthor=H.+Gulgezeauthor=A.+Trehanauthor=J.+Jamesauthor=L.+Lambauthor=I.+Medinaauthor=J.+Roachauthor=R.+Colonnoauthor=J.+Clarkauthor=N.+Meanwellauthor=M.+Krystal&title=Orally+active+fusion+inhibitor+of+respiratory+syncytial+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DCombrink%26aufirst%3DK.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DPearce%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DCiviello%26aufirst%3DR.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DG.%26aulast%3DKadow%26aufirst%3DK.%26aulast%3DGenovesi%26aufirst%3DE.%26aulast%3DVenables%26aufirst%3DB.%26aulast%3DGulgeze%26aufirst%3DH.%26aulast%3DTrehan%26aufirst%3DA.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DLamb%26aufirst%3DL.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DRoach%26aufirst%3DJ.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DOrally%2520active%2520fusion%2520inhibitor%2520of%2520respiratory%2520syncytial%2520virus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26spage%3D413%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cianci, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovesi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zadjura, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combrink, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span> </span><span class="NLM_article-title">Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2448</span><span class="NLM_x">–</span> <span class="NLM_lpage">2454</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=2448-2454&author=C.+Cianciauthor=E.+Genovesiauthor=L.+Lambauthor=I.+Medinaauthor=Z.+Yangauthor=L.+Zadjuraauthor=H.-Y.+Yangauthor=C.+D%E2%80%99Arienzoauthor=N.+Sinauthor=K.-L.+Yuauthor=K.+Combrinkauthor=Z.+Liauthor=R.+Colonnoauthor=N.+Meanwellauthor=J.+Clarkauthor=M.+Krystal&title=Oral+efficacy+of+a+respiratory+syncytial+virus+inhibitor+in+rodent+models+of+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DGenovesi%26aufirst%3DE.%26aulast%3DLamb%26aufirst%3DL.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZadjura%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DH.-Y.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DCombrink%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DMeanwell%26aufirst%3DN.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DOral%2520efficacy%2520of%2520a%2520respiratory%2520syncytial%2520virus%2520inhibitor%2520in%2520rodent%2520models%2520of%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26spage%3D2448%26epage%3D2454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Cianci, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dischino, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roach, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalterio, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span> </span><span class="NLM_article-title">Targeting a binding pocket within the trimer-of-hairpins: small molecule inhibition of viral fusion</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">15046</span><span class="NLM_x">–</span> <span class="NLM_lpage">15051</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=15046-15051&author=C.+Cianciauthor=D.+R.+Langleyauthor=D.+D.+Dischinoauthor=Y.+Sunauthor=K.-L.+Yuauthor=A.+Stanleyauthor=J.+Roachauthor=Z.+Liauthor=R.+Dalterioauthor=R.+Colonnoauthor=N.+A.+Meanwellauthor=M.+Krystal&title=Targeting+a+binding+pocket+within+the+trimer-of-hairpins%3A+small+molecule+inhibition+of+viral+fusion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DDischino%26aufirst%3DD.%2BD.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DStanley%26aufirst%3DA.%26aulast%3DRoach%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DDalterio%26aufirst%3DR.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DTargeting%2520a%2520binding%2520pocket%2520within%2520the%2520trimer-of-hairpins%253A%2520small%2520molecule%2520inhibition%2520of%2520viral%2520fusion%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D15046%26epage%3D15051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Wang, X. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianci, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combrink, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuring, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civiello, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roach, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4592</span><span class="NLM_x">–</span> <span class="NLM_lpage">4598</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=4592-4598&author=X.+A.+Wangauthor=C.+W.+Cianciauthor=K.-L.+Yuauthor=K.+D.+Combrinkauthor=J.+W.+Thuringauthor=Y.+Zhangauthor=R.+L.+Civielloauthor=K.+F.+Kadowauthor=J.+Roachauthor=Z.+Liauthor=D.+R.+Langleyauthor=M.+Krystalauthor=N.+A.+Meanwell&title=Respiratory+syncytial+virus+fusion+inhibitors.+Part+5%3A+Optimization+of+benzimidazole+substitution+patterns+towards+derivatives+with+improved+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BA.%26aulast%3DCianci%26aufirst%3DC.%2BW.%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DThuring%26aufirst%3DJ.%2BW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCiviello%26aufirst%3DR.%2BL.%26aulast%3DKadow%26aufirst%3DK.%2BF.%26aulast%3DRoach%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DRespiratory%2520syncytial%2520virus%2520fusion%2520inhibitors.%2520Part%25205%253A%2520Optimization%2520of%2520benzimidazole%2520substitution%2520patterns%2520towards%2520derivatives%2520with%2520improved%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D4592%26epage%3D4598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span> </span><span class="NLM_article-title">Respiratory syncytial virus—the discovery and optimization of orally bioavailable fusion inhibitors</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">455</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1358%2Fdof.2007.032.05.1087141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFWqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=441-455&author=N.+A.+Meanwellauthor=M.+Krystal&title=Respiratory+syncytial+virus%E2%80%94the+discovery+and+optimization+of+orally+bioavailable+fusion+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7fR"><div class="casContent"><span class="casTitleNuber">7f</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus - the discovery and optimization of orally bioavailable fusion inhibitors</span></div><div class="casAuthors">Meanwell, Nicholas A.; Krystal, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">441-455</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Using a tissue cell culture assay to screen for leads, potent inhibitors of respiratory syncytial virus (RSV) that function early in the virus life cycle were discovered.  Structure-activity relationship studies optimized these leads into compds. with antiviral activity in animal models of infection.  Guided by in vitro measures of cell permeability and metabolic stability in human liver microsomes, 1-cyclopropyl-3-[[1-(4-hydroxybutyl)-1H-benzo[d]imidazol-2-yl]methyl]-1H-imidazo[4,5-c]pyridin-2(3H)-one (BMS-433771, 12) was identified as a clin. candidate with potential for the treatment of RSV infections.  BMS-433771 is a potent inhibitor of RSV lab. and clin. strains in cell culture that demonstrates antiviral activity in murine and cotton rat models of infection following oral administration.  The characterization of mutations in resistant viruses generated in response to serial passage with increasing concns. of this class of RSV inhibitor, coupled with mechanistic studies, indicated interference with the virus-host fusion process.  A radioaffinity probe was developed which, upon irradn. with light to generate a carbene, specifically labeled the RSV F protein in intact virus in a region mapped to the N-terminal heptad repeat element HR-N.  In vitro labeling expts. conducted with a portion of the HR-N known to be involved in 6-helix bundle formation identified the major site of labeling as tyrosine-198.  This finding localized the binding of these RSV inhibitors to a hydrophobic cavity created in the HR-N element after it assembles into a trimeric fusion core that subsequently assocs. with the C-terminal heptad repeats during the final stages of virus and host membrane fusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPcYuM4LQvM7Vg90H21EOLACvtfcHk0lh1lMURF7h_Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFWqtr8%253D&md5=86cfa9eb6d503ef62ee1948581754ab2</span></div><a href="/servlet/linkout?suffix=cit7f&amp;dbid=16384&amp;doi=10.1358%2Fdof.2007.032.05.1087141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2007.032.05.1087141%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DRespiratory%2520syncytial%2520virus%25E2%2580%2594the%2520discovery%2520and%2520optimization%2520of%2520orally%2520bioavailable%2520fusion%2520inhibitors%26jtitle%3DDrugs%2520Future%26date%3D2007%26volume%3D32%26spage%3D441%26epage%3D455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshpande, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zadjura, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tweedie, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranadive, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricarrdi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicer, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deminie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.-G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, P.-f.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">The discovery of 4-benzoyl-1-[(4-methoxy-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)oxoacetyl]-2-(<i>R</i>)-methylpiperazine (BMS-378806)—a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4239</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm034082o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4236-4239&author=T.+Wangauthor=Z.+Zhangauthor=O.+B.+Wallaceauthor=M.+Deshpandeauthor=H.+Fangauthor=Z.+Yangauthor=L.+M.+Zadjuraauthor=D.+L.+Tweedieauthor=S.+Huangauthor=F.+Zhaoauthor=S.+Ranadiveauthor=B.+S.+Robinsonauthor=Y.-F.+Gongauthor=K.+Ricarrdiauthor=T.+P.+Spicerauthor=C.+Deminieauthor=R.+Roseauthor=H.-G.+H.+Wangauthor=W.+S.+Blairauthor=P.-Y.+Shiauthor=P.-f.+Linauthor=R.+J.+Colonnoauthor=N.+A.+Meanwell&title=The+discovery+of+4-benzoyl-1-%5B%284-methoxy-1H-pyrrolo%5B2%2C3-b%5Dpyridin-3-yl%29oxoacetyl%5D-2-%28R%29-methylpiperazine+%28BMS-378806%29%E2%80%94a+novel+HIV-1+attachment+inhibitor+that+interferes+with+CD4-gp120+interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1021%2Fjm034082o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034082o%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWallace%26aufirst%3DO.%2BB.%26aulast%3DDeshpande%26aufirst%3DM.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZadjura%26aufirst%3DL.%2BM.%26aulast%3DTweedie%26aufirst%3DD.%2BL.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DRanadive%26aufirst%3DS.%26aulast%3DRobinson%26aufirst%3DB.%2BS.%26aulast%3DGong%26aufirst%3DY.-F.%26aulast%3DRicarrdi%26aufirst%3DK.%26aulast%3DSpicer%26aufirst%3DT.%2BP.%26aulast%3DDeminie%26aufirst%3DC.%26aulast%3DRose%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DH.-G.%2BH.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DShi%26aufirst%3DP.-Y.%26aulast%3DLin%26aufirst%3DP.-f.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DThe%2520discovery%2520of%25204-benzoyl-1-%255B%25284-methoxy-1H-pyrrolo%255B2%252C3-b%255Dpyridin-3-yl%2529oxoacetyl%255D-2-%2528R%2529-methylpiperazine%2520%2528BMS-378806%2529%25E2%2580%2594a%2520novel%2520HIV-1%2520attachment%2520inhibitor%2520that%2520interferes%2520with%2520CD4-gp120%2520interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4236%26epage%3D4239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lin, P.-f.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicer, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.-G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamanaka, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimmel, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demers, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deminie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zadjura, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span> </span><span class="NLM_article-title">A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">11013</span><span class="NLM_x">–</span> <span class="NLM_lpage">11018</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1073%2Fpnas.1832214100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=12930892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnslynurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=11013-11018&author=P.-f.+Linauthor=W.+S.+Blairauthor=T.+Wangauthor=T.+P.+Spicerauthor=Q.+Guoauthor=N.+Zhouauthor=Y.-F.+Gongauthor=H.-G.+H.+Wangauthor=R.+Roseauthor=G.+A.+Yamanakaauthor=B.+S.+Robinsonauthor=C.-B.+Liauthor=B.+J.+Kimmelauthor=H.+Fangauthor=G.+S.+Demersauthor=C.+Deminieauthor=R.+A.+Fridellauthor=Z.+Yangauthor=L.+M.+Zadjuraauthor=N.+A.+Meanwellauthor=R.+J.+Colonno&title=A+small+molecule+HIV-1+inhibitor+that+targets+the+HIV-1+envelope+and+inhibits+CD4+receptor+binding"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding</span></div><div class="casAuthors">Lin, Pin-Fang; Blair, Wade; Wang, Tao; Spicer, Timothy; Guo, Qi; Zhou, Nannan; Gong, Yi-Fei; Wang, H. -G. Heidi; Rose, Ronald; Yamanaka, Gregory; Robinson, Brett; Li, Chang-Ben; Fridell, Robert; Deminie, Carol; Demers, Gwendeline; Yang, Zheng; Zadjura, Lisa; Meanwell, Nicholas; Colonno, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">11013-11018</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">BMS-378806 is a recently discovered small mol. HIV-1 inhibitor that blocks viral entrance to cells.  The compd. exhibits potent inhibitory activity against a panel of R5- (virus using the CCR5 coreceptor), X4- (virus using the CXCR4 coreceptor), and R5/X4 HIV-1 lab. and clin. isolates of the B subtype (median EC50 of 0.04 μM) in culture assays.  BMS-378806 is selective for HIV-1 and inactive against HIV-2, SIV and a panel of other viruses, and exhibits no significant cytotoxicity in the 14 cell types tested (concn. for 50% redn. of cell growth, >225 μM).  Mechanism of action studies demonstrated that BMS-378806 binds to gp120 and inhibits the interactions of the HIV-1 envelope protein to cellular CD4 receptors.  Further confirmation that BMS-378806 targets the envelope in infected cells was obtained through the isolation of resistant variants and the mapping of resistance substitutions to the HIV-1 envelope.  In particular, two substitutions, M426L and M475I, are situated in the CD4 binding pocket of gp120.  Recombinant HIV-1 carrying these two substitutions demonstrated significantly reduced susceptibility to compd. inhibition.  BMS-378806 displays many favorable pharmacol. traits, such as low protein binding, minimal human serum effect on anti-HIV-1 potency, good oral bioavailability in animal species, and a clean safety profile in initial animal toxicol. studies.  Together, the data show that BMS-378806 is a representative of a new class of HIV inhibitors that has the potential to become a valued addn. to our current armamentarium of antiretroviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRxcq5wksNmrVg90H21EOLACvtfcHk0lip9Bzhf1K2VQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnslynurg%253D&md5=9066843a4e1b65984343fccd70ae4323</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1832214100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1832214100%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DP.-f.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DSpicer%26aufirst%3DT.%2BP.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DGong%26aufirst%3DY.-F.%26aulast%3DWang%26aufirst%3DH.-G.%2BH.%26aulast%3DRose%26aufirst%3DR.%26aulast%3DYamanaka%26aufirst%3DG.%2BA.%26aulast%3DRobinson%26aufirst%3DB.%2BS.%26aulast%3DLi%26aufirst%3DC.-B.%26aulast%3DKimmel%26aufirst%3DB.%2BJ.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DDemers%26aufirst%3DG.%2BS.%26aulast%3DDeminie%26aufirst%3DC.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZadjura%26aufirst%3DL.%2BM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26atitle%3DA%2520small%2520molecule%2520HIV-1%2520inhibitor%2520that%2520targets%2520the%2520HIV-1%2520envelope%2520and%2520inhibits%2520CD4%2520receptor%2520binding%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2003%26volume%3D100%26spage%3D11013%26epage%3D11018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Gerritz, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianci, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deminie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discotto, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAuliffe, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minassian, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pendri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edavettal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maskos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mörtl, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefersauer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbacher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldwin, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metzler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoeckler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schartman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leya-Grado, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, H.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span> </span><span class="NLM_article-title">Small molecules that induce higher-order nucleoprotein oligomers: a novel mode of action for the inhibition of influenza virus replication</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">15366</span><span class="NLM_x">–</span> <span class="NLM_lpage">15371</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=15366-15371&author=S.+W.+Gerritzauthor=C.+Cianciauthor=S.+Kimauthor=B.+C.+Pearceauthor=C.+Deminieauthor=L.+Discottoauthor=B.+McAuliffeauthor=B.+F.+Minassianauthor=S.+Shiauthor=S.+Zhuauthor=W.+Zhaiauthor=A.+Pendriauthor=G.+Liauthor=M.+A.+Possauthor=S.+Edavettalauthor=P.+A.+McDonnellauthor=H.+A.+Lewisauthor=K.+Maskosauthor=M.+M%C3%B6rtlauthor=R.+Kiefersauerauthor=S.+Steinbacherauthor=E.+T.+Baldwinauthor=W.+Metzlerauthor=J.+Brysonauthor=M.+Healyauthor=T.+Philipauthor=M.+Zoecklerauthor=R.+Schartmanauthor=M.+Sinzauthor=V.+Leya-Gradoauthor=H.-H.+Hoffmanauthor=D.+R.+Langleyauthor=N.+A.+Meanwellauthor=M.+Krystal&title=Small+molecules+that+induce+higher-order+nucleoprotein+oligomers%3A+a+novel+mode+of+action+for+the+inhibition+of+influenza+virus+replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGerritz%26aufirst%3DS.%2BW.%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPearce%26aufirst%3DB.%2BC.%26aulast%3DDeminie%26aufirst%3DC.%26aulast%3DDiscotto%26aufirst%3DL.%26aulast%3DMcAuliffe%26aufirst%3DB.%26aulast%3DMinassian%26aufirst%3DB.%2BF.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DW.%26aulast%3DPendri%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DEdavettal%26aufirst%3DS.%26aulast%3DMcDonnell%26aufirst%3DP.%2BA.%26aulast%3DLewis%26aufirst%3DH.%2BA.%26aulast%3DMaskos%26aufirst%3DK.%26aulast%3DM%25C3%25B6rtl%26aufirst%3DM.%26aulast%3DKiefersauer%26aufirst%3DR.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DBaldwin%26aufirst%3DE.%2BT.%26aulast%3DMetzler%26aufirst%3DW.%26aulast%3DBryson%26aufirst%3DJ.%26aulast%3DHealy%26aufirst%3DM.%26aulast%3DPhilip%26aufirst%3DT.%26aulast%3DZoeckler%26aufirst%3DM.%26aulast%3DSchartman%26aufirst%3DR.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DLeya-Grado%26aufirst%3DV.%26aulast%3DHoffman%26aufirst%3DH.-H.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DSmall%2520molecules%2520that%2520induce%2520higher-order%2520nucleoprotein%2520oligomers%253A%2520a%2520novel%2520mode%2520of%2520action%2520for%2520the%2520inhibition%2520of%2520influenza%2520virus%2520replication%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D15366%26epage%3D15371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Baldick, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wichroski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pendri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzucco, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pokornowski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggers, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerritz, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockett, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenney, D. J.</span><span> </span><span class="NLM_article-title">Identification of a small molecule antiviral inhibitor of the entry stage of hepatitis C virus infection</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">e1001086</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=e1001086&issue=9&author=C.+J.+Baldickauthor=M.+Wichroskiauthor=A.+Pendriauthor=A.+W.+Walshauthor=J.+Fangauthor=C.+Mazzuccoauthor=K.+Pokornowskiauthor=R.+Roseauthor=B.+Eggersauthor=M.+Hsuauthor=G.+Zhaiauthor=S.+W.+Gerritzauthor=M.+Possauthor=N.+A.+Meanwellauthor=M.+I.+Cockettauthor=D.+J.+Tenney&title=Identification+of+a+small+molecule+antiviral+inhibitor+of+the+entry+stage+of+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaldick%26aufirst%3DC.%2BJ.%26aulast%3DWichroski%26aufirst%3DM.%26aulast%3DPendri%26aufirst%3DA.%26aulast%3DWalsh%26aufirst%3DA.%2BW.%26aulast%3DFang%26aufirst%3DJ.%26aulast%3DMazzucco%26aufirst%3DC.%26aulast%3DPokornowski%26aufirst%3DK.%26aulast%3DRose%26aufirst%3DR.%26aulast%3DEggers%26aufirst%3DB.%26aulast%3DHsu%26aufirst%3DM.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DGerritz%26aufirst%3DS.%2BW.%26aulast%3DPoss%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DCockett%26aufirst%3DM.%2BI.%26aulast%3DTenney%26aufirst%3DD.%2BJ.%26atitle%3DIdentification%2520of%2520a%2520small%2520molecule%2520antiviral%2520inhibitor%2520of%2520the%2520entry%2520stage%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DPLoS%2520Pathog.%26date%3D2010%26volume%3D6%26issue%3D9%26spage%3De1001086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Watkins, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, M. C.</span><span> </span><span class="NLM_article-title">HCV versus HIV drug discovery: déjà vu all over again?</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">2281</span><span class="NLM_x">–</span> <span class="NLM_lpage">2287</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2281-2287&author=W.+J.+Watkinsauthor=M.+C.+Desai&title=HCV+versus+HIV+drug+discovery%3A+d%C3%A9j%C3%A0+vu+all+over+again%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DW.%2BJ.%26aulast%3DDesai%26aufirst%3DM.%2BC.%26atitle%3DHCV%2520versus%2520HIV%2520drug%2520discovery%253A%2520d%25C3%25A9j%25C3%25A0%2520vu%2520all%2520over%2520again%253F%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D2281%26epage%3D2287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sarrazin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieffer, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartels, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanzelka, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müh, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wincheringer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, H.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weegink, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reesink, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwong, A. D.</span><span> </span><span class="NLM_article-title">Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">1767</span><span class="NLM_x">–</span> <span class="NLM_lpage">1777</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2007&pages=1767-1777&author=C.+Sarrazinauthor=T.+L.+Kiefferauthor=D.+Bartelsauthor=B.+Hanzelkaauthor=U.+M%C3%BChauthor=M.+Welkerauthor=D.+Wincheringerauthor=Y.+Zhouauthor=H.-M.+Chuauthor=C.+Linauthor=C.+Weeginkauthor=H.+Reesinkauthor=S.+Zeuzemauthor=A.+D.+Kwong&title=Dynamic+hepatitis+C+virus+genotypic+and+phenotypic+changes+in+patients+treated+with+the+protease+inhibitor+telaprevir"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSarrazin%26aufirst%3DC.%26aulast%3DKieffer%26aufirst%3DT.%2BL.%26aulast%3DBartels%26aufirst%3DD.%26aulast%3DHanzelka%26aufirst%3DB.%26aulast%3DM%25C3%25BCh%26aufirst%3DU.%26aulast%3DWelker%26aufirst%3DM.%26aulast%3DWincheringer%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DChu%26aufirst%3DH.-M.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DWeegink%26aufirst%3DC.%26aulast%3DReesink%26aufirst%3DH.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DKwong%26aufirst%3DA.%2BD.%26atitle%3DDynamic%2520hepatitis%2520C%2520virus%2520genotypic%2520and%2520phenotypic%2520changes%2520in%2520patients%2520treated%2520with%2520the%2520protease%2520inhibitor%2520telaprevir%26jtitle%3DGastroenterology%26date%3D2007%26volume%3D132%26spage%3D1767%26epage%3D1777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Rapid emergence of protease inhibitor resistance in hepatitis C virus</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1126%2Fscitranslmed.3000544" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=1-9&author=L.+Rongauthor=H.+Dahariauthor=R.+M.+Ribeiroauthor=A.+S.+Perelson&title=Rapid+emergence+of+protease+inhibitor+resistance+in+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3000544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3000544%26sid%3Dliteratum%253Aachs%26aulast%3DRong%26aufirst%3DL.%26aulast%3DDahari%26aufirst%3DH.%26aulast%3DRibeiro%26aufirst%3DR.%2BM.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DRapid%2520emergence%2520of%2520protease%2520inhibitor%2520resistance%2520in%2520hepatitis%2520C%2520virus%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Susser, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zettler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domingues, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karey, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ralston, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarrazin, C.</span><span> </span><span class="NLM_article-title">Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1709</span><span class="NLM_x">–</span> <span class="NLM_lpage">1718</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=1709-1718&author=S.+Susserauthor=C.+Welschauthor=Y.+Wangauthor=M.+Zettlerauthor=F.+S.+Dominguesauthor=U.+Kareyauthor=E.+Hughesauthor=R.+Ralstonauthor=X.+Tongauthor=E.+Herrmannauthor=S.+Zeuzemauthor=C.+Sarrazin&title=Characterization+of+resistance+to+the+protease+inhibitor+boceprevir+in+hepatitis+C+virus-infected+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSusser%26aufirst%3DS.%26aulast%3DWelsch%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZettler%26aufirst%3DM.%26aulast%3DDomingues%26aufirst%3DF.%2BS.%26aulast%3DKarey%26aufirst%3DU.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DRalston%26aufirst%3DR.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DHerrmann%26aufirst%3DE.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DSarrazin%26aufirst%3DC.%26atitle%3DCharacterization%2520of%2520resistance%2520to%2520the%2520protease%2520inhibitor%2520boceprevir%2520in%2520hepatitis%2520C%2520virus-infected%2520patients%26jtitle%3DHepatology%26date%3D2009%26volume%3D50%26spage%3D1709%26epage%3D1718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Neumann, A. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gretch, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiley, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Layden, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=1998&pages=103-107&author=A.+U.+Neumannauthor=N.+P.+Lamauthor=H.+Dahariauthor=D.+R.+Gretchauthor=T.+E.+Wileyauthor=T.+J.+Laydenauthor=A.+S.+Perelson&title=Hepatitis+C+viral+dynamics+in+vivo+and+the+antiviral+efficacy+of+interferon-%CE%B1+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNeumann%26aufirst%3DA.%2BU.%26aulast%3DLam%26aufirst%3DN.%2BP.%26aulast%3DDahari%26aufirst%3DH.%26aulast%3DGretch%26aufirst%3DD.%2BR.%26aulast%3DWiley%26aufirst%3DT.%2BE.%26aulast%3DLayden%26aufirst%3DT.%2BJ.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DHepatitis%2520C%2520viral%2520dynamics%2520in%2520vivo%2520and%2520the%2520antiviral%2520efficacy%2520of%2520interferon-%25CE%25B1%2520therapy%26jtitle%3DScience%26date%3D1998%26volume%3D282%26spage%3D103%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Perelson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Micol, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span> </span><span class="NLM_article-title">New kinetic models for the hepatitis C virus</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">749</span><span class="NLM_x">–</span> <span class="NLM_lpage">754</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2005&pages=749-754&author=A.+S.+Perelsonauthor=E.+Herrmannauthor=F.+Micolauthor=S.+Zeuzem&title=New+kinetic+models+for+the+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26aulast%3DHerrmann%26aufirst%3DE.%26aulast%3DMicol%26aufirst%3DF.%26aulast%3DZeuzem%26aufirst%3DS.%26atitle%3DNew%2520kinetic%2520models%2520for%2520the%2520hepatitis%2520C%2520virus%26jtitle%3DHepatology%26date%3D2005%26volume%3D42%26spage%3D749%26epage%3D754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Shudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Modeling HCV kinetics under therapy using PK and PD information</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">–</span> <span class="NLM_lpage">332</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1517%2F17425250902787616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=19331594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkt1SmtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=321-332&author=E.+Shudoauthor=R.+M.+Ribeiroauthor=A.+S.+Perelson&title=Modeling+HCV+kinetics+under+therapy+using+PK+and+PD+information"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling HCV kinetics under therapy using PK and PD information</span></div><div class="casAuthors">Shudo, Emi; Ribeiro, Ruy M.; Perelson, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">321-332</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Math. models have proven helpful in analyzing the virol. response to antiviral therapy in hepatitis C virus (HCV) infected subjects.  Objective: To summarize the uses and limitations of different models for analyzing HCV kinetic data under pegylated IFN therapy.  Methods: We formulate math. models and fit them by nonlinear least square regression to patient data to est. model parameters.  We compare the goodness of fit and parameter values estd. by different models statistically.  Results/conclusion: The best model for parameter estn. depends on the availability and the quality of data as well as the therapy used.  We also discuss the math. models that will be needed to analyze HCV kinetic data from clin. trials with new antiviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7kS3YsFzpdrVg90H21EOLACvtfcHk0lgbKdHtK51q3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkt1SmtL8%253D&md5=eb7d5f818c186ce3e2f80bf6e29a5b4a</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1517%2F17425250902787616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425250902787616%26sid%3Dliteratum%253Aachs%26aulast%3DShudo%26aufirst%3DE.%26aulast%3DRibeiro%26aufirst%3DR.%2BM.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DModeling%2520HCV%2520kinetics%2520under%2520therapy%2520using%2520PK%2520and%2520PD%2520information%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2009%26volume%3D5%26spage%3D321%26epage%3D332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Rong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling</span> <span class="citation_source-journal">Crit. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1615%2FCritRevImmunol.v30.i2.30" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=20370626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntValsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=131-148&author=L.+Rongauthor=A.+S.+Perelson&title=Treatment+of+hepatitis+C+virus+infection+with+interferon+and+small+molecule+direct+antivirals%3A+viral+kinetics+and+modeling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13dR"><div class="casContent"><span class="casTitleNuber">13d</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling</span></div><div class="casAuthors">Rong, Libin; Perelson, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-148</span>CODEN:
                <span class="NLM_cas:coden">CCRIDE</span>;
        ISSN:<span class="NLM_cas:issn">1040-8401</span>.
    
            (<span class="NLM_cas:orgname">Begell House, Inc.</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) infection remains a threat to global public health.  Treatment with pegylated interferon (IFN) plus ribavirin leads to a sustained virol. response in about 50% of patients.  New therapies using direct antiviral agents have the potential to cure patients unresponsive to IFN-based therapies.  Math. modeling has played an important role in studying HCV kinetics.  Using models, one can evaluate the effectiveness of new treatment agents, est. important parameters that govern virus-host interactions, explore possible mechanisms of drug action against HCV, investigate the development of drug resistance, and study quasispecies dynamics during therapy.  Here we review our current knowledge of HCV kinetics under IFN-based therapy and newly developed antiviral agents specifically targeted to attack HCV, and show how math. models have helped to improve our understanding of HCV infection and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRdLbw3w12frVg90H21EOLACvtfcHk0lgbKdHtK51q3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntValsr4%253D&md5=ee1f9e95d0f1670f51739b4fa377e840</span></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=10.1615%2FCritRevImmunol.v30.i2.30&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1615%252FCritRevImmunol.v30.i2.30%26sid%3Dliteratum%253Aachs%26aulast%3DRong%26aufirst%3DL.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DTreatment%2520of%2520hepatitis%2520C%2520virus%2520infection%2520with%2520interferon%2520and%2520small%2520molecule%2520direct%2520antivirals%253A%2520viral%2520kinetics%2520and%2520modeling%26jtitle%3DCrit.%2520Rev.%2520Immunol.%26date%3D2010%26volume%3D30%26spage%3D131%26epage%3D148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Ribeiro, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoddard, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Learn, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korber, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guedj, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parrish, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">e1002881</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=e1002881&issue=8&author=R.+M.+Ribeiroauthor=H.+Liauthor=S.+Wangauthor=M.+B.+Stoddardauthor=G.+H.+Learnauthor=B.+T.+Korberauthor=T.+Bhattacharyaauthor=J.+Guedjauthor=E.+H.+Parrishauthor=B.+H.+Hahnauthor=G.+M.+Shawauthor=A.+S.+Perelson&title=Quantifying+the+diversification+of+hepatitis+C+virus+%28HCV%29+during+primary+infection%3A+estimates+of+the+in+vivo+mutation+rate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRibeiro%26aufirst%3DR.%2BM.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DStoddard%26aufirst%3DM.%2BB.%26aulast%3DLearn%26aufirst%3DG.%2BH.%26aulast%3DKorber%26aufirst%3DB.%2BT.%26aulast%3DBhattacharya%26aufirst%3DT.%26aulast%3DGuedj%26aufirst%3DJ.%26aulast%3DParrish%26aufirst%3DE.%2BH.%26aulast%3DHahn%26aufirst%3DB.%2BH.%26aulast%3DShaw%26aufirst%3DG.%2BM.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DQuantifying%2520the%2520diversification%2520of%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%2520during%2520primary%2520infection%253A%2520estimates%2520of%2520the%2520in%2520vivo%2520mutation%2520rate%26jtitle%3DPLoS%2520Pathog.%26date%3D2012%26volume%3D8%26issue%3D8%26spage%3De1002881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Chatterjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guedj, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Mathematical modeling of HCV infection: What can it teach us in the era of direct-acting antiviral agents?</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1171</span><span class="NLM_x">–</span> <span class="NLM_lpage">1182</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=1171-1182&author=A.+Chatterjeeauthor=J.+Guedjauthor=A.+S.+Perelson&title=Mathematical+modeling+of+HCV+infection%3A+What+can+it+teach+us+in+the+era+of+direct-acting+antiviral+agents%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChatterjee%26aufirst%3DA.%26aulast%3DGuedj%26aufirst%3DJ.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DMathematical%2520modeling%2520of%2520HCV%2520infection%253A%2520What%2520can%2520it%2520teach%2520us%2520in%2520the%2520era%2520of%2520direct-acting%2520antiviral%2520agents%253F%26jtitle%3DAntiviral%2520Ther.%26date%3D2012%26volume%3D17%26spage%3D1171%26epage%3D1182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Körner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herian, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theilmann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">–</span> <span class="NLM_lpage">113</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1126%2Fscience.285.5424.110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=10390360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADyaK1MXksVCqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1999&pages=110-113&author=V.+Lohmannauthor=F.+K%C3%B6rnerauthor=J.+O.+Kochauthor=U.+Herianauthor=L.+Theilmannauthor=R.+Bartenschlager&title=Replication+of+subgenomic+hepatitis+C+virus+RNAs+in+a+hepatoma+cell+line"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line</span></div><div class="casAuthors">Lohmann, V.; Korner, F.; Koch, J.-O.; Herian, U.; Theilmann, L.; Bartenschlager, R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">5424</span>),
    <span class="NLM_cas:pages">110-113</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">An estd. 170 million persons worldwide are infected with hepatitis C virus (HCV), a major cause of chronic liver disease.  Despite increasing knowledge of genome structure and individual viral proteins, studies on virus replication and pathogenesis have been hampered by the lack of reliable and efficient cell culture systems.  A full-length consensus genome was cloned from viral RNA isolated from an infected human liver and used to construct subgenomic selectable replicons.  Upon transfection into a human hepatoma cell line, these RNAs replicated to high levels, permitting metabolic radiolabeling of viral RNA and proteins.  This work defines the structure of HCV replicons functional in cell culture and provides the basis for a long-sought cellular system that should allow detailed mol. studies of HCV and the development of antiviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7X754RT8y1LVg90H21EOLACvtfcHk0ljSDrHUVHxQeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksVCqurk%253D&md5=b075621b316209ecf4498c9b5b33e4b5</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1126%2Fscience.285.5424.110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.285.5424.110%26sid%3Dliteratum%253Aachs%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DK%25C3%25B6rner%26aufirst%3DF.%26aulast%3DKoch%26aufirst%3DJ.%2BO.%26aulast%3DHerian%26aufirst%3DU.%26aulast%3DTheilmann%26aufirst%3DL.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DReplication%2520of%2520subgenomic%2520hepatitis%2520C%2520virus%2520RNAs%2520in%2520a%2520hepatoma%2520cell%2520line%26jtitle%3DScience%26date%3D1999%26volume%3D285%26spage%3D110%26epage%3D113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Hepatitis C virus replicons: potential role for drug development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">911</span><span class="NLM_x">–</span> <span class="NLM_lpage">916</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=911-916&author=R.+Bartenschlager&title=Hepatitis+C+virus+replicons%3A+potential+role+for+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DHepatitis%2520C%2520virus%2520replicons%253A%2520potential%2520role%2520for%2520drug%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D911%26epage%3D916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">The hepatitis C virus replicon system: from basic research to clinical application</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">216</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2Fj.jhep.2005.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=15964655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvFals74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2005&pages=210-216&author=R.+Bartenschlager&title=The+hepatitis+C+virus+replicon+system%3A+from+basic+research+to+clinical+application"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14cR"><div class="casContent"><span class="casTitleNuber">14c</span><div class="casTitle"><span class="NLM_cas:atitle">The hepatitis C virus replicon system: From basic research to clinical application</span></div><div class="casAuthors">Bartenschlager, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">210-216</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The hepatitis C virus (HCV) replicon system is a valuable tool to study various aspects of the viral life cycle.  Although these RNAs are propagated in tumor cells and highly efficient RNA replication often depends on cell culture adaptive mutations, it can be assumed that HCV replicons mimic the basic principle of HCV replication as it occurs in vivo.  The recent demonstration of antiviral activity of a proteinase inhibitor in the replicon system and in HCV infected patients clearly supports this conclusion.  Caution is however, required when analyzing processes that are dominated by the host cell.  It is obvious that cell lines differ from hepatocytes in several respects and therefore, a host cell factor required for RNA replication in Huh-7 cells may not necessarily play the same role in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryr3ZhbaSqLbVg90H21EOLACvtfcHk0ljSDrHUVHxQeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvFals74%253D&md5=416cdbec90929728e19a6406a6546a1c</span></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2005.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2005.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DThe%2520hepatitis%2520C%2520virus%2520replicon%2520system%253A%2520from%2520basic%2520research%2520to%2520clinical%2520application%26jtitle%3DJ.%2520Hepatol.%26date%3D2005%26volume%3D43%26spage%3D210%26epage%3D216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Taylor, D. R.</span><span> </span><span class="NLM_article-title">Evolution of cell culture systems for HCV</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">530</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=523-530&author=D.+R.+Taylor&title=Evolution+of+cell+culture+systems+for+HCV"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DD.%2BR.%26atitle%3DEvolution%2520of%2520cell%2520culture%2520systems%2520for%2520HCV%26jtitle%3DAntiviral%2520Ther.%26date%3D2013%26volume%3D18%26spage%3D523%26epage%3D530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">On the history of hepatitis C virus cell culture systems</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1627</span><span class="NLM_x">–</span> <span class="NLM_lpage">1642</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm401401n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1627-1642&author=V.+Lohmannauthor=R.+Bartenschlager&title=On+the+history+of+hepatitis+C+virus+cell+culture+systems"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14e&amp;dbid=16384&amp;doi=10.1021%2Fjm401401n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401401n%26sid%3Dliteratum%253Aachs%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DOn%2520the%2520history%2520of%2520hepatitis%2520C%2520virus%2520cell%2520culture%2520systems%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1627%26epage%3D1642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Wakita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietschmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Date, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murthy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habermann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krausslich, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizokami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, T. J.</span><span> </span><span class="NLM_article-title">Production of infectious hepatitis C virus in tissue culture from a cloned viral genome</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">791</span><span class="NLM_x">–</span> <span class="NLM_lpage">796</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14f&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1038%2Fnm1268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14f&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=15951748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14f&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt1aju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=791-796&author=T.+Wakitaauthor=T.+Pietschmannauthor=T.+Katoauthor=T.+Dateauthor=M.+Miyamotoauthor=Z.+Zhaoauthor=K.+Murthyauthor=A.+Habermannauthor=H.+G.+Krausslichauthor=M.+Mizokamiauthor=R.+Bartenschlagerauthor=T.+J.+Liang&title=Production+of+infectious+hepatitis+C+virus+in+tissue+culture+from+a+cloned+viral+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14fR"><div class="casContent"><span class="casTitleNuber">14f</span><div class="casTitle"><span class="NLM_cas:atitle">Production of infectious hepatitis C virus in tissue culture from a cloned viral genome</span></div><div class="casAuthors">Wakita, Takaji; Pietschmann, Thomas; Kato, Takanobu; Date, Tomoko; Miyamoto, Michiko; Zhao, Zijiang; Murthy, Krishna; Habermann, Anja; Kraeusslich, Hans-Georg; Mizokami, Masashi; Bartenschlager, Ralf; Liang, T. Jake</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">791-796</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection causes chronic liver diseases and is a global public health problem.  Detailed analyses of HCV have been hampered by the lack of viral culture systems.  Subgenomic replicons of the JFH1 genotype 2a strain cloned from an individual with fulminant hepatitis replicate efficiently in cell culture.  Here we show that the JFH1 genome replicates efficiently and supports secretion of viral particles after transfection into a human hepatoma cell line (Huh7).  Particles have a d. of about 1.15-1.17 g/mL and a spherical morphol. with an av. diam. of about 55 nm.  Secreted virus is infectious for Huh7 cells and infectivity can be neutralized by CD81-specific antibodies and by Igs from chronically infected individuals.  The cell culture-generated HCV is infectious for chimpanzee.  This system provides a powerful tool for studying the viral life cycle and developing antiviral strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqra8QhVAEyJ7Vg90H21EOLACvtfcHk0lg_LbtBu8kBUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt1aju7c%253D&md5=91235eedec98d1b3d6a4bc4bc68f6d11</span></div><a href="/servlet/linkout?suffix=cit14f&amp;dbid=16384&amp;doi=10.1038%2Fnm1268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1268%26sid%3Dliteratum%253Aachs%26aulast%3DWakita%26aufirst%3DT.%26aulast%3DPietschmann%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DT.%26aulast%3DDate%26aufirst%3DT.%26aulast%3DMiyamoto%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DMurthy%26aufirst%3DK.%26aulast%3DHabermann%26aufirst%3DA.%26aulast%3DKrausslich%26aufirst%3DH.%2BG.%26aulast%3DMizokami%26aufirst%3DM.%26aulast%3DBartenschlager%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DT.%2BJ.%26atitle%3DProduction%2520of%2520infectious%2520hepatitis%2520C%2520virus%2520in%2520tissue%2520culture%2520from%2520a%2520cloned%2520viral%2520genome%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D791%26epage%3D796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Zhong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gastaminza, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapadia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wieland, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uprichard, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chisari, F. V.</span><span> </span><span class="NLM_article-title">Robust hepatitis C virus infection in vitro</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">9294</span><span class="NLM_x">–</span> <span class="NLM_lpage">9299</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14g&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1073%2Fpnas.0503596102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14g&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=15939869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14g&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvF2rs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=9294-9299&author=J.+Zhongauthor=P.+Gastaminzaauthor=G.+Chengauthor=S.+Kapadiaauthor=T.+Katoauthor=D.+R.+Burtonauthor=S.+F.+Wielandauthor=S.+L.+Uprichardauthor=T.+Wakitaauthor=F.+V.+Chisari&title=Robust+hepatitis+C+virus+infection+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14gR"><div class="casContent"><span class="casTitleNuber">14g</span><div class="casTitle"><span class="NLM_cas:atitle">Robust hepatitis C virus infection in vitro</span></div><div class="casAuthors">Zhong, Jin; Gastaminza, Pablo; Cheng, Guofeng; Kapadia, Sharookh; Kato, Takanobu; Burton, Dennis R.; Wieland, Stefan F.; Uprichard, Susan L.; Wakita, Takaji; Chisari, Francis V.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">9294-9299</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The absence of a robust cell culture model of hepatitis C virus (HCV) infection has severely limited anal. of the HCV life cycle and the development of effective antivirals and vaccines.  Here we report the establishment of a simple yet robust HCV cell culture infection system based on the HCV JFH-1 mol. clone and Huh-7-derived cell lines that allows the prodn. of virus that can be efficiently propagated in tissue culture.  This system provides a powerful tool for the anal. of host-virus interactions that should facilitate the discovery of antiviral drugs and vaccines for this important human pathogen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi3c9MseYJNbVg90H21EOLACvtfcHk0lg_LbtBu8kBUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvF2rs78%253D&md5=6b02e510e6ed7c8f4917f26cde188ae8</span></div><a href="/servlet/linkout?suffix=cit14g&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0503596102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0503596102%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DJ.%26aulast%3DGastaminza%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DKapadia%26aufirst%3DS.%26aulast%3DKato%26aufirst%3DT.%26aulast%3DBurton%26aufirst%3DD.%2BR.%26aulast%3DWieland%26aufirst%3DS.%2BF.%26aulast%3DUprichard%26aufirst%3DS.%2BL.%26aulast%3DWakita%26aufirst%3DT.%26aulast%3DChisari%26aufirst%3DF.%2BV.%26atitle%3DRobust%2520hepatitis%2520C%2520virus%2520infection%2520in%2520vitro%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D9294%26epage%3D9299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Lindenbach, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Syder, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolk, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tellinghuisen, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, R. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeating, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span> </span><span class="NLM_article-title">Complete replication of hepatitis C virus in cell culture</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">309</span><span class="NLM_x">, </span> <span class="NLM_fpage">623</span><span class="NLM_x">–</span> <span class="NLM_lpage">626</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14h&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1126%2Fscience.1114016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14h&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=15947137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14h&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmsFChtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2005&pages=623-626&author=B.+D.+Lindenbachauthor=M.+J.+Evansauthor=A.+J.+Syderauthor=B.+Wolkauthor=T.+L.+Tellinghuisenauthor=C.+C.+Liuauthor=T.+Maruyamaauthor=R.+O.+Hynesauthor=D.+R.+Burtonauthor=J.+A.+McKeatingauthor=C.+M.+Rice&title=Complete+replication+of+hepatitis+C+virus+in+cell+culture"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14hR"><div class="casContent"><span class="casTitleNuber">14h</span><div class="casTitle"><span class="NLM_cas:atitle">Complete Replication of Hepatitis C Virus in Cell Culture</span></div><div class="casAuthors">Lindenbach, Brett D.; Evans, Matthew J.; Syder, Andrew J.; Woelk, Benno; Tellinghuisen, Timothy L.; Liu, Christopher C.; Maruyama, Toshiaki; Hynes, Richard O.; Burton, Dennis R.; McKeating, Jane A.; Rice, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">5734</span>),
    <span class="NLM_cas:pages">623-626</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Many aspects of the hepatitis C virus (HCV) life cycle have not been reproduced in cell culture, which has slowed research progress on this important human pathogen.  Here, we describe a full-length HCV genome that replicates and produces virus particles that are infectious in cell culture (HCVcc).  Replication of HCVcc was robust, producing nearly 105 infectious units per mL within 48 h.  Virus particles were filterable and neutralized with a monoclonal antibody against the viral glycoprotein E2.  Viral entry was dependent on cellular expression of a putative HCV receptor, CD81.  HCVcc replication was inhibited by interferon-α and by several HCV-specific antiviral compds., suggesting that this in vitro system will aid in the search for improved antivirals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroGMVonlJq-rVg90H21EOLACvtfcHk0lg_LbtBu8kBUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmsFChtr4%253D&md5=05a4723cb8bf6b4e33cecab9be5bcdea</span></div><a href="/servlet/linkout?suffix=cit14h&amp;dbid=16384&amp;doi=10.1126%2Fscience.1114016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1114016%26sid%3Dliteratum%253Aachs%26aulast%3DLindenbach%26aufirst%3DB.%2BD.%26aulast%3DEvans%26aufirst%3DM.%2BJ.%26aulast%3DSyder%26aufirst%3DA.%2BJ.%26aulast%3DWolk%26aufirst%3DB.%26aulast%3DTellinghuisen%26aufirst%3DT.%2BL.%26aulast%3DLiu%26aufirst%3DC.%2BC.%26aulast%3DMaruyama%26aufirst%3DT.%26aulast%3DHynes%26aufirst%3DR.%2BO.%26aulast%3DBurton%26aufirst%3DD.%2BR.%26aulast%3DMcKeating%26aufirst%3DJ.%2BA.%26aulast%3DRice%26aufirst%3DC.%2BM.%26atitle%3DComplete%2520replication%2520of%2520hepatitis%2520C%2520virus%2520in%2520cell%2520culture%26jtitle%3DScience%26date%3D2005%26volume%3D309%26spage%3D623%26epage%3D626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Miller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purcell, R. H.</span><span> </span><span class="NLM_article-title">Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus super group</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">2057</span><span class="NLM_x">–</span> <span class="NLM_lpage">2061</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1990&pages=2057-2061&author=R.+H.+Millerauthor=R.+H.+Purcell&title=Hepatitis+C+virus+shares+amino+acid+sequence+similarity+with+pestiviruses+and+flaviviruses+as+well+as+members+of+two+plant+virus+super+group"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DR.%2BH.%26aulast%3DPurcell%26aufirst%3DR.%2BH.%26atitle%3DHepatitis%2520C%2520virus%2520shares%2520amino%2520acid%2520sequence%2520similarity%2520with%2520pestiviruses%2520and%2520flaviviruses%2520as%2520well%2520as%2520members%2520of%2520two%2520plant%2520virus%2520super%2520group%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1990%26volume%3D87%26spage%3D2057%26epage%3D2061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Colett, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gold, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strick, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purchio, A. F.</span><span> </span><span class="NLM_article-title">Molecular cloning and nucleotide sequence of the pestivirus bovine viral diarrhea virus</span> <span class="citation_source-journal">Virology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">165</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">199</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=1998&pages=191-199&author=M.+S.+Colettauthor=R.+Larsonauthor=C.+Goldauthor=D.+Strickauthor=D.+K.+Andersonauthor=A.+F.+Purchio&title=Molecular+cloning+and+nucleotide+sequence+of+the+pestivirus+bovine+viral+diarrhea+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DColett%26aufirst%3DM.%2BS.%26aulast%3DLarson%26aufirst%3DR.%26aulast%3DGold%26aufirst%3DC.%26aulast%3DStrick%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DD.%2BK.%26aulast%3DPurchio%26aufirst%3DA.%2BF.%26atitle%3DMolecular%2520cloning%2520and%2520nucleotide%2520sequence%2520of%2520the%2520pestivirus%2520bovine%2520viral%2520diarrhea%2520virus%26jtitle%3DVirology%26date%3D1998%26volume%3D165%26spage%3D191%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Buckwold, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beer, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donis, R. O.</span><span> </span><span class="NLM_article-title">Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2FS0166-3542%2803%2900174-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=14516916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnsVansLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2003&pages=1-15&author=V.+E.+Buckwoldauthor=B.+E.+Beerauthor=R.+O.+Donis&title=Bovine+viral+diarrhea+virus+as+a+surrogate+model+of+hepatitis+C+virus+for+the+evaluation+of+antiviral+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15cR"><div class="casContent"><span class="casTitleNuber">15c</span><div class="casTitle"><span class="NLM_cas:atitle">Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents</span></div><div class="casAuthors">Buckwold, Victor E.; Beer, Brigitte E.; Donis, Ruben O.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-15</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The identification and development of new antiviral agents that can be used to combat hepatitis C virus (HCV) infection was complicated by both tech. and logistic issues.  There are few, if any, robust methods by which HCV virions can be grown in vitro.  The development of HCV RNA replicons was a great breakthrough that has allowed for the undertaking of significant screening efforts to identify inhibitors of HCV intracellular replication.  However, since replicons do not undergo a complete replication cycle, drug screening programs and mechanism of action studies based solely on these assays will not identify compds. targeting either early (virion attachment, entry, uncoating) or late (virion assembly, egress) stages of the viral replication cycle.  Drugs that neg. affect the infectivity of new virions will also not be identified using HCV RNA replicons.  Bovine viral diarrhea virus (BVDV) shares a similar structural organization with HCV, and both viruses generally cause chronic long-term infections in their resp. hosts.  The BVDV surrogate model is attractive, since it is a virus-based system.  It is easy to culture the virus in vitro, mol. clones are available for genetic studies, and the virus undergoes a complete replication cycle.  Like HCV, BVDV utilizes the LDL receptor to enter cells, uses a functionally similar internal ribosome entry site (IRES) for translation, uses an NS4A cofactor with its homologous NS3 protease, has a similar NS3 helicase/NTPase, a mechanistically similar NS5B RNA-dependent RNA polymerase, and a seemingly equiv. mechanism of virion maturation, assembly and egress.  While the concordance between drugs active in either BVDV or HCV is largely unknown at this time, BVDV remains a popular model system with which drugs can be evaluated for potential antiviral activity against HCV and in studies of drug mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovmWXl_t8xT7Vg90H21EOLACvtfcHk0lh6buAVUD_OXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnsVansLg%253D&md5=aeb8d9bbbd58122b8c302266bbf409ed</span></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1016%2FS0166-3542%2803%2900174-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0166-3542%252803%252900174-8%26sid%3Dliteratum%253Aachs%26aulast%3DBuckwold%26aufirst%3DV.%2BE.%26aulast%3DBeer%26aufirst%3DB.%2BE.%26aulast%3DDonis%26aufirst%3DR.%2BO.%26atitle%3DBovine%2520viral%2520diarrhea%2520virus%2520as%2520a%2520surrogate%2520model%2520of%2520hepatitis%2520C%2520virus%2520for%2520the%2520evaluation%2520of%2520antiviral%2520agents%26jtitle%3DAntiviral%2520Res.%26date%3D2003%26volume%3D60%26spage%3D1%26epage%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Pierra, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amador, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benzaria, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cretton-Scott, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Amours, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moussa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Standring, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommadossi, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gosselin, G.</span><span> </span><span class="NLM_article-title">Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-<i>C</i>-methylcytidine</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6614</span><span class="NLM_x">–</span> <span class="NLM_lpage">6620</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0603623" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6614-6620&author=C.+Pierraauthor=A.+Amadorauthor=S.+Benzariaauthor=E.+Cretton-Scottauthor=M.+D%E2%80%99Amoursauthor=J.+Maoauthor=S.+Mathieuauthor=A.+Moussaauthor=E.+G.+Bridgesauthor=D.+N.+Standringauthor=J.-P.+Sommadossiauthor=R.+Storerauthor=G.+Gosselin&title=Synthesis+and+pharmacokinetics+of+valopicitabine+%28NM283%29%2C+an+efficient+prodrug+of+the+potent+anti-HCV+agent+2%E2%80%B2-C-methylcytidine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15d&amp;dbid=16384&amp;doi=10.1021%2Fjm0603623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603623%26sid%3Dliteratum%253Aachs%26aulast%3DPierra%26aufirst%3DC.%26aulast%3DAmador%26aufirst%3DA.%26aulast%3DBenzaria%26aufirst%3DS.%26aulast%3DCretton-Scott%26aufirst%3DE.%26aulast%3DD%25E2%2580%2599Amours%26aufirst%3DM.%26aulast%3DMao%26aufirst%3DJ.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DMoussa%26aufirst%3DA.%26aulast%3DBridges%26aufirst%3DE.%2BG.%26aulast%3DStandring%26aufirst%3DD.%2BN.%26aulast%3DSommadossi%26aufirst%3DJ.-P.%26aulast%3DStorer%26aufirst%3DR.%26aulast%3DGosselin%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520pharmacokinetics%2520of%2520valopicitabine%2520%2528NM283%2529%252C%2520an%2520efficient%2520prodrug%2520of%2520the%2520potent%2520anti-HCV%2520agent%25202%25E2%2580%25B2-C-methylcytidine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6614%26epage%3D6620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Racela, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Specific inhibition of bovine diarrhea virus replicase</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">6753</span><span class="NLM_x">–</span> <span class="NLM_lpage">6760</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15e&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1128%2FJVI.77.12.6753-6760.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15e&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=12767995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15e&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksFGhsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2003&pages=6753-6760&author=J.-H.+Sunauthor=J.+A.+Lemmauthor=D.+R.+O%E2%80%99Boyleauthor=J.+Racelaauthor=R.+Colonnoauthor=M.+Gao&title=Specific+inhibition+of+bovine+diarrhea+virus+replicase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15eR"><div class="casContent"><span class="casTitleNuber">15e</span><div class="casTitle"><span class="NLM_cas:atitle">Specific inhibition of bovine viral diarrhea virus replicase</span></div><div class="casAuthors">Sun, Jin-Hua; Lemm, Julie A.; O'Boyle, Donald R.; Racela, Jason; Colonno, Richard; Gao, Min</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6753-6760</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Compd.-1453 was identified and characterized as a specific inhibitor of bovine viral diarrhea virus (BVDV).  The concn. of compd.-1453 which results in 50% protection from virus-induced cytopathic effect is ∼2.2, μM, with a therapeutic index of 60, and it is not active against a panel of RNA and DNA viruses.  A time-of-addn. expt. suggested that compd.-1453 targets a stage of the viral life cycle after viral entry.  To det. the target of compd.-1453, resistant virus was generated.  Resistant variants grew efficiently in the presence or absence of 33,IM compd.-1453 and exhibited replication efficiency in the presence of compd.-1453 approx. 1,000-fold higher than that of the wild-type (wt.) virus.  Functional mapping and sequence anal. of resistant cDNAs revealed a single amino acid substitution (Glu to Gly) at residue 291 in the NS5B polymerase in all eight independently generated cDNA clones.  Recombinant virus contg. this single mutation retained the resistance phenotype and a replication efficiency similar to that of the original isolated resistant virus.  Since compd.-1453 did not inhibit BVDV polymerase activity in vitro (50% inhibitory concn. >300,IM), we developed a membrane-based assay that consisted of a BVDV RNA replicase complex isolated from virus-infected cells.  Compd.-1453 inhibited the activity of the wt., but not the drug-resistant, replicase in the membrane assay at concns. similar to those obsd. in the viral infection assay.  This work presents a novel inhibitor of a viral RNA-dependent RNA replicase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt-Ptgl6-5NLVg90H21EOLACvtfcHk0lh6buAVUD_OXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksFGhsr4%253D&md5=0e5da514bbc5c33c9bc8c35c50bd2062</span></div><a href="/servlet/linkout?suffix=cit15e&amp;dbid=16384&amp;doi=10.1128%2FJVI.77.12.6753-6760.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.77.12.6753-6760.2003%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DRacela%26aufirst%3DJ.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DSpecific%2520inhibition%2520of%2520bovine%2520diarrhea%2520virus%2520replicase%26jtitle%3DJ.%2520Virol.%26date%3D2003%26volume%3D77%26spage%3D6753%26epage%3D6760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1346</span><span class="NLM_x">–</span> <span class="NLM_lpage">1353</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1128%2FAAC.49.4.1346-1353.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=15793110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjt1GjsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=1346-1353&author=D.+R.+O%E2%80%99Boyleauthor=P.+T.+Nowerauthor=J.+A.+Lemmauthor=L.+Valeraauthor=J.-H.+Sunauthor=K.+Rigatauthor=R.+Colonnoauthor=M.+Gao&title=Development+of+a+cell-based+high-throughput+specificity+screen+using+a+hepatitis+C+virus-bovine+viral+diarrhea+virus+dual+replicon+assay"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay</span></div><div class="casAuthors">O'Boyle, Donald R., II; Nower, Peter T.; Lemm, Julie A.; Valera, Lourdes; Sun, Jin-Hua; Rigat, Karen; Colonno, Richard; Gao, Min</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1346-1353</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The hepatitis C virus (HCV) replicon is a unique system for the development of a high-throughput screen (HTS), since the anal. of inhibitors requires the quantification of a decrease in a steady-state level of HCV RNA.  HCV replicon replication is dependent on host cell factors, and any toxic effects may have a significant impact on HCV replicon replication.  Therefore, detg. the antiviral specificity of compds. presents a challenge for the identification of specific HCV inhibitors.  Here we report the development of an HCV/bovine viral diarrhea virus (BVDV) dual replicon assay suitable for HTS to address these issues.  The HCV reporter enzyme is the endogenous NS3 protease contained within the HCV genome, while the BVDV reporter enzyme is a luciferase enzyme engineered into the BVDV genome.  The HTS uses a mixt. of HCV and BVDV replicon cell lines placed in the same well of a 96-well plate and isolated in the same cell backgrounds (Huh-7).  The format consists of three sep. but compatible assays: the first quantitates the amt. of cytotoxicity based upon the conversion of Alamar blue dye via cellular enzymes, while the second indirectly quantitates HCV replicon replication through measurement of the amt. of NS3 protease activity present.  The final assay measures the amt. of luciferase activity present from the BVDV replicon cells, as an indicator of the specificity of the test compds.  This HCV/BVDV dual replicon assay provides a reliable format to det. the potency and specificity of HCV replicon inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX8Ni-3CK40LVg90H21EOLACvtfcHk0ljnwUXnMblvow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjt1GjsrY%253D&md5=0f9a5c1fa35bf1aa1ea4ac5b2d71b859</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FAAC.49.4.1346-1353.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.49.4.1346-1353.2005%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DRigat%26aufirst%3DK.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DDevelopment%2520of%2520a%2520cell-based%2520high-throughput%2520specificity%2520screen%2520using%2520a%2520hepatitis%2520C%2520virus-bovine%2520viral%2520diarrhea%2520virus%2520dual%2520replicon%2520assay%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D1346%26epage%3D1353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Schamberger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmeyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillisch, A.</span><span> </span><span class="NLM_article-title">Rendezvous in chemical space? Comparing the small molecule compound libraries of Bayer and Schering</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">636</span><span class="NLM_x">–</span> <span class="NLM_lpage">641</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=636-641&author=J.+Schambergerauthor=M.+Grimmauthor=A.+Steinmeyerauthor=A.+Hillisch&title=Rendezvous+in+chemical+space%3F+Comparing+the+small+molecule+compound+libraries+of+Bayer+and+Schering"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchamberger%26aufirst%3DJ.%26aulast%3DGrimm%26aufirst%3DM.%26aulast%3DSteinmeyer%26aufirst%3DA.%26aulast%3DHillisch%26aufirst%3DA.%26atitle%3DRendezvous%2520in%2520chemical%2520space%253F%2520Comparing%2520the%2520small%2520molecule%2520compound%2520libraries%2520of%2520Bayer%2520and%2520Schering%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D636%26epage%3D641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshpande, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Identification of hepatitis C virus NS5A inhibitors</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">482</span><span class="NLM_x">–</span> <span class="NLM_lpage">491</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1128%2FJVI.01360-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=19812153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A280%3ADC%252BD1Mfhslamtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=482-491&author=J.+A.+Lemmauthor=D.+R.+O%E2%80%99Boyleauthor=M.+Liuauthor=P.+T.+Nowerauthor=R.+Colonnoauthor=M.+S.+Deshpandeauthor=L.+B.+Snyderauthor=S.+W.+Martinauthor=D.+R.+St.+Laurentauthor=M.+H.+Serrano-Wuauthor=J.+L.+Romineauthor=N.+A.+Meanwellauthor=M.+Gao&title=Identification+of+hepatitis+C+virus+NS5A+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of hepatitis C virus NS5A inhibitors</span></div><div class="casAuthors">Lemm Julie A; O'Boyle Donald 2nd; Liu Mengping; Nower Peter T; Colonno Richard; Deshpande Milind S; Snyder Lawrence B; Martin Scott W; St Laurent Denis R; Serrano-Wu Michael H; Romine Jeffrey L; Meanwell Nicholas A; Gao Min</div><div class="citationInfo"><span class="NLM_cas:title">Journal of virology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">482-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Using a cell-based replicon screen, we identified a class of compounds with a thiazolidinone core structure as inhibitors of hepatitis C virus (HCV) replication.  The concentration of one such compound, BMS-824, that resulted in a 50% inhibition of HCV replicon replication was approximately 5 nM, with a therapeutic index of >10,000.  The compound showed good specificity for HCV, as it was not active against several other RNA and DNA viruses.  Replicon cells resistant to BMS-824 were isolated, and mutations were identified.  A combination of amino acid substitutions of leucine to valine at residue 31 (L31V) and glutamine to leucine at residue 54 (Q54L) in NS5A conferred resistance to this chemotype, as did a single substitution of tyrosine to histidine at amino acid 93 (Y93H) in NS5A.  To further explore the region(s) of NS5A involved in inhibitor sensitivity, genotype-specific NS5A inhibitors were used to evaluate a series of genotype 1a/1b hybrid replicons.  Our results showed that, consistent with resistance mapping, the inhibitor sensitivity domain also mapped to the N terminus of NS5A, but it could be distinguished from the key resistance sites.  In addition, we demonstrated that NS5A inhibitors, as well as an active-site inhibitor that specifically binds NS3 protease, could block the hyperphosphorylation of NS5A, which is believed to play an essential role in the viral life cycle.  Clinical proof of concept has recently been achieved with derivatives of these NS5A inhibitors, indicating that small molecules targeting a nontraditional viral protein like NS5A, without any known enzymatic activity, can also have profound antiviral effects on HCV-infected subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTeii-SeNfkQYUSrryheKE6fW6udTcc2eafnmMmKiAJwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mfhslamtg%253D%253D&md5=691db815a886509d5b225bbbd068b82c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1128%2FJVI.01360-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01360-09%26sid%3Dliteratum%253Aachs%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DDeshpande%26aufirst%3DM.%2BS.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520hepatitis%2520C%2520virus%2520NS5A%2520inhibitors%26jtitle%3DJ.%2520Virol.%26date%3D2010%26volume%3D84%26spage%3D482%26epage%3D491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alberts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantone, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">3795</span><span class="NLM_x">–</span> <span class="NLM_lpage">3802</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1128%2FAAC.00146-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=21576451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslGgs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=3795-3802&author=J.+A.+Lemmauthor=J.+E.+Leetauthor=D.+R.+O%E2%80%99Boyleauthor=J.+L.+Romineauthor=X.+S.+Huangauthor=D.+R.+Schroederauthor=J.+Albertsauthor=J.+L.+Cantoneauthor=J.-H.+Sunauthor=P.+T.+Nowerauthor=S.+W.+Martinauthor=M.+H.+Serrano-Wuauthor=N.+A.+Meanwellauthor=L.+B.+Snyderauthor=M.+Gao&title=Discovery+of+potent+hepatitis+C+virus+NS5A+inhibitors+with+dimeric+structures"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures</span></div><div class="casAuthors">Lemm, Julie A.; Leet, John E.; O'Boyle, Donald R., II; Romine, Jeffrey L.; Huang, Xiaohua Stella; Schroeder, Daniel R.; Alberts, Jeffrey; Cantone, Joseph L.; Sun, Jin-Hua; Nower, Peter T.; Martin, Scott W.; Serrano-Wu, Michael H.; Meanwell, Nicholas A.; Snyder, Lawrence B.; Gao, Min</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3795-3802</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The exceptional in vitro potency of the hepatitis C virus (HCV) NS5A inhibitor BMS-790052 has translated into an in vivo effect in proof-of-concept clin. trials.  Although the 50% effective concn. (EC50) of the initial lead, the thiazolidinone BMS-824, was ∼10 nM in the replicon assay, it underwent transformation to other inhibitory species after incubation in cell culture medium.  The biol. profile of BMS-824, including the EC50, the drug concn. required to reduce cell growth by 50% (CC50), and the resistance profile, however, remained unchanged, triggering an investigation to identify the biol. active species.  High-performance liq. chromatog. (HPLC) biogram fractionation of a sample of BMS-824 incubated in medium revealed that the most active fractions could readily be sepd. from the parental compd. and retained the biol. profile of BMS-824.  From mass spectral and NMR data, the active species was detd. to be a dimer of BMS-824 derived from an intermol. radical-mediated reaction of the parent compd.  Based upon an anal. of the structural elements of the dimer deemed necessary for anti-HCV activity, the stilbene deriv. BMS-346 was synthesized.  This compd. exhibited excellent anti-HCV activity and showed a resistance profile similar to that of BMS-824, with changes in compd. sensitivity mapped to the N terminus of NS5A.  The N terminus of NS5A has been crystd. as a dimer, complementing the symmetry of BMS-346 and allowing a potential mode of inhibition of NS5A to be discussed.  Identification of the stable, active pharmacophore assocd. with these NS5A inhibitors provided the foundation for the design of more potent inhibitors with broad genotype inhibition.  This culminated in the identification of BMS-790052, a compd. that preserves the symmetry discovered with BMS-346.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5YeVXSMPBNLVg90H21EOLACvtfcHk0ljnwUXnMblvow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslGgs74%253D&md5=8a0fea78b0d42bf7285e6916c40fbc91</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1128%2FAAC.00146-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00146-11%26sid%3Dliteratum%253Aachs%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DLeet%26aufirst%3DJ.%2BE.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DHuang%26aufirst%3DX.%2BS.%26aulast%3DSchroeder%26aufirst%3DD.%2BR.%26aulast%3DAlberts%26aufirst%3DJ.%26aulast%3DCantone%26aufirst%3DJ.%2BL.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520potent%2520hepatitis%2520C%2520virus%2520NS5A%2520inhibitors%2520with%2520dimeric%2520structures%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D3795%26epage%3D3802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Macdonald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, M.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A: tales of a promiscuous protein</span> <span class="citation_source-journal">J. Gen. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">2485</span><span class="NLM_x">–</span> <span class="NLM_lpage">2502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1099%2Fvir.0.80204-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=15302943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsVegsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2004&pages=2485-2502&author=A.+Macdonaldauthor=M.+Harris&title=Hepatitis+C+virus+NS5A%3A+tales+of+a+promiscuous+protein"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus NS5A: Tales of a promiscuous protein</span></div><div class="casAuthors">MacDonald, Andrew; Harris, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2485-2502</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    
            (<span class="NLM_cas:orgname">Society for General Microbiology</span>)
        </div><div class="casAbstract">A review.  The non-structural 5A (NS5A) protein of hepatitis C virus (HCV) has been the subject of intensive research over the last decade.  It is generally accepted that NS5A is a pleiotropic protein with key roles in both viral RNA replication and modulation of the physiol. of the host cell.  Our understanding of the role of NS5A in the virus life cycle has been hampered by the lack of a robust in vitro system for the study of HCV replication, although the recent development of the subgenomic replicon has at least allowed us to begin to dissect the involvement of NS5A in the process of viral RNA replication.  Early studies into the effects of NS5A on cell physiol. relied on expression of NS5A either alone or in the context of other non-structural proteins; the advent of the replicon system has allowed the extrapolation of these studies to a more physiol. relevant cellular context.  Despite recent progress, this field is controversial, and there is much work to be accomplished before we fully understand the many functions of this protein.  In this article, the current state of our knowledge of NS5A, discussing in detail its direct involvement in virus replication, together with its role in modulating the cellular environment to favor virus replication and persistence, are reviewed.  The effects of NS5A on interferon signaling, and the regulation of cell growth and apoptosis are highlighted, demonstrating that this protein is indeed of crit. importance for HCV and is worthy of further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqk1qXYUj29LVg90H21EOLACvtfcHk0lhar2AdD5ONlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsVegsr4%253D&md5=784583dfdcae57864433db2941acd985</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1099%2Fvir.0.80204-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fvir.0.80204-0%26sid%3Dliteratum%253Aachs%26aulast%3DMacdonald%26aufirst%3DA.%26aulast%3DHarris%26aufirst%3DM.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%253A%2520tales%2520of%2520a%2520promiscuous%2520protein%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2004%26volume%3D85%26spage%3D2485%26epage%3D2502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Szabo, G.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A protein—a master regulator?</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">996</span><span class="NLM_x">–</span> <span class="NLM_lpage">999</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2006&pages=996-999&author=G.+Szabo&title=Hepatitis+C+virus+NS5A+protein%E2%80%94a+master+regulator%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSzabo%26aufirst%3DG.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%2520protein%25E2%2580%2594a%2520master%2520regulator%253F%26jtitle%3DGastroenterology%26date%3D2006%26volume%3D130%26spage%3D996%26epage%3D999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Najarro, P.; Mathews, N.; Cockerill, S.</span><span> </span><span class="NLM_article-title">NS5A inhibitors</span>. In  <span class="citation_source-book">Hepatitis C Viruses</span>; <span class="NLM_contrib-group">Tan, S.-L.</span>, Ed., <span class="NLM_publisher-name">Horizon Bioscience</span>: <span class="NLM_publisher-loc">Wymondham, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">292</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=271-292&author=P.+Najarro&author=N.+Mathews&author=S.+Cockerillauthor=S.-L.+Tan&title=Hepatitis+C+Viruses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DNajarro%26aufirst%3DP.%26atitle%3DNS5A%2520inhibitors%26btitle%3DHepatitis%2520C%2520Viruses%26aulast%3DTan%26aufirst%3DS.-L.%26pub%3DHorizon%2520Bioscience%26date%3D2006%26spage%3D271%26epage%3D292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Schmitz, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, S.-L.</span><span> </span><span class="NLM_article-title">NS5A—from obscurity to new target for HCV therapy</span> <span class="citation_source-journal">Recent Pat. Anti-Infect. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20d&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.2174%2F157489108784746597" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20d&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXos1Kjs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=77-92&author=U.+Schmitzauthor=S.-L.+Tan&title=NS5A%E2%80%94from+obscurity+to+new+target+for+HCV+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20dR"><div class="casContent"><span class="casTitleNuber">20d</span><div class="casTitle"><span class="NLM_cas:atitle">NS5A - from obscurity to new target for HCV therapy</span></div><div class="casAuthors">Schmitz, Uli; Tan, Seng-Lai</div><div class="citationInfo"><span class="NLM_cas:title">Recent Patents on Anti-Infective Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">77-92</span>CODEN:
                <span class="NLM_cas:coden">RPADCX</span>;
        ISSN:<span class="NLM_cas:issn">1574-891X</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The hepatitis C virus (HCV) non-structural 5A (NS5A) protein is essential for viral RNA replication and may play a role in subverting host intracellular signaling pathways.  Although no intrinsic enzymic activity has been ascribed to NS5A, this proline-rich hydrophilic phosphoprotein is likely to exert its functions by interacting with viral and cellular factors.  Recent studies using the HCV replicon cell culture system as a model for HCV RNA replication as well as for high-throughput screening of pharmacol. inhibitors have revealed blockade of NS5A as a promising therapeutic strategy for the treatment of HCV.  This review will summarize our progress in understanding the role of NS5A in HCV RNA replication and will introduce the most recent patents on inhibitors of NS5A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEYaqZrcncjbVg90H21EOLACvtfcHk0lhar2AdD5ONlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXos1Kjs70%253D&md5=29d24e11907fe2c10f5649426b864a87</span></div><a href="/servlet/linkout?suffix=cit20d&amp;dbid=16384&amp;doi=10.2174%2F157489108784746597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157489108784746597%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitz%26aufirst%3DU.%26aulast%3DTan%26aufirst%3DS.-L.%26atitle%3DNS5A%25E2%2580%2594from%2520obscurity%2520to%2520new%2520target%2520for%2520HCV%2520therapy%26jtitle%3DRecent%2520Pat.%2520Anti-Infect.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D77%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Cordek, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bechtel, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maynard, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazmierski, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, C. E.</span><span> </span><span class="NLM_article-title">Targeting the NS5A protein of HCV: an emerging option</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">711</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20e&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1358%2Fdof.2011.036.09.1641618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20e&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=23378700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20e&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1eis7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=691-711&author=D.+G.+Cordekauthor=J.+T.+Bechtelauthor=A.+T.+Maynardauthor=W.+M.+Kazmierskiauthor=C.+E.+Cameron&title=Targeting+the+NS5A+protein+of+HCV%3A+an+emerging+option"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20eR"><div class="casContent"><span class="casTitleNuber">20e</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the protein NS5A protein of HCV: an emerging option</span></div><div class="casAuthors">Cordek, D. G.; Bechtel, J. T.; Maynard, A. T.; Kazmierski, W. M.; Cameron, C. E.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">691-711</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) infects more than 3% of the world's population, leading to an increased risk of cirrhosis and hepatocellular carcinoma.  The current std. of care, a combination of pegylated interferon alfa and ribavirin, is poorly tolerated and often ineffective against the most prevalent genotype of the virus, genotype 7.  The very recent approval of boceprevir and telaprevir, two HCV protease inhibitors, promises to significantly improve treatment options and outcomes.  In addn. to the viral protease NS3 and the viral polymerase NS5B, direct-acting antivirals are now in development against NS5A.  A multifunctional phosphoprotein, NS5A is essential to HCV genome replication, but has no known enzymic function.  Here we report how the design of small-mol. inhibitors against NS5A has evolved from promising monomers to highly potent dimeric compds. effective against many HCV genotypes.  We also highlight recent clin. data and how the inhibitors may bind to NS5A, itself capable of forming dimers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2lefIUXhmK7Vg90H21EOLACvtfcHk0lhar2AdD5ONlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1eis7nE&md5=7e779d99491df4f8631c7848cb9e56dc</span></div><a href="/servlet/linkout?suffix=cit20e&amp;dbid=16384&amp;doi=10.1358%2Fdof.2011.036.09.1641618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2011.036.09.1641618%26sid%3Dliteratum%253Aachs%26aulast%3DCordek%26aufirst%3DD.%2BG.%26aulast%3DBechtel%26aufirst%3DJ.%2BT.%26aulast%3DMaynard%26aufirst%3DA.%2BT.%26aulast%3DKazmierski%26aufirst%3DW.%2BM.%26aulast%3DCameron%26aufirst%3DC.%2BE.%26atitle%3DTargeting%2520the%2520NS5A%2520protein%2520of%2520HCV%253A%2520an%2520emerging%2520option%26jtitle%3DDrugs%2520Future%26date%3D2011%26volume%3D36%26spage%3D691%26epage%3D711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Hamatake, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maynard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazmierski, W. M.</span><span> </span><span class="NLM_article-title">HCV inhibition mediated through the non-structural protein 5A (NS5A) replication complex</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">345</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2012&pages=331-345&author=R.+Hamatakeauthor=A.+Maynardauthor=W.+M.+Kazmierski&title=HCV+inhibition+mediated+through+the+non-structural+protein+5A+%28NS5A%29+replication+complex"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHamatake%26aufirst%3DR.%26aulast%3DMaynard%26aufirst%3DA.%26aulast%3DKazmierski%26aufirst%3DW.%2BM.%26atitle%3DHCV%2520inhibition%2520mediated%2520through%2520the%2520non-structural%2520protein%25205A%2520%2528NS5A%2529%2520replication%2520complex%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2012%26volume%3D47%26spage%3D331%26epage%3D345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">The discovery and development of hepatitis C virus NS5A replication complex inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1643</span><span class="NLM_x">–</span> <span class="NLM_lpage">1672</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm401793m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1643-1672&author=M.+Belemaauthor=O.+D.+Lopezauthor=J.+A.+Benderauthor=J.+L.+Romineauthor=D.+R.+Laurentauthor=D.+R.+Langleyauthor=J.+A.+Lemmauthor=D.+R.+O%E2%80%99Boyleauthor=J.-H.+Sunauthor=C.+Wangauthor=R.+A.+Fridellauthor=N.+A.+Meanwell&title=The+discovery+and+development+of+hepatitis+C+virus+NS5A+replication+complex+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20g&amp;dbid=16384&amp;doi=10.1021%2Fjm401793m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401793m%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DBender%26aufirst%3DJ.%2BA.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DLaurent%26aufirst%3DD.%2BR.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DThe%2520discovery%2520and%2520development%2520of%2520hepatitis%2520C%2520virus%2520NS5A%2520replication%2520complex%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1643%26epage%3D1672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshpande, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">Inhibitors of HCV NS5A: from iminothiazolidinones to symmetrical stilbenes</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">224</span><span class="NLM_x">–</span> <span class="NLM_lpage">229</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml1002647" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFCmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=224-229&author=J.+L.+Romineauthor=D.+R.+St.+Laurentauthor=J.+E.+Leetauthor=S.+W.+Martinauthor=M.+H.+Serrano-Wuauthor=F.+Yangauthor=M.+Gaoauthor=D.+R.+O%E2%80%99Boyleauthor=J.+A.+Lemmauthor=J.-H.+Sunauthor=P.+T.+Nowerauthor=X.+Huangauthor=M.+S.+Deshpandeauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=Inhibitors+of+HCV+NS5A%3A+from+iminothiazolidinones+to+symmetrical+stilbenes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes</span></div><div class="casAuthors">Romine, Jeffrey L.; St. Laurent, Denis R.; Leet, John E.; Martin, Scott W.; Serrano-Wu, Michael H.; Yang, Fukang; Gao, Min; O'Boyle, Donald R.; Lemm, Julie A.; Sun, Jin-Hua; Nower, Peter T.; Huang, Xiaohua; Deshpande, Milind S.; Meanwell, Nicholas A.; Snyder, Lawrence B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">224-229</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The iminothiazolidinone BMS-858 (2) was identified as a specific inhibitor of HCV replication in a genotype 1b replicon assay via a high-throughput screening campaign.  A more potent analog, BMS-824 (18), was used in resistance mapping studies, which revealed that inhibitory activity was related to disrupting the function of the HCV nonstructural protein 5A.  Despite the development of coherent and interpretable SAR, it was subsequently discovered that in DMSO 18 underwent an oxidn. and structural rearrangement to afford the thiohydantoin 47, a compd. with reduced HCV inhibitory activity.  However, HPLC bioassay fractionation studies performed after incubation of 18 in assay media led to the identification of fractions contg. a dimeric species 48 that exhibited potent antiviral activity.  Excision of the key elements hypothesized to be responsible for antiviral activity based on SAR observations reduced 48 to a simplified, sym., pharmacophore realized most effectively with the stilbene 55, a compd. that demonstrated potent inhibition of HCV in a genotype 1b replicon with an EC50 = 86 pM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj8qij0fE1q7Vg90H21EOLACvtfcHk0ljp4RYsLQkzAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFCmsg%253D%253D&md5=466b1f5dc09b9e2ecc6b581069506169</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fml1002647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1002647%26sid%3Dliteratum%253Aachs%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DLeet%26aufirst%3DJ.%2BE.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DDeshpande%26aufirst%3DM.%2BS.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DInhibitors%2520of%2520HCV%2520NS5A%253A%2520from%2520iminothiazolidinones%2520to%2520symmetrical%2520stilbenes%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D224%26epage%3D229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tellinghuisen, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotrigiano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span> </span><span class="NLM_article-title">Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">435</span><span class="NLM_x">, </span> <span class="NLM_fpage">374</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=435&publication_year=2005&pages=374-379&author=T.+L.+Tellinghuisenauthor=J.+Marcotrigianoauthor=C.+M.+Rice&title=Structure+of+the+zinc-binding+domain+of+an+essential+component+of+the+hepatitis+C+virus+replicase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTellinghuisen%26aufirst%3DT.%2BL.%26aulast%3DMarcotrigiano%26aufirst%3DJ.%26aulast%3DRice%26aufirst%3DC.%2BM.%26atitle%3DStructure%2520of%2520the%2520zinc-binding%2520domain%2520of%2520an%2520essential%2520component%2520of%2520the%2520hepatitis%2520C%2520virus%2520replicase%26jtitle%3DNature%26date%3D2005%26volume%3D435%26spage%3D374%26epage%3D379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Love, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodsky, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, C. N.</span><span> </span><span class="NLM_article-title">Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">4395</span><span class="NLM_x">–</span> <span class="NLM_lpage">4403</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1128%2FJVI.02352-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=19244328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlt1Kqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2009&pages=4395-4403&author=R.+A.+Loveauthor=O.+Brodskyauthor=M.+J.+Hickeyauthor=P.+A.+Wellsauthor=C.+N.+Cronin&title=Crystal+structure+of+a+novel+dimeric+form+of+NS5A+domain+I+protein+from+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus</span></div><div class="casAuthors">Love, Robert A.; Brodsky, Oleg; Hickey, Michael J.; Wells, Peter A.; Cronin, Ciaran N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4395-4403</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A new protein expression vector design utilizing an N-terminal six-histidine tag and tobacco etch virus protease cleavage site upstream of the hepatitis C virus NS5A sequence has resulted in a more straightforward purifn. method and improved yields of purified NS5A domain I protein.  High-resoln. diffracting crystals of NS5A domain I (amino acids 33 to 202) [NS5A(33-202)] were obtained by using detergent additive crystn. screens, leading to the structure of a homodimer which is organized differently from that published previously, yet is consistent with a membrane assocn. model for NS5A.  The monomer-monomer interface of NS5A(33-202) features an extensive buried surface area involving the most-highly conserved face of each monomer.  The two alternate structural forms of domain I now available may be indicative of the multiple roles emerging for NS5A in viral RNA replication and viral particle assembly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNYc2eJlR_hLVg90H21EOLACvtfcHk0ljp4RYsLQkzAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlt1Kqu7s%253D&md5=70ea61461a99afb962e76a4c3f5495db</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1128%2FJVI.02352-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02352-08%26sid%3Dliteratum%253Aachs%26aulast%3DLove%26aufirst%3DR.%2BA.%26aulast%3DBrodsky%26aufirst%3DO.%26aulast%3DHickey%26aufirst%3DM.%2BJ.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DCronin%26aufirst%3DC.%2BN.%26atitle%3DCrystal%2520structure%2520of%2520a%2520novel%2520dimeric%2520form%2520of%2520NS5A%2520domain%2520I%2520protein%2520from%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Virol.%26date%3D2009%26volume%3D83%26spage%3D4395%26epage%3D4403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lambert, S. M.; Langley, D. R.; Garnett, J. A.; Hedgethorne, K.; Meanwell, N. A.; Matthews, S. J.</span><span> </span><span class="NLM_article-title">The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors</span>.  <span class="citation_source-journal">Protein Sci.</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1002/pro.2456</span> . Published Online: Apr 5,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1002%2Fpro.2456" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=S.+M.+Lambert&author=D.+R.+Langley&author=J.+A.+Garnett&author=K.+Hedgethorne&author=N.+A.+Meanwell&author=S.+J.+Matthews&title=The+crystal+structure+of+NS5A+domain+1+from+genotype+1a+reveals+new+clues+to+the+mechanism+of+action+for+dimeric+HCV+inhibitors&doi=10.1002%2Fpro.2456"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22c&amp;dbid=16384&amp;doi=10.1002%2Fpro.2456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.2456%26sid%3Dliteratum%253Aachs%26aulast%3DLambert%26aufirst%3DS.%2BM.%26atitle%3DThe%2520crystal%2520structure%2520of%2520NS5A%2520domain%25201%2520from%2520genotype%25201a%2520reveals%2520new%2520clues%2520to%2520the%2520mechanism%2520of%2520action%2520for%2520dimeric%2520HCV%2520inhibitors%26jtitle%3DProtein%2520Sci.%26doi%3D10.1002%2Fpro.2456%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Benigni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruska, A.</span><span> </span><span class="NLM_article-title">Quantitative structure–activity relationships of mutagenic and carcinogenic aromatic amines</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">3697</span><span class="NLM_x">–</span> <span class="NLM_lpage">3714</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr9901079" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2000&pages=3697-3714&author=R.+Benigniauthor=A.+Giulianiauthor=R.+Frankeauthor=A.+Gruska&title=Quantitative+structure%E2%80%93activity+relationships+of+mutagenic+and+carcinogenic+aromatic+amines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=10.1021%2Fcr9901079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr9901079%26sid%3Dliteratum%253Aachs%26aulast%3DBenigni%26aufirst%3DR.%26aulast%3DGiuliani%26aufirst%3DA.%26aulast%3DFranke%26aufirst%3DR.%26aulast%3DGruska%26aufirst%3DA.%26atitle%3DQuantitative%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520mutagenic%2520and%2520carcinogenic%2520aromatic%2520amines%26jtitle%3DChem.%2520Rev.%26date%3D2000%26volume%3D100%26spage%3D3697%26epage%3D3714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kugler-Steigmeier, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friederich, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graf, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlatter, C.</span><span> </span><span class="NLM_article-title">Genotoxicity of aniline derivatives in various short-term tests</span> <span class="citation_source-journal">Mutat. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">211</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">289</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2F0027-5107%2889%2990011-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=2494442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADyaL1MXitVOmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=211&publication_year=1989&pages=279-289&author=M.+E.+Kugler-Steigmeierauthor=U.+Friederichauthor=U.+Grafauthor=W.+K.+Lutzauthor=P.+Maierauthor=C.+Schlatter&title=Genotoxicity+of+aniline+derivatives+in+various+short-term+tests"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">Genotoxicity of aniline derivatives in various short-term tests</span></div><div class="casAuthors">Kugler-Steigmeier, M. E.; Friederich, U.; Graf, U.; Lutz, W. K.; Maier, P.; Schlatter, C.</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research, Fundamental and Molecular Mechanisms of Mutagenesis</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">211</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">279-89</span>CODEN:
                <span class="NLM_cas:coden">MUREAV</span>;
        ISSN:<span class="NLM_cas:issn">0027-5107</span>.
    </div><div class="casAbstract">Various substituted aniline derivs. were tested for genotoxicity in several short-term tests to examine the hypothesis that a substitution at both ortho positions (2,6-disubstitution) could prevent genotoxicity due to steric hindrance of an enzymic activation to electrophilic intermediates.  In the Salmonella/microsome assay, 2,6-dialkylsubstituted anilines and 2,4,6-trimethylaniline (2,4,6-TMA) were weakly mutagenic in strain TA100 when 20% S9 mix was used, although effects were small compared to those of 2,4-dimethylaniline and 2,4,5-trimethylaniline (2,4,5-TMA).  In Drosophila melanogaster, however, 2,4,6-TMA and 2,4,6-trichloroaniline were mutagenic in the wing spot test at 2-3 times lower doses than 2,4,5-TMA.  In the 6-thioguanine resistance test in cultured fibroblasts, 2,4,6-TMA was again mutagenic at lower doses than 2,4,5-TMA.  Two methylene-bis-aniline derivs. were also tested with the above methods: 4,4'-methylene-bis-[(2-chloroaniline)] (MOCA) was moderately genotoxic in all 3 tests systems whereas 4,4'-methylene-bis-[(2-ethyl-6-methylaniline)] (MMEA) showed no genotoxicity at all.  DNA binding studies in rats, however, revealed that MOCA and MMEA produced DNA adducts in the liver at levels typically found for moderately strong genotoxic carcinogens.  Thus, the predictive value of the in vitro test systems and particularly the Salmonella/microsome assay is inadequate to detect genotoxicity in arom. amines.  Genotoxicity seems to be a general property of aniline derivs. and does not seem to be greatly influenced by substitution at both ortho positions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7X8K383lt8bVg90H21EOLACvtfcHk0lg2y6UfTVO-8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXitVOmtbg%253D&md5=f362df1cf93da42f697b7ca4d19ff59f</span></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1016%2F0027-5107%2889%2990011-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0027-5107%252889%252990011-0%26sid%3Dliteratum%253Aachs%26aulast%3DKugler-Steigmeier%26aufirst%3DM.%2BE.%26aulast%3DFriederich%26aufirst%3DU.%26aulast%3DGraf%26aufirst%3DU.%26aulast%3DLutz%26aufirst%3DW.%2BK.%26aulast%3DMaier%26aufirst%3DP.%26aulast%3DSchlatter%26aufirst%3DC.%26atitle%3DGenotoxicity%2520of%2520aniline%2520derivatives%2520in%2520various%2520short-term%2520tests%26jtitle%3DMutat.%2520Res.%26date%3D1989%26volume%3D211%26spage%3D279%26epage%3D289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Shamovsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ripa, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Börjesson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordén, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasselgren, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjö, P.</span><span> </span><span class="NLM_article-title">Explanation for main features of structure–genotoxicity relationships of aromatic amines by theoretical studies of their activation pathways in CYP1A2</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">16168</span><span class="NLM_x">–</span> <span class="NLM_lpage">16185</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja206427u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=16168-16185&author=I.+Shamovskyauthor=L.+Ripaauthor=L.+B%C3%B6rjessonauthor=C.+Meeauthor=B.+Nord%C3%A9nauthor=P.+Hansenauthor=C.+Hasselgrenauthor=M.+O%E2%80%99Donovanauthor=P.+Sj%C3%B6&title=Explanation+for+main+features+of+structure%E2%80%93genotoxicity+relationships+of+aromatic+amines+by+theoretical+studies+of+their+activation+pathways+in+CYP1A2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23c&amp;dbid=16384&amp;doi=10.1021%2Fja206427u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja206427u%26sid%3Dliteratum%253Aachs%26aulast%3DShamovsky%26aufirst%3DI.%26aulast%3DRipa%26aufirst%3DL.%26aulast%3DB%25C3%25B6rjesson%26aufirst%3DL.%26aulast%3DMee%26aufirst%3DC.%26aulast%3DNord%25C3%25A9n%26aufirst%3DB.%26aulast%3DHansen%26aufirst%3DP.%26aulast%3DHasselgren%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%26aulast%3DSj%25C3%25B6%26aufirst%3DP.%26atitle%3DExplanation%2520for%2520main%2520features%2520of%2520structure%25E2%2580%2593genotoxicity%2520relationships%2520of%2520aromatic%2520amines%2520by%2520theoretical%2520studies%2520of%2520their%2520activation%2520pathways%2520in%2520CYP1A2%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26spage%3D16168%26epage%3D16185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Garcia, G. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pye, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galbreath, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isovitsch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fradinger, E. A.</span><span> </span><span class="NLM_article-title">The functional group on (<i>E</i>)-4,4′-disubstituted stilbenes influences toxicity and antioxidative activity in differentiated PC-12 cells</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">6355</span><span class="NLM_x">–</span> <span class="NLM_lpage">6359</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=6355-6359&author=G.+X.+Garciaauthor=S.+W.+Larsenauthor=C.+Pyeauthor=M.+Galbreathauthor=R.+Isovitschauthor=E.+A.+Fradinger&title=The+functional+group+on+%28E%29-4%2C4%E2%80%B2-disubstituted+stilbenes+influences+toxicity+and+antioxidative+activity+in+differentiated+PC-12+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%26aufirst%3DG.%2BX.%26aulast%3DLarsen%26aufirst%3DS.%2BW.%26aulast%3DPye%26aufirst%3DC.%26aulast%3DGalbreath%26aufirst%3DM.%26aulast%3DIsovitsch%26aufirst%3DR.%26aulast%3DFradinger%26aufirst%3DE.%2BA.%26atitle%3DThe%2520functional%2520group%2520on%2520%2528E%2529-4%252C4%25E2%2580%25B2-disubstituted%2520stilbenes%2520influences%2520toxicity%2520and%2520antioxidative%2520activity%2520in%2520differentiated%2520PC-12%2520cells%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D6355%26epage%3D6359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Cunningham, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, E.</span><span> </span><span class="NLM_article-title">Hydrolysis of oleylanilide in the rat</span> <span class="citation_source-journal">Arch. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23e&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1007%2FBF01261384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23e&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=6651528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23e&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADyaL3sXmtFWhu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1983&pages=157-162&author=V.+J.+Cunninghamauthor=S.+P.+Tuckerauthor=E.+Bailey&title=Hydrolysis+of+oleylanilide+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23eR"><div class="casContent"><span class="casTitleNuber">23e</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrolysis of oleylanilide in the rat</span></div><div class="casAuthors">Cunningham, V. J.; Tucker, S. P.; Bailey, E.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Toxicology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-62</span>CODEN:
                <span class="NLM_cas:coden">ARTODN</span>;
        ISSN:<span class="NLM_cas:issn">0340-5761</span>.
    </div><div class="casAbstract">The fate of oleylanilide  [637-54-7], administered as a single intragastric dose in rape oil, was studied in rats.  Following a dose of oleyl[U-14C]anilide, ∼60% of the label was recovered in the feces over a 3-day period, and identified principally as unchanged anilide.  Most of the remainder of the dose was recovered in urine as hydrophilic metabolites.  p-Hydroxyacetanilide  [103-90-2], which is a major metabolite of aniline in the rat, was identified in the hydrolyzed samples of urine from anilide-treated rats.  Following administration of [9,10(n)-3H]oleyl[U-14C]-anilide to rats which had been fitted with a cannula in the thoracic lymph duct, the [3H]label which was absorbed was recovered principally in triglycerides showing that extensive hydrolysis of the anilide occurs prior to or during uptake from the gut.  Oleylanilide was identified in lymph by gas chromatog. but amounted to <6% of the dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpPELq46rYJ7Vg90H21EOLACvtfcHk0lg2y6UfTVO-8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXmtFWhu70%253D&md5=6140abfffc8bda65bb72fada61ce3e1a</span></div><a href="/servlet/linkout?suffix=cit23e&amp;dbid=16384&amp;doi=10.1007%2FBF01261384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01261384%26sid%3Dliteratum%253Aachs%26aulast%3DCunningham%26aufirst%3DV.%2BJ.%26aulast%3DTucker%26aufirst%3DS.%2BP.%26aulast%3DBailey%26aufirst%3DE.%26atitle%3DHydrolysis%2520of%2520oleylanilide%2520in%2520the%2520rat%26jtitle%3DArch.%2520Toxicol.%26date%3D1983%26volume%3D54%26spage%3D157%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mondelli, M. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silini, E.</span><span> </span><span class="NLM_article-title">Clinical signficance of hepatitis C virus genotypes</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2FS0168-8278%2899%2980377-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252Fos1aktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1999&pages=65-70&issue=Suppl.+1&author=M.+U.+Mondelliauthor=E.+Silini&title=Clinical+signficance+of+hepatitis+C+virus+genotypes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24aR"><div class="casContent"><span class="casTitleNuber">24a</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical significance of hepatitis C virus genotypes</span></div><div class="casAuthors">Mondelli M U; Silini E</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hepatology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">31 Suppl 1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">65-70</span>
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    </div><div class="casAbstract">The advent of genotyping assays has stimulated investigators around the world to study the molecular epidemiology of hepatitis C virus (HCV) infection in specific patient categories, as well as possible correlations with the clinical and histological features of chronic liver disease and response to antiviral treatment.  While a general consensus has been reached on the worldwide epidemiology and distribution of HCV types in certain risk categories (i.e. intravenous drug users), the association between genotype 1b and severe liver disease is still controversial.  Although generalized use of genotyping is not presently recommended for clinical or epidemiological monitoring, several studies emphasize to the importance of HCV genotyping as part of a therapeutic algorithm.  This recommendation is based on overwhelming evidence in support of a correlation between genotype 1 and a poor response to interferon-a alone or in combination with ribavirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTHH6NTPVN1lPx2phytoz6_fW6udTcc2eagLVKA6t7OALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252Fos1aktw%253D%253D&md5=4e3961532bb293dd940f40339fad01a0</span></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1016%2FS0168-8278%2899%2980377-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0168-8278%252899%252980377-8%26sid%3Dliteratum%253Aachs%26aulast%3DMondelli%26aufirst%3DM.%2BU.%26aulast%3DSilini%26aufirst%3DE.%26atitle%3DClinical%2520signficance%2520of%2520hepatitis%2520C%2520virus%2520genotypes%26jtitle%3DJ.%2520Hepatol.%26date%3D1999%26volume%3D31%26issue%3DSuppl.%25201%26spage%3D65%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zein, N. N.</span><span> </span><span class="NLM_article-title">Clinical significance of hepatitis C virus genotypes</span> <span class="citation_source-journal">Clin. Microbiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">235</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1128%2FCMR.13.2.223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=10755999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtVOqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2000&pages=223-235&author=N.+N.+Zein&title=Clinical+significance+of+hepatitis+C+virus+genotypes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical significance of hepatitis C virus genotypes</span></div><div class="casAuthors">Zein, Nizar N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-235</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">0893-8512</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review with 149 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIyz_GrutS8LVg90H21EOLACvtfcHk0ljyIndBvVYc_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtVOqs7k%253D&md5=c3dbf9e23541db288f77cfabdf5c2e45</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1128%2FCMR.13.2.223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.13.2.223%26sid%3Dliteratum%253Aachs%26aulast%3DZein%26aufirst%3DN.%2BN.%26atitle%3DClinical%2520significance%2520of%2520hepatitis%2520C%2520virus%2520genotypes%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2000%26volume%3D13%26spage%3D223%26epage%3D235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Simmonds, P.</span><span> </span><span class="NLM_article-title">Genetic diversity and evolution of hepatitis C virus—15 years on</span> <span class="citation_source-journal">J. Gen. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">3173</span><span class="NLM_x">–</span> <span class="NLM_lpage">3188</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1099%2Fvir.0.80401-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=15483230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVSmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2004&pages=3173-3188&author=P.+Simmonds&title=Genetic+diversity+and+evolution+of+hepatitis+C+virus%E2%80%9415+years+on"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24cR"><div class="casContent"><span class="casTitleNuber">24c</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic diversity and evolution of hepatitis C virus - 15 years on</span></div><div class="casAuthors">Simmonds, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3173-3188</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    
            (<span class="NLM_cas:orgname">Society for General Microbiology</span>)
        </div><div class="casAbstract">A review.  In the 15 years since the discovery of hepatitis C virus (HCV), much has been learned about its role as a major causative agent of human liver disease and its ability to persist in the face of host-cell defenses and the immune system.  This review describes what is known about the diversity of HCV, the current classification of HCV genotypes within the family Flaviviridae and how this genetic diversity contributes to its pathogenesis.  On one hand, diversification of HCV was constrained by its intimate adaptation to its host.  Despite the >30% nucleotide sequence divergence between genotypes, HCV variants nevertheless remain remarkably similar in their transmission dynamics, persistence and disease development.  Nowhere is this more evident than in the evolutionary conservation of numerous evasion methods to counteract the cell's innate antiviral defense pathways; this series of highly complex virus-host interactions may represent key components in establishing its ecol. niche in the human liver.  On the other hand, the mutability and large population size of HCV enables it to respond very rapidly to new selection pressures, manifested by immune-driven changes in T- and B-cell epitopes that are encountered on transmission between individuals with different antigen-recognition repertoires.  If human immunodeficiency virus type 1 is a precedent, future therapies that target virus protease or polymerase enzymes may also select very rapidly for antiviral-resistant mutants.  These contrasting aspects of conservatism and adaptability provide a fascinating paradigm in which to explore the complex selection pressures that underlie the evolution of HCV and other persistent viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotwOpXQZprmrVg90H21EOLACvtfcHk0ljyIndBvVYc_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVSmsr0%253D&md5=a07b3411b6b18b5e7ab3cf9bc3b89026</span></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=10.1099%2Fvir.0.80401-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fvir.0.80401-0%26sid%3Dliteratum%253Aachs%26aulast%3DSimmonds%26aufirst%3DP.%26atitle%3DGenetic%2520diversity%2520and%2520evolution%2520of%2520hepatitis%2520C%2520virus%25E2%2580%259415%2520years%2520on%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2004%26volume%3D85%26spage%3D3173%26epage%3D3188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Nainan, O. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alter, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruszon-Moran, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, F.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQuillan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margolis, H. S.</span><span> </span><span class="NLM_article-title">Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">478</span><span class="NLM_x">–</span> <span class="NLM_lpage">484</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2006&pages=478-484&author=O.+V.+Nainanauthor=M.+J.+Alterauthor=D.+Kruszon-Moranauthor=F.-X.+Gaoauthor=G.+Xiaauthor=G.+McQuillanauthor=H.+S.+Margolis&title=Hepatitis+C+virus+genotypes+and+viral+concentrations+in+participants+of+a+general+population+survey+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNainan%26aufirst%3DO.%2BV.%26aulast%3DAlter%26aufirst%3DM.%2BJ.%26aulast%3DKruszon-Moran%26aufirst%3DD.%26aulast%3DGao%26aufirst%3DF.-X.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DMcQuillan%26aufirst%3DG.%26aulast%3DMargolis%26aufirst%3DH.%2BS.%26atitle%3DHepatitis%2520C%2520virus%2520genotypes%2520and%2520viral%2520concentrations%2520in%2520participants%2520of%2520a%2520general%2520population%2520survey%2520in%2520the%2520United%2520States%26jtitle%3DGastroenterology%26date%3D2006%26volume%3D131%26spage%3D478%26epage%3D484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakarla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 2: Investigation of stilbene prolinamides</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">6063</span><span class="NLM_x">–</span> <span class="NLM_lpage">6066</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2Fj.bmcl.2012.08.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=22959243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlajsLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6063-6066&author=D.+R.+St.+Laurentauthor=M.+Belemaauthor=M.+Gaoauthor=J.+Goodrichauthor=R.+Kakarlaauthor=J.+O.+Knipeauthor=J.+A.+Lemmauthor=M.+Liuauthor=O.+D.+Lopezauthor=V.+N.+Nguyenauthor=P.+T.+Nowerauthor=D.+O%E2%80%99Boyleauthor=Y.+Qiuauthor=J.+L.+Romineauthor=M.+H.+Serrano-Wuauthor=J.-H.+Sunauthor=L.+Valeraauthor=F.+Yangauthor=X.+Yangauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+2%3A+Investigation+of+stilbene+prolinamides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">HCV NS5A replication complex inhibitors. Part 2: Investigation of stilbene prolinamides</span></div><div class="casAuthors">St. Laurent, Denis R.; Belema, Makonen; Gao, Min; Goodrich, Jason; Kakarla, Ramesh; Knipe, Jay O.; Lemm, Julie A.; Liu, Mengping; Lopez, Omar D.; Nguyen, Van N.; Nower, Peter T.; O'Boyle, Donald; Qiu, Yuping; Romine, Jeffrey L.; Serrano-Wu, Michael H.; Sun, Jin-Hua; Valera, Lourdes; Yang, Fukang; Yang, Xuejie; Meanwell, Nicholas A.; Snyder, Lawrence B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6063-6066</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein the preliminary structure-activity relationships and early PK characterization for a series of stilbene prolinamides I [R = Me, Ph, PhCH2, (R)-PhCHMe, 3-pyridylmethyl, 3-indolyl, etc.] and their analogs that formed a basis for the ultimate identification of daclatasvir (BMS-79052), a compd. that has demonstrated clin. proof-of-concept for inhibiting the NS5A replication complex in the treatment of HCV infection, are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vTKMN_UrxLVg90H21EOLACvtfcHk0lh1BSioEmWHDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlajsLjK&md5=48ceadc7d3a60a5f99c0d02984e3a2b4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.049%26sid%3Dliteratum%253Aachs%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DGoodrich%26aufirst%3DJ.%26aulast%3DKakarla%26aufirst%3DR.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25202%253A%2520Investigation%2520of%2520stilbene%2520prolinamides%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6063%26epage%3D6066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ripka, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 3: Discovery of potent analogs with distinct core topologies</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">779</span><span class="NLM_x">–</span> <span class="NLM_lpage">784</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=779-784&author=O.+D.+Lopezauthor=V.+N.+Nguyenauthor=D.+R.+St.+Laurentauthor=M.+Belemaauthor=M.+H.+Serrano-Wuauthor=J.+T.+Goodrichauthor=F.+Yangauthor=Y.+Qiuauthor=A.+S.+Ripkaauthor=P.+T.+Nowerauthor=L.+Valeraauthor=M.+Liuauthor=D.+R.+O%E2%80%99Boyleauthor=J.-H.+Sunauthor=R.+A.+Fridellauthor=J.+A.+Lemmauthor=M.+Gaoauthor=A.+C.+Goodauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+3%3A+Discovery+of+potent+analogs+with+distinct+core+topologies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DGoodrich%26aufirst%3DJ.%2BT.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DRipka%26aufirst%3DA.%2BS.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25203%253A%2520Discovery%2520of%2520potent%2520analogs%2520with%2520distinct%2520core%2520topologies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D779%26epage%3D784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 4: Optimization for genotype 1a replicon inhibitory activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1976</span><span class="NLM_x">–</span> <span class="NLM_lpage">1994</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301796k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1976-1994&author=D.+R.+St.+Laurentauthor=M.+H.+Serrano-Wuauthor=M.+Belemaauthor=M.+Dingauthor=H.+Fangauthor=M.+Gaoauthor=J.+T.+Goodrichauthor=R.+G.+Krauseauthor=J.+A.+Lemmauthor=M.+Liuauthor=O.+D.+Lopezauthor=V.+N.+Nguyenauthor=P.+T.+Nowerauthor=D.+R.+O%E2%80%99Boyleauthor=B.+C.+Pearceauthor=J.+L.+Romineauthor=L.+Valeraauthor=J.-H.+Sunauthor=Y.-K.+Wangauthor=F.+Yangauthor=X.+Yangauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+4%3A+Optimization+for+genotype+1a+replicon+inhibitory+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm301796k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301796k%26sid%3Dliteratum%253Aachs%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DGoodrich%26aufirst%3DJ.%2BT.%26aulast%3DKrause%26aufirst%3DR.%2BG.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DPearce%26aufirst%3DB.%2BC.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DWang%26aufirst%3DY.-K.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25204%253A%2520Optimization%2520for%2520genotype%25201a%2520replicon%2520inhibitory%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1976%26epage%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic HCV NS5A replication complex inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4428</span><span class="NLM_x">–</span> <span class="NLM_lpage">4435</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4428-4435&author=M.+Belemaauthor=V.+N.+Nguyenauthor=D.+R.+St.+Laurentauthor=O.+D.+Lopezauthor=Y.+Qiuauthor=A.+C.+Goodauthor=P.+T.+Nowerauthor=L.+Valeraauthor=D.+R.+O%E2%80%99Boyleauthor=J.-H.+Sunauthor=R.+A.+Fridellauthor=J.+A.+Lemmauthor=M.+Gaoauthor=J.+O.+Knipeauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+5%3A+Discovery+of+potent+and+pan-genotypic+HCV+NS5A+replication+complex+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25205%253A%2520Discovery%2520of%2520potent%2520and%2520pan-genotypic%2520HCV%2520NS5A%2520replication%2520complex%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4428%26epage%3D4435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A replication complex inhibitors. Part 6: The discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotype 1a and 1b replicons</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1995</span><span class="NLM_x">–</span> <span class="NLM_lpage">2012</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm4016203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1995-2012&author=M.+Belemaauthor=V.+N.+Nguyenauthor=J.+L.+Romineauthor=D.+R.+St.+Laurentauthor=O.+D.+Lopezauthor=J.+Goodrichauthor=P.+T.+Nowerauthor=D.+R.+O%E2%80%99Boyleauthor=J.+A.+Lemmauthor=R.+A.+Fridellauthor=M.+Gaoauthor=H.+Fangauthor=R.+G.+Krauseauthor=Y.-K.+Wangauthor=A.+J.+Oliverauthor=A.+C.+Goodauthor=J.+O.+Knipeauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=Hepatitis+C+virus+NS5A+replication+complex+inhibitors.+Part+6%3A+The+discovery+of+a+novel+and+highly+potent+biarylimidazole+chemotype+with+inhibitory+activity+toward+genotype+1a+and+1b+replicons"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm4016203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016203%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DGoodrich%26aufirst%3DJ.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DKrause%26aufirst%3DR.%2BG.%26aulast%3DWang%26aufirst%3DY.-K.%26aulast%3DOliver%26aufirst%3DA.%2BJ.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25206%253A%2520The%2520discovery%2520of%2520a%2520novel%2520and%2520highly%2520potent%2520biarylimidazole%2520chemotype%2520with%2520inhibitory%2520activity%2520toward%2520genotype%25201a%2520and%25201b%2520replicons%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1995%26epage%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachand, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deon, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavoie, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruediger, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantor, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chimalakonda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, L. G.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2013</span><span class="NLM_x">–</span> <span class="NLM_lpage">2032</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm401836p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2013-2032&author=M.+Belemaauthor=V.+N.+Nguyenauthor=C.+Bachandauthor=D.+H.+Deonauthor=J.+T.+Goodrichauthor=C.+A.+Jamesauthor=R.+Lavoieauthor=O.+D.+Lopezauthor=A.+Martelauthor=J.+L.+Romineauthor=E.+H.+Ruedigerauthor=L.+B.+Snyderauthor=D.+R.+St.+Laurentauthor=F.+Yangauthor=J.+Zhuauthor=H.+S.+Wongauthor=D.+R.+Langleyauthor=S.+P.+Adamsauthor=G.+H.+Cantorauthor=A.+Chimalakondaauthor=A.+Furaauthor=B.+M.+Johnsonauthor=J.+O.+Knipeauthor=D.+D.+Parkerauthor=K.+S.+Santoneauthor=R.+A.+Fridellauthor=J.+A.+Lemmauthor=D.+R.+O%E2%80%99Boyleauthor=R.+J.+Colonnoauthor=M.+Gaoauthor=N.+A.+Meanwellauthor=L.+G.+Hamann&title=Hepatitis+C+virus+NS5A+replication+complex+inhibitors%3A+the+discovery+of+daclatasvir"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm401836p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401836p%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DBachand%26aufirst%3DC.%26aulast%3DDeon%26aufirst%3DD.%2BH.%26aulast%3DGoodrich%26aufirst%3DJ.%2BT.%26aulast%3DJames%26aufirst%3DC.%2BA.%26aulast%3DLavoie%26aufirst%3DR.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DMartel%26aufirst%3DA.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DRuediger%26aufirst%3DE.%2BH.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DH.%2BS.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DAdams%26aufirst%3DS.%2BP.%26aulast%3DCantor%26aufirst%3DG.%2BH.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DB.%2BM.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DParker%26aufirst%3DD.%2BD.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%2520replication%2520complex%2520inhibitors%253A%2520the%2520discovery%2520of%2520daclatasvir%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2013%26epage%3D2032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettles, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, L. G.</span><span> </span><span class="NLM_article-title">Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">465</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1038%2Fnature08960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=20410884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2010&pages=96-100&author=M.+Gaoauthor=R.+E.+Nettlesauthor=M.+Belemaauthor=L.+B.+Snyderauthor=V.+N.+Nguyenauthor=R.+A.+Fridellauthor=M.+H.+Serrano-Wuauthor=D.+R.+Langleyauthor=J.-H.+Sunauthor=D.+R.+O%E2%80%99Boyleauthor=J.+A.+Lemmauthor=C.+Wangauthor=J.+O.+Knipeauthor=C.+Chienauthor=R.+J.+Colonnoauthor=D.+M.+Graselaauthor=N.+A.+Meanwellauthor=L.+G.+Hamann&title=Chemical+genetics+strategy+identifies+an+HCV+NS5A+inhibitor+with+a+potent+clinical+effect"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect</span></div><div class="casAuthors">Gao, Min; Nettles, Richard E.; Belema, Makonen; Snyder, Lawrence B.; Nguyen, Van N.; Fridell, Robert A.; Serrano-Wu, Michael H.; Langley, David R.; Sun, Jin-Hua; O'Boyle, Donald R., II; Lemm, Julie A.; Wang, Chunfu; Knipe, Jay O.; Chien, Caly; Colonno, Richard J.; Grasela, Dennis M.; Meanwell, Nicholas A.; Hamann, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">7294</span>),
    <span class="NLM_cas:pages">96-100</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estd. to be approaching 200 million people.  Current therapy relies upon a combination of pegylated interferon-α and ribavirin, a poorly tolerated regimen typically assocd. with less than 50% sustained virol. response rate in those infected with genotype 1 virus.  The development of direct-acting antiviral agents to treat HCV has focused predominantly on inhibitors of the viral enzymes NS3 protease and the RNA-dependent RNA polymerase NS5B.  Here we describe the profile of BMS-790052, a small mol. inhibitor of the HCV NS5A protein that exhibits picomolar half-max. effective concns. (EC50) towards replicons expressing a broad range of HCV genotypes and the JFH-1 genotype 2a infectious virus in cell culture.  In a phase I clin. trial in patients chronically infected with HCV, administration of a single 100-mg dose of BMS-790052 was assocd. with a 3.3 log10 redn. in mean viral load measured 24 h post-dose that was sustained for an addnl. 120 h in two patients infected with genotype 1b virus.  Genotypic anal. of samples taken at baseline, 24 and 144 h post-dose revealed that the major HCV variants obsd. had substitutions at amino-acid positions identified using the in vitro replicon system.  These results provide the first clin. validation of an inhibitor of HCV NS5A, a protein with no known enzymic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations of HCV inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAY7Lig0xT9LVg90H21EOLACvtfcHk0limeCoKv2coaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbo%253D&md5=620427e987f2bccd153270cde2ef5027</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnature08960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08960%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DM.%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DChien%26aufirst%3DC.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26atitle%3DChemical%2520genetics%2520strategy%2520identifies%2520an%2520HCV%2520NS5A%2520inhibitor%2520with%2520a%2520potent%2520clinical%2520effect%26jtitle%3DNature%26date%3D2010%26volume%3D465%26spage%3D96%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bachand, C.; Belema, M.; Deon, D. H.; Good, A. C.; Goodrich, J.; James, C. A.; Lavoie, R.; Lopez, O. D.; Martel, A.; Meanwell, N. A.; Nguyen, V. N.; Romine, J. L.; Ruediger, E. H.; Snyder, L. B.; St. Laurent, D. R.; Yang, F.; Langley, D. R.; Wang, G.; Hamann, L. G.</span><span> </span><span class="NLM_article-title">Hepatitis C virus inhibitors</span>. World Patent Application WO-2008-021927, February 21,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=C.+Bachand&author=M.+Belema&author=D.+H.+Deon&author=A.+C.+Good&author=J.+Goodrich&author=C.+A.+James&author=R.+Lavoie&author=O.+D.+Lopez&author=A.+Martel&author=N.+A.+Meanwell&author=V.+N.+Nguyen&author=J.+L.+Romine&author=E.+H.+Ruediger&author=L.+B.+Snyder&author=D.+R.+St.+Laurent&author=F.+Yang&author=D.+R.+Langley&author=G.+Wang&author=L.+G.+Hamann&title=Hepatitis+C+virus+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBachand%26aufirst%3DC.%26atitle%3DHepatitis%2520C%2520virus%2520inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pack, S. K.; Geng, P.; Smith, M. J.; Hamm, J.</span><span> </span><span class="NLM_article-title">Process for synthesizing compounds useful for treating hepatitis C</span>. World Patent Application WO-2009-020825, February 11,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=S.+K.+Pack&author=P.+Geng&author=M.+J.+Smith&author=J.+Hamm&title=Process+for+synthesizing+compounds+useful+for+treating+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPack%26aufirst%3DS.%2BK.%26atitle%3DProcess%2520for%2520synthesizing%2520compounds%2520useful%2520for%2520treating%2520hepatitis%2520C%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Reviriego, C.</span><span> </span><span class="NLM_article-title">Daclatasvir hydrochloride: treatment of hepatitis C virus HCV NS5A inhibitor</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">735</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVCksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=735-739&author=C.+Reviriego&title=Daclatasvir+hydrochloride%3A+treatment+of+hepatitis+C+virus+HCV+NS5A+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33aR"><div class="casContent"><span class="casTitleNuber">33a</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir dihydrochloride: treatment of hepatitis C virus HCV NS5A inhibitor</span></div><div class="casAuthors">Reviriego, C.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">735-739</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) is a major chronic disease and infected individuals are at risk of developing multiple and highly severe liver complications, such as cirrhosis or liver carcinoma.  The current std. of care for the treatment of HCV is a combination of pegylated interferon alfa and ribavirin, a poorly tolerated regimen with limiting side effects and low sustained virol. response rates in genotype 1-infected patients.  Therefore, the exploration of alternative treatment regimens is of utmost importance.  Daclatasvir dihydrochloride (BMS-790052) is a novel, small-mol., first-in-class inhibitor of HCV replication that targets non-structural protein 5A (NS5A).  It has shown impressive clin. efficacy, high selectivity, picomolar activity and broad genotype coverage in vitro.  Daclatasvir is safe and generally well tolerated, and it has a pharmacokinetic profile suggestive of once-daily administration.  With its extraordinary potency and non-overlapping resistance profile, daclatasvir has the potential to be an important component in future combination strategies for HCV therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrALLJfJjhdI7Vg90H21EOLACvtfcHk0limeCoKv2coaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVCksr8%253D&md5=5e4a7324e33a0351f609304f88e289cd</span></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReviriego%26aufirst%3DC.%26atitle%3DDaclatasvir%2520hydrochloride%253A%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520HCV%2520NS5A%2520inhibitor%26jtitle%3DDrugs%2520Future%26date%3D2011%26volume%3D36%26spage%3D735%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit33b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Herbst, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span> </span><span class="NLM_article-title">NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1337</span><span class="NLM_x">–</span> <span class="NLM_lpage">1346</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1517%2F13543784.2013.826189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=23931586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVekurzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=1337-1346&author=D.+A.+Herbstauthor=K.+R.+Reddy&title=NS5A+inhibitor%2C+daclatasvir%2C+for+the+treatment+of+chronic+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33bR"><div class="casContent"><span class="casTitleNuber">33b</span><div class="casTitle"><span class="NLM_cas:atitle">NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection</span></div><div class="casAuthors">Herbst, D. Alan; Reddy, K. Rajender</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1337-1346</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Chronic Hepatitis C virus (HCV) infection is a major pandemic.  The current std. of care includes peginterferon and ribavirin plus one of two protease inhibitors, boceprevir and telaprevir, for Genotype 1 patients and peginterferon and ribavirin for all other genotypes.  The treatment landscape is rapidly evolving as a no. of direct-acting antivirals (DAA) are being developed in clin. trials.  Areas covered: , formerly labeled BMS-790052, is a first-in-class HCV NS5A inhibitor that has been demonstrated in Phase I and II trials to have a very potent antiviral effect across all genotypes and to have a potent clin. efficacy in both treatment naive and experienced cohorts.  This review covers the whole spectrum of development of daclatasvir from Phase I to III programs.  Expert opinion: While daclatasvir has pangenotypic activity, it has a lower barrier to resistance in Genotype 1a but has been found to be very effective in Genotype 1b patients.  However, Genotype 1a patients can be successfully treated with the addn. of one or more DAAs alone or in combination with peginterferon and ribavirin.  The future for daclatasvir and other DAAs is very encouraging in that all-oral therapies are likely to be effective and well-tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouHATdIV9yA7Vg90H21EOLACvtfcHk0lgCbSbHLl6Wmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVekurzK&md5=d1b220d6ed004a580cd6920ffaecde19</span></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=10.1517%2F13543784.2013.826189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2013.826189%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DD.%2BA.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26atitle%3DNS5A%2520inhibitor%252C%2520daclatasvir%252C%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2013%26volume%3D22%26spage%3D1337%26epage%3D1346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshpande, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. D.</span><span> </span><span class="NLM_article-title">Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">338</span><span class="NLM_x">–</span> <span class="NLM_lpage">348</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1111%2Fj.1365-2893.2010.01314.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=20456634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A280%3ADC%252BC3Mvht1yrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=338-348&author=H.+Moauthor=C.+Yangauthor=K.+Wangauthor=Y.+Wangauthor=M.+Huangauthor=B.+Murrayauthor=X.+Qiauthor=S.-C.+Sunauthor=M.+Deshpandeauthor=G.+Rhodesauthor=M.+D.+Miller&title=Estimation+of+inhibitory+quotient+using+a+comparative+equilibrium+dialysis+assay+for+prediction+of+viral+response+to+hepatitis+C+virus+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34aR"><div class="casContent"><span class="casTitleNuber">34a</span><div class="casTitle"><span class="NLM_cas:atitle">Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors</span></div><div class="casAuthors">Mo H; Yang C; Wang K; Wang Y; Huang M; Murray B; Qi X; Sun S-C; Deshpande M; Rhodes G; Miller M D</div><div class="citationInfo"><span class="NLM_cas:title">Journal of viral hepatitis</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">338-48</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The relationship of inhibitory quotient (IQ) with the virologic response to specific inhibitors of human hepatitis C virus (HCV) and the best method to correct for serum protein binding in calculating IQ have not been addressed.  A common method is to determine a fold shift by comparing the EC(50) values determined in cell culture in the absence and presence of human serum (fold shift in EC(50) ), but this method has a number of disadvantages.  In the present study, the fold shifts in drug concentrations between 100% human plasma (HP) and cell culture medium (CCM) were directly measured using a modified comparative equilibrium dialysis (CED) assay for three HCV protease inhibitors (PIs) and for a novel HCV inhibitor GS-9132.  The fold shift values in drug concentration between the HP and CCM (CED ratio) were ∼1 for SCH-503034, VX-950 and GS-9132 and 13 for BILN-2061.  These values were ∼3-10-fold lower than the fold shift values calculated from the EC(50) assay for all inhibitors except BILN-2061.  Using the CED values, a consistent pharmacokinetic and pharmacodynamic relationship was observed for the four HCV inhibitors analysed.  Specifically, an approximate 1 log(10) reduction in HCV RNA was achieved with an IQ close to 1, while 2-3 and greater log(10) reductions in HCV RNA were achieved with IQ values of 3-5 and greater, respectively.  Thus, use of CED to define IQ provides a predictive and quantitative approach for the assessment of the in vivo potency of HCV PIs and GS-9132.  This method provides a framework for the evaluation of other classes of drugs that are bound by serum proteins but require the presence of serum for in vitro evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWE-deUA9i3xFwe7cAcrfPfW6udTcc2eYTNSpTAn24ibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mvht1yrtw%253D%253D&md5=5d92ab2852b739d5e7b4809b40d3d98e</span></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2893.2010.01314.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2893.2010.01314.x%26sid%3Dliteratum%253Aachs%26aulast%3DMo%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DB.%26aulast%3DQi%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DS.-C.%26aulast%3DDeshpande%26aufirst%3DM.%26aulast%3DRhodes%26aufirst%3DG.%26aulast%3DMiller%26aufirst%3DM.%2BD.%26atitle%3DEstimation%2520of%2520inhibitory%2520quotient%2520using%2520a%2520comparative%2520equilibrium%2520dialysis%2520assay%2520for%2520prediction%2520of%2520viral%2520response%2520to%2520hepatitis%2520C%2520virus%2520inhibitors%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D2011%26volume%3D18%26spage%3D338%26epage%3D348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit34b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Reddy, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morcos, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Pogam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lave, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span> </span><span class="NLM_article-title">Pharmacokinetic/pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">3144</span><span class="NLM_x">–</span> <span class="NLM_lpage">3156</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=3144-3156&author=M.+B.+Reddyauthor=P.+N.+Morcosauthor=S.+Le+Pogamauthor=Y.+Ouauthor=K.+Frankauthor=T.+Laveauthor=P.+Smith&title=Pharmacokinetic%2Fpharmacodynamic+predictors+of+clinical+potency+for+hepatitis+C+virus+nonnucleoside+polymerase+and+protease+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DM.%2BB.%26aulast%3DMorcos%26aufirst%3DP.%2BN.%26aulast%3DLe%2BPogam%26aufirst%3DS.%26aulast%3DOu%26aufirst%3DY.%26aulast%3DFrank%26aufirst%3DK.%26aulast%3DLave%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DP.%26atitle%3DPharmacokinetic%252Fpharmacodynamic%2520predictors%2520of%2520clinical%2520potency%2520for%2520hepatitis%2520C%2520virus%2520nonnucleoside%2520polymerase%2520and%2520protease%2520inhibitors%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D3144%26epage%3D3156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit34c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batonga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montpetit, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jutras, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapeyre, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhéaume, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethell, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span> </span><span class="NLM_article-title">The liver partition coefficient-corrected inhibitory quotient and the pharmacokinetic–pharmacodynamic relationship of directly acting anti-hepatitis C virus agents in humans</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5381</span><span class="NLM_x">–</span> <span class="NLM_lpage">5386</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=5381-5386&author=J.+Duanauthor=G.+Bolgerauthor=M.+Garneauauthor=M.+Amadauthor=J.+Batongaauthor=H.+Montpetitauthor=F.+Otisauthor=M.+Jutrasauthor=N.+Lapeyreauthor=M.+Rh%C3%A9aumeauthor=G.+Kukoljauthor=P.+W.+Whiteauthor=R.+C.+Bethellauthor=M.+G.+Cordingley&title=The+liver+partition+coefficient-corrected+inhibitory+quotient+and+the+pharmacokinetic%E2%80%93pharmacodynamic+relationship+of+directly+acting+anti-hepatitis+C+virus+agents+in+humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DAmad%26aufirst%3DM.%26aulast%3DBatonga%26aufirst%3DJ.%26aulast%3DMontpetit%26aufirst%3DH.%26aulast%3DOtis%26aufirst%3DF.%26aulast%3DJutras%26aufirst%3DM.%26aulast%3DLapeyre%26aufirst%3DN.%26aulast%3DRh%25C3%25A9aume%26aufirst%3DM.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DWhite%26aufirst%3DP.%2BW.%26aulast%3DBethell%26aufirst%3DR.%2BC.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26atitle%3DThe%2520liver%2520partition%2520coefficient-corrected%2520inhibitory%2520quotient%2520and%2520the%2520pharmacokinetic%25E2%2580%2593pharmacodynamic%2520relationship%2520of%2520directly%2520acting%2520anti-hepatitis%2520C%2520virus%2520agents%2520in%2520humans%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D5381%26epage%3D5386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargittai, M. R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raney, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, C. E.</span><span> </span><span class="NLM_article-title">Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">36417</span><span class="NLM_x">–</span> <span class="NLM_lpage">36428</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=36417-36428&author=L.+Huangauthor=J.+Hwangauthor=S.+D.+Sharmaauthor=M.+R.+S.+Hargittaiauthor=Y.+Chenauthor=J.+J.+Arnoldauthor=K.+D.+Raneyauthor=C.+E.+Cameron&title=Hepatitis+C+virus+nonstructural+protein+5A+%28NS5A%29+is+an+RNA-binding+protein"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DHwang%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%2BD.%26aulast%3DHargittai%26aufirst%3DM.%2BR.%2BS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DArnold%26aufirst%3DJ.%2BJ.%26aulast%3DRaney%26aufirst%3DK.%2BD.%26aulast%3DCameron%26aufirst%3DC.%2BE.%26atitle%3DHepatitis%2520C%2520virus%2520nonstructural%2520protein%25205A%2520%2528NS5A%2529%2520is%2520an%2520RNA-binding%2520protein%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D36417%26epage%3D36428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hwang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordek, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kihara, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raney, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kao, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, C. E.</span><span> </span><span class="NLM_article-title">Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">12480</span><span class="NLM_x">–</span> <span class="NLM_lpage">12491</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1128%2FJVI.01319-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=20926572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVaruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=12480-12491&author=J.+Hwangauthor=L.+Huangauthor=D.+G.+Cordekauthor=R.+Vaughanauthor=S.+L.+Reynoldsauthor=G.+Kiharaauthor=K.+D.+Raneyauthor=C.+C.+Kaoauthor=C.+E.+Cameron&title=Hepatitis+C+virus+nonstructural+protein+5A%3A+biochemical+characterization+of+a+novel+structural+class+of+RNA-binding+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35bR"><div class="casContent"><span class="casTitleNuber">35b</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins</span></div><div class="casAuthors">Hwang, Jungwook; Huang, Luyun; Cordek, Daniel G.; Vaughan, Robert; Reynolds, Shelley L.; Kihara, George; Raney, Kevin D.; Kao, C. Cheng; Cameron, Craig E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">12480-12491</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) nonstructural protein 5A (NS5A) exhibits a preference for G/U-rich RNA in vitro.  Biol. anal. of the NS5A RNA-binding activity and its target sites in the genome will be facilitated by a description of the NS5A-RNA complex.  We demonstrate that the C-4 carbonyl of the uracil base and, by inference, the C-6 carbonyl of the guanine base interact with NS5A.  U-rich RNA of 5 to 6 nucleotides (nt) is sufficient for high-affinity binding to NS5A.  The minimal RNA-binding domain of NS5A consists of residues 2005 to 2221 (referred to as domain I-plus).  This region of the protein includes the amino-terminal domain I as well as the subsequent linker that separates domains I and II.  This linker region is the site of adaptive mutations.  U-rich RNA-binding activity is not obsd. for an NS5A deriv. contg. only residues 2194 to 2419 (domains II and III).  Mass spectrometric anal. of an NS5A-poly(rU) complex identified domains I and II as sites for interaction with RNA.  Dimerization of NS5A was demonstrated by glutaraldehyde crosslinking.  This dimerization is likely mediated by domain I-plus, as dimers of this protein are trapped by crosslinking.  Dimers of the domain II-III protein are not obsd.  The monomer-dimer equil. of NS5A shifts in favor of dimer when U-rich RNA is present but not when A-rich RNA is present, consistent with an NS5A dimer being the RNA-binding-competent form of the protein.  These data provide a mol. perspective of the NS5A-RNA complex and suggest possible mechanisms for regulation of HCV and cellular gene expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWrqxkVkORnLVg90H21EOLACvtfcHk0lgdHx21xvsDUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVaruw%253D%253D&md5=fd6bac5b9f24a27c39e63dcdfbb12f4d</span></div><a href="/servlet/linkout?suffix=cit35b&amp;dbid=16384&amp;doi=10.1128%2FJVI.01319-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01319-10%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DCordek%26aufirst%3DD.%2BG.%26aulast%3DVaughan%26aufirst%3DR.%26aulast%3DReynolds%26aufirst%3DS.%2BL.%26aulast%3DKihara%26aufirst%3DG.%26aulast%3DRaney%26aufirst%3DK.%2BD.%26aulast%3DKao%26aufirst%3DC.%2BC.%26aulast%3DCameron%26aufirst%3DC.%2BE.%26atitle%3DHepatitis%2520C%2520virus%2520nonstructural%2520protein%25205A%253A%2520biochemical%2520characterization%2520of%2520a%2520novel%2520structural%2520class%2520of%2520RNA-binding%2520proteins%26jtitle%3DJ.%2520Virol.%26date%3D2010%26volume%3D84%26spage%3D12480%26epage%3D12491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Foster, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belyaeva, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stonehouse, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, M.</span><span> </span><span class="NLM_article-title">All three domains of the hepatitis C virus nonstructural NS5A protein contribute to RNA binding</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">9267</span><span class="NLM_x">–</span> <span class="NLM_lpage">9277</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1128%2FJVI.00616-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=20592076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1WgtLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=9267-9277&author=T.+L.+Fosterauthor=T.+Belyaevaauthor=N.+J.+Stonehouseauthor=A.+R.+Pearsonauthor=M.+Harris&title=All+three+domains+of+the+hepatitis+C+virus+nonstructural+NS5A+protein+contribute+to+RNA+binding"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35cR"><div class="casContent"><span class="casTitleNuber">35c</span><div class="casTitle"><span class="NLM_cas:atitle">All three domains of the hepatitis C virus nonstructural NS5A protein contribute to RNA binding</span></div><div class="casAuthors">Foster, Toshana L.; Belyaeva, Tamara; Stonehouse, Nicola J.; Pearson, Arwen R.; Harris, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">9267-9277</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The hepatitis C virus (HCV) nonstructural protein NS5A is crit. for viral genome replication and is thought to interact directly with both the RNA-dependent RNA polymerase, NS5B, and viral RNA.  NS5A consists of three domains which have, as yet, undefined roles in viral replication and assembly.  To define the regions that mediate the interaction with RNA, specifically the HCV 3' untranslated region (UTR) pos.-strand RNA, constructs of different domain combinations were cloned, bacterially expressed, and purified to homogeneity.  Each of these purified proteins was probed for its ability to interact with the 3' UTR RNA using filter binding and gel electrophoretic mobility shift assays, revealing differences in their RNA binding efficiencies and affinities.  A specific interaction between domains I and II of NS5A and the 3' UTR RNA was identified, suggesting that these are the RNA binding domains of NS5A.  Domain III showed low in vitro RNA binding capacity.  Filter binding and competition analyses identified differences between NS5A and NS5B in their specificities for defined regions of the 3' UTR.  The preference of NS5A, in contrast to NS5B, for the polypyrimidine tract highlights an aspect of 3' UTR RNA recognition by NS5A which may play a role in the control or enhancement of HCV genome replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCPXBZZdd7WLVg90H21EOLACvtfcHk0lgdHx21xvsDUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1WgtLbP&md5=29a7e066d5ac2cc589c0125e3504e9ff</span></div><a href="/servlet/linkout?suffix=cit35c&amp;dbid=16384&amp;doi=10.1128%2FJVI.00616-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00616-10%26sid%3Dliteratum%253Aachs%26aulast%3DFoster%26aufirst%3DT.%2BL.%26aulast%3DBelyaeva%26aufirst%3DT.%26aulast%3DStonehouse%26aufirst%3DN.%2BJ.%26aulast%3DPearson%26aufirst%3DA.%2BR.%26aulast%3DHarris%26aufirst%3DM.%26atitle%3DAll%2520three%2520domains%2520of%2520the%2520hepatitis%2520C%2520virus%2520nonstructural%2520NS5A%2520protein%2520contribute%2520to%2520RNA%2520binding%26jtitle%3DJ.%2520Virol.%26date%3D2010%26volume%3D84%26spage%3D9267%26epage%3D9277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Lim, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterju, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordek, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Rivera, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Targett-Adams, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallay, P. A.</span><span> </span><span class="NLM_article-title">Correlation between NS5A dimerization and HCV replication</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">30861</span><span class="NLM_x">–</span> <span class="NLM_lpage">30873</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=30861-30873&author=P.+J.+Limauthor=U.+Chatterjuauthor=D.+Cordekauthor=S.+D.+Sharmaauthor=J.+A.+Garcia-Riveraauthor=C.+E.+Cameronauthor=K.+Linauthor=P.+Targett-Adamsauthor=P.+A.+Gallay&title=Correlation+between+NS5A+dimerization+and+HCV+replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DP.%2BJ.%26aulast%3DChatterju%26aufirst%3DU.%26aulast%3DCordek%26aufirst%3DD.%26aulast%3DSharma%26aufirst%3DS.%2BD.%26aulast%3DGarcia-Rivera%26aufirst%3DJ.%2BA.%26aulast%3DCameron%26aufirst%3DC.%2BE.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DTargett-Adams%26aufirst%3DP.%26aulast%3DGallay%26aufirst%3DP.%2BA.%26atitle%3DCorrelation%2520between%2520NS5A%2520dimerization%2520and%2520HCV%2520replication%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D30861%26epage%3D30873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Targett-Adams, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, E. J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavender, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brain, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakenhut, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stammen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pryde, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickford, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westby, M.</span><span> </span><span class="NLM_article-title">Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">6353</span><span class="NLM_x">–</span> <span class="NLM_lpage">6368</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1128%2FJVI.00215-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=21507963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFOntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=6353-6368&author=P.+Targett-Adamsauthor=E.+J.+S.+Grahamauthor=J.+Middletonauthor=A.+Palmerauthor=S.+M.+Shawauthor=H.+Lavenderauthor=P.+Brainauthor=T.+D.+Tranauthor=L.+H.+Jonesauthor=F.+Wakenhutauthor=B.+Stammenauthor=D.+Prydeauthor=C.+Pickfordauthor=M.+Westby&title=Small+molecules+targeting+hepatitis+C+virus-encoded+NS5A+cause+subcellular+redistribution+of+their+target%3A+insights+into+compound+modes+of+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37aR"><div class="casContent"><span class="casTitleNuber">37a</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: Insights into compound modes of action</span></div><div class="casAuthors">Targett-Adams, Paul; Graham, Emily J. S.; Middleton, Jenny; Palmer, Amy; Shaw, Stephen M.; Lavender, Helen; Brain, Philip; Tran, Thien Duc; Jones, Lyn H.; Wakenhut, Florian; Stammen, Blanda; Pryde, David; Pickford, Chris; Westby, Mike</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6353-6368</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The current std. of care for hepatitis C virus (HCV)-infected patients consists of lengthy treatment with interferon and ribavirin.  To increase the effectiveness of HCV therapy, future regimens will incorporate multiple direct-acting antiviral (DAA) drugs.  Recently, the HCV-encoded NS5A protein has emerged as a promising DAA target.  Compds. targeting NS5A exhibit remarkable potency in vitro and demonstrate early clin. promise, suggesting that NS5A inhibitors could feature in future DAA combination therapies.  Since the mechanisms through which these mols. operate are unknown, we have used NS5A inhibitors as tools to investigate their modes of action.  Anal. of replicon-contg. cells revealed dramatic phenotypic alterations in NS5A localization following treatment with NS5A inhibitors; NS5A was redistributed from the endoplasmic reticulum to lipid droplets.  The NS5A relocalization did not occur in cells treated with other classes of HCV inhibitors, and NS5A-targeting mols. did not cause similar alterations in the localization of other HCV-encoded proteins.  Time course anal. of the redistribution of NS5A revealed that the transfer of protein to lipid droplets was concomitant with the onset of inhibition, as judged by the kinetic profiles for these compds.  Furthermore, anal. of the kinetic profile of inhibition for a panel of test mols. permitted the sepn. of compds. into different kinetic classes based on their modes of action.  The results from this approach suggested that NS5A inhibitors perturbed the function of new replication complexes, rather than acting on preformed complexes.  The data reveal novel biol. consequences of NS5A inhibition, which may help enable the development of future assay platforms for the identification of new and/or different NS5A inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_D0ZIz1nPk7Vg90H21EOLACvtfcHk0lil-du7PROXyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFOntbg%253D&md5=99efbc4b114c7f8129b43f51b4d584b7</span></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=10.1128%2FJVI.00215-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00215-11%26sid%3Dliteratum%253Aachs%26aulast%3DTargett-Adams%26aufirst%3DP.%26aulast%3DGraham%26aufirst%3DE.%2BJ.%2BS.%26aulast%3DMiddleton%26aufirst%3DJ.%26aulast%3DPalmer%26aufirst%3DA.%26aulast%3DShaw%26aufirst%3DS.%2BM.%26aulast%3DLavender%26aufirst%3DH.%26aulast%3DBrain%26aufirst%3DP.%26aulast%3DTran%26aufirst%3DT.%2BD.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DWakenhut%26aufirst%3DF.%26aulast%3DStammen%26aufirst%3DB.%26aulast%3DPryde%26aufirst%3DD.%26aulast%3DPickford%26aufirst%3DC.%26aulast%3DWestby%26aufirst%3DM.%26atitle%3DSmall%2520molecules%2520targeting%2520hepatitis%2520C%2520virus-encoded%2520NS5A%2520cause%2520subcellular%2520redistribution%2520of%2520their%2520target%253A%2520insights%2520into%2520compound%2520modes%2520of%2520action%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26spage%3D6353%26epage%3D6368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hang, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leveque, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sklan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elazar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klumpp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, J. S.</span><span> </span><span class="NLM_article-title">The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein</span> <span class="citation_source-journal">Virology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">414</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2Fj.virol.2011.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=21513964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvVyit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=414&publication_year=2011&pages=10-18&author=C.+Leeauthor=H.+Maauthor=J.+Q.+Hangauthor=V.+Levequeauthor=E.+H.+Sklanauthor=M.+Elazarauthor=K.+Klumppauthor=J.+S.+Glenn&title=The+hepatitis+C+virus+NS5A+inhibitor+%28BMS-790052%29+alters+the+subcellular+localization+of+the+NS5A+non-structural+viral+protein"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37bR"><div class="casContent"><span class="casTitleNuber">37b</span><div class="casTitle"><span class="NLM_cas:atitle">The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein</span></div><div class="casAuthors">Lee, Choongho; Ma, Han; Hang, Julie Qi; Leveque, Vincent; Sklan, Ella H.; Elazar, Menashe; Klumpp, Klaus; Glenn, Jeffrey S.</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">414</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-18</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The hepatitis C virus (HCV) non-structural (NS) 5A protein plays an essential role in the replication of the viral RNA by the membrane-assocd. replication complex (RC).  Recently, a putative NS5A inhibitor, BMS-790052, exhibited the highest potency of any known anti-HCV compd. in inhibiting HCV replication in vitro and showed a promising clin. effect in HCV-infected patients.  The precise mechanism of action for this new class of potential anti-HCV therapeutics, however, is still unclear.  In order to gain further insight into its mode of action, we sought to test the hypothesis that the antiviral effect of BMS-790052 might be mediated by interfering with the functional assembly of the HCV RC.  We obsd. that BMS-790052 indeed altered the subcellular localization and biochem. fractionation of NS5A.  Taken together, our data suggest that NS5A inhibitors such as BMS-790052 can suppress viral genome replication by altering the proper localization of NS5A into functional RCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYMSRcOmX36rVg90H21EOLACvtfcHk0lil-du7PROXyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvVyit7c%253D&md5=b4212a1dd1365aedfd384e685afdefeb</span></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2011.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2011.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DHang%26aufirst%3DJ.%2BQ.%26aulast%3DLeveque%26aufirst%3DV.%26aulast%3DSklan%26aufirst%3DE.%2BH.%26aulast%3DElazar%26aufirst%3DM.%26aulast%3DKlumpp%26aufirst%3DK.%26aulast%3DGlenn%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520hepatitis%2520C%2520virus%2520NS5A%2520inhibitor%2520%2528BMS-790052%2529%2520alters%2520the%2520subcellular%2520localization%2520of%2520the%2520NS5A%2520non-structural%2520viral%2520protein%26jtitle%3DVirology%26date%3D2011%26volume%3D414%26spage%3D10%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Gao, M.</span> Bristol-Myers Squibb. Personal communication.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Gao%2C+M.+Bristol-Myers+Squibb.+Personal+communication."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DM." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Appel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">From structure to function: new insights into hepatitis C virus RNA replication</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">9833</span><span class="NLM_x">–</span> <span class="NLM_lpage">9836</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=9833-9836&author=N.+Appelauthor=T.+Schallerauthor=F.+Peninauthor=R.+Bartenschlager&title=From+structure+to+function%3A+new+insights+into+hepatitis+C+virus+RNA+replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAppel%26aufirst%3DN.%26aulast%3DSchaller%26aufirst%3DT.%26aulast%3DPenin%26aufirst%3DF.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DFrom%2520structure%2520to%2520function%253A%2520new%2520insights%2520into%2520hepatitis%2520C%2520virus%2520RNA%2520replication%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D9833%26epage%3D9836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Characterizations of HCV NS5A replication complex inhibitors</span> <span class="citation_source-journal">Virology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">444</span><span class="NLM_x">, </span> <span class="NLM_fpage">343</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=444&publication_year=2013&pages=343-354&author=D.+R.+O%E2%80%99Boyleauthor=J.-H.+Sunauthor=P.+Nowerauthor=J.+Lemmauthor=R.+Fridellauthor=C.+Wangauthor=J.+L.+Romineauthor=M.+Belemaauthor=V.+Nguyenauthor=D.+R.+St.+Laurentauthor=M.+Serrano-Wuauthor=L.+B.+Snyderauthor=N.+A.+Meanwellauthor=D.+R.+Langleyauthor=M.+Gao&title=Characterizations+of+HCV+NS5A+replication+complex+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DNower%26aufirst%3DP.%26aulast%3DLemm%26aufirst%3DJ.%26aulast%3DFridell%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DV.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DSerrano-Wu%26aufirst%3DM.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DCharacterizations%2520of%2520HCV%2520NS5A%2520replication%2520complex%2520inhibitors%26jtitle%3DVirology%26date%3D2013%26volume%3D444%26spage%3D343%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Ghosh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. H.</span><span> </span><span class="NLM_article-title">Target validation using in-cell small molecule clickable imaging probes</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">–</span> <span class="NLM_lpage">254</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=247-254&author=B.+Ghoshauthor=L.+H.+Jones&title=Target+validation+using+in-cell+small+molecule+clickable+imaging+probes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DB.%26aulast%3DJones%26aufirst%3DL.%2BH.%26atitle%3DTarget%2520validation%2520using%2520in-cell%2520small%2520molecule%2520clickable%2520imaging%2520probes%26jtitle%3DMedChemComm%26date%3D2014%26volume%3D5%26spage%3D247%26epage%3D254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Choo, Q. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overby, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, M.</span><span> </span><span class="NLM_article-title">Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">244</span><span class="NLM_x">, </span> <span class="NLM_fpage">359</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1126%2Fscience.2523562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=2523562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADyaL1MXit1Khtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=244&publication_year=1989&pages=359-362&author=Q.+L.+Chooauthor=G.+Kuoauthor=A.+J.+Weinerauthor=L.+R.+Overbyauthor=D.+W.+Bradleyauthor=M.+Houghton&title=Isolation+of+a+cDNA+clone+derived+from+a+blood-borne+non-A%2C+non-B+viral+hepatitis+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome</span></div><div class="casAuthors">Choo, Qui Lim; Kuo, George; Weiner, Amy J.; Overby, Lacy R.; Bradley, Daniel W.; Houghton, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">244</span>
        (<span class="NLM_cas:issue">4902</span>),
    <span class="NLM_cas:pages">359-62</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A random-primed cDNA library was constructed from plasma contg. the uncharacterized non-A, non-B hepatitis (NANBH) agent and screened with serum from a patient diagnosed with NANBH.  A cDNA clone was isolated that was shown to encode an antigen assocd. specifically with NANBH infections.  This clone is not derived from host DNA but from an RNA mol. present in NANBH infections that consists of ≥10,000 nucleotides, and that is pos.-stranded with respect to the encoded NANBH antigen.  These data indicate that this clone is derived from the genome of the NANBH agent and are consistent with the agent being similar to the togaviridae or flaviviridae.  This mol. approach should be of great value in the isolation and characterization of other unidentified infectious agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqorpVFx7nEkrVg90H21EOLACvtfcHk0lgnZ7nmQTS14g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXit1Khtrk%253D&md5=25161cf212790856dd29d3aaf78f20b8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1126%2Fscience.2523562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2523562%26sid%3Dliteratum%253Aachs%26aulast%3DChoo%26aufirst%3DQ.%2BL.%26aulast%3DKuo%26aufirst%3DG.%26aulast%3DWeiner%26aufirst%3DA.%2BJ.%26aulast%3DOverby%26aufirst%3DL.%2BR.%26aulast%3DBradley%26aufirst%3DD.%2BW.%26aulast%3DHoughton%26aufirst%3DM.%26atitle%3DIsolation%2520of%2520a%2520cDNA%2520clone%2520derived%2520from%2520a%2520blood-borne%2520non-A%252C%2520non-B%2520viral%2520hepatitis%2520genome%26jtitle%3DScience%26date%3D1989%26volume%3D244%26spage%3D359%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chevaliez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawlotsky, J.-M.</span><span> </span><span class="NLM_article-title">Interferon-based therapy of hepatitis C</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1222</span><span class="NLM_x">–</span> <span class="NLM_lpage">1241</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2Fj.addr.2007.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=17869375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1yls73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2007&pages=1222-1241&author=S.+Chevaliezauthor=J.-M.+Pawlotsky&title=Interferon-based+therapy+of+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43aR"><div class="casContent"><span class="casTitleNuber">43a</span><div class="casTitle"><span class="NLM_cas:atitle">Interferon-based therapy of hepatitis C</span></div><div class="casAuthors">Chevaliez, Stephane; Pawlotsky, Jean-Michel</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1222-1241</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In 2007, the world celebrated the 50th anniversary of the discovery of interferon (IFN).  The first clin. trial of recombinant IFN-α in patients with chronic hepatitis C was published in 1986.  This article reviews the classification of IFNs, IFN prodn. during viral infections, IFN signaling pathways and the mechanisms of their antiviral and immunomodulatory properties.  Hepatitis C virus infection treatment is currently based on the combination of pegylated IFN-α and ribavirin.  The pegylated IFN-α mols. are described, as well as the putative mechanisms of action of ribavirin.  Current treatment guidelines are discussed and new results suggesting that the treatment schedule should be tailored to the early virol. response during therapy are presented.  Finally, insights into new hepatitis C drug developments are given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppHRhqAbvmRrVg90H21EOLACvtfcHk0lgnZ7nmQTS14g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1yls73M&md5=aec8eda578b92a56112b241930ff7b85</span></div><a href="/servlet/linkout?suffix=cit43a&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2007.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2007.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DChevaliez%26aufirst%3DS.%26aulast%3DPawlotsky%26aufirst%3DJ.-M.%26atitle%3DInterferon-based%2520therapy%2520of%2520hepatitis%2520C%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2007%26volume%3D59%26spage%3D1222%26epage%3D1241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit43b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Keating, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, M. P.</span><span> </span><span class="NLM_article-title">Peginterferon-α2a (40kD) plus ribavirin—a review of its use in the management of chronic hepatitis C</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">701</span><span class="NLM_x">–</span> <span class="NLM_lpage">730</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=701-730&author=G.+M.+Keatingauthor=M.+P.+Curran&title=Peginterferon-%CE%B12a+%2840kD%29+plus+ribavirin%E2%80%94a+review+of+its+use+in+the+management+of+chronic+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DG.%2BM.%26aulast%3DCurran%26aufirst%3DM.%2BP.%26atitle%3DPeginterferon-%25CE%25B12a%2520%252840kD%2529%2520plus%2520ribavirin%25E2%2580%2594a%2520review%2520of%2520its%2520use%2520in%2520the%2520management%2520of%2520chronic%2520hepatitis%2520C%26jtitle%3DDrugs%26date%3D2003%26volume%3D63%26spage%3D701%26epage%3D730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Sulkowski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunyady, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogurtsov, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peck-Radosavljevic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiffman, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yurdaydin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgard, O.</span><span> </span><span class="NLM_article-title">Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">212</span><span class="NLM_x">–</span> <span class="NLM_lpage">223</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1038%2Fnrgastro.2011.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=21386812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFKntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=212-223&author=M.+S.+Sulkowskiauthor=C.+Cooperauthor=B.+Hunyadyauthor=J.+Jiaauthor=P.+Ogurtsovauthor=M.+Peck-Radosavljevicauthor=M.+L.+Shiffmanauthor=C.+Yurdaydinauthor=O.+Dalgard&title=Management+of+adverse+effects+of+Peg-IFN+and+ribavirin+therapy+for+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C</span></div><div class="casAuthors">Sulkowski, Mark S.; Cooper, Curtis; Hunyady, Bela; Jia, Jidong; Ogurtsov, Pavel; Peck-Radosavljevic, Markus; Shiffman, Mitchell L.; Yurdaydin, Cihan; Dalgard, Olav</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">212-223</span>CODEN:
                <span class="NLM_cas:coden">NRGHA9</span>;
        ISSN:<span class="NLM_cas:issn">1759-5045</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A major barrier to hepatitis C treatment uptake and delivery is the assocn. of this therapy with frequent, and at times serious, adverse effects.  This Review article provides a comprehensive literature review that systematically describes the adverse effects of Peg-IFN-α and ribavirin on various organ systems and, more importantly, recommends consensus approaches to managing those effects.  HCV infects approx. 2-3% of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma.  Treatment of HCV infection with Peg-IFN in combination with ribavirin can eradicate HCV infection in 40-90% of patients; however, a major barrier to treatment uptake and delivery is the assocn. of this therapy with frequent and, at times, serious adverse effects.  Recognition and effective management of these adverse effects are crit. components of the successful treatment of chronic HCV infection.  In clin. trials, approx. 10-15% of patients discontinue Peg-IFN and ribavirin therapy due to adverse effects; however, in clin. practice, the rate of treatment discontinuation has been reported to be substantially higher.  The off-target effect of Peg-IFN and ribavirin impacts most, if not all, organ systems; the most common adverse effects are hematol., dermatol., neurol., immunol., gastrointestinal, pulmonary, cardiovascular, and ocular.  Regional and global variability exists in the nature of these adverse effects and the strategies employed to ameliorate their impact.  This article provides a comprehensive literature review that systematically describes the adverse effects of Peg-IFN-α and ribavirin on various organ systems and, more importantly, recommends consensus approaches to managing those effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr33IzKUC2BjLVg90H21EOLACvtfcHk0lgh0tZ8me8wNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFKntr0%253D&md5=ca3908f7d85bd8b857c1c7e9429a769f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2011.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2011.21%26sid%3Dliteratum%253Aachs%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DHunyady%26aufirst%3DB.%26aulast%3DJia%26aufirst%3DJ.%26aulast%3DOgurtsov%26aufirst%3DP.%26aulast%3DPeck-Radosavljevic%26aufirst%3DM.%26aulast%3DShiffman%26aufirst%3DM.%2BL.%26aulast%3DYurdaydin%26aufirst%3DC.%26aulast%3DDalgard%26aufirst%3DO.%26atitle%3DManagement%2520of%2520adverse%2520effects%2520of%2520Peg-IFN%2520and%2520ribavirin%2520therapy%2520for%2520hepatitis%2520C%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2011%26volume%3D8%26spage%3D212%26epage%3D223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Guedj, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sansone, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettles, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotler, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Layden, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uprichard, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">3991</span><span class="NLM_x">–</span> <span class="NLM_lpage">3996</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1073%2Fpnas.1203110110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=23431163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVWms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=3991-3996&author=J.+Guedjauthor=H.+Dahariauthor=L.+Rongauthor=N.+D.+Sansoneauthor=R.+E.+Nettlesauthor=S.+J.+Cotlerauthor=T.+J.+Laydenauthor=S.+L.+Uprichardauthor=A.+S.+Perelson&title=Modeling+shows+that+the+NS5A+inhibitor+daclatasvir+has+two+modes+of+action+and+yields+a+shorter+estimate+of+the+hepatitis+C+virus+half-life"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life</span></div><div class="casAuthors">Guedj, Jeremie; Dahari, Harel; Rong, Libin; Sansone, Natasha D.; Nettles, Richard E.; Cotler, Scott J.; Layden, Thomas J.; Uprichard, Susan L.; Perelson, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3991-3996, S3991/1-S3991/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The nonstructural 5A (NS5A) protein is a target for drug development against hepatitis C virus (HCV).  Interestingly, the NS5A inhibitor daclatasvir (BMS-790052) caused a decrease in serum HCV RNA levels by about two orders of magnitude within 6 h of administration.  However, NS5A has no known enzymic functions, making it difficult to understand daclatasvir's mode of action (MOA) and to est. its antiviral effectiveness.  Modeling viral kinetics during therapy has provided important insights into the MOA and effectiveness of a variety of anti-HCV agents.  Here, we show that understanding the effects of daclatasvir in vivo requires a multiscale model that incorporates drug effects on the HCV intracellular lifecycle, and we validated this approach with in vitro HCV infection expts.  The model predicts that daclatasvir efficiently blocks two distinct stages of the viral lifecycle, namely viral RNA synthesis and virion assembly/secretion with mean effectiveness of 99% and 99.8%, resp., and yields a more precise est. of the serum HCV half-life, 45 min, i.e., around four times shorter than previous ests.  Intracellular HCV RNA in HCV-infected cells treated with daclatasvir and the HCV polymerase inhibitor NM107 showed a similar pattern of decline.  However, daclatasvir treatment led to an immediate and rapid decline of extracellular HCV titers compared to a delayed (6-9 h) and slower decline with NM107, confirming an effect of daclatasvir on both viral replication and assembly/secretion.  The multiscale modeling approach, validated with in vitro kinetic expts., brings a unique conceptual framework for understanding the mechanism of action of a variety of agents in development for the treatment of HCV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSYdT4WQUN7LVg90H21EOLACvtfcHk0lgh0tZ8me8wNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVWms7g%253D&md5=81f3b8c49b97120f70b440211b4bf979</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1203110110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1203110110%26sid%3Dliteratum%253Aachs%26aulast%3DGuedj%26aufirst%3DJ.%26aulast%3DDahari%26aufirst%3DH.%26aulast%3DRong%26aufirst%3DL.%26aulast%3DSansone%26aufirst%3DN.%2BD.%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DCotler%26aufirst%3DS.%2BJ.%26aulast%3DLayden%26aufirst%3DT.%2BJ.%26aulast%3DUprichard%26aufirst%3DS.%2BL.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DModeling%2520shows%2520that%2520the%2520NS5A%2520inhibitor%2520daclatasvir%2520has%2520two%2520modes%2520of%2520action%2520and%2520yields%2520a%2520shorter%2520estimate%2520of%2520the%2520hepatitis%2520C%2520virus%2520half-life%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2013%26volume%3D110%26spage%3D3991%26epage%3D3996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Nettles, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marbury, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldwater, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMicco, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vutikullird, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuentes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Talavera, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span> </span><span class="NLM_article-title">Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1956</span><span class="NLM_x">–</span> <span class="NLM_lpage">1965</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1956-1965&author=R.+E.+Nettlesauthor=M.+Gaoauthor=M.+Bifanoauthor=E.+Chungauthor=A.+Perssonauthor=T.+C.+Marburyauthor=R.+Goldwaterauthor=M.+P.+DeMiccoauthor=M.+Rodriguez-Torresauthor=A.+Vutikullirdauthor=E.+Fuentesauthor=E.+Lawitzauthor=J.+C.+Lopez-Talaveraauthor=D.+M.+Grasela&title=Multiple+ascending+dose+study+of+BMS-790052%2C+a+nonstructural+protein+5A+replication+complex+inhibitor%2C+in+patients+infected+with+hepatitis+C+virus+genotype+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DBifano%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DE.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DMarbury%26aufirst%3DT.%2BC.%26aulast%3DGoldwater%26aufirst%3DR.%26aulast%3DDeMicco%26aufirst%3DM.%2BP.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DVutikullird%26aufirst%3DA.%26aulast%3DFuentes%26aufirst%3DE.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DLopez-Talavera%26aufirst%3DJ.%2BC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26atitle%3DMultiple%2520ascending%2520dose%2520study%2520of%2520BMS-790052%252C%2520a%2520nonstructural%2520protein%25205A%2520replication%2520complex%2520inhibitor%252C%2520in%2520patients%2520infected%2520with%2520hepatitis%2520C%2520virus%2520genotype%25201%26jtitle%3DHepatology%26date%3D2011%26volume%3D54%26spage%3D1956%26epage%3D1965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Cento, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mirabelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salpini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimonte, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artese, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercurio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svicher, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parrotta, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciotti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Paolo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarrecchia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreoni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alcaro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angelico, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Federico Perno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceccherini-Silberstein, F.</span><span> </span><span class="NLM_article-title">HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">e39652</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e39652&issue=7&author=V.+Centoauthor=C.+Mirabelliauthor=R.+Salpiniauthor=S.+Dimonteauthor=A.+Arteseauthor=G.+Costaauthor=F.+Mercurioauthor=V.+Svicherauthor=L.+Parrottaauthor=A.+Bertoliauthor=M.+Ciottiauthor=D.+Di+Paoloauthor=C.+Sarrecchiaauthor=M.+Andreoniauthor=S.+Alcaroauthor=M.+Angelicoauthor=C.+Federico+Pernoauthor=F.+Ceccherini-Silberstein&title=HCV+genotypes+are+differently+prone+to+the+development+of+resistance+to+linear+and+macrocyclic+protease+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCento%26aufirst%3DV.%26aulast%3DMirabelli%26aufirst%3DC.%26aulast%3DSalpini%26aufirst%3DR.%26aulast%3DDimonte%26aufirst%3DS.%26aulast%3DArtese%26aufirst%3DA.%26aulast%3DCosta%26aufirst%3DG.%26aulast%3DMercurio%26aufirst%3DF.%26aulast%3DSvicher%26aufirst%3DV.%26aulast%3DParrotta%26aufirst%3DL.%26aulast%3DBertoli%26aufirst%3DA.%26aulast%3DCiotti%26aufirst%3DM.%26aulast%3DDi%2BPaolo%26aufirst%3DD.%26aulast%3DSarrecchia%26aufirst%3DC.%26aulast%3DAndreoni%26aufirst%3DM.%26aulast%3DAlcaro%26aufirst%3DS.%26aulast%3DAngelico%26aufirst%3DM.%26aulast%3DFederico%2BPerno%26aufirst%3DC.%26aulast%3DCeccherini-Silberstein%26aufirst%3DF.%26atitle%3DHCV%2520genotypes%2520are%2520differently%2520prone%2520to%2520the%2520development%2520of%2520resistance%2520to%2520linear%2520and%2520macrocyclic%2520protease%2520inhibitors%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26issue%3D7%26spage%3De39652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Nakamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirasawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokosuka, O.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A inhibitors and drug resistance mutations</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2902</span><span class="NLM_x">–</span> <span class="NLM_lpage">2912</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.3748%2Fwjg.v20.i11.2902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=24659881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovFWhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2902-2912&author=S.+Nakamotoauthor=T.+Kandaauthor=S.+Wuauthor=H.+Shirasawaauthor=O.+Yokosuka&title=Hepatitis+C+virus+NS5A+inhibitors+and+drug+resistance+mutations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus NS5A inhibitors and drug resistance mutations</span></div><div class="casAuthors">Nakamoto, Shingo; Kanda, Tatsuo; Wu, Shuang; Shirasawa, Hiroshi; Yokosuka, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2902-2912, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">Baishideng Publishing Group Co., Ltd.</span>)
        </div><div class="casAbstract">Some direct-acting antiviral agents for hepatitis C virus (HCV), such as telaprevir and boceprevir have been available since 2011.  It was reported that HCV NS5A is assocd. with interferon signaling related to HCV replication and hepatocarcinogenesis.  HCV NS5A inhibitors efficiently inhibited HCV replication in vitro.  Human studies showed that dual, triple and quad regimens with HCV NS5A inhibitors, such as daclatasvir and ledipasvir, in combination with other direct-acting antiviral agents against other regions of HCV with or without peginterferon/ribavirin, could efficiently inhibit HCV replication according to HCV genotypes.  These combinations might be a powerful tool for "difficult-to-treat" HCV-infected patients. "First generation" HCV NS5A inhibitors such as daclatasvir, ledipasvir and ABT-267, which are now in phase III clin. trials, could result in resistance mutations. "Second generation" NS5A inhibitors such as GS-5816, ACH-3102, and MK-8742, have displayed improvements in the genetic barrier while maintaining potency.  HCV NS5A inhibitors are safe at low concns., which make them attractive for use despite low genetic barriers, although, in fact, HCV NS5A inhibitors should be used with HCV NS3/4A inhibitors, HCV NS5B inhibitors or peginterferon plus ribavirin.  This review article describes HCV NS5A inhibitor resistance mutations and recommends that HCV NS5A inhibitors be used in combination regimens potent enough to prevent the emergence of resistant variants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaLRN4u5IUN7Vg90H21EOLACvtfcHk0liBLTZxJDVaaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovFWhsL4%253D&md5=b068987f16ed03672fb57194e492264d</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v20.i11.2902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v20.i11.2902%26sid%3Dliteratum%253Aachs%26aulast%3DNakamoto%26aufirst%3DS.%26aulast%3DKanda%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DShirasawa%26aufirst%3DH.%26aulast%3DYokosuka%26aufirst%3DO.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%2520inhibitors%2520and%2520drug%2520resistance%2520mutations%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2014%26volume%3D20%26spage%3D2902%26epage%3D2912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matorell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatum, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hezode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronowicki, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reindollar, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diva, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hindes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnittman, S.</span><span> </span><span class="NLM_article-title">Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomized, parallel-group, double-blind, placebo-controlled, dose-finding phase 2a trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">677</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2FS1473-3099%2812%2970138-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=22714001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GlsL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=671-677&author=S.+Polauthor=R.+H.+Ghalibauthor=V.+K.+Rustgiauthor=C.+Matorellauthor=G.+T.+Eversonauthor=H.+A.+Tatumauthor=C.+Hezodeauthor=J.+K.+Limauthor=J.+P.+Bronowickiauthor=G.+A.+Abramsauthor=N.+Brauauthor=D.+W.+Morrisauthor=P.+J.+Thuluvathauthor=R.+W.+Reindollarauthor=P.+D.+Yinauthor=U.+Divaauthor=R.+Hindesauthor=F.+McPheeauthor=D.+Hernandezauthor=M.+Wind-Rotoloauthor=E.+A.+Hughesauthor=S.+Schnittman&title=Daclatasvir+for+previously+untreated+chronic+hepatitis+C+genotype-1+infection%3A+a+randomized%2C+parallel-group%2C+double-blind%2C+placebo-controlled%2C+dose-finding+phase+2a+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial</span></div><div class="casAuthors">Pol, Stanislas; Ghalib, Reem H.; Rustgi, Vinod K.; Martorell, Claudia; Everson, Greg T.; Tatum, Harvey A.; Hezode, Christophe; Lim, Joseph K.; Bronowicki, Jean-Pierre; Abrams, Gary A.; Braeu, Norbert; Morris, David W.; Thuluvath, Paul J.; Reindollar, Robert W.; Yin, Philip D.; Diva, Ulysses; Hindes, Robert; McPhee, Fiona; Hernandez, Dennis; Wind-Rotolo, Megan; Hughes, Eric A.; Schnittman, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">671-677</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Several direct-acting antivirals for chronic hepatitis C virus (HCV) infection are available, but they are limited by tolerability and dosing schedules.  Once-daily daclatasvir, a potent NS5A replication complex inhibitor, was generally well tolerated in phase 1 studies.  We assessed daclatasvir in combination with pegylated interferon (peginterferon) and ribavirin for chronic HCV.  Methods: In this double-blind, parallel-group, dose-finding, phase 2a study, treatment-naive patients with HCV genotype-1 infection (without cirrhosis) from 14 centers in the USA and France were randomly assigned (1:1:1:1) to receive peginterferon alfa-2a (180 μg per wk) and ribavirin (1000-1200 mg daily) plus placebo or 3 mg, 10 mg, or 60 mg of daclatasvir taken once daily, for 48 wk.  The primary efficacy endpoint was undetectable HCV RNA at 4 wk and 12 wk after start of treatment (extended rapid virol. response, eRVR).  Anal. was of all participants who received one dose of study drug.  We used descriptive analyses to compare results.  This study is registered with ClinicalTrials.gov, no. NCT00874770.  Findings: 48 patients were randomly assigned (12 per group); all received at least one dose of study drug. 15 patients discontinued treatment before week 48.  Five of 12 patients (42%, 80% CI 22-64%) who received 3 mg daclatasvir achieved eRVR, compared with ten of 12 (83%, 61-96%) who received 10 mg daclatasvir, nine of 12 (75%, 53-90%) who received 60 mg daclatasvir, and one of 12 (8%, 1-29%) who received placebo.  Adverse events and discontinuations as a result of adverse events occurred with similar frequency across groups.  Interpretation: Daclatasvir seems to be a potent NS5A replication complex inhibitor that increases the antiviral potency of peginterferon and ribavirin.  Our findings support the further development of regimens contg. 60 mg daclatasvir for the treatment of chronic genotype-1 HCV infection.  Funding: Bristol-Myers Squibb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0jrF6ixurObVg90H21EOLACvtfcHk0liBLTZxJDVaaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GlsL%252FJ&md5=fb310d15629ecd376196a92faa8291ba</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2812%2970138-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252812%252970138-X%26sid%3Dliteratum%253Aachs%26aulast%3DPol%26aufirst%3DS.%26aulast%3DGhalib%26aufirst%3DR.%2BH.%26aulast%3DRustgi%26aufirst%3DV.%2BK.%26aulast%3DMatorell%26aufirst%3DC.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DTatum%26aufirst%3DH.%2BA.%26aulast%3DHezode%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DBronowicki%26aufirst%3DJ.%2BP.%26aulast%3DAbrams%26aufirst%3DG.%2BA.%26aulast%3DBrau%26aufirst%3DN.%26aulast%3DMorris%26aufirst%3DD.%2BW.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DReindollar%26aufirst%3DR.%2BW.%26aulast%3DYin%26aufirst%3DP.%2BD.%26aulast%3DDiva%26aufirst%3DU.%26aulast%3DHindes%26aufirst%3DR.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26aulast%3DSchnittman%26aufirst%3DS.%26atitle%3DDaclatasvir%2520for%2520previously%2520untreated%2520chronic%2520hepatitis%2520C%2520genotype-1%2520infection%253A%2520a%2520randomized%252C%2520parallel-group%252C%2520double-blind%252C%2520placebo-controlled%252C%2520dose-finding%2520phase%25202a%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D12%26spage%3D671%26epage%3D677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lok, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martorell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reindollar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrova, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span> </span><span class="NLM_article-title">Preliminary study of two antiviral agents for hepatitis C genotype 1</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">216</span><span class="NLM_x">–</span> <span class="NLM_lpage">224</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50a&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1056%2FNEJMoa1104430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50a&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=22256805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50a&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=216-224&author=A.+S.+Lokauthor=D.+F.+Gardinerauthor=E.+Lawitzauthor=C.+Martorellauthor=G.+T.+Eversonauthor=R.+Ghalibauthor=R.+Reindollarauthor=V.+Rustgiauthor=F.+McPheeauthor=M.+Wind-Rotoloauthor=A.+Perssonauthor=K.+Zhuauthor=D.+I.+Dimitrovaauthor=T.+Eleyauthor=T.+Guoauthor=D.+M.+Graselaauthor=C.+Pasquinelli&title=Preliminary+study+of+two+antiviral+agents+for+hepatitis+C+genotype+1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50aR"><div class="casContent"><span class="casTitleNuber">50a</span><div class="casTitle"><span class="NLM_cas:atitle">Preliminary study of two antiviral agents for hepatitis C genotype 1</span></div><div class="casAuthors">Lok, Anna S.; Gardiner, David F.; Lawitz, Eric; Martorell, Claudia; Everson, Gregory T.; Ghalib, Reem; Reindollar, Robert; Rustgi, Vinod; McPhee, Fiona; Wind-Rotolo, Megan; Persson, Anna; Zhu, Kurt; Dimitrova, Dessislava I.; Eley, Timothy; Guo, Tong; Grasela, Dennis M.; Pasquinelli, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">216-224</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addn. of multiple direct-acting antiviral agents to their treatment regimen.  METHODS: This open-label, phase 2a study included an exploratory cohort of 21 patients with chronic HCV genotype 1 infection who had not had a response to previous therapy (i.e., had not had ≥2 log10 decline in HCV RNA after ≥12 wk of treatment with peginterferon and ribavirin).  We randomly assigned patients to receive the NS5A replication complex inhibitor daclatasvir (60 mg once daily) and the NS3 protease inhibitor asunaprevir (600 mg twice daily) alone (group A, 11 patients) or in combination with peginterferon alfa-2a and ribavirin (group B, 10 patients) for 24 wk.  The primary end point was the percentage of patients with a sustained virol. response 12 wk after the end of the treatment period.  RESULTS: A total of 4 patients in group A (36%; 2 of 9 with HCV genotype la and 2 of 2 with genotype lb) had a sustained virol. response at 12 wk after treatment and also at 24 wk after treatment.  Six patients (all with HCV genotype la) had viral breakthrough while receiving therapy, and resistance mutations to both antiviral agents were found in all cases; 1 patient had a viral response at the end of treatment but had a relapse after the treatment period.  All 10 patients in group B had a sustained virol. response at 12 wk after treatment, and 9 had a sustained virol. response at 24 wk after treatment Diarrhea was the most common adverse event in both groups.  Six patients had transient elevations of alanine aminotransferase levels to more than 3 times the upper limit of the normal range.  CONCLUSIONS: This preliminary study involving patients with HCV genotype 1 infection who had not had a response to prior therapy showed that a sustained virol. response can be achieved with two direct-acting antiviral agents only.  In addn., a high rate of sustained virol. response was achieved when the two direct-acting antiviral agents were combined with peginterferon alfa-2a and ribavirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiY7QiDziiRbVg90H21EOLACvtfcHk0lhtnL5WoC7Qag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yltrw%253D&md5=5b986bac6ea53144898c91e8e2eaf5bc</span></div><a href="/servlet/linkout?suffix=cit50a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1104430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1104430%26sid%3Dliteratum%253Aachs%26aulast%3DLok%26aufirst%3DA.%2BS.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DMartorell%26aufirst%3DC.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DGhalib%26aufirst%3DR.%26aulast%3DReindollar%26aufirst%3DR.%26aulast%3DRustgi%26aufirst%3DV.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DDimitrova%26aufirst%3DD.%2BI.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DPasquinelli%26aufirst%3DC.%26atitle%3DPreliminary%2520study%2520of%2520two%2520antiviral%2520agents%2520for%2520hepatitis%2520C%2520genotype%25201%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D216%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit50b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lok, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serfaty, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span> </span><span class="NLM_article-title">Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">490</span><span class="NLM_x">–</span> <span class="NLM_lpage">499</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2Fj.jhep.2013.10.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=24444658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlartw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=490-499&author=A.+S.+Lokauthor=D.+F.+Gardinerauthor=C.+H%C3%A9zodeauthor=E.+J.+Lawitzauthor=M.+Bourli%C3%A8reauthor=G.+T.+Eversonauthor=P.+Marcellinauthor=M.+Rodriguez-Torresauthor=S.+Polauthor=L.+Serfatyauthor=T.+Eleyauthor=S.-P.+Huangauthor=J.+Liauthor=M.+Wind-Rotoloauthor=F.+Yuauthor=F.+McPheeauthor=D.+M.+Graselaauthor=C.+Pasquinelli&title=Randomized+trial+of+daclatasvir+and+asunaprevir+with+or+without+PegIFN%2FRBV+for+hepatitis+C+virus+genotype+1+null+responders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50bR"><div class="casContent"><span class="casTitleNuber">50b</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders</span></div><div class="casAuthors">Lok, Anna S.; Gardiner, David F.; Hezode, Christophe; Lawitz, Eric J.; Bourliere, Marc; Everson, Gregory T.; Marcellin, Patrick; Rodriguez-Torres, Maribel; Pol, Stanislas; Serfaty, Lawrence; Eley, Timothy; Huang, Shu-Pang; Li, Jianling; Wind-Rotolo, Megan; Yu, Fei; McPhee, Fiona; Grasela, Dennis M.; Pasquinelli, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">490-499</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Patients with chronic hepatitis C virus (HCV) infection and prior null response (<2 log HCV RNA decline after ≥12 wk of PegIFN/RBV) have limited options.  We evaluated daclatasvir plus once- or twice-daily asunaprevir in non-cirrhotic genotype 1 null responders.  In this randomized, phase 2a, open-label, 24-wk treatment study, 101 patients received daclatasvir (60 mg) once-daily.  In addn., 38 genotype 1b patients received asunaprevir (200 mg) twice- (DUAL A1) or once-daily (DUAL A2); 36 genotype 1a and 5 genotype 1b patients received asunaprevir twice- (QUAD B1) or once-daily (QUAD B2) plus PegIFN/RBV; and 18 genotype 1a and 4 genotype 1b patients received asunaprevir twice-daily plus ribavirin (TRIPLE B3).  The primary endpoint was undetectable HCV RNA 12 wk post-treatment (sustained virol. response, SVR12).  Across all groups, mean HCV RNA was ≥6 log IU/mL, and 99% of patients had a non-CC IL28B genotype.  SVR12 rates were 78% (A1), 65% (A2), 95% (B1), and 95% (B2).  In B3, most genotype 1a patients experienced virol. breakthrough.  The most common adverse events were headache, diarrhea, and asthenia.  Grade 3-4 aminotransferase elevations were infrequent and not treatment-limiting.  In genotype 1 null responders, daclatasvir plus twice-daily asunaprevir DUAL therapy is effective for most genotype 1b patients, and daclatasvir, asunaprevir, and PegIFN/RBV QUAD therapy is effective for nearly all genotype 1a and 1b patients; but neither DUAL nor TRIPLE therapy is effective for genotype 1a patients.  Interferon-free regimens including daclatasvir and twice-daily asunaprevir for genotype 1 null responders should be tailored to subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmaQLpKkbNoLVg90H21EOLACvtfcHk0lhtnL5WoC7Qag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlartw%253D%253D&md5=d216b31a62adc838c4f2215fcfff4838</span></div><a href="/servlet/linkout?suffix=cit50b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2013.10.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2013.10.019%26sid%3Dliteratum%253Aachs%26aulast%3DLok%26aufirst%3DA.%2BS.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DLawitz%26aufirst%3DE.%2BJ.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DSerfaty%26aufirst%3DL.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DS.-P.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DPasquinelli%26aufirst%3DC.%26atitle%3DRandomized%2520trial%2520of%2520daclatasvir%2520and%2520asunaprevir%2520with%2520or%2520without%2520PegIFN%252FRBV%2520for%2520hepatitis%2520C%2520virus%2520genotype%25201%2520null%2520responders%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D60%26spage%3D490%26epage%3D499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Scola, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venables, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sit, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocuzza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilder, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friborg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schartman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donoso, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosure, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajamani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tredup, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levesque, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span> </span><span class="NLM_article-title">The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1730</span><span class="NLM_x">–</span> <span class="NLM_lpage">1752</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm500297k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVeqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1730-1752&author=P.+M.+Scolaauthor=L.-Q.+Sunauthor=A.+X.+Wangauthor=J.+Chenauthor=N.+Sinauthor=B.+L.+Venablesauthor=S.-Y.+Sitauthor=Y.+Chenauthor=A.+Cocuzzaauthor=D.+M.+Bilderauthor=S.+V.+D%E2%80%99Andreaauthor=B.+Zhengauthor=P.+Hewawasamauthor=Y.+Tuauthor=J.+Friborgauthor=P.+Falkauthor=D.+Hernandezauthor=S.+Levineauthor=C.+Chenauthor=F.+Yuauthor=A.+K.+Sheafferauthor=G.+Zhaiauthor=D.+Barryauthor=J.+O.+Knipeauthor=Y.-H.+Hanauthor=R.+Schartmanauthor=M.+Donosoauthor=K.+Mosureauthor=M.+W.+Sinzauthor=T.+Zvyagaauthor=A.+C.+Goodauthor=R.+Rajamaniauthor=K.+Kishauthor=J.+Tredupauthor=H.+E.+Kleiauthor=Q.+Gaoauthor=L.+Muellerauthor=R.+J.+Colonnoauthor=D.+M.+Graselaauthor=S.+P.+Adamsauthor=J.+Loyauthor=P.+C.+Levesqueauthor=H.+Sunauthor=H.+Shiauthor=L.+Sunauthor=W.+Warnerauthor=D.+Liauthor=J.+Zhuauthor=N.+A.+Meanwellauthor=F.+McPhee&title=The+discovery+of+asunaprevir+%28BMS-650032%29%2C+an+orally+efficacious+NS3+protease+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Scola, Paul M.; Sun, Li-Qiang; Wang, Alan Xiangdong; Chen, Jie; Sin, Ny; Venables, Brian L.; Sit, Sing-Yuen; Chen, Yan; Cocuzza, Anthony; Bilder, Donna M.; D'Andrea, Stanley V.; Zheng, Barbara; Hewawasam, Piyasena; Tu, Yong; Friborg, Jacques; Falk, Paul; Hernandez, Dennis; Levine, Steven; Chen, Chaoqun; Yu, Fei; Sheaffer, Amy K.; Zhai, Guangzhi; Barry, Diana; Knipe, Jay O.; Han, Yong-Hae; Schartman, Richard; Donoso, Maria; Mosure, Kathy; Sinz, Michael W.; Zvyaga, Tatyana; Good, Andrew C.; Rajamani, Ramkumar; Kish, Kevin; Tredup, Jeffrey; Klei, Herbert E.; Gao, Qi; Mueller, Luciano; Colonno, Richard J.; Grasela, Dennis M.; Adams, Stephen P.; Loy, James; Levesque, Paul C.; Sun, Huabin; Shi, Hong; Sun, Lucy; Warner, William; Li, Danshi; Zhu, Jialong; Meanwell, Nicholas A.; McPhee, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1730-1752</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of asunaprevir (BMS-650032) is described.  This tripeptidic acylsulfonamide inhibitor of the NS3/4A enzyme is currently in phase III clin. trials for the treatment of hepatitis C virus infection.  The discovery of Asunaprevir was enabled by employing an isolated rabbit heart model to screen for the cardiovascular (CV) liabilities (changes to HR and SNRT) that were responsible for the discontinuation of an earlier lead from this chem. series, BMS-605339, from clin. trials.  The structure-activity relationships (SARs) developed with respect to CV effects established that small structural changes to the P2* subsite of the mol. had a significant impact on the CV profile of a given compd.  The antiviral activity, preclin. PK profile, and toxicol. studies in rat and dog supported clin. development of BMS-650032.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCzMFiXs8YO7Vg90H21EOLACvtfcHk0lhtnL5WoC7Qag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVeqsLc%253D&md5=e8015d3874b80be645a9b80b5bd05865</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm500297k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500297k%26sid%3Dliteratum%253Aachs%26aulast%3DScola%26aufirst%3DP.%2BM.%26aulast%3DSun%26aufirst%3DL.-Q.%26aulast%3DWang%26aufirst%3DA.%2BX.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DSit%26aufirst%3DS.-Y.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCocuzza%26aufirst%3DA.%26aulast%3DBilder%26aufirst%3DD.%2BM.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DS.%2BV.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DFriborg%26aufirst%3DJ.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DLevine%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DBarry%26aufirst%3DD.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DHan%26aufirst%3DY.-H.%26aulast%3DSchartman%26aufirst%3DR.%26aulast%3DDonoso%26aufirst%3DM.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DRajamani%26aufirst%3DR.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DMueller%26aufirst%3DL.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DAdams%26aufirst%3DS.%2BP.%26aulast%3DLoy%26aufirst%3DJ.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DWarner%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DMcPhee%26aufirst%3DF.%26atitle%3DThe%2520discovery%2520of%2520asunaprevir%2520%2528BMS-650032%2529%252C%2520an%2520orally%2520efficacious%2520NS3%2520protease%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1730%26epage%3D1752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><div class="note"><p class="first last">The first clinical trial with a combination of HCV DAAs in the absence of interferon and ribavirin evaluated the nucleoside analog RG7128 (mericitabine) with the NS3 protease inhibitor danoprevir dosed for 13 days. For details, see:</p></div><span class="NLM_contrib-group">Gane, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stedman, C. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angus, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritchie, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elston, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ipe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morcos, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Najera, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopatin, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berrey, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradford, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laughlin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shulman, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. F.</span><span> </span><span class="NLM_article-title">Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">376</span><span class="NLM_x">, </span> <span class="NLM_fpage">1467</span><span class="NLM_x">–</span> <span class="NLM_lpage">1475</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2010&pages=1467-1475&author=E.+J.+Ganeauthor=S.+K.+Robertsauthor=C.+A.+M.+Stedmanauthor=P.+W.+Angusauthor=B.+Ritchieauthor=R.+Elstonauthor=D.+Ipeauthor=P.+N.+Morcosauthor=L.+Baherauthor=I.+Najeraauthor=T.+Chuauthor=U.+Lopatinauthor=M.+M.+Berreyauthor=W.+Bradfordauthor=M.+Laughlinauthor=N.+S.+Shulmanauthor=P.+F.+Smith&title=Oral+combination+therapy+with+a+nucleoside+polymerase+inhibitor+%28RG7128%29+and+danoprevir+for+chronic+hepatitis+C+genotype+1+infection+%28INFORM-1%29%3A+a+randomised%2C+double-blind%2C+placebo-controlled%2C+dose-escalation+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DRoberts%26aufirst%3DS.%2BK.%26aulast%3DStedman%26aufirst%3DC.%2BA.%2BM.%26aulast%3DAngus%26aufirst%3DP.%2BW.%26aulast%3DRitchie%26aufirst%3DB.%26aulast%3DElston%26aufirst%3DR.%26aulast%3DIpe%26aufirst%3DD.%26aulast%3DMorcos%26aufirst%3DP.%2BN.%26aulast%3DBaher%26aufirst%3DL.%26aulast%3DNajera%26aufirst%3DI.%26aulast%3DChu%26aufirst%3DT.%26aulast%3DLopatin%26aufirst%3DU.%26aulast%3DBerrey%26aufirst%3DM.%2BM.%26aulast%3DBradford%26aufirst%3DW.%26aulast%3DLaughlin%26aufirst%3DM.%26aulast%3DShulman%26aufirst%3DN.%2BS.%26aulast%3DSmith%26aufirst%3DP.%2BF.%26atitle%3DOral%2520combination%2520therapy%2520with%2520a%2520nucleoside%2520polymerase%2520inhibitor%2520%2528RG7128%2529%2520and%2520danoprevir%2520for%2520chronic%2520hepatitis%2520C%2520genotype%25201%2520infection%2520%2528INFORM-1%2529%253A%2520a%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%252C%2520dose-escalation%2520trial%26jtitle%3DLancet%26date%3D2010%26volume%3D376%26spage%3D1467%26epage%3D1475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, H.</span><span> </span><span class="NLM_article-title">Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=742-748&author=K.+Chayamaauthor=S.+Takahashiauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Ikedaauthor=H.+Ishikawaauthor=H.+Watanabeauthor=F.+McPheeauthor=E.+Hughesauthor=H.+Kumada&title=Dual+therapy+with+the+nonstructural+protein+5A+inhibitor%2C+daclatasvir%2C+and+the+nonstructural+protein+3+protease+inhibitor%2C+asunaprevir%2C+in+hepatitis+C+virus+genotype+1b-infected+null+responders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DDual%2520therapy%2520with%2520the%2520nonstructural%2520protein%25205A%2520inhibitor%252C%2520daclatasvir%252C%2520and%2520the%2520nonstructural%2520protein%25203%2520protease%2520inhibitor%252C%2520asunaprevir%252C%2520in%2520hepatitis%2520C%2520virus%2520genotype%25201b-infected%2520null%2520responders%26jtitle%3DHepatology%26date%3D2012%26volume%3D55%26spage%3D742%26epage%3D748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit53b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, H.</span><span> </span><span class="NLM_article-title">Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">646</span><span class="NLM_x">–</span> <span class="NLM_lpage">654</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53b&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2Fj.jhep.2012.11.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53b&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=23178977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvFeksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=646-654&author=Y.+Karinoauthor=J.+Toyotaauthor=K.+Ikedaauthor=F.+Suzukiauthor=K.+Chayamaauthor=Y.+Kawakamiauthor=H.+Ishikawaauthor=H.+Watanabeauthor=D.+Hernandezauthor=F.+Yuauthor=F.+McPheeauthor=H.+Kumada&title=Characterization+of+virologic+escape+in+hepatitis+C+virus+genotype+1b+patients+treated+with+the+direct-acting+antivirals+daclatasvir+and+asunaprevir"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53bR"><div class="casContent"><span class="casTitleNuber">53b</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir</span></div><div class="casAuthors">Karino, Yoshiyasu; Toyota, Joji; Ikeda, Kenji; Suzuki, Fumitaka; Chayama, Kazuaki; Kawakami, Yoshiiku; Ishikawa, Hiroki; Watanabe, Hideaki; Hernandez, Dennis; Yu, Fei; McPhee, Fiona; Kumada, Hiromitsu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">646-654</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Daclatasvir and asunaprevir are NS5A and NS3 protease-targeted antivirals currently under development for treatment of chronic hepatitis C virus infection.  Clin. data on baseline and on-treatment correlates of drug resistance and response to these agents are currently limited.Hepatitis C virus genotype 1b Japanese patients (prior null responders to PegIFN-α/RBV [n = 21] or PegIFN-α/RBV ineligible or intolerant [n = 22]) were administered daclatasvir/asunaprevir for 24 wk during a phase 2a open-label study.  Genotypic and phenotypic analyses of NS3 and NS5A substitutions were performed at baseline, after virol. failure, and post-treatment through follow-up week 36.There were three viral breakthroughs and four relapsers.  Baseline NS3 polymorphisms (T54S, Q80L, V170M) at amino acid positions previously assocd. with low-level resistance (<9-fold) to select NS3 protease inhibitors were detected in four null responders and three ineligibles, but were not assocd. with virol. failure.  Baseline NS5A polymorphisms (L28M, L31M, Y93H) assocd. with daclatasvir resistance (<25-fold) were detected in five null responders and six ineligibles.  All three viral breakthroughs and 2/4 relapsers carried a baseline NS5A-Y93H polymorphism.  NS3 and NS5A resistance-assocd. variants were detected together (NS3-D168A/V, NS5A-L31M/V-Y93H) after virol. failure.  Generally, daclatasvir-resistant substitutions persisted through 48 wk post-treatment, whereas asunaprevir-resistant substitutions were no longer detectable.  Overall, 5/10 patients with baseline NS5A-Y93H experienced virol. failure, while 5/10 achieved a sustained virol. response.The potential assocn. of a pre-existing NS5A-Y93H polymorphism with virol. failure on daclatasvir/asunaprevir combination treatment will be examd. in larger studies.  The persistence of treatment-emergent daclatasvir- and asunaprevir-resistant substitutions will require assessment in longer-term follow-up studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6FdD0algZ2rVg90H21EOLACvtfcHk0liRE4Aq5OY_fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvFeksQ%253D%253D&md5=be5c769092743c85ce74039cb262b6ac</span></div><a href="/servlet/linkout?suffix=cit53b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.11.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.11.012%26sid%3Dliteratum%253Aachs%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DF.%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DCharacterization%2520of%2520virologic%2520escape%2520in%2520hepatitis%2520C%2520virus%2520genotype%25201b%2520patients%2520treated%2520with%2520the%2520direct-acting%2520antivirals%2520daclatasvir%2520and%2520asunaprevir%26jtitle%3DJ.%2520Hepatol.%26date%3D2013%26volume%3D58%26spage%3D646%26epage%3D654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit53c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, H.</span><span> </span><span class="NLM_article-title">Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">–</span> <span class="NLM_lpage">662</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53c&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1016%2Fj.jhep.2012.09.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53c&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=23183526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53c&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2jtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=655-662&author=Y.+Suzukiauthor=K.+Ikedaauthor=F.+Suzukiauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Chayamaauthor=Y.+Kawakamiauthor=H.+Ishikawaauthor=J.+Watanabeauthor=W.+Huauthor=T.+Eleyauthor=F.+McPheeauthor=E.+Hughesauthor=H.+Kumada&title=Dual+oral+therapy+with+daclatasvir+and+asunaprevir+for+patients+with+HCV+genotype+1b+infection+and+limited+treatment+options"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53cR"><div class="casContent"><span class="casTitleNuber">53c</span><div class="casTitle"><span class="NLM_cas:atitle">Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options</span></div><div class="casAuthors">Suzuki, Yoshiyuki; Ikeda, Kenji; Suzuki, Fumitaka; Toyota, Joji; Karino, Yoshiyasu; Chayama, Kazuaki; Kawakami, Yoshiiku; Ishikawa, Hiroki; Watanabe, Hideaki; Hu, Wenhua; Eley, Timothy; McPhee, Fiona; Hughes, Eric; Kumada, Hiromitsu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">655-662</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Improved therapeutic options for chronic hepatitis C virus (HCV) infection are needed for patients who are poor candidates for treatment with current regimens due to anticipated intolerability or low likelihood of response.  In this open-label, phase 2a study of Japanese patients with chronic HCV genotype 1b infection, 21 null responders (<2 log10 HCV RNA redn. after 12 wk of peginterferon/ribavirin) and 22 patients intolerant to or medically ineligible for peginterferon/ribavirin therapy received dual oral treatment for 24 wk with the NS5A replication complex inhibitor daclatasvir (DCV) and the NS3 protease inhibitor asunaprevir (ASV).  The primary efficacy end point was sustained virol. response at 12 wk post-treatment (SVR12).  Thirty-six of 43 enrolled patients completed 24 wk of therapy.  Serum HCV RNA levels declined rapidly, becoming undetectable in all patients on therapy by week 8.  Overall, 76.7% of patients achieved SVR12 and SVR24, including 90.5% of null responders and 63.6% of ineligible/intolerant patients.  There were no virol. failures among null responders.  Three ineligible/intolerant patients experienced viral breakthrough and four relapsed post-treatment.  Diarrhea, nasopharyngitis, headache, and ALT/AST increases, generally mild, were the most common adverse events; three discontinuations before week 24 were due to adverse events that included hyperbilirubinemia and transaminase elevations (two patients).  Dual therapy with daclatasvir and asunaprevir, without peginterferon/ribavirin, was well tolerated and achieved high SVR rates in two groups of difficult-to-treat patients with hepatitis C virus genotype 1b infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq1ZlrHtPRHLVg90H21EOLACvtfcHk0lgqIZaa_lg6OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2jtbw%253D&md5=48caec88fbfc444ea629aac577c2ed95</span></div><a href="/servlet/linkout?suffix=cit53c&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.09.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.09.037%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DF.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DDual%2520oral%2520therapy%2520with%2520daclatasvir%2520and%2520asunaprevir%2520for%2520patients%2520with%2520HCV%2520genotype%25201b%2520infection%2520and%2520limited%2520treatment%2520options%26jtitle%3DJ.%2520Hepatol.%26date%3D2013%26volume%3D58%26spage%3D655%26epage%3D662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit53d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Kumada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ido, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izumi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koike, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takehara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyagoshi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damokosh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span> </span><span class="NLM_article-title">Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1002/hep.27113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53d&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1002%2Fhep.27113" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=H.+Kumadaauthor=Y.+Suzukiauthor=K.+Ikedaauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Chayamaauthor=Y.+Kawakamiauthor=A.+Idoauthor=K.+Yamamotoauthor=K.+Takaguchiauthor=N.+Izumiauthor=K.+Koikeauthor=T.+Takeharaauthor=N.+Kawadaauthor=M.+Sataauthor=H.+Miyagoshiauthor=T.+Eleyauthor=F.+McPheeauthor=A.+Damokoshauthor=H.+Ishikawaauthor=E.+Hughes&title=Daclatasvir+plus+asunaprevir+for+chronic+HCV+genotype+1b+infection&doi=10.1002%2Fhep.27113"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53d&amp;dbid=16384&amp;doi=10.1002%2Fhep.27113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27113%26sid%3Dliteratum%253Aachs%26aulast%3DKumada%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DIdo%26aufirst%3DA.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DTakaguchi%26aufirst%3DK.%26aulast%3DIzumi%26aufirst%3DN.%26aulast%3DKoike%26aufirst%3DK.%26aulast%3DTakehara%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DN.%26aulast%3DSata%26aufirst%3DM.%26aulast%3DMiyagoshi%26aufirst%3DH.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DDamokosh%26aufirst%3DA.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DHughes%26aufirst%3DE.%26atitle%3DDaclatasvir%2520plus%2520asunaprevir%2520for%2520chronic%2520HCV%2520genotype%25201b%2520infection%26jtitle%3DHepatology%26date%3D2014%26doi%3D10.1002%2Fhep.27113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Manion, D.</span><span> </span><span class="NLM_article-title">Daclatasvir: present and future DAA combinations</span>. Presented at HepDart, The Big Island, HI, December 8–12,<span class="NLM_x"> </span><span class="NLM_year">2013</span>. Available at <a href="http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Manion_REVISED%20HepDart2013_V3_3Dec2013_FINAL%20(v2).pdf" class="extLink">http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Manion_REVISED%20HepDart2013_V3_3Dec2013_FINAL%20(v2).pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=D.+Manion&title=Daclatasvir%3A+present+and+future+DAA+combinations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DManion%26aufirst%3DD.%26atitle%3DDaclatasvir%253A%2520present%2520and%2520future%2520DAA%2520combinations%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loustaud-Ratti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatum, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span> </span><span class="NLM_article-title">Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">420</span><span class="NLM_x">–</span> <span class="NLM_lpage">429</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2014&pages=420-429&author=G.+T.+Eversonauthor=K.+D.+Simsauthor=M.+Rodriguez-Torresauthor=C.+H%C3%A9zodeauthor=E.+Lawitzauthor=M.+Bourli%C3%A8reauthor=V.+Loustaud-Rattiauthor=V.+Rustgiauthor=H.+Schwartzauthor=H.+Tatumauthor=P.+Marcellinauthor=S.+Polauthor=P.+J.+Thuluvathauthor=T.+Eleyauthor=X.+Wangauthor=S.-P.+Huangauthor=F.+McPheeauthor=M.+Wind-Rotoloauthor=E.+Chungauthor=C.+Pasquinelliauthor=D.+M.+Graselaauthor=D.+F.+Gardiner&title=Efficacy+of+an+interferon-+and+ribavirin-free+regimen+of+daclatasvir%2C+asunaprevir%2C+and+BMS-791325+in+treatment-naive+patients+with+HCV+genotype+1+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DSims%26aufirst%3DK.%2BD.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DLoustaud-Ratti%26aufirst%3DV.%26aulast%3DRustgi%26aufirst%3DV.%26aulast%3DSchwartz%26aufirst%3DH.%26aulast%3DTatum%26aufirst%3DH.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DS.-P.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DE.%26aulast%3DPasquinelli%26aufirst%3DC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26atitle%3DEfficacy%2520of%2520an%2520interferon-%2520and%2520ribavirin-free%2520regimen%2520of%2520daclatasvir%252C%2520asunaprevir%252C%2520and%2520BMS-791325%2520in%2520treatment-naive%2520patients%2520with%2520HCV%2520genotype%25201%2520infection%26jtitle%3DGastroenterology%26date%3D2014%26volume%3D146%26spage%3D420%26epage%3D429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Gentles, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant-Young, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudyma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regueiro-Ren, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, K.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beno, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camac, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheriff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tredup, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witmer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanumegowda, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosure, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuo, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelosi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J. F.</span><span> </span><span class="NLM_article-title">Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1855</span><span class="NLM_x">–</span> <span class="NLM_lpage">1879</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm4016894" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1855-1879&author=R.+G.+Gentlesauthor=M.+Dingauthor=J.+A.+Benderauthor=C.+P.+Bergstromauthor=K.+Grant-Youngauthor=P.+Hewawasamauthor=T.+Hudymaauthor=S.+Martinauthor=A.+Nickelauthor=A.+Regueiro-Renauthor=Y.+Tuauthor=Z.+Yangauthor=K.-S.+Yeungauthor=X.+Zhengauthor=B.+R.+Benoauthor=D.+M.+Camacauthor=C.-H.+Changauthor=M.+Gaoauthor=P.+E.+Morinauthor=S.+Sheriffauthor=J.+Tredupauthor=J.+Wanauthor=M.+R.+Witmerauthor=D.+Xieauthor=U.+Hanumegowdaauthor=J.+Knipeauthor=K.+Mosureauthor=K.+S.+Santoneauthor=D.+D.+Parkerauthor=X.+Zhuoauthor=J.+Lemmauthor=M.+Liuauthor=L.+Pelosiauthor=K.+Rigatauthor=S.+Vossauthor=Y.+Wangauthor=Y.-K.+Wangauthor=R.+J.+Colonnoauthor=M.+Gaoauthor=S.+B.+Robertsauthor=Q.+Gaoauthor=A.+Ngauthor=N.+A.+Meanwellauthor=J.+F.+Kadow&title=Discovery+and+preclinical+characterization+of+the+cyclopropylindolobenzazepine+BMS-791325%2C+a+potent+allosteric+inhibitor+of+the+hepatitis+C+virus+NS5B+polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm4016894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016894%26sid%3Dliteratum%253Aachs%26aulast%3DGentles%26aufirst%3DR.%2BG.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DBender%26aufirst%3DJ.%2BA.%26aulast%3DBergstrom%26aufirst%3DC.%2BP.%26aulast%3DGrant-Young%26aufirst%3DK.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DHudyma%26aufirst%3DT.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DNickel%26aufirst%3DA.%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYeung%26aufirst%3DK.-S.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DChang%26aufirst%3DC.-H.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DMorin%26aufirst%3DP.%2BE.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DWitmer%26aufirst%3DM.%2BR.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DHanumegowda%26aufirst%3DU.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DParker%26aufirst%3DD.%2BD.%26aulast%3DZhuo%26aufirst%3DX.%26aulast%3DLemm%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DPelosi%26aufirst%3DL.%26aulast%3DRigat%26aufirst%3DK.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.-K.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DNg%26aufirst%3DA.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26atitle%3DDiscovery%2520and%2520preclinical%2520characterization%2520of%2520the%2520cyclopropylindolobenzazepine%2520BMS-791325%252C%2520a%2520potent%2520allosteric%2520inhibitor%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1855%26epage%3D1879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Sulkowski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassanein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lok, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinestrosa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hindes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">AI444040 Study Group</span><span> </span><span class="NLM_article-title">Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1056%2FNEJMoa1306218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=24428467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFymtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=211-221&author=M.+S.+Sulkowskiauthor=D.+F.+Gardinerauthor=M.+Rodriguez-Torresauthor=K.+R.+Reddyauthor=T.+Hassaneinauthor=I.+Jacobsonauthor=E.+Lawitzauthor=A.+S.+Lokauthor=F.+Hinestrosaauthor=P.+J.+Thuluvathauthor=H.+Schwartzauthor=D.+R.+Nelsonauthor=G.+T.+Eversonauthor=T.+Eleyauthor=M.+Wind-Rotoloauthor=S.-P.+Huangauthor=M.+Gaoauthor=D.+Hernandezauthor=F.+McPheeauthor=D.+Shermanauthor=R.+Hindesauthor=W.+Symondsauthor=C.+Pasquinelliauthor=D.+M.+Graselaauthor=AI444040+Study+Group&title=Daclatasvir+plus+sofosbuvir+for+previously+treated+or+untreated+chronic+HCV+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection</span></div><div class="casAuthors">Sulkowski, Mark S.; Gardiner, David F.; Rodriguez-Torres, Maribel; Reddy, K. Rajender; Hassanein, Tarek; Jacobson, Ira; Lawitz, Eric; Lok, Anna S.; Hinestrosa, Federico; Thuluvath, Paul J.; Schwartz, Howard; Nelson, David R.; Everson, Gregory T.; Eley, Timothy; Wind-Rotolo, Megan; Huang, Shu-Pang; Gao, Min; Hernandez, Dennis; McPhee, Fiona; Sherman, Diane; Hindes, Robert; Symonds, William; Pasquinelli, Claudio; Grasela, Dennis M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">211-221</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection.  We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analog HCV NS5B polymerase inhibitor) in patients infected with HCV genotype 1, 2, or 3.  METHODS In this open-label study, we initially randomly assigned 44 previously untreated patients with HCV genotype 1 infection and 44 patients infected with HCV genotype 2 or 3 to daclatasvir at a dose of 60 mg orally once daily plus sofosbuvir at a dose of 400 mg orally once daily, with or without ribavirin, for 24 wk.  The study was expanded to include 123 addnl. patients with genotype 1 infection who were randomly assigned to daclatasvir plus sofosbuvir, with or without ribavirin, for 12 wk (82 previously untreated patients) or 24 wk (41 patients who had previous virol. failure with telaprevir or boceprevir plus peginterferon alfa ribavirin).  The primary end point was a sustained virol. response (an HCV RNA level of <25 IU per mL) at week 12 after the end of therapy.  RESULTS Overall, 211 patients received treatment.  Among patients with genotype 1 infection, 98% of 126 previously untreated patients and 98% of 41 patients who did not have a sustained virol. response with HCV protease inhibitors had a sustained virol. response at week 12 after the end of therapy.  A total of 92% of 26 patients with genotype 2 infection and 89% of 18 patients with genotype 3 infection had a sustained virol. response at week 12.  High rates of sustained virol. response at week 12 were obsd. among patients with HCV subtypes 1a and 1b (98% and 100%, resp.) and those with CC and non-CC IL28B genotypes (93% and 98%, resp.), as well as among patients who received ribavirin and those who did not (94% and 98%, resp.).  The most common adverse events were fatigue, headache, and nausea.  CONCLUSIONS Once-daily oral daclatasvir plus sofosbuvir was assocd. with high rates of sustained virol. response among patients infected with HCV genotype 1, 2, or 3, including patients with no response to prior therapy with telaprevir or boceprevir.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMiCkoKS-KUrVg90H21EOLACvtfcHk0lgrkkQ8imgyAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFymtb0%253D&md5=bc9eff52401d2f1e00505d30fcffd2c5</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1306218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1306218%26sid%3Dliteratum%253Aachs%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DHassanein%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DI.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DLok%26aufirst%3DA.%2BS.%26aulast%3DHinestrosa%26aufirst%3DF.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DSchwartz%26aufirst%3DH.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DS.-P.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DSherman%26aufirst%3DD.%26aulast%3DHindes%26aufirst%3DR.%26aulast%3DSymonds%26aufirst%3DW.%26aulast%3DPasquinelli%26aufirst%3DC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3D%26atitle%3DDaclatasvir%2520plus%2520sofosbuvir%2520for%2520previously%2520treated%2520or%2520untreated%2520chronic%2520HCV%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D211%26epage%3D221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Sofia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagarathnam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rachakonda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bansal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espiritu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keilman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steuer, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, P. A.</span><span> </span><span class="NLM_article-title">Discovery of a β-<span class="smallcaps smallerCapital">d</span>-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7202</span><span class="NLM_x">–</span> <span class="NLM_lpage">7218</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100863x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKmtb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7202-7218&author=M.+J.+Sofiaauthor=D.+Baoauthor=W.+Changauthor=J.+Duauthor=D.+Nagarathnamauthor=S.+Rachakondaauthor=P.+G.+Reddyauthor=B.+S.+Rossauthor=P.+Wangauthor=H.-R.+Zhangauthor=S.+Bansalauthor=C.+Espirituauthor=M.+Keilmanauthor=A.+M.+Lamauthor=H.+M.+Steuerauthor=C.+Niuauthor=M.+J.+Ottoauthor=P.+A.+Furman&title=Discovery+of+a+%CE%B2-d-2%E2%80%B2-deoxy-2%E2%80%B2-%CE%B1-fluoro-2%E2%80%B2-%CE%B2-C-methyluridine+nucleotide+prodrug+%28PSI-7977%29+for+the+treatment+of+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a β-D-2'-Deoxy-2'-α-fluoro-2'-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus</span></div><div class="casAuthors">Sofia, Michael J.; Bao, Donghui; Chang, Wonsuk; Du, Jinfa; Nagarathnam, Dhanapalan; Rachakonda, Suguna; Reddy, P. Ganapati; Ross, Bruce S.; Wang, Peiyuan; Zhang, Hai-Ren; Bansal, Shalini; Espiritu, Christine; Keilman, Meg; Lam, Angela M.; Steuer, Holly M. Micolochick; Niu, Congrong; Otto, Michael J.; Furman, Phillip A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7202-7218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is a global health problem requiring novel approaches for effective treatment of this disease.  The HCV NS5B polymerase has been demonstrated to be a viable target for the development of HCV therapies.  β-D-2'-Deoxy-2'-α-fluoro-2'-β-C-Me nucleosides are selective inhibitors of the HCV NS5B polymerase and have demonstrated potent activity in the clinic.  Phosphoramidate prodrugs of the 5'-phosphate deriv. of the β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleoside were prepd. and showed significant potency in the HCV subgenomic replicon assay (<1 μM) and produced high levels of triphosphate 6 in primary hepatocytes and in the livers of rats, dogs, and monkeys when administered in vivo.  The single diastereomer 51 of diastereomeric mixt. 14 was crystd., and an X-ray structure was detd. establishing the phosphoramidate stereochem. as Sp, thus correlating for the first time the stereochem. of a phosphoramidate prodrug with biol. activity.  51 (PSI-7977) was selected as a clin. development candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWAkLi9-odWbVg90H21EOLACvtfcHk0lhP45lMq-Hoyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKmtb%252FO&md5=33d371e557e9d70562a326f97798f45c</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm100863x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100863x%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DBao%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DRachakonda%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.-R.%26aulast%3DBansal%26aufirst%3DS.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DKeilman%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DSteuer%26aufirst%3DH.%2BM.%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520%25CE%25B2-d-2%25E2%2580%25B2-deoxy-2%25E2%2580%25B2-%25CE%25B1-fluoro-2%25E2%2580%25B2-%25CE%25B2-C-methyluridine%2520nucleotide%2520prodrug%2520%2528PSI-7977%2529%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7202%26epage%3D7218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wenlock, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span> </span><span class="NLM_article-title">A comparison of physiochemical property profiles of development and marketed oral drugs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1250</span><span class="NLM_x">–</span> <span class="NLM_lpage">1256</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm021053p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59a&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1250-1256&author=M.+C.+Wenlockauthor=R.+P.+Austinauthor=P.+Bartonauthor=A.+M.+Davisauthor=P.+D.+Leeson&title=A+comparison+of+physiochemical+property+profiles+of+development+and+marketed+oral+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59aR"><div class="casContent"><span class="casTitleNuber">59a</span><div class="casTitle"><span class="NLM_cas:atitle">A Comparison of Physiochemical Property Profiles of Development and Marketed Oral Drugs</span></div><div class="casAuthors">Wenlock, Mark C.; Austin, Rupert P.; Barton, Patrick; Davis, Andrew M.; Leeson, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1250-1256</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The process of drug discovery applies rigorous selection pressures.  Marketed oral drugs will generally possess favorable physiochem. properties with respect to absorption, metab., distribution, and clearance.  This paper describes a study in which the distributions of physiochem. properties of oral drugs in different phases of clin. development are compared to those already marketed.  The aim is to identify the trends in physiochem. properties that favor a drug's successful passage through clin. development and on to the market.  Two libraries were created, one of current development oral drugs and one of marketed oral drugs.  Statistical anal. of the two showed that the mean mol. wt. of orally administered drugs in development decreases on passing through each of the different clin. phases and gradually converges toward the mean mol. wt. of marketed oral drugs.  It is also clear that the most lipophilic compds. are being discontinued from development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF0PksUFJq0bVg90H21EOLACvtfcHk0ljXJeo1vXWRKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbY%253D&md5=b9809c803a61ec99a1b4171e97952452</span></div><a href="/servlet/linkout?suffix=cit59a&amp;dbid=16384&amp;doi=10.1021%2Fjm021053p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm021053p%26sid%3Dliteratum%253Aachs%26aulast%3DWenlock%26aufirst%3DM.%2BC.%26aulast%3DAustin%26aufirst%3DR.%2BP.%26aulast%3DBarton%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DA.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26atitle%3DA%2520comparison%2520of%2520physiochemical%2520property%2520profiles%2520of%2520development%2520and%2520marketed%2520oral%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1250%26epage%3D1256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit59b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Perola, E.</span><span> </span><span class="NLM_article-title">An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2986</span><span class="NLM_x">–</span> <span class="NLM_lpage">2997</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100118x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59b&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtlWqu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2986-2997&author=E.+Perola&title=An+analysis+of+the+binding+efficiencies+of+drugs+and+their+leads+in+successful+drug+discovery+programs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59bR"><div class="casContent"><span class="casTitleNuber">59b</span><div class="casTitle"><span class="NLM_cas:atitle">An Analysis of the Binding Efficiencies of Drugs and their Leads in Successful Drug Discovery Programs</span></div><div class="casAuthors">Perola, Emanuele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2986-2997</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to investigate the evolution of binding efficiency in successful drug discovery programs, a data set of 60 lead/drug pairs with known binding affinities has been compiled and analyzed.  Low-end thresholds for the binding efficiencies of viable leads and drugs have been derived.  On av., the drugs in the set are significantly larger and more potent but have similar lipophilicity relative to their originating leads, suggesting that the ability to maintain low levels of lipophilicity while increasing mol. wt. is one of the keys to a successful drug discovery program.  A no. of examples demonstrate that large increases in binding efficiency from leads to more elaborate drugs sharing the same scaffold can be achieved.  The importance of dissecting a lead structure to identify the most efficient fragments and the option of sacrificing binding efficiency to optimize other properties are discussed, and relevant examples are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRqzYFBuX2Q7Vg90H21EOLACvtfcHk0ljXJeo1vXWRKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtlWqu7o%253D&md5=a7eaad792f1518d093588951df64d22f</span></div><a href="/servlet/linkout?suffix=cit59b&amp;dbid=16384&amp;doi=10.1021%2Fjm100118x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100118x%26sid%3Dliteratum%253Aachs%26aulast%3DPerola%26aufirst%3DE.%26atitle%3DAn%2520analysis%2520of%2520the%2520binding%2520efficiencies%2520of%2520drugs%2520and%2520their%2520leads%2520in%2520successful%2520drug%2520discovery%2520programs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2986%26epage%3D2997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit59c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keserü, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, C. H.</span><span> </span><span class="NLM_article-title">The role of ligand efficiency metrics in drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59c&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1038%2Fnrd4163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59c&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=24481311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59c&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=105-121&author=A.+L.+Hopkinsauthor=G.+M.+Keser%C3%BCauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynolds&title=The+role+of+ligand+efficiency+metrics+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59cR"><div class="casContent"><span class="casTitleNuber">59c</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ligand efficiency metrics in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.; Keserue, Gyoergy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-121</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The judicious application of ligand or binding efficiency metrics, which quantify the mol. properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads.  Retrospective anal. of recently marketed oral drugs shows that they frequently have highly optimized ligand efficiency values for their targets.  Optimizing ligand efficiency metrics based on both mol. mass and lipophilicity, when set in the context of the specific target, has the potential to ameliorate the inflation of these properties that has been obsd. in current medicinal chem. practice, and to increase the quality of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96uhvE1OZ5LVg90H21EOLACvtfcHk0lhyB16XVIIcYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D&md5=344030e59f499180f79d311302a27532</span></div><a href="/servlet/linkout?suffix=cit59c&amp;dbid=16384&amp;doi=10.1038%2Fnrd4163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4163%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeser%25C3%25BC%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26atitle%3DThe%2520role%2520of%2520ligand%2520efficiency%2520metrics%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D105%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit59d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Hann, M. M.</span><span> </span><span class="NLM_article-title">Molecular obesity, potency and other addictions in drug discovery</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">355</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59d&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.1039%2FC1MD00017A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59d&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Kht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=349-355&author=M.+M.+Hann&title=Molecular+obesity%2C+potency+and+other+addictions+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59dR"><div class="casContent"><span class="casTitleNuber">59d</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular obesity, potency and other addictions in drug discovery</span></div><div class="casAuthors">Hann, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">349-355</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Despite the increase in global biol. and chem. knowledge the discovery of effective and safe new drugs seems to become harder rather than easier.  Some of this challenge is due to increasing demands for safety and novelty, but some of the risk involved in this should be controllable if we had more effectively learned from our failures.  This perspective reflects on some of the learnings of recent years in relation to the causes of attrition.  The term Mol. Obesity is introduced to describe our tendency to build potency into mols. by the inappropriate use of lipophilicity which leads to the premature demise of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSlF7TPy6fHLVg90H21EOLACvtfcHk0lhyB16XVIIcYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Kht7g%253D&md5=954870db4b1d9e846612c3bb256582f7</span></div><a href="/servlet/linkout?suffix=cit59d&amp;dbid=16384&amp;doi=10.1039%2FC1MD00017A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC1MD00017A%26sid%3Dliteratum%253Aachs%26aulast%3DHann%26aufirst%3DM.%2BM.%26atitle%3DMolecular%2520obesity%252C%2520potency%2520and%2520other%2520addictions%2520in%2520drug%2520discovery%26jtitle%3DMedChemComm%26date%3D2011%26volume%3D2%26spage%3D349%26epage%3D355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Ly, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klevens, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiles, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmberg, S. D.</span><span> </span><span class="NLM_article-title">The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">278</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm500335h&amp;key=10.7326%2F0003-4819-156-4-201202210-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm500335h&amp;key=22351712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm500335h&amp;key=1%3ACAS%3A280%3ADC%252BC383kvFCkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2012&pages=271-278&author=K.+N.+Lyauthor=J.+Xingauthor=R.+M.+Klevensauthor=R.+B.+Jilesauthor=J.+W.+Wardauthor=S.+D.+Holmberg&title=The+increasing+burden+of+mortality+from+viral+hepatitis+in+the+United+States+between+1999+and+2007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007</span></div><div class="casAuthors">Ly Kathleen N; Xing Jian; Klevens R Monina; Jiles Ruth B; Ward John W; Holmberg Scott D</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">271-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The increasing health burden and mortality from hepatitis B virus (HBV) and hepatitis C virus (HCV) in the United States are underappreciated.  OBJECTIVE:  To examine mortality from HBV; HCV; and, for comparison, HIV.  DESIGN:  Analysis of U.S. multiple-cause mortality data from 1999 to 2007 from the National Center for Health Statistics.  SETTING:  All U.S. states and the District of Columbia.  PARTICIPANTS:  Approximately 22 million decedents.  MEASUREMENTS:  Age-adjusted mortality rates from HBV, HCV, and HIV.  Logistic regression analyses of 2007 data generated 4 independent models per outcome (HCV- or HBV-related deaths) that each included 1 of 4 comorbid conditions and all sociodemographic characteristics.  RESULTS:  Between 1999 and 2007, recorded deaths from HCV [corrected] increased significantly to 15,106, whereas deaths from HIV declined to 12,734 by 2007.  Factors associated with HCV-related deaths included chronic liver disease, HBV co-infection, alcohol-related conditions, minority status, and HIV co-infection.  Factors that increased odds of HBV-related death included chronic liver disease, HCV co-infection, Asian or Pacific Islander descent, HIV co-infection, and alcohol-related conditions.  Most deaths from HBV and HCV occurred in middle-aged persons.  LIMITATION:  A person other than the primary physician of the decedent frequently completed the death certificate, and HCV and HBV often were not detected and thus not reported as causes of death.  CONCLUSION:  By 2007, HCV had superseded HIV as a cause of death in the United States, and deaths from HCV and HBV disproportionately occurred in middle-aged persons.  To achieve decreases in mortality similar to those seen with HIV requires new policy initiatives to detect patients with chronic hepatitis and link them to care and treatment.  PRIMARY FUNDING SOURCE:  Centers for Disease Control and Prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4NjyWh_C-GsrRqEXsZufAfW6udTcc2eag3TubcxKCebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383kvFCkuw%253D%253D&md5=365f7666e37e4aefd608b4e3cd2a8d8c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-156-4-201202210-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-156-4-201202210-00004%26sid%3Dliteratum%253Aachs%26aulast%3DLy%26aufirst%3DK.%2BN.%26aulast%3DXing%26aufirst%3DJ.%26aulast%3DKlevens%26aufirst%3DR.%2BM.%26aulast%3DJiles%26aufirst%3DR.%2BB.%26aulast%3DWard%26aufirst%3DJ.%2BW.%26aulast%3DHolmberg%26aufirst%3DS.%2BD.%26atitle%3DThe%2520increasing%2520burden%2520of%2520mortality%2520from%2520viral%2520hepatitis%2520in%2520the%2520United%2520States%2520between%25201999%2520and%25202007%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2012%26volume%3D156%26spage%3D271%26epage%3D278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Rein, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittenborn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinbaum, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesesne, S. B.</span><span> </span><span class="NLM_article-title">Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States</span> <span class="citation_source-journal">Dig. Liver Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">66</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2011&pages=66-72&author=D.+B.+Reinauthor=J.+S.+Wittenbornauthor=C.+M.+Weinbaumauthor=M.+Sabinauthor=B.+D.+Smithauthor=S.+B.+Lesesne&title=Forecasting+the+morbidity+and+mortality+associated+with+prevalent+cases+of+pre-cirrhotic+chronic+hepatitis+C+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRein%26aufirst%3DD.%2BB.%26aulast%3DWittenborn%26aufirst%3DJ.%2BS.%26aulast%3DWeinbaum%26aufirst%3DC.%2BM.%26aulast%3DSabin%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DLesesne%26aufirst%3DS.%2BB.%26atitle%3DForecasting%2520the%2520morbidity%2520and%2520mortality%2520associated%2520with%2520prevalent%2520cases%2520of%2520pre-cirrhotic%2520chronic%2520hepatitis%2520C%2520in%2520the%2520United%2520States%26jtitle%3DDig.%2520Liver%2520Dis.%26date%3D2011%26volume%3D43%26spage%3D66%26epage%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm500335h&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-12%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm500335h%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm500335h" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                803KB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799cd767f4e3c64","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
